<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21562267</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>19</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Critical role of astroglial apolipoprotein E and liver X receptor-&#x3b1; expression for microglial A&#x3b2; phagocytosis.</ArticleTitle><Pagination><StartPage>7049</StartPage><EndPage>7059</EndPage><MedlinePgn>7049-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6546-10.2011</ELocationID><Abstract><AbstractText>Liver X receptors (LXRs) regulate immune cell function and cholesterol metabolism, both factors that are critically involved in Alzheimer's disease (AD). To investigate the therapeutic potential of long-term LXR activation in amyloid-&#x3b2; (A&#x3b2;) peptide deposition in an AD model, 13-month-old, amyloid plaque-bearing APP23 mice were treated with the LXR agonist TO901317. Postmortem analysis demonstrated that TO901317 efficiently crossed the blood-brain barrier. Insoluble and soluble A&#x3b2; levels in the treated APP23 mice were reduced by 80% and 40%, respectively, compared with untreated animals. Amyloid precursor protein (APP) processing, however, was hardly changed by the compound, suggesting that the observed effects were instead mediated by A&#x3b2; disposal. Despite the profound effect on A&#x3b2; levels, spatial learning in the Morris water maze was only slightly improved by the treatment. ABCA1 (ATP-binding cassette transporter 1) and apolipoprotein E (ApoE) protein levels were increased and found to be primarily localized in astrocytes. Experiments using primary microglia demonstrated that medium derived from primary astrocytes exposed to TO901317 stimulated phagocytosis of fibrillar A&#x3b2;. Conditioned medium from TO901317-treated ApoE(-/-) or LXR&#x3b1;(-/-) astrocytes did not increase phagocytosis of A&#x3b2;. In APP23 mice, long-term treatment with TO901317 strongly increased the association of microglia and A&#x3b2; plaques. Short-term treatment of APP/PS1 mice with TO901317 also increased this association, which was dependent on the presence of LXR&#x3b1; and was accompanied by increased ApoE lipidation. Together, these data suggest that astrocytic LXR&#x3b1; activation and subsequent release of ApoE by astrocytes is critical for the ability of microglia to remove fibrillar A&#x3b2; in response to treatment with TO901317.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Terwel</LastName><ForeName>Dick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffensen</LastName><ForeName>Knut R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Verghese</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Gustafsson</LastName><ForeName>Jan-&#xc5;ke</ForeName><Initials>J&#xc5;</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000605214">Nr1h3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423915">T0901317</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006845" MajorTopicYN="N">Hydrocarbons, Fluorinated</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21562267</ArticleId><ArticleId IdType="pmc">PMC6703224</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6546-10.2011</ArticleId><ArticleId IdType="pii">31/19/7049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, de Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M. 24(S)-Hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem. 2006;281:12799&#x2013;12808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524875</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Steffensen KR, Gustafsson JA. Structural characterisation of the mouse nuclear oxysterol receptor genes LXRalpha and LXRbeta. Gene. 2000;243:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10675617</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bj&#xf6;rkhem I, Pettersson S, Gustafsson JA. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest. 2001;107:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC199420</ArticleId><ArticleId IdType="pubmed">11238557</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson S, Gustafsson N, Warner M, Gustafsson JA. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci U S A. 2005;102:3857&#x2013;3862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553330</ArticleId><ArticleId IdType="pubmed">15738425</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol. 2008;59:31&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19258656</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med. 2006;57:313&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, Li AC, Schulman IG. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res. 2010;51:900&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853457</ArticleId><ArticleId IdType="pubmed">20388921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A beta toxicity. Proc Natl Acad Sci U S A. 2008;105:2681&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268196</ArticleId><ArticleId IdType="pubmed">18272491</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-beta (A beta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fi&#xe9;vet C, Staels B. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem Pharmacol. 2009;77:1316&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">19101522</ArticleId></ArticleIdList></Reference><Reference><Citation>Floden AM, Combs CK. beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci. 2006;26:4644&#x2013;4648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674057</ArticleId><ArticleId IdType="pubmed">16641245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita SC, Sakura K, Tsuchiya R, Hamanaka H. Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain. Neurosci Res. 1999;35:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616916</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Baker TJ. Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci. 1986;6:2163&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568755</ArticleId><ArticleId IdType="pubmed">3018187</ArticleId></ArticleIdList></Reference><Reference><Citation>Giunta B, Zhou Y, Hou H, Rrapo E, Fernandez F, Tan J. HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol. 2008;1:260&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2480563</ArticleId><ArticleId IdType="pubmed">18784813</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 2004;173:6366&#x2013;6375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528376</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007;184:69&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging. 2004;25:885&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212842</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of A beta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Fan X, Gabbi C, Yakimchuk K, Parini P, Warner M, Gustafsson JA. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc Natl Acad Sci U S A. 2008;105:2094&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2542868</ArticleId><ArticleId IdType="pubmed">18238900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Rahmanto AS, Kamili A, Rye KA, Guillemin GJ, Gelissen IC, Jessup W, Hill AF, Garner B. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem. 2007;282:2851&#x2013;2861.</Citation><ArticleIdList><ArticleId IdType="pubmed">17121837</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106:4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem. 2003;278:13244&#x2013;13256.</Citation><ArticleIdList><ArticleId IdType="pubmed">12547833</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005a;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005b;280:4079&#x2013;4088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med. 2001;7:609&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950067</ArticleId><ArticleId IdType="pubmed">11778650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R. Expression profiling in APP23 mouse brain: inhibition of A beta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener. 2007;2:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2214725</ArticleId><ArticleId IdType="pubmed">17953774</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder M, Terwel D. Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: a role for high-density lipoproteins? Haemostasis. 1998;28:174&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">10420065</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y, Kohyama K, Park IK, Matsumoto Y. Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model. J Neuropathol Exp Neurol. 2008;67:1063&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957895</ArticleId></ArticleIdList></Reference><Reference><Citation>Plump AS, Smith JD, Hayek T, Aalto-Set&#xe4;l&#xe4; K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">1423598</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007;34:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. On the discovery of the genetic association of apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis. 2006;9:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914873</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci. 2009;29:1846&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699573</ArticleId><ArticleId IdType="pubmed">19211891</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader-Fischer G, Paganetti PA. Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res. 1996;716:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738224</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffensen KR, Neo SY, Stulnig TM, Vega VB, Rahman SS, Schuster GU, Gustafsson JA, Liu ET. Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. J Mol Endocrinol. 2004;33:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">15591022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB. Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol. 2006;413:20&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol Endocrinol. 2000;14:741&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809236</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17:388&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542676</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam D, Coen K, De Deyn PP. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology. 2008;197:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">18008065</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmierlo T, Rutten K, Dederen J, Bloks VW, van Vark-van der Zee LC, Kuipers F, Kiliaan A, Blokland A, Sijbrands EJ, Steinbusch H, Prickaerts J, Lutjohann D, Mulder M. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.07.005</ArticleId><ArticleId IdType="pubmed">19674815</ArticleId></ArticleIdList></Reference><Reference><Citation>Vloeberghs E, Van Dam D, Franck F, Serroyen J, Geert M, Staufenbiel M, De Deyn PP. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behav Neurosci. 2008;122:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">18513119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A. 2002;99:13878&#x2013;13883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129791</ArticleId><ArticleId IdType="pubmed">12368482</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, Wilson JG, Willson TM, Collins JL, Kliewer SA. Liver X receptor (LXR) regulation of the LMR alpha gene in human macrophages. J Biol Chem. 2001;276:43509&#x2013;43515.</Citation><ArticleIdList><ArticleId IdType="pubmed">11546778</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol. 2002;16:1378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040022</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006;116:607&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1386115</ArticleId><ArticleId IdType="pubmed">16511593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20083042</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>128</EndPage><MedlinePgn>119-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(09)70299-6</ELocationID><Abstract><AbstractText>Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. jack.cliff ord@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. CRJ is an investigator in clinical trials sponsored by Pfizer and Baxter, and consults for Elan and Lilly. DSK has served on a data and safety monitoring board for Lilly, has been a consultant for GlaxoSmithKline, and receives grant funding for clinical trials by Baxter, Elan, and Forest. WJJ has consulted for Genentech, Synarc, Elan Pharmaceuticals, Ceregene, Schering Plough, Merck &amp; Co, and Lilly. LMS has consulted for Pfizer. PSA has consulted for Elan, Wyeth, Eisai, Neurochem, Schering-Plough, Bristol-Myers-Squibb, Lilly, Neurophase, Merck, Roche, Amgen, Genentech, Abbott, Pfizer, Novartis, and Medivation, has stock options with Medivation and Neurophase, and has received grant support from Pfizer, Baxter, and Neuro-Hitech. MWW has been on the scientific advisory boards for the Alzheimer&#x2019;s Study Group, Bayer Schering Pharma, Lilly, CoMentis, Neurochem, Eisai, Avid, Aegis, Genentech, Allergan, Bristol-Myers Squibb, Forest, Pfizer, McKinsey, Mitsubishi, and Novartis, has received travel funding from Nestl&#xe9;, honoraria from BOLT International, commercial research support from Merck and Avid, and has stock options in Synarc and Elan. RCP has been a chair, member of the safety monitoring committee, and consultant for Elan, has chaired a data monitoring committee for Wyeth, and has been a consultant for GE Healthcare. JQT has received lecture honoraria from Wyeth, Pfizer, and Takeda.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20083042</ArticleId><ArticleId IdType="mid">NIHMS170909</ArticleId><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId><ArticleId IdType="pii">S1474-4422(09)70299-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Small BJ, Petrovitch H, et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol. 2005;18:224&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306244</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer&#x2019;s disease? Neurology. 2003;60:1374&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment; a meta-analysis. AJNR Am J Neuroradiol. 2009;30:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051416</ArticleId><ArticleId IdType="pubmed">19001534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Haan MN, Eberling JL, Wolfe N, Reed BR. Functional imaging predicts cognitive decline in Alzheimer&#x2019;s disease. J Neuroimaging. 1996;6:156&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">8704290</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Stine WB, Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer&#x2019;s disease. Neurobiol Aging. 2004;25:569&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172732</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-&#x3b2; (A&#x3b2;) oligomerization in an in vivo model of Alzheimer disease. A link between A&#x3b2; and tau pathology. J Biol Chem. 2006;281:1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631949</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347655</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, Ciliax BJ, Wingo TS, et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer&#x2019;s disease. Acta Neuropathol. 2009 published online Aug 19. DOI:10.1007/ s00401-009-0583-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045810</ArticleId><ArticleId IdType="pubmed">19690877</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF A&#x3b2; 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NS, van der Flier WM, Blankenstein MA, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 2008;29:669&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">17208336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer&#x2019;s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50:1464&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pubmed">19690025</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ost M, Nylen K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67:1600&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101890</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer&#x2019;s disease. Ann Neurol. 1995;38:649&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574462</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">8748926</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer&#x2019;s disease. Neuroreport. 1997;8:3961&#x2013;3963.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462474</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707002</ArticleId><ArticleId IdType="pubmed">18458217</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer&#x2019;s disease. Ann Neurol. 2005;57:721&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz WJ, Smith CB, Davidsen L, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science. 1979;205:723&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">462184</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21:1133&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11598490</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage. 2003;20:1894&#x2013;1898.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642499</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer&#x2019;s disease. Neurology. 1998;50:1585&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079505</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie EC, Cross DJ, Galasko D, et al. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol. 2009;66:632&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718788</ArticleId><ArticleId IdType="pubmed">19433663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer&#x2019;s disease. Neuroscience. 2000;95:721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, O&#x2019;Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer&#x2019;s disease. Neurology. 1992;42:183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999;52:1687&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer&#x2019;s disease pathology. Neurology. 2003;61:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, et al. Early A&#x3b2; accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63:936&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, Schoonenboom NS, Verwey NA, et al. CSF biomarker levels in early and late onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2009;30:1895&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403055</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid A&#x3b2; (42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, et al. CSF tau/A&#x3b2;42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1&#x2013;42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord. 2007;24:118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622715</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport. 2002;13:1939&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">12395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology. 2007;69:2205&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluimer JD, Bouwman FH, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging. 2008 published online Aug 7. DOI:10.1016/j.neurobiolaging.2008.06.016.</Citation><ArticleIdList><ArticleId IdType="pubmed">18692273</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc Natl Acad Sci USA. 2001;98:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer&#x2019;s disease in normal aging. Ann Neurol. 2006;59:673&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470518</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer&#x2019;s disease. Lancet. 1999;353:2125.</Citation><ArticleIdList><ArticleId IdType="pubmed">10382699</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997;48:1297&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153461</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735194</ArticleId><ArticleId IdType="pubmed">17894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology. 2009;72:1504&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">19398705</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445252</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer&#x2019;s disease. Ann Neurol. 1998;44:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708558</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715210</ArticleId><ArticleId IdType="pubmed">19636048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Wolozin B, Galasko D. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999;46:750&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">10494442</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology. 2007;69:1006&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785669</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715214</ArticleId><ArticleId IdType="pubmed">19636049</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer&#x2019;s disease. J Magn Reson Imaging. 1997;7:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">9400851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D, Janssen JC, Whitwell JL, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer&#x2019;s disease: longitudinal MRI study. Lancet. 2003;362:1121&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">14550701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: a serial MRI study. Lancet Neurol. 2006;5:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett. 2003;339:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614904</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2007;130:1777&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752411</ArticleId><ArticleId IdType="pubmed">17533169</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20 suppl 2:S69&#x2013;S74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 2008 published online Nov 19. DOI:10.1111/ j.1750-3639.2008.00244.x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864342</ArticleId><ArticleId IdType="pubmed">19021630</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, et al. Long-term effects of A&#x3b2;42 immunisation in Alzheimer&#x2019;s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Alzheimer&#x2019;s disease: progress in prediction. Lancet Neurol. 2010;9:4&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098141</ArticleId><ArticleId IdType="pubmed">20083022</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer&#x2019;s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32:412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am. 1998;8:809&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">9769343</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Hauw JJ. Prevalence, incidence and duration of Braak&#x2019;s stages in the general population: can we know? Neurobiol Aging. 1997;18:362&#x2013;369. 89&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9380250</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci USA. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Habeck CG, Stern Y, Anderson KE. APOE genotype and cerebral blood flow in healthy young individuals. JAMA. 2003;290:1581&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026566</ArticleId><ArticleId IdType="pubmed">14506116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E &#x3b5;4 allele in young individuals with very mild Alzheimer&#x2019;s disease-related neurofibrillary changes. Exp Neurol. 1998;153:152&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743577</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol. 1994;53:429&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083686</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">19339712</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O&#x2019;Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer&#x2019;s disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17115048</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation.</ArticleTitle><Pagination><StartPage>1390</StartPage><EndPage>1396</EndPage><MedlinePgn>1390-6</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid plaque is the hallmark and primary cause of Alzheimer disease. Mutations of presenilin-1, the gamma-secretase catalytic subunit, can affect amyloid-beta (Abeta) production and Alzheimer disease pathogenesis. However, it is largely unknown whether and how gamma-secretase activity and amyloid plaque formation are regulated by environmental factors such as stress, which is mediated by receptors including beta(2)-adrenergic receptor (beta(2)-AR). Here we report that activation of beta(2)-AR enhanced gamma-secretase activity and thus Abeta production. This enhancement involved the association of beta(2)-AR with presenilin-1 and required agonist-induced endocytosis of beta(2)-AR and subsequent trafficking of gamma-secretase to late endosomes and lysosomes, where Abeta production was elevated. Similar effects were observed after activation of delta-opioid receptor. Furthermore, chronic treatment with beta(2)-AR agonists increased cerebral amyloid plaques in an Alzheimer disease mouse model. Thus, beta(2)-AR activation can stimulate gamma-secretase activity and amyloid plaque formation, which suggests that abnormal activation of beta(2)-AR might contribute to Abeta accumulation in Alzheimer disease pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Yanxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Guobin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Jiaxiang</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C449186">PS1 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018343">Receptors, Adrenergic, beta-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2006 Dec;12(12):1352-4. doi: 10.1038/nm1206-1352.</RefSource><PMID Version="1">17151688</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018343" MajorTopicYN="N">Receptors, Adrenergic, beta-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17115048</ArticleId><ArticleId IdType="doi">10.1038/nm1485</ArticleId><ArticleId IdType="pii">nm1485</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19823761</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1463</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neural transmission (Vienna, Austria : 1996)</Title><ISOAbbreviation>J Neural Transm (Vienna)</ISOAbbreviation></Journal><ArticleTitle>Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.</ArticleTitle><Pagination><StartPage>85</StartPage><EndPage>96</EndPage><MedlinePgn>85-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00702-009-0314-x</ELocationID><Abstract><AbstractText>The presence of Abeta(pE3) (N-terminal truncated Abeta starting with pyroglutamate) in Alzheimer's disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of Abeta peptides in senile plaques of AD brains. This was later confirmed by other reports investigating AD and Down's syndrome postmortem brain tissue. Importantly, Abeta(pE3) has a higher aggregation propensity, and stability, and shows an increased toxicity compared to full-length Abeta. We have recently shown that intraneuronal accumulation of Abeta(pE3) peptides induces a severe neuron loss and an associated neurological phenotype in the TBA2 mouse model for AD. Given the increasing interest in Abeta(pE3), we have generated two novel monoclonal antibodies which were characterized as highly specific for Abeta(pE3) peptides and herein used to analyze plaque deposition in APP/PS1KI mice, an AD model with severe neuron loss and learning deficits. This was compared with the plaque pattern present in brain tissue from sporadic and familial AD cases. Abundant plaques positive for Abeta(pE3) were present in patients with sporadic AD and familial AD including those carrying mutations in APP (arctic and Swedish) and PS1. Interestingly, in APP/PS1KI mice we observed a continuous increase in Abeta(pE3) plaque load with increasing age, while the density for Abeta(1-x ) plaques declined with aging. We therefore assume that, in particular, the peptides starting with position 1 of Abeta are N-truncated as disease progresses, and that, Abeta(pE3) positive plaques are resistant to age-dependent degradation likely due to their high stability and propensity to aggregate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wirths</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Department of Psychiatry, University of Goettingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bethge</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Marcello</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Harmeier</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jawhar</LastName><ForeName>Sadim</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lucassen</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>Gerd</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Esparza</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kalimo</LastName><ForeName>Hannu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bayer</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm (Vienna)</MedlineTA><NlmUniqueID>9702341</NlmUniqueID><ISSNLinking>0300-9564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>SZB83O1W42</RegistryNumber><NameOfSubstance UI="D011761">Pyrrolidonecarboxylic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011761" MajorTopicYN="N">Pyrrolidonecarboxylic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19823761</ArticleId><ArticleId IdType="pmc">PMC2789212</ArticleId><ArticleId IdType="doi">10.1007/s00702-009-0314-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, et al. Intraneuronal Abeta causes the onset of early Alzheimer&#x2019;s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45(5):675&#x2013;688. doi: 10.1016/j.neuron.2005.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.01.040</ArticleId><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Breyhan H, Wirths O, Duan K, Marcello A, et al. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol. 2009;117(6):677&#x2013;685. doi: 10.1007/s00401-009-0539-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0539-7</ArticleId><ArticleId IdType="pubmed">19387667</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C, Sergeant N, Itier JM, Blanchard V, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated A{beta}42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165(4):1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004;25(10):1263&#x2013;1272. doi: 10.1016/j.neurobiolaging.2004.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.02.027</ArticleId><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen DZ, Bayer TA, Wirths O (2008a) Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2008.07.022</Citation><ArticleIdList><ArticleId IdType="pubmed">18771817</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen DZ, Kraus SL, Flohr A, Cotel MC, et al. Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 2008;116(6):647&#x2013;655. doi: 10.1007/s00401-008-0451-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0451-6</ArticleId><ArticleId IdType="pubmed">18974993</ArticleId></ArticleIdList></Reference><Reference><Citation>Cynis H, Schilling S, Bodnar M, Hoffmann T, et al. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta. 2006;1764(10):1618&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">17005457</ArticleId></ArticleIdList></Reference><Reference><Citation>Cynis H, Scheel E, Saido TC, Schilling S, et al. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry. 2008;47(28):7405&#x2013;7413. doi: 10.1021/bi800250p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi800250p</ArticleId><ArticleId IdType="pubmed">18570439</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea MR, Nagele RG, Wang HY, Lee DH. Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer&#x2019;s disease entorhinal cortex. Neurosci Lett. 2002;333(3):163&#x2013;166. doi: 10.1016/S0304-3940(02)00875-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(02)00875-3</ArticleId><ArticleId IdType="pubmed">12429373</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115(1):5&#x2013;38. doi: 10.1007/s00401-007-0312-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0312-8</ArticleId><ArticleId IdType="pmc">PMC2100431</ArticleId><ArticleId IdType="pubmed">18038275</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorevic PD, Goni F, Pons-Estel B, Alvarez F, et al. Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer&#x2019;s disease: immunohistological studies. J Neuropathol Exp Neurol. 1986;45(6):647&#x2013;664. doi: 10.1097/00005072-198611000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198611000-00004</ArticleId><ArticleId IdType="pubmed">3772397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156(1):15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntert A, Dobeli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006;143(2):461&#x2013;475. doi: 10.1016/j.neuroscience.2006.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.08.027</ArticleId><ArticleId IdType="pubmed">17008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y, Saido TC, Eckman CB, Prada CM, et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer&#x2019;s disease brain. Biochem Biophys Res Commun. 2000;276(2):422&#x2013;427. doi: 10.1006/bbrc.2000.3490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2000.3490</ArticleId><ArticleId IdType="pubmed">11027491</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmeier A, Wozny C, Rost BR, Munter LM, et al. Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci. 2009;29(23):7582&#x2013;7590. doi: 10.1523/JNEUROSCI.1336-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1336-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665404</ArticleId><ArticleId IdType="pubmed">19515926</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Barrow CJ. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry. 1999;38(33):10871&#x2013;10877. doi: 10.1021/bi990563r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi990563r</ArticleId><ArticleId IdType="pubmed">10451383</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4(1):97&#x2013;100. doi: 10.1038/nm0198-097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0198-097</ArticleId><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, et al. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999;29(3):177&#x2013;185. doi: 10.1023/A:1021691918517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1021691918517</ArticleId><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoda R, Saido TC, Otvos L, Jr, Arai T, et al. Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol. 1998;57(11):1089&#x2013;1095. doi: 10.1097/00005072-199811000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199811000-00012</ArticleId><ArticleId IdType="pubmed">9825946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, et al. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA. 1999;96(6):3228&#x2013;3233. doi: 10.1073/pnas.96.6.3228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.6.3228</ArticleId><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Saido TC, Mann DM, Lee VM, et al. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol. 1996;149(6):1823&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865366</ArticleId><ArticleId IdType="pubmed">8952519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalback W, Watson MD, Kokjohn TA, Kuo YM, et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer&#x2019;s disease senile plaques. Biochemistry. 2002;41(3):922&#x2013;928. doi: 10.1021/bi015685+.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi015685+</ArticleId><ArticleId IdType="pubmed">11790115</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer&#x2019;s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41(5):345&#x2013;352. doi: 10.1016/S0197-0186(02)00050-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(02)00050-5</ArticleId><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Woods AS, Cotter RJ, et al. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun. 1997;237(1):188&#x2013;191. doi: 10.1006/bbrc.1997.7083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1997.7083</ArticleId><ArticleId IdType="pubmed">9266855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Webster S, Emmerling MR, De Lima N, et al. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Abeta peptides of Alzheimer&#x2019;s disease. Biochim Biophys Acta. 1998;1406(3):291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Kokjohn TA, Beach TG, Sue LI, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer&#x2019;s disease brains. J Biol Chem. 2001;276(16):12991&#x2013;12998. doi: 10.1074/jbc.M007859200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M007859200</ArticleId><ArticleId IdType="pubmed">11152675</ArticleId></ArticleIdList></Reference><Reference><Citation>Langui D, Girardot N, El Hachimi KH, Allinquant B, et al. Subcellular topography of neuronal A{beta} peptide in APPxPS1 transgenic mice. Am J Pathol. 2004;165(5):1465&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618656</ArticleId><ArticleId IdType="pubmed">15509518</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda J, Ji B, Tomiyama T, Maruyama M, et al. Longitudinal, quantitative assesment of amyloid, neuroinflammation and anti-amyloid treatment in a living mouse model of Alzheimer&#x2019;s disease enabled by PET. J Neurosci. 2007;27(41):10957&#x2013;10968. doi: 10.1523/JNEUROSCI.0673-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0673-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672864</ArticleId><ArticleId IdType="pubmed">17928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M et al. (2009) Reduced levels of IgM autoantibodies against N-truncated pyroglutamate A&#x3b2; in plasma of patients with Alzheimer&#x2019;s disease. Neurobiol Aging 10.1016/j.neurobiolaging.2009.08.011</Citation><ArticleIdList><ArticleId IdType="pubmed">19781815</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Multhaup G, Simms G, Pottgiesser J, et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer&#x2019;s disease contain the same protein as the amyloid of plaque cores and blood vessels. Embo J. 1985;4(11):2757&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC554575</ArticleId><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245&#x2013;4249. doi: 10.1073/pnas.82.12.4245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.12.4245</ArticleId><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1999;46(6):860&#x2013;866. doi: 10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M</ArticleId><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Miravalle L, Calero M, Takao M, Roher AE, et al. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry. 2005;44(32):10810&#x2013;10821. doi: 10.1021/bi0508237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0508237</ArticleId><ArticleId IdType="pubmed">16086583</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Reverse D, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274(10):6483&#x2013;6492. doi: 10.1074/jbc.274.10.6483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.10.6483</ArticleId><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer&#x2019;s disease. J Biol Chem. 1992;267(24):17082&#x2013;17086.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512246</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571&#x2013;1577. doi: 10.1001/jama.283.12.1571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.12.1571</ArticleId><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A, Russo C, Gliozzi A, Relini A, et al. {beta}-Amyloid is different in normal aging and in Alzheimer disease. J Biol Chem. 2005;280(40):34186&#x2013;34192. doi: 10.1074/jbc.M501694200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501694200</ArticleId><ArticleId IdType="pubmed">16103127</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A, Zanusso G, Borghi R, Noviello C, et al. Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch Neurol. 2007;64(5):738&#x2013;745. doi: 10.1001/archneur.64.5.738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.5.738</ArticleId><ArticleId IdType="pubmed">17502474</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem. 1995;270(41):23895&#x2013;23898. doi: 10.1074/jbc.270.41.23895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.41.23895</ArticleId><ArticleId IdType="pubmed">7592576</ArticleId></ArticleIdList></Reference><Reference><Citation>Puolivali J, Wang J, Heikkinen T, Heikkila M, et al. Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis. 2002;9(3):339&#x2013;347. doi: 10.1006/nbdi.2002.0481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0481</ArticleId><ArticleId IdType="pubmed">11950278</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Saido TC, DeBusk LM, Tabaton M, et al. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer&#x2019;s disease and Down&#x2019;s syndrome brains. FEBS Lett. 1997;409(3):411&#x2013;416. doi: 10.1016/S0014-5793(97)00564-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(97)00564-4</ArticleId><ArticleId IdType="pubmed">9224700</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Salis S, Dolcini V, Venezia V, et al. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer&#x2019;s disease and Down&#x2019;s syndrome brain. Neurobiol Dis. 2001;8(1):173&#x2013;180. doi: 10.1006/nbdi.2000.0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0357</ArticleId><ArticleId IdType="pubmed">11162251</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, Violani E, Salis S, Venezia V, et al. Pyroglutamate-modified amyloid&#x2013;peptides&#x2013;AbetaN3(pE)&#x2014;strongly affect cultured neuron and astrocyte survival. J Neurochem. 2002;82(6):1480&#x2013;1489. doi: 10.1046/j.1471-4159.2002.01107.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01107.x</ArticleId><ArticleId IdType="pubmed">12354296</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Iwatsubo T, Mann DM, Shimada H, et al. Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques. Neuron. 1995;14(2):457&#x2013;466. doi: 10.1016/0896-6273(95)90301-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90301-1</ArticleId><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett. 1996;215(3):173&#x2013;176. doi: 10.1016/0304-3940(96)12970-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(96)12970-0</ArticleId><ArticleId IdType="pubmed">8899741</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, et al. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302&#x2013;2309. doi: 10.1056/NEJMoa0806142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806142</ArticleId><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Hoffmann T, Manhart S, Hoffmann M, et al. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004;563(1&#x2013;3):191&#x2013;196. doi: 10.1016/S0014-5793(04)00300-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(04)00300-X</ArticleId><ArticleId IdType="pubmed">15063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Lauber T, Schaupp M, Manhart S, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) Biochemistry. 2006;45(41):12393&#x2013;12399. doi: 10.1021/bi0612667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0612667</ArticleId><ArticleId IdType="pubmed">17029395</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Zeitschel U, Hoffmann T, Heiser U, et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer&#x2019;s disease-like pathology. Nat Med. 2008;14(10):1106&#x2013;1111. doi: 10.1038/nm.1872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1872</ArticleId><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer&#x2019;s disease. Trends Cell Biol. 1998;8(11):447&#x2013;453. doi: 10.1016/S0962-8924(98)01363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(98)01363-4</ArticleId><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer&#x2019;s disease. J Neurochem. 1986;46(6):1820&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">3517233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevalle J, Amoyel A, Robert P, Fournie-Zaluski MC, et al. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem. 2009;109(1):248&#x2013;256. doi: 10.1111/j.1471-4159.2009.05950.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.05950.x</ArticleId><ArticleId IdType="pubmed">19187443</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161(5):1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, et al. Oligomerization of Alzheimer&#x2019;s beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24(14):3592&#x2013;3599. doi: 10.1523/JNEUROSCI.5167-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5167-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekirian TL, Saido TC, Markesbery WR, Russell MJ, et al. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol. 1998;57(1):76&#x2013;94. doi: 10.1097/00005072-199801000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199801000-00009</ArticleId><ArticleId IdType="pubmed">9600199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng BP, Kitazawa M, LaFerla FM. Amyloid beta-peptide: the inside story. Curr Alzheimer Res. 2004;1(4):231&#x2013;239. doi: 10.2174/1567205043332045.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205043332045</ArticleId><ArticleId IdType="pubmed">15975052</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, et al. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39(35):10831&#x2013;10839. doi: 10.1021/bi001048s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi001048s</ArticleId><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Kuchna I, Nowicki K, Frackowiak J, et al. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol. 2007;113(4):389&#x2013;402. doi: 10.1007/s00401-006-0191-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0191-4</ArticleId><ArticleId IdType="pmc">PMC1824787</ArticleId><ArticleId IdType="pubmed">17237937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Feldmann N, et al. Intraneuronal APP/Abeta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 2002;12:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095864</ArticleId><ArticleId IdType="pubmed">12146796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide&#x2014;the first step of a fatal cascade. J Neurochem. 2004;91(3):513&#x2013;520. doi: 10.1111/j.1471-4159.2004.02737.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02737.x</ArticleId><ArticleId IdType="pubmed">15485483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Weis J, Kayed R, Saido TC, et al. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging. 2007;28:1689&#x2013;1699. doi: 10.1016/j.neurobiolaging.2006.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.07.021</ArticleId><ArticleId IdType="pubmed">16963164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Breyhan H, Sch&#xe4;fer S, Roth C, et al. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer&#x2019;s disease. Neurobiol Aging. 2008;29(6):891&#x2013;901. doi: 10.1016/j.neurobiolaging.2006.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.12.004</ArticleId><ArticleId IdType="pubmed">17215062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Breyhan H, Cynis H, Schilling S, et al. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009;118(4):487&#x2013;496. doi: 10.1007/s00401-009-0557-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0557-5</ArticleId><ArticleId IdType="pmc">PMC2737116</ArticleId><ArticleId IdType="pubmed">19547991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22728825</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>14</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>22</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons.</ArticleTitle><Pagination><StartPage>3157</StartPage><EndPage>3168</EndPage><MedlinePgn>3157-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2012.173</ELocationID><Abstract><AbstractText>Cell surface proteolysis is essential for communication between cells and results in the shedding of membrane-protein ectodomains. However, physiological substrates of the contributing proteases are largely unknown. We developed the secretome protein enrichment with click sugars (SPECS) method, which allows proteome-wide identification of shedding substrates and secreted proteins from primary cells, even in the presence of serum proteins. SPECS combines metabolic glycan labelling and click chemistry-mediated biotinylation and distinguishes between cellular and serum proteins. SPECS identified 34, mostly novel substrates of the Alzheimer protease BACE1 in primary neurons, making BACE1 a major sheddase in the nervous system. Selected BACE1 substrates-seizure-protein 6, L1, CHL1 and contactin-2-were validated in brains of BACE1 inhibitor-treated and BACE1 knock-out mice. For some substrates, BACE1 was the major sheddase, whereas for other substrates additional proteases contributed to total substrate shedding. The new substrates point to a central function of BACE1 in neurite outgrowth and synapse formation. SPECS is also suitable for quantitative secretome analyses of primary cells and may be used for the discovery of biomarkers secreted from tumour or stem cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Peer-Hendrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>DZNE-German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koroniak</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hogl</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Alessio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zeitschel</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Volbracht</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schepers</LastName><ForeName>Ute</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Imhof</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hoffmeister</LastName><ForeName>Albrecht</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ro&#xdf;ner</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Br&#xe4;se</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>CV is an employee of H. Lundbeck, Denmark.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22728825</ArticleId><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="doi">10.1038/emboj.2012.173</ArticleId><ArticleId IdType="pii">emboj2012173</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almaraz RT, Aich U, Khanna HS, Tan E, Bhattacharya R, Shah S, Yarema KJ (2012) Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnol Bioeng 109: 992&#x2013;1006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288793</ArticleId><ArticleId IdType="pubmed">22068462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai G, Pfaff SL (2011) Protease regulation: the Yin and Yang of neural development and disease. Neuron 72: 9&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221598</ArticleId><ArticleId IdType="pubmed">21982365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW (2012) The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2: 231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262176</ArticleId><ArticleId IdType="pubmed">22355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 1367&#x2013;1372</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10: 1794&#x2013;1805</Citation><ArticleIdList><ArticleId IdType="pubmed">21254760</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D&#x2019;Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280: 30797&#x2013;30806</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Esterhazy D, Stutzer I, Wang H, Rechsteiner MP, Beauchamp J, Dobeli H, Hilpert H, Matile H, Prummer M, Schmidt A, Lieske N, Boehm B, Marselli L, Bosco D, Kerr-Conte J, Aebersold R, Spinas GA, Moch H, Migliorini C, Stoffel M (2011) Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab 14: 365&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pubmed">21907142</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah MH, Pan BH, Hoffman PN, Ferraris D, Tsukamoto T, Nguyen T, Wong PC, Price DL, Slusher BS, Griffin JW (2011) Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci 31: 5744&#x2013;5754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302726</ArticleId><ArticleId IdType="pubmed">21490216</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman M (2009) Rhomboids: 7 years of a new protease family. Semin Cell Dev Biol 20: 231&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pubmed">19022390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnersen JM, Kim MH, Fuller SJ, De Silva M, Britto JM, Hammond VE, Davies PJ, Petrou S, Faber ES, Sah P, Tan SS (2007) Sez-6 proteins affect dendritic arborization patterns and excitability of cortical pyramidal neurons. Neuron 56: 621&#x2013;639</Citation><ArticleIdList><ArticleId IdType="pubmed">18031681</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, Gonzalez MI, Upton N, Pangalos MN, Dingwall C (2003) BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci 24: 646&#x2013;655</Citation><ArticleIdList><ArticleId IdType="pubmed">14664815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ (2009) Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS ONE 4: e8477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillenbrand R, Molthagen M, Montag D, Schachner M (1999) The close homologue of the neural adhesion molecule L1 (CHL1): patterns of expression and promotion of neurite outgrowth by heterophilic interactions. Eur JNeurosci 11: 813&#x2013;826</Citation><ArticleIdList><ArticleId IdType="pubmed">10103075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogl S, Kuhn PH, Colombo A, Lichtenthaler SF (2011) Determination of the proteolytic cleavage sites of the amyloid precursor-like protein 2 by the proteases ADAM10, BACE1 and gamma-secretase. PLoS ONE 6: e21337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117885</ArticleId><ArticleId IdType="pubmed">21695060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9: 1520&#x2013;1525</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R (2010) BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci 30: 8819&#x2013;8829</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Liu K, Pijak DS, Carlin D, Lee VM, Doms RW (2002) Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer&#x2019;s disease brain. J Biol Chem 14: 14</Citation><ArticleIdList><ArticleId IdType="pubmed">11847218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson T, Causevic M, auf dem Keller U, Schilling O, Isbert S, Geyer R, Maier W, Tschickardt S, Jumpertz T, Weggen S, Bond JS, Overall CM, Pietrzik CU, Becker-Pauly C (2011) Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem 286: 27741&#x2013;27750</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149364</ArticleId><ArticleId IdType="pubmed">21646356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewett JC, Bertozzi CR (2010) Cu-free click cycloaddition reactions in chemical biology. Chem Soc Rev 39: 1272&#x2013;1279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865253</ArticleId><ArticleId IdType="pubmed">20349533</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagogeos D (2003) Neural GPI-anchored cell adhesion molecules. Front Biosci 8: s1304&#x2013;s1320</Citation><ArticleIdList><ArticleId IdType="pubmed">12957835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29: 3020&#x2013;3032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944055</ArticleId><ArticleId IdType="pubmed">20676056</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693&#x2013;11709</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Sudhof TC, Zheng H (2010) Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci USA 107: 17362&#x2013;17367</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951422</ArticleId><ArticleId IdType="pubmed">20855613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis &#x2013; lessons from amyloid precursor protein processing. J Neurochem 117: 779&#x2013;796</Citation><ArticleIdList><ArticleId IdType="pubmed">21413990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng L, Takeda Y, Xu RX, Bagnard D, Schachner M, Furley AJ, Karagogeos D, Watanabe K, Dawe GS, Xiao ZC (2008) A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. Nat Cell Biol 10: 283&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pubmed">18278038</ArticleId></ArticleIdList></Reference><Reference><Citation>Makridakis M, Vlahou A (2010) Secretome proteomics for discovery of cancer biomarkers. J Proteomics 73: 2291&#x2013;2305</Citation><ArticleIdList><ArticleId IdType="pubmed">20637910</ArticleId></ArticleIdList></Reference><Reference><Citation>Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P, Reiss K (2005) L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 25: 9040&#x2013;9053</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265787</ArticleId><ArticleId IdType="pubmed">16199880</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO et al. (2011) Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 31: 16507&#x2013;16516</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633289</ArticleId><ArticleId IdType="pubmed">22090477</ArticleId></ArticleIdList></Reference><Reference><Citation>Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, Vaanholt LM, Bannon KA, Latcham J, Hussain I, Speakman JR, Howlett DR, Ashford ML (2011) Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 441: 281&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242510</ArticleId><ArticleId IdType="pubmed">21880018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitterreiter S, Page RM, Kamp F, Hopson J, Winkler E, Ha HR, Hamid R, Herms J, Mayer TU, Nelson DJ, Steiner H, Stahl T, Zeitschel U, Rossner S, Haass C, Lichtenthaler SF (2010) Bepridil and amiodarone simultaneously target the Alzheimer&#x2019;s disease beta- and gamma-secretase via distinct mechanisms. J Neurosci 30: 8974&#x2013;8983</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632893</ArticleId><ArticleId IdType="pubmed">20592218</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki T, Hashimoto K, Uda A, Sakagami H, Nakamura Y, Saito SY, Nishi M, Kume H, Tohgo A, Kaneko I, Kondo H, Fukunaga K, Kano M, Watanabe M, Takeshima H (2006) Disturbance of cerebellar synaptic maturation in mutant mice lacking BSRPs, a novel brain-specific receptor-like protein family. FEBS Lett 580: 4057&#x2013;4064</Citation><ArticleIdList><ArticleId IdType="pubmed">16814779</ArticleId></ArticleIdList></Reference><Reference><Citation>Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW (2004) Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 279: 16083&#x2013;16090</Citation><ArticleIdList><ArticleId IdType="pubmed">14761956</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki G, Mitsui S, Yuri K (2011) The distribution of the seizure-related gene 6 (Sez-6) protein during postnatal development of the mouse forebrain suggests multiple functions for this protein: an analysis using a new antibody. Brain Res 1386: 58&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pubmed">21334315</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliak S, Peles E (2003) The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 4: 968&#x2013;980</Citation><ArticleIdList><ArticleId IdType="pubmed">14682359</ArticleId></ArticleIdList></Reference><Reference><Citation>Price PJ, Brewer GJ (2001) Serum-free media for neural cell cultures. InProtocols for Neural Cell Culture Fedoroff S, Richardson A (eds)Vol. 19: pp255&#x2013;264Springer: Totowa, NJ</Citation></Reference><Reference><Citation>Rajapaksha TW, Eimer WA, Bozza TC, Vassar R (2011) The Alzheimer&#x2019;s beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener 6: 88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269394</ArticleId><ArticleId IdType="pubmed">22204380</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss K, Saftig P (2009) The &#x2018;A Disintegrin And Metalloprotease&#x2019; (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol 20: 126&#x2013;137</Citation><ArticleIdList><ArticleId IdType="pubmed">19049889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, Buchholz C, Eckman CB, Korte M, Wolfer DP, Muller UC (2007) The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci 27: 7817&#x2013;7826</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, Fadeeva JV, Minogue AM, Citron M, Van Leuven F, Staufenbiel M, Paganetti P, Selkoe DJ, Walsh DM (2010) beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J 277: 1503&#x2013;1518</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847843</ArticleId><ArticleId IdType="pubmed">20163459</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC (2008) Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 105: 5585&#x2013;5590</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2006) In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1: 2856&#x2013;2860</Citation><ArticleIdList><ArticleId IdType="pubmed">17406544</ArticleId></ArticleIdList></Reference><Reference><Citation>Sletten EM, Bertozzi CR (2011) From mechanism to mouse: a tale of two bioorthogonal reactions. Acc Chem Res 44: 666&#x2013;676</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3184615</ArticleId><ArticleId IdType="pubmed">21838330</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi XP, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo L et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem 47: 6447&#x2013;6450</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM (2004) Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci USA 101: 6917&#x2013;6922</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406442</ArticleId><ArticleId IdType="pubmed">15118097</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E, Urbach S, Dantec C, Poncet J, Seveno M, Demettre E, Jouin P, Touchon J, Bockaert J, Marin P (2008) Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. J Proteome Res 7: 4409&#x2013;4421</Citation><ArticleIdList><ArticleId IdType="pubmed">18774838</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC et al. (1999) Beta-secretase cleavage of Alzheimer&#x2018;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science (New York, NY) 286: 735&#x2013;741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer&#x2019;s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29: 12787&#x2013;12794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Song L, Laird F, Wong PC, Lee HK (2008) BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci 28: 8677&#x2013;8681</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728626</ArticleId><ArticleId IdType="pubmed">18753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science (New York, NY) 314: 664&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ZL, Jiang JM, Wu DH, Xie HJ, Jiang JJ, Zhou L, Peng L, Bao GS (2007) Febrile seizures are associated with mutation of seizure-related (SEZ) 6, a brain-specific gene. J Neurosci Res 85: 166&#x2013;172</Citation><ArticleIdList><ArticleId IdType="pubmed">17086543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yeh J, Richardson PM, Bo X (2008) Cell adhesion molecules of the immunoglobulin superfamily in axonal regeneration and neural repair. Restor Neurol Neurosci 26: 81&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pubmed">18820404</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21148560</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.</ArticleTitle><Pagination><StartPage>4454</StartPage><EndPage>4460</EndPage><MedlinePgn>4454-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.185819</ELocationID><Abstract><AbstractText>Pyroglutamate-modified A&#x3b2; (A&#x3b2;pE3-42) peptides are gaining considerable attention as potential key players in the pathology of Alzheimer disease (AD) due to their abundance in AD brain, high aggregation propensity, stability, and cellular toxicity. Overexpressing A&#x3b2;pE3-42 induced a severe neuron loss and neurological phenotype in TBA2 mice. In vitro and in vivo experiments have recently proven that the enzyme glutaminyl cyclase (QC) catalyzes the formation of A&#x3b2;pE3-42. The aim of the present work was to analyze the role of QC in an AD mouse model with abundant A&#x3b2;pE3-42 formation. 5XFAD mice were crossed with transgenic mice expressing human QC (hQC) under the control of the Thy1 promoter. 5XFAD/hQC bigenic mice showed significant elevation in TBS, SDS, and formic acid-soluble A&#x3b2;pE3-42 peptides and aggregation in plaques. In 6-month-old 5XFAD/hQC mice, a significant motor and working memory impairment developed compared with 5XFAD. The contribution of endogenous QC was studied by generating 5XFAD/QC-KO mice (mouse QC knock-out). 5XFAD/QC-KO mice showed a significant rescue of the wild-type mice behavioral phenotype, demonstrating the important contribution of endogenous mouse QC and transgenic overexpressed QC. These data clearly demonstrate that QC is crucial for modulating A&#x3b2;pE3-42 levels in vivo and prove on a genetic base the concept that reduction of QC activity is a promising new therapeutic approach for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jawhar</LastName><ForeName>Sadim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Psychiatry. Graduate School, University Medicine Goettingen, 37075 Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirths</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Graubner</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Demuth</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials></Author><Author ValidYN="Y"><LastName>Bayer</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.-</RegistryNumber><NameOfSubstance UI="D019881">Aminoacyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.5</RegistryNumber><NameOfSubstance UI="C059280">glutaminyl-peptide cyclotransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>SZB83O1W42</RegistryNumber><NameOfSubstance UI="D011761">Pyrrolidonecarboxylic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019881" MajorTopicYN="N">Aminoacyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="Y">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011761" MajorTopicYN="N">Pyrrolidonecarboxylic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21148560</ArticleId><ArticleId IdType="pmc">PMC3039372</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.185819</ArticleId><ArticleId IdType="pii">S0021-9258(20)56149-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D. J. (1998) Trends Cell Biol. 8, 447&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 4245&#x2013;4249</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Abraham C. R., Podlisny M. B., Duffy L. K. (1986) J. Neurochem. 46, 1820&#x2013;1834</Citation><ArticleIdList><ArticleId IdType="pubmed">3517233</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorevic P. D., Go&#xf1;i F., Pons-Estel B., Alvarez F., Peress N. S., Frangione B. (1986) J. Neuropathol. Exp. Neurol. 45, 647&#x2013;664</Citation><ArticleIdList><ArticleId IdType="pubmed">3772397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H., Takio K., Ogawara M., Selkoe D. J. (1992) J. Biol. Chem. 267, 17082&#x2013;17086</Citation><ArticleIdList><ArticleId IdType="pubmed">1512246</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T. C., Iwatsubo T., Mann D. M., Shimada H., Ihara Y., Kawashima S. (1995) Neuron 14, 457&#x2013;466</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Bogdanovic N., Gustavsson M. K., Volkmann I., Brinkmalm G., Zetterberg H., Winblad B., Blennow K. (2010) Acta Neuropathol. 120, 185&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H. U., Bayer T. A. (2009) Acta Neuropathol. 118, 487&#x2013;496</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737116</ArticleId><ArticleId IdType="pubmed">19547991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cynis H., Scheel E., Saido T. C., Schilling S., Demuth H. U. (2008) Biochemistry 47, 7405&#x2013;7413</Citation><ArticleIdList><ArticleId IdType="pubmed">18570439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H. U., Rossner S. (2008) Nat. Med. 14, 1106&#x2013;1111</Citation><ArticleIdList><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. (2006) J. Neurosci. 26, 10129&#x2013;10140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O., Bethge T., Marcello A., Harmeier A., Jawhar S., Lucassen P. J., Multhaup G., Brody D. L., Esparza T., Ingelsson M., Kalimo H., Lannfelt L., Bayer T. A. (2010) J. Neural Transm. 117, 85&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789212</ArticleId><ArticleId IdType="pubmed">19823761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage-R&#xfc;bsamen M., Staffa K., Waniek A., Wermann M., Hoffmann T., Cynis H., Schilling S., Demuth H. U., Rossner S. (2009) Int. J. Dev. Neurosci. 27, 825&#x2013;835</Citation><ArticleIdList><ArticleId IdType="pubmed">19699792</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jawhar S., Trawicka A., Jenneckens C., Bayer T. A., Wirths O. (2010) Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2010.05.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.027</ArticleId><ArticleId IdType="pubmed">20619937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S., Hoffmann T., Manhart S., Hoffmann M., Demuth H. U. (2004) FEBS Lett. 563, 191&#x2013;196</Citation><ArticleIdList><ArticleId IdType="pubmed">15063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cynis H., Schilling S., Bodn&#xe1;r M., Hoffmann T., Heiser U., Saido T. C., Demuth H. U. (2006) Biochim. Biophys. Acta 1764, 1618&#x2013;1625</Citation><ArticleIdList><ArticleId IdType="pubmed">17005457</ArticleId></ArticleIdList></Reference><Reference><Citation>
Marcello A., Wirths O., Schneider-Axmann T., Degerman-Gunnarsson M., Lannfelt L., Bayer T. A. (2009) Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2009.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.08.011</ArticleId><ArticleId IdType="pubmed">19781815</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C., Sergeant N., Itier J. M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T. A., Benoit P., Pradier L. (2004) Am. J. Pathol. 165, 1289&#x2013;1300</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Breyhan H., Wirths O., Duan K., Marcello A., Rettig J., Bayer T. A. (2009) Acta Neuropathol. 117, 677&#x2013;685</Citation><ArticleIdList><ArticleId IdType="pubmed">19387667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevalle J., Amoyel A., Robert P., Fourni&#xe9;-Zaluski M. C., Roques B., Checler F. (2009) J. Neurochem. 109, 248&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pubmed">19187443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T. C., Yamao-Harigaya W., Iwatsubo T., Kawashima S. (1996) Neurosci. Lett. 215, 173&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">8899741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y. M., Emmerling M. R., Woods A. S., Cotter R. J., Roher A. E. (1997) Biochem. Biophys. Res. Commun. 237, 188&#x2013;191</Citation><ArticleIdList><ArticleId IdType="pubmed">9266855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y. M., Kokjohn T. A., Beach T. G., Sue L. I., Brune D., Lopez J. C., Kalback W. M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Roher A. E. (2001) J. Biol. Chem. 276, 12991&#x2013;12998</Citation><ArticleIdList><ArticleId IdType="pubmed">11152675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoda R., Saido T. C., Otvos L., Jr., Arai T., Mann D. M., Lee V. M., Trojanowski J. Q., Iwatsubo T. (1998) J. Neuropathol. Exp. Neurol. 57, 1089&#x2013;1095</Citation><ArticleIdList><ArticleId IdType="pubmed">9825946</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y., Saido T. C., Eckman C. B., Prada C. M., Shoji M., Younkin S. G. (2000) Biochem. Biophys. Res. Commun. 276, 422&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">11027491</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T., Saido T. C., Mann D. M., Lee V. M., Trojanowski J. Q. (1996) Am. J. Pathol. 149, 1823&#x2013;1830</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865366</ArticleId><ArticleId IdType="pubmed">8952519</ArticleId></ArticleIdList></Reference><Reference><Citation>Miravalle L., Calero M., Takao M., Roher A. E., Ghetti B., Vidal R. (2005) Biochemistry 44, 10810&#x2013;10821</Citation><ArticleIdList><ArticleId IdType="pubmed">16086583</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A., Russo C., Gliozzi A., Relini A., Vitali A., Borghi R., Giliberto L., Armirotti A., D'Arrigo C., Bachi A., Cattaneo A., Canale C., Torrassa S., Saido T. C., Markesbery W., Gambetti P., Tabaton M. (2005) J. Biol. Chem. 280, 34186&#x2013;34192</Citation><ArticleIdList><ArticleId IdType="pubmed">16103127</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A., Zanusso G., Borghi R., Noviello C., Monaco S., Russo R., Damonte G., Armirotti A., Gelati M., Giordano R., Zambenedetti P., Russo C., Ghetti B., Tabaton M. (2007) Arch. Neurol. 64, 738&#x2013;745</Citation><ArticleIdList><ArticleId IdType="pubmed">17502474</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C., Saido T. C., DeBusk L. M., Tabaton M., Gambetti P., Teller J. K. (1997) FEBS Lett. 409, 411&#x2013;416</Citation><ArticleIdList><ArticleId IdType="pubmed">9224700</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ntert A., D&#xf6;beli H., Bohrmann B. (2006) Neuroscience 143, 461&#x2013;475</Citation><ArticleIdList><ArticleId IdType="pubmed">17008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekirian T. L., Saido T. C., Markesbery W. R., Russell M. J., Wekstein D. R., Patel E., Geddes J. W. (1998) J. Neuropathol. Exp. Neurol. 57, 76&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pubmed">9600199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike C. J., Overman M. J., Cotman C. W. (1995) J. Biol. Chem. 270, 23895&#x2013;23898</Citation><ArticleIdList><ArticleId IdType="pubmed">7592576</ArticleId></ArticleIdList></Reference><Reference><Citation>He W., Barrow C. J. (1999) Biochemistry 38, 10871&#x2013;10877</Citation><ArticleIdList><ArticleId IdType="pubmed">10451383</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S., Lauber T., Schaupp M., Manhart S., Scheel E., B&#xf6;hm G., Demuth H. U. (2006) Biochemistry 45, 12393&#x2013;12399</Citation><ArticleIdList><ArticleId IdType="pubmed">17029395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y. M., Webster S., Emmerling M. R., De Lima N., Roher A. E. (1998) Biochim. Biophys. Acta 1406, 291&#x2013;298</Citation><ArticleIdList><ArticleId IdType="pubmed">9630681</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C., Violani E., Salis S., Venezia V., Dolcini V., Damonte G., Benatti U., D'Arrigo C., Patrone E., Carlo P., Schettini G. (2002) J. Neurochem. 82, 1480&#x2013;1489</Citation><ArticleIdList><ArticleId IdType="pubmed">12354296</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C., Salis S., Dolcini V., Venezia V., Song X. H., Teller J. K., Schettini G. (2001) Neurobiol. Dis. 8, 173&#x2013;180</Citation><ArticleIdList><ArticleId IdType="pubmed">11162251</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T. C., Suzuki K., Mori H., Higuchi M., Suhara T. (2007) J. Neurosci. 27, 10957&#x2013;10968</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672864</ArticleId><ArticleId IdType="pubmed">17928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan A., Wermann M., von Bohlen A., Koch B., Cynis H., Demuth H. U., Schilling S. (2009) FEBS J. 276, 6522&#x2013;6536</Citation><ArticleIdList><ArticleId IdType="pubmed">19804409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17928437</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>41</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.</ArticleTitle><Pagination><StartPage>10957</StartPage><EndPage>10968</EndPage><MedlinePgn>10957-68</MedlinePgn></Pagination><Abstract><AbstractText>We provide the first evidence for the capability of a high-resolution positron emission tomographic (PET) imaging system in quantitatively mapping amyloid accumulation in living amyloid precursor protein transgenic (Tg) mice. After the intravenous administration of N-[11C]methyl-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (or [11C]PIB for "Pittsburgh Compound-B") with high-specific radioactivity, the Tg mice exhibited high-level retention of radioactivity in amyloid-rich regions. PET investigation for Tg mice over an extended range of ages, including longitudinal assessments, demonstrated age-dependent increase in radioligand binding consistent with progressive amyloid accumulation. Reduction in amyloid levels in the hippocampus of Tg mice was also successfully monitored by multiple PET scans along the time course of anti-amyloid treatment using an antibody against amyloid beta peptide (Abeta). Moreover, PET scans with [18F]fluoroethyl-DAA1106, a radiotracer for activated glia, were conducted for these individuals parallel to amyloid imaging, revealing treatment-induced neuroinflammatory responses, the magnitude of which intimately correlated with the levels of pre-existing amyloid estimated by [11C]PIB. It is also noteworthy that the localization and abundance of [11C]PIB autoradiographic signals were closely associated with those of N-terminally truncated and modified Abeta, AbetaN3-pyroglutamate, in Alzheimer's disease (AD) and Tg mouse brains, implying that the detectability of amyloid by [11C]PIB positron emission tomography is dependent on the accumulation of specific Abeta subtypes. Our results support the usefulness of the small animal-dedicated PET system in conjunction with high-specific radioactivity probes and appropriate Tg models not only for clarifying the mechanistic properties of amyloidogenesis in mouse models but also for preclinical tests of emerging diagnostic and therapeutic approaches to AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Chiba 263-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Irie</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tomiyama</LastName><ForeName>Takami</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Okauchi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Nobuhisa</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Maiko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kazutoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suhara</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17928437</ArticleId><ArticleId IdType="pmc">PMC6672864</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0673-07.2007</ArticleId><ArticleId IdType="pii">27/41/10957</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, Mathis CA, Klunk WE, Hyman BT. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA. 2003;100:12462&#x2013;12467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218780</ArticleId><ArticleId IdType="pubmed">14517353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Ye D, Liow JS, Hong J, Cohen RM, Pike VW, Innis RB. PET imaging of transgenic mice TG2576 using the beta-amyloid radioligand, [C-11]PIB. NeuroImage. 2006;31:T141&#x2013;T142.</Citation></Reference><Reference><Citation>Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol. 2003;2:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849209</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-&#x3b2;42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ntert A, D&#xf6;beli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006;143:461&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008022</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Barrow CJ. The A&#x3b2; 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater &#x3b2;-sheet forming and aggregation propensities in vitro than full-length A&#x3b2;. Biochemistry. 1999;38:10871&#x2013;10877.</Citation><ArticleIdList><ArticleId IdType="pubmed">10451383</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC. 19F and 1H MRI detection of amyloid b plaques in vivo. Nat Neurosci. 2005;8:527&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">15768036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintersteiner M, Enz A, Frey P, Jaton AL, Kinzy W, Kneuer R, Neumann U, Rudin M, Staufenbiel M, Stoeckli M, Wiederhold KH, Gremlich HU. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol. 2005;23:577&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">12973026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Abrahamson EE, Isanski BA, Debnath ML, Mathis CA, Dekosky ST, Klunk WE. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol. 2006;412:123&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Usami M, Tanaka K, Kume H, Mori H. Mutant presenilin (A260V) affects Rab8 in PC12D cell. Neurochem Int. 2004;44:313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-&#x3b2; in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8530554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol Aging. 2002;23:1039&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470800</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. Small molecule inhibitors of &#x3b1;-synuclein filament assembly. Biochemistry. 2006;45:6085&#x2013;6094.</Citation><ArticleIdList><ArticleId IdType="pubmed">16681381</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols L, Pike VW, Cai L, Innis RB. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease? Biol Psychiatry. 2006;59:940&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">16487944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi J, Suzuki K. Automated synthesis of the ultra high specific activity of [11C]Ro15-4513 and its application in an extremely low concentration region to an ARG study. Nucl Med Biol. 2003;30:335&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12745025</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after A&#x3b2;42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct &#x3b2;-amyloid peptide species, A&#x3b2;N3(pE), in senile plaques. Neuron. 1995;14:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sair HI, Doraiswamy PM, Petrella JR. In vivo amyloid imaging in Alzheimer's disease. Neuroradiology. 2004;46:93&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Higuchi M, Iwata N, Saido TC, Sasamoto K. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem. 2004;39:573&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">15236837</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003;2:539&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">12941576</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, B&#xf6;hm G, Demuth HU. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) Biochemistry. 2006;45:12393&#x2013;12399.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029395</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem. 2000;48:1223&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Inoue O, Hashimoto K, Yamasaki T, Kuchiki M, Tamate K. Computer-controlled large scale production of high specific activity [11C]RO 15-1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot. 1985;36:971&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">3002988</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, Laforest R. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750159</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB. PET imaging of brain with the &#x3b2;-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2005;32:593&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791432</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S. In-vivo imaging of Alzheimer disease &#x3b2;-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-A&#x3b2; antibodies reduce &#x3b2;-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MR, Suzuki K. Sources of carbon which decrease the specific activity of [11C]CH3I synthesized by the single pass I2 method. Appl Radiat Isot. 2005;62:447&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607922</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MR, Maeda J, Ogawa M, Noguchi J, Ito T, Yoshida Y, Okauchi T, Obayashi S, Suhara T, Suzuki K. Development of a new radioligand, FN-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem. 2004;47:2228&#x2013;2235.</Citation><ArticleIdList><ArticleId IdType="pubmed">15084121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22660329</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>485</Volume><Issue>7400</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-&#x3b2;.</ArticleTitle><Pagination><StartPage>651</StartPage><EndPage>655</EndPage><MedlinePgn>651-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature11060</ELocationID><Abstract><AbstractText>Extracellular plaques of amyloid-&#x3b2; and intraneuronal neurofibrillary tangles made from tau are the histopathological signatures of Alzheimer's disease. Plaques comprise amyloid-&#x3b2; fibrils that assemble from monomeric and oligomeric intermediates, and are prognostic indicators of Alzheimer's disease. Despite the importance of plaques to Alzheimer's disease, oligomers are considered to be the principal toxic forms of amyloid-&#x3b2;. Interestingly, many adverse responses to amyloid-&#x3b2;, such as cytotoxicity, microtubule loss, impaired memory and learning, and neuritic degeneration, are greatly amplified by tau expression. Amino-terminally truncated, pyroglutamylated (pE) forms of amyloid-&#x3b2; are strongly associated with Alzheimer's disease, are more toxic than amyloid-&#x3b2;, residues 1-42 (A&#x3b2;(1-42)) and A&#x3b2;(1-40), and have been proposed as initiators of Alzheimer's disease pathogenesis. Here we report a mechanism by which pE-A&#x3b2; may trigger Alzheimer's disease. A&#x3b2;(3(pE)-42) co-oligomerizes with excess A&#x3b2;(1-42) to form metastable low-n oligomers (LNOs) that are structurally distinct and far more cytotoxic to cultured neurons than comparable LNOs made from A&#x3b2;(1-42) alone. Tau is required for cytotoxicity, and LNOs comprising 5% A&#x3b2;(3(pE)-42) plus 95% A&#x3b2;(1-42) (5% pE-A&#x3b2;) seed new cytotoxic LNOs through multiple serial dilutions into A&#x3b2;(1-42) monomers in the absence of additional A&#x3b2;(3(pE)-42). LNOs isolated from human Alzheimer's disease brain contained A&#x3b2;(3(pE)-42), and enhanced A&#x3b2;(3(pE)-42) formation in mice triggered neuron loss and gliosis at 3 months, but not in a tau-null background. We conclude that A&#x3b2;(3(pE)-42) confers tau-dependent neuronal death and causes template-induced misfolding of A&#x3b2;(1-42) into structurally distinct LNOs that propagate by a prion-like mechanism. Our results raise the possibility that A&#x3b2;(3(pE)-42) acts similarly at a primary step in Alzheimer's disease pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nussbaum</LastName><ForeName>Justin M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Virginia, Charlottesville, Virginia 22904, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cynis</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Antonia</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wangsanut</LastName><ForeName>Tanaporn</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tayler</LastName><ForeName>Kaycie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wiltgen</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hatami</LastName><ForeName>Asa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>R&#xf6;nicke</LastName><ForeName>Raik</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Reymann</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hutter-Paier</LastName><ForeName>Birgit</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Alexandru</LastName><ForeName>Anca</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jagla</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Graubner</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Demuth</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials></Author><Author ValidYN="Y"><LastName>Bloom</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG033069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG033069</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM008136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22660329</ArticleId><ArticleId IdType="mid">NIHMS364574</ArticleId><ArticleId IdType="pmc">PMC3367389</ArticleId><ArticleId IdType="doi">10.1038/nature11060</ArticleId><ArticleId IdType="pii">nature11060</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gandy S, et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010;68:220&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094694</ArticleId><ArticleId IdType="pubmed">20641005</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to &#x3b2;-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>King ME, et al. Tau-dependent microtubule disassembly initiated by pre-fibrillar &#x3b2;-amyloid. J Cell Biol. 2006;175:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064590</ArticleId><ArticleId IdType="pubmed">17101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, et al. Soluble amyloid {beta}-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA. 2011;108:5819&#x2013;5824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer&#x2019;s disease. J Biol Chem. 1992;267:17082&#x2013;17086.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512246</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995;14:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. J Biol Chem. 2011;286:38825&#x2013;38832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234707</ArticleId><ArticleId IdType="pubmed">21965666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer&#x2019;s disease-like pathology. Nature Med. 2008;14:1106&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaton M, et al. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994;200:1598&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">8185615</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, et al. Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J Neurochem. 2002;82:1480&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354296</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) Biochem. 2006;45:12393&#x2013;12399.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029395</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlenzig D, et al. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochem. 2009;48:7072&#x2013;7078.</Citation><ArticleIdList><ArticleId IdType="pubmed">19518051</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Thioflavine T interaction with synthetic Alzheimer&#x2019;s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XM, et al. A new microcellular cytotoxicity test based on calcein AM release. Human Immunol. 1993;37:264&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">8300411</ArticleId></ArticleIdList></Reference><Reference><Citation>Scudiero DA, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48:4827&#x2013;4833.</Citation><ArticleIdList><ArticleId IdType="pubmed">3409223</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandru A, et al. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. J Neurosci. 2011;31:12790&#x2013;12801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623394</ArticleId><ArticleId IdType="pubmed">21900558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nature Neurosci. 2001;4:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135642</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1&#x2013;42) J Neurosci Res. 2001;66:573&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, et al. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem. 2011;286:4454&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039372</ArticleId><ArticleId IdType="pubmed">21148560</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanghe A, et al. Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer&#x2019;s Disease of the APP[V717I] London Transgenic Mouse Model. Inter J Alzheimer&#x2019;s Dis. 2010;2010 doi: 10.4061/2010/417314.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/417314</ArticleId><ArticleId IdType="pmc">PMC2939388</ArticleId><ArticleId IdType="pubmed">20862386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Progression of amyloid pathology to Alzheimer&#x2019;s disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci. 2008;28:1537&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2621082</ArticleId><ArticleId IdType="pubmed">18272675</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Barrow CJ. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochem. 1999;38:10871&#x2013;10877.</Citation><ArticleIdList><ArticleId IdType="pubmed">10451383</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, et al. Intraneuronal pyroglutamate-Abeta 3&#x2013;42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009;118:487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737116</ArticleId><ArticleId IdType="pubmed">19547991</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntert A, Dobeli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neurosci. 2006;143:461&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A, et al. beta-amyloid is different in normal aging and in Alzheimer disease. The J Biol Chem. 2005;280:34186&#x2013;34192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage-Rubsamen M, et al. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol. 2011;121:705&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098988</ArticleId><ArticleId IdType="pubmed">21301857</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330:198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Lacor PN, Pitt J, Klein WL. Abeta oligomer-induced synapse degeneration in Alzheimer&#x2019;s disease. Cell Mol Neurobiol. 2011;31:939&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146579</ArticleId><ArticleId IdType="pubmed">21538118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20472326</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.</ArticleTitle><Pagination><StartPage>1275</StartPage><EndPage>1283</EndPage><MedlinePgn>1275-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2010.04.007</ELocationID><Abstract><AbstractText>The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), performed (11)C-Pittsburgh Compound B (PiB) scans in 177 healthy controls (HC), 57 mild cognitive impairment (MCI) subjects, and 53 mild Alzheimer's disease (AD) patients. High PiB binding was present in 33% of HC (49% in ApoE-epsilon4 carriers vs 21% in noncarriers) and increased with age, most strongly in epsilon4 carriers. 18% of HC aged 60-69 had high PiB binding rising to 65% in those over 80 years. Subjective memory complaint was only associated with elevated PiB binding in epsilon4 carriers. There was no correlation with cognition in HC or MCI. PiB binding in AD was unrelated to age, hippocampal volume or memory. Beta-amyloid (Abeta) deposition seems almost inevitable with advanced age, amyloid burden is similar at all ages in AD, and secondary factors or downstream events appear to play a more direct role than total beta amyloid burden in hippocampal atrophy and cognitive decline.</AbstractText><CopyrightInformation>Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Austin Health, Department of Nuclear Medicine and Centre for PET, Heidelberg, Victoria, Australia. Christopher.Rowe@austin.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Rimajova</LastName><ForeName>Miroslava</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bourgeat</LastName><ForeName>Pierrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Fripp</LastName><ForeName>Jurgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tochon-Danguy</LastName><ForeName>Henri</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Morandeau</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Graeme</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Raniga</LastName><ForeName>Parnesh</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Robins</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Lenzo</LastName><ForeName>Nat</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Szoeke</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Salvado</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017352" MajorTopicYN="N">Echo-Planar Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="Y">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.007</ArticleId><ArticleId IdType="pii">S0197-4580(10)00164-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">14688411</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>101</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>289</EndPage><MedlinePgn>284-9</MedlinePgn></Pagination><Abstract><AbstractText>Fluorodeoxyglucose positron emission tomography (PET) studies have found that patients with Alzheimer's dementia (AD) have abnormally low rates of cerebral glucose metabolism in posterior cingulate, parietal, temporal, and prefrontal cortex. We previously found that cognitively normal, late-middle-aged carriers of the apolipoprotein E epsilon4 allele, a common susceptibility gene for late-onset Alzheimer's dementia, have abnormally low rates of glucose metabolism in the same brain regions as patients with probable AD. We now consider whether epsilon4 carriers have these regional brain abnormalities as relatively young adults. Apolipoprotein E genotypes were established in normal volunteers 20-39 years of age. Clinical ratings, neuropsychological tests, magnetic resonance imaging, and PET were performed in 12 epsilon4 heterozygotes, all with the epsilon3/epsilon4 genotype, and 15 noncarriers of the epsilon4 allele, 12 of whom were individually matched for sex, age, and educational level. An automated algorithm was used to generate an aggregate surface-projection map that compared regional PET measurements in the two groups. The young adult epsilon4 carriers and noncarriers did not differ significantly in their sex, age, educational level, clinical ratings, or neuropsychological test scores. Like previously studied patients with probable AD and late-middle-aged epsilon4 carriers, the young epsilon4 carriers had abnormally low rates of glucose metabolism bilaterally in the posterior cingulate, parietal, temporal, and prefrontal cortex. Carriers of a common Alzheimer's susceptibility gene have functional brain abnormalities in young adulthood, several decades before the possible onset of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Positron Emission Tomography Center, Banner Good Samaritan Medical Center, Phoenix, AZ 85006, USA. eric.reiman@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Bandy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Osborne</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH057899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH57899-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14688411</ArticleId><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="doi">10.1073/pnas.2635903100</ArticleId><ArticleId IdType="pii">2635903100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans, D. A., Funkenstein, H. H., Albert, M. S., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H. &amp; Taylor, J. O. (1989) J. Am. Med. Assoc. 262, 2551-2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D. &amp; Frost, J. (2001) Proc. Natl. Acad. Sci. USA 98, 3334-3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer, E. G., Peppard, R. P., McGeer, P. L., Tuokko, H., Crockett, D., Parks, R., Akiyam, H., Calne, D. B., Beattie, B. L. &amp; Harrop, R. (1990) Can. J. Neurol. Sci. 17, 1-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">2311010</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, G. S., de Leon, M. J., George, A. E., Kluger, A., Volkow, N. D., McRae, T., Golomb, J., Ferris, S. H., Reisberg, B., Ciaravino, J., et al. (1992) Arch. Neurol. 49, 1142-1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">1444881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke, R., Herholz, K. &amp; Grond, M. (1994) Dementia 5, 36-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8156085</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima, S., Frey, K. A., Koeppe, R. A., Foster, N. L. &amp; Kuhl, D. E. (1995) J. Nucl. Med. 36, 1238-1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman, D. H., Small, G. W., Chang, C. Y., Lu, C. S., Kung De Aburto, M. A., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) J. Am. Med. Assoc. 286, 2120-2127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694153</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. &amp; Reiman, E. M. (2002) Am. J. Psychiatry 159, 738-745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N. &amp; Osborne, D. (1996) N. Engl. J. Med. 334, 752-758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman, E. M., Caselli, R. J., Alexander, G. E. &amp; Chen, K. (2001) Clin. Neurosci. Res. 1, 194-206.</Citation></Reference><Reference><Citation>Small, G. W., Mazziotta, J. C., Collins, M. T., Baxter, L. R., Phelps, M. E., Mandelkern, M. A., Kaplan, A., La Rue, A., Adamson, C. F., Chang, L., et al. (1995) J. Am. Med. Assoc. 273, 942-947.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) Proc. Natl. Acad. Sci. USA 97, 6037-6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S. &amp; Roses, A. D. (1993) Proc. Natl. Acad. Sci. USA 90, 1977-1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L. &amp; Pericak-Vance, M. A. (1993) Science 261, 921-923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) Neurology 43, 1467-1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley, R. W. (1988) Science 240, 622-630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallman, D. M., Boerwinkle, E., Saha, N., Sandholzer, C., Menzel, H. J., Csazar, A. &amp; Utermann, G. (1991) Am. J. Hum. Genet. 49, 338-349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683282</ArticleId><ArticleId IdType="pubmed">1867194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson, J. E. &amp; Vernier, D. T. (1990) J. Lipid Res. 31, 545-548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer, R. L., Williams, J. B. W., Gibbon, M. &amp; First, M. D. (1990) User's Guide for the Structured Clinical Interview for DSM-III-R (SCID) (Am. Psychiatric Press, Washington, DC).</Citation></Reference><Reference><Citation>Folstein, M. F., Folstein, S. E. &amp; McHugh, P. R. (1975) J. Psychiatr. Res. 12, 189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton, M. (1960) J. Neurol. Neurosurg. Psychiatry 23, 56-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak, M. D. (1983) Neuropsychological Assessment (Oxford Univ. Press, New York), 2nd Ed.</Citation></Reference><Reference><Citation>Reiman, E. M., Uecke, A., Caselli, R. J., Lewis, S., Bandy, D., de Leon, M. J., De Santi, S., Convit, A., Osborne, D., Weaver, A., et al. (1998) Ann. Neurol. 44, 288-291.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, K., Bandy, D., Reiman, E., Huang, S. C., Lawson, M., Feng, D., Yun, L. S. &amp; Palant, A. (1998) J. Cereb. Blood Flow Metab. 18, 716-723.</Citation><ArticleIdList><ArticleId IdType="pubmed">9663501</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach, J. &amp; Tournoux, P. (1988) Coplanar Stereotaxic Atlas of the Human Brain (Thieme, New York).</Citation></Reference><Reference><Citation>Minoshima, S., Frey, K. A., Foster, N. L. &amp; Kuhl, D. E. (1995) J. Comput. Assist. Tomogr. 19, 541-547.</Citation><ArticleIdList><ArticleId IdType="pubmed">7622680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, K. C., Reiman, E. M., Bandy, D. &amp; Alexander, G. E. (2003) in Modeling and Control in Biomedical Systems, eds. Feng, D. D. &amp; Carson E. R. (Elsevier, Hong Kong), pp. 11-15.</Citation></Reference><Reference><Citation>Frackowiak, R. S. J., Friston K. J., Frith, C. D., Dolan, R. J. &amp; Mazziotta, J. C. (1997) Human Brain Function (Academic, San Diego).</Citation></Reference><Reference><Citation>Ibanez, V., Pietrini, P., Alexander, G. E., Furey, M. L., Teichberg, D., Rajapakse, J. C., Rapoport, S. I., Schapiro, M. B. &amp; Horwitz, B. (1998) Neurology 50, 1585-1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, W. J., Smith, C. B., Davidsen, L., Savaki, H., Sokoloff, L., Mata, M., Fink, D. J. &amp; Gainer, H. (1979) Science 205, 723-725.</Citation><ArticleIdList><ArticleId IdType="pubmed">462184</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti, P. J. &amp; Pellerin, L. (1996) Cereb. Cortex 6, 50-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8670638</ArticleId></ArticleIdList></Reference><Reference><Citation>Piert, M., Koeppe, R. A., Giordani, B., Berent, S. &amp; Kuhl, D. E. (1996) J. Nucl. Med. 37, 201-208.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667045</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark, R. J., Pang, Z., Geddes, J. W., Uchida, K. &amp; Mattson, M. P. (1997) J. Neurosci. 17, 1046-1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573165</ArticleId><ArticleId IdType="pubmed">8994059</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. (1991) Acta Neuropathol. 82, 239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. (1997) Neurobiol. Aging 18, 351-357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebremedhin, E., Schultz, C., Braak, E. &amp; Braak, H. (1998) Exp. Neurol. 153, 152-155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm, T. G., M&#xfc;ller, H., Braak, H. &amp; Bohl, J. (1994) Neuroscience 64, 209-217.</Citation><ArticleIdList><ArticleId IdType="pubmed">7708206</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro, K., Blaizot, X., Kondoh, Y., Le Mestric, C., Baron, J. C. &amp; Chavoix, C. (1999) Brain 122, 1519-1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman, B. T., Van Hoesen, G. W., Kromer, L. J. &amp; Damasio, A. R. (1986) Ann. Neurol. 20, 472-481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3789663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S. C., et al. (2002) Am. J. Geriatr. Psychiatry 10, 24-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis, C. A., Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., Holt, D. P., Wang, Y., Huang, G. F., Debnath, M. L., et al. (2002) Biorg. Med. Chem. Lett. 12, 295-298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski, T., Castano, E. M., Golabek, A., Vogel, T. &amp; Frangione, B. (1994) Am. J. Pathol. 145, 1030-1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata, M. &amp; Smith, J. D. (1996) Nat. Genet. 14, 55-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8782820</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter, W. J., Weisgraber, K. H., Goedert, M., Saunders, A. M., Huang, D., Corder, E. H., Dong, L. M., Jakes, R., Alberts, M. J., Gilbert, J. R., et al. (1994) Exp. Neurol. 125, 1663-1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">8313935</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W. &amp; Pitas, R. E. (1994) Science 264, 850-852.</Citation><ArticleIdList><ArticleId IdType="pubmed">8171342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke, R., Zerres, K., Uhlhaas, S., Kessler, J. &amp; Heiss, W. D. (1998) Neurosci. Lett. 254, 49-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9780089</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi, M., Arai, H., Nakagawa, T., Higuchi, S., Muramatsu, T., Matsushita, S., Kosaka, Y., Itoh, M. &amp; Sasaki, H. (1997) NeuroReport 8, 2639-2643.</Citation><ArticleIdList><ArticleId IdType="pubmed">9295092</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder, E. H., Jelic, V., Basun, H., Lannfelt, L., Valind, S., Winblad, B. &amp; Nordberg, A. (1997) Arch. Neurol. 54, 273-277.</Citation><ArticleIdList><ArticleId IdType="pubmed">9074396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono, N., Mori, E., Yasuda, M., Ishii, K., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H. &amp; Sasaki, M. (1998) Alzheimer Dis. Assoc. Disord. 12, 362-367.</Citation><ArticleIdList><ArticleId IdType="pubmed">9876966</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen, R. C., Smith, G. E., Ivnik, R. J., Tangalos, E. G., Schaid, D. J., Thibodeau, S. N., Kokmen, E., Waring, S. C. &amp; Kurland, L. T. (1995) J. Am. Med. Assoc. 273, 1274-1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646655</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz, D. G., Ganapathy, G. R., Eliasziw, M. &amp; Hachinski, V. (2000) Arch. Neurol. 57, 85-89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634453</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli, R. J., Hentz, J. G., Osborne, D., Graff-Radford, N. R., Barbieri, C. J., Alexander, G. E., Hall, G. R., Reiman, E. M., Hardy, J. &amp; Saunders, A. M. (2002) J. Am. Geriatr. Soc. 50, 49-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12028246</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon, D. A., Kemper, S. J., Mortimer, J. A., Greiner, L. H., Wekstein, D. R. &amp; Markesbery, W. R. (1996) J. Am. Med. Assoc. 275, 528-532.</Citation><ArticleIdList><ArticleId IdType="pubmed">8606473</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley, L. J., Starr, J. M., Athawes, R., Hunter, D., Pattie, A. &amp; Deary, I. J. (2000) Neurology 55, 1455-1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094097</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, D. A., Beckett, L. A., Albert, M. S., Hebert, L. E., Scherr, P. A., Funkenstein, H. H. &amp; Taylor, J. O. (1993) Ann. Epidemiol. 3, 71-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287159</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern, Y., Gurland, B., Tatemichi, T. K., Tang, M. X., Wilder, D. &amp; Mayeux, R. (1994) J. Am. Med. Assoc. 271, 1004-1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, G. E., Furey, M. L., Grady, C. L., Pietrini, P., Brady, D. R., Mentis, M. J. &amp; Schapiro, M. B. (1997) Am. J. Psychiatry 154, 165-172.</Citation><ArticleIdList><ArticleId IdType="pubmed">9016263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesslak, J. P., So, V., Choi, J., Cotman, C. W. &amp; Gomez-Pinilla, F. (1998) Behav. Neurosci. 112, 1012-1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">9733207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhl, D. E., Metter, E. J., Riege, W. H. &amp; Phelps, M. E. (1982) J. Cereb. Blood Flow Metab. 2, 163-171.</Citation><ArticleIdList><ArticleId IdType="pubmed">6978885</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon, E., Maquet, P., Sadzot, B., Degueldre, C., Lemaire, C. &amp; Franck G. (1991) Acta Neurol. Belg. 91, 288-295.</Citation><ArticleIdList><ArticleId IdType="pubmed">1781265</ArticleId></ArticleIdList></Reference><Reference><Citation>Loessner, A., Alavi, A., Lewandrowski, K. U., Mozley, D., Souder, E. &amp; Gur, R. E. (1995) J. Nucl. Med. 36, 1141-1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790936</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey, C. E., Wilkinson, W. E., Parashos, I. A., Soady, S. A., Sullivan, R. J., Patterson, L. J., Figiel, G. S., Webb, M. C., Spritzer, C. E. &amp; Djang, W. T. (1992) Neurology 42, 527-536.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549213</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry, R. D., DeTeresa, R. &amp; Hansen, L. A. (1976) Arch. Psychiatr. Nervenkr. 223, 15-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy, A. M., Frackowiak, R. S., Newman, S. K., Bloomfield, P. M., Seaward, J., Roques, P., Lewington, G., Cunningham, V. J. &amp; Rossor, M. N. (1995) Neurosci. Lett. 186, 17-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783942</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrini, P., Azari, N. P., Grady, C. L., Salerno, J. A., Gonzales-Aviles, A., Heston, L. L., Pettigrew, K. D., Horwitz, B., Haxby, J. V. &amp; Schapiro, M. B. (1993) Dementia 4, 94-101.</Citation><ArticleIdList><ArticleId IdType="pubmed">8358518</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Medical Genetics, American Society of Human Genetics Working Group on ApoE and Alzheimer Disease (1995) J. Am. Med. Assoc. 274, 1627-1629.</Citation><ArticleIdList><ArticleId IdType="pubmed">7474250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">14506116</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>290</Volume><Issue>12</Issue><PubDate><Year>2003</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>APOE genotype and cerebral blood flow in healthy young individuals.</ArticleTitle><Pagination><StartPage>1581</StartPage><EndPage>1582</EndPage><MedlinePgn>1581-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scarmeas</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Habeck</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG014671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14506116</ArticleId><ArticleId IdType="mid">NIHMS262612</ArticleId><ArticleId IdType="pmc">PMC3026566</ArticleId><ArticleId IdType="doi">10.1001/jama.290.12.1581</ArticleId><ArticleId IdType="pii">290/12/1581</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Schindler C, Bruckner MK, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer&#x2019;s disease carrying apolipoprotein epsilon 4 allele. J Neurosci. 1997;17:516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573225</ArticleId><ArticleId IdType="pubmed">8987775</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Oshima N, Ogata H, et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol. 2000;157:2093&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885772</ArticleId><ArticleId IdType="pubmed">11106581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer&#x2019;s disease-related neurofibrillary changes. Exp Neurol. 1998;153:152&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer&#x2019;s disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19357304</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>17</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>28</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele.</ArticleTitle><Pagination><StartPage>7209</StartPage><EndPage>7214</EndPage><MedlinePgn>7209-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0811879106</ELocationID><Abstract><AbstractText>The APOE epsilon4 allele is a risk factor for late-life pathological changes that is also associated with anatomical and functional brain changes in middle-aged and elderly healthy subjects. We investigated structural and functional effects of the APOE polymorphism in 18 young healthy APOE epsilon4-carriers and 18 matched noncarriers (age range: 20-35 years). Brain activity was studied both at rest and during an encoding memory paradigm using blood oxygen level-dependent fMRI. Resting fMRI revealed increased "default mode network" (involving retrosplenial, medial temporal, and medial-prefrontal cortical areas) coactivation in epsilon4-carriers relative to noncarriers. The encoding task produced greater hippocampal activation in epsilon4-carriers relative to noncarriers. Neither result could be explained by differences in memory performance, brain morphology, or resting cerebral blood flow. The APOE epsilon4 allele modulates brain function decades before any clinical or neurophysiological expression of neurodegenerative processes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Filippini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, University of Oxford, Oxford OX3 9DU, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacIntosh</LastName><ForeName>Bradley J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Hough</LastName><ForeName>Morgan G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Beckmann</LastName><ForeName>Christian F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Clare E</ForeName><Initials>CE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G9409634</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19357304</ArticleId><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="doi">10.1073/pnas.0811879106</ArticleId><ArticleId IdType="pii">0811879106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahley RW, Rall SC., Jr Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32:778&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">3698268</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuizumi K, et al. ApoE-epsilon 4 and early-onset Alzheimer's. Nat Genet. 1994;7:10&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8075630</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:8098&#x2013;8102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997;350:1069&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213549</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, et al. Cognitive change and the APOE epsilon 4 allele. Nature. 2002;418:932.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198535</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart HA, et al. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology. 2006;67:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030756</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Burggren AC, Small GW, Sabb FW, Bookheimer SY. Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005;64:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart HA, et al. Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. Am J Psychiatry. 2006;163:1603&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16946187</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol. 2005;62:1881&#x2013;1888.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondadori CR, et al. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex. 2007;17:1934&#x2013;1947.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077159</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbey FM, Slack KJ, Sunderland TP, Cohen RM. Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults. NeuroReport. 2006;17:1585&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">17001273</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. Lancet Neurol. 2007;6:494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, et al. APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry. 2005;76:1440&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739360</ArticleId><ArticleId IdType="pubmed">16170092</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Boly M, et al. Intrinsic brain activity in altered states of consciousness: How conscious is the default mode of brain function? Ann NY Acad Sci. 2008;1129:119&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855379</ArticleId><ArticleId IdType="pubmed">18591474</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, Zimmerman HM. Alzheimer's neurofibrillary changes. A topographic study. Arch Neurol. 1962;7:227&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">13907611</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Willnow TE. Lipoprotein receptors in Alzheimer's disease. Trends Neurosci. 2006;29:687&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000013</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896849</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulving E, Markowitsch HJ, Kapur S, Habib R, Houle S. Novelty encoding networks in the human brain: Positron emission tomography data. NeuroReport. 1994;5:2525&#x2013;2528.</Citation><ArticleIdList><ArticleId IdType="pubmed">7696595</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes TR, et al. Integrating VBM into the General Linear Model with voxelwise anatomical covariates. NeuroImage. 2007;34:500&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586764</ArticleId><ArticleId IdType="pubmed">17113790</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc London B. 2005;360:1001&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1854918</ArticleId><ArticleId IdType="pubmed">16087444</ArticleId></ArticleIdList></Reference><Reference><Citation>Golby A, et al. Memory encoding in Alzheimer's disease: An fMRI study of explicit and implicit memory. Brain. 2005;128(Pt 4):773&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705615</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007;130(Pt 9):2375&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrieli JD, Brewer JB, Desmond JE, Glover GH. Separate neural bases of two fundamental memory processes in the human medial temporal lobe. Science. 1997;276:264&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">9092477</ArticleId></ArticleIdList></Reference><Reference><Citation>Shohamy D, Wagner AD. Integrating memories in the human brain: Hippocampal-midbrain encoding of overlapping events. Neuron. 2008;60:378&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628634</ArticleId><ArticleId IdType="pubmed">18957228</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, et al. Short-term and long-term verbal memory: A positron emission tomography study. Proc Natl Acad Sci USA. 1995;92:5111&#x2013;5115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41858</ArticleId><ArticleId IdType="pubmed">7761457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fliessbach K, Trautner P, Quesada CM, Elger CE, Weber B. Cerebellar contributions to episodic memory encoding as revealed by fMRI. NeuroImage. 2007;35:1330&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pubmed">17350289</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxton RB, Uludag K, Dubowitz DJ, Liu TT. Modeling the hemodynamic response to brain activation. NeuroImage. 2004;23(Suppl 1):S220&#x2013;S233.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501093</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GG, et al. BOLD and perfusion response to finger-thumb apposition after acetazolamide administration: Differential relationship to global perfusion. J Cereb Blood Flow Metab. 2003;23:829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">12843786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, et al. Cerebral perfusion and oxygenation differences in Alzheimer's disease risk. Neurobiol Aging. 2008 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746874</ArticleId><ArticleId IdType="pubmed">18325636</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci. 1997;17:516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573225</ArticleId><ArticleId IdType="pubmed">8987775</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol. 1995;136:107&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">7498401</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, et al. Expression of human apolipoprotein E3 or E4 in the brains of Apoe&#x2212;/&#x2212; mice: Isoform-specific effects on neurodegeneration. J Neurosci. 1999;19:4867&#x2013;4880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782676</ArticleId><ArticleId IdType="pubmed">10366621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: Astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 1998;18:3261&#x2013;3272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792658</ArticleId><ArticleId IdType="pubmed">9547235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellosta S, et al. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem. 1995;270:27063&#x2013;27071.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592957</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommer BL, et al. ApoE isoform-specific effects on LTP: Blockade by oligomeric amyloid-beta1&#x2013;42. Neurobiol Dis. 2005;18:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649697</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun SH, et al. Blockade of nicotinic acetylcholine receptors suppresses hippocampal long-term potentiation in wild-type but not ApoE4 targeted replacement mice. J Neurosci Res. 2005;82:771&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JH, Errington ML, Lynch MA, Bliss TV. Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus. Nature. 1989;341:739&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">2571939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mejia RO, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008;11:1311&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597064</ArticleId><ArticleId IdType="pubmed">18931664</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983;3:310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">6882285</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin R, et al. Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet. 1994;343:1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">7911882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PW, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. Jama. 1994;272:1666&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">7966894</ArticleId></ArticleIdList></Reference><Reference><Citation>Schachter F, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 1994;6:29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8136829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: A primer with examples. Hum Brain Mapp. 2002;15:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. NeuroImage. 2004;21:1732&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050594</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolrich M. Robust group analysis using outlier inference. NeuroImage. 2008;41:286&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407525</ArticleId></ArticleIdList></Reference><Reference><Citation>MacIntosh BJ, et al. Measuring the effects of remifentanil on cerebral blood flow and arterial arrival time using 3D GRASE MRI with pulsed arterial spin labelling. J Cereb Blood Flow Metab. 2008;28:1514&#x2013;1522.</Citation><ArticleIdList><ArticleId IdType="pubmed">18506198</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19838177</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia.</ArticleTitle><Pagination><StartPage>1361</StartPage><EndPage>1363</EndPage><MedlinePgn>1361-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2432</ELocationID><Abstract><AbstractText>In Alzheimer's disease, microglia cluster around beta-amyloid deposits, suggesting that these cells are important for amyloid plaque formation, maintenance and/or clearance. We crossed two distinct APP transgenic mouse strains with CD11b-HSVTK mice, in which nearly complete ablation of microglia was achieved for up to 4 weeks after ganciclovir application. Neither amyloid plaque formation and maintenance nor amyloid-associated neuritic dystrophy depended on the presence of microglia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grathwohl</LastName><ForeName>Stefan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xe4;lin</LastName><ForeName>Roland E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>Tristan</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Prokop</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Winkelmann</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Odenthal</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Radde</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Eldh</LastName><ForeName>Therese</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aguzzi</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Wolburg</LastName><ForeName>Hartwig</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Heppner</LastName><ForeName>Frank L</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS045205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046006</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS045205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039481">CD11b Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C067980">CD68 antigen, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.21</RegistryNumber><NameOfSubstance UI="D013937">Thymidine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>P9G3CKZ4P5</RegistryNumber><NameOfSubstance UI="D015774">Ganciclovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015214" MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039481" MajorTopicYN="N">CD11b Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015774" MajorTopicYN="N">Ganciclovir</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007270" MajorTopicYN="N">Injections, Intra-Articular</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019150" MajorTopicYN="N">Neuroaxonal Dystrophies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010930" MajorTopicYN="N">Plague</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013937" MajorTopicYN="N">Thymidine Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19838177</ArticleId><ArticleId IdType="mid">NIHMS172970</ArticleId><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="doi">10.1038/nn.2432</ArticleId><ArticleId IdType="pii">nn.2432</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heppner FL, et al. Nat Med. 2005;11:146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665833</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, et al. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, et al. Nat Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, et al. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Heppner FL. Neuron. 2008;59:8&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676343</ArticleId><ArticleId IdType="pubmed">18614025</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruys E, Timmermans HJ, van Ederen AM. Lab Anim. 1979;13:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">439836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Luster AD. Trends Pharmacol Sci. 2008;29:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">18835047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Nat Neurosci. 2007;10:1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18760694</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation.</ArticleTitle><Pagination><StartPage>568</StartPage><EndPage>580</EndPage><MedlinePgn>568-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.07.033</ELocationID><Abstract><AbstractText>Presenilin 1 (PS1) regulates environmental enrichment (EE)-mediated neural progenitor cell (NPC) proliferation and neurogenesis in the adult hippocampus. We now report that transgenic mice that ubiquitously express human PS1 variants linked to early-onset familial Alzheimer's disease (FAD) neither exhibit EE-induced proliferation, nor neuronal lineage commitment of NPCs. Remarkably, the proliferation and differentiation of cultured NPCs from standard-housed mice expressing wild-type PS1 or PS1 variants are indistinguishable. On the other hand, wild-type NPCs cocultured with primary microglia from mice expressing PS1 variants exhibit impaired proliferation and neuronal lineage commitment, phenotypes that are recapitulated with mutant microglia conditioned media in which we detect altered levels of selected soluble signaling factors. These findings lead us to conclude that factors secreted from microglia play a central role in modulating hippocampal neurogenesis, and argue for non-cell-autonomous mechanisms that govern FAD-linked PS1-mediated impairments in adult hippocampal neurogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Committee on Neurobiology, University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veeraraghavalu</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Orly</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Marler</LastName><ForeName>Seoan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jan Marino</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2008 Aug 28;59(4):527-9. doi: 10.1016/j.neuron.2008.08.005.</RefSource><PMID Version="1">18760689</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18760694</ArticleId><ArticleId IdType="mid">NIHMS68178</ArticleId><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.07.033</ArticleId><ArticleId IdType="pii">S0896-6273(08)00632-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aarum J, Sandberg K, Haeberlein SL, Persson MA. Migration and differentiation of neural precursor cells can be directed by microglia. Proc Natl Acad Sci U S A. 2003;100:15983&#x2013;15988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307679</ArticleId><ArticleId IdType="pubmed">14668448</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MF, Aberg MA, Nilsson M, Eriksson PS. Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res. 2002;134:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11947942</ArticleId></ArticleIdList></Reference><Reference><Citation>Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci. 2006;23:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420418</ArticleId></ArticleIdList></Reference><Reference><Citation>Belmadani A, Tran PB, Ren D, Miller RJ. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J Neurosci. 2006;26:3182&#x2013;3191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740990</ArticleId><ArticleId IdType="pubmed">16554469</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price DL. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996a;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996b;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull ND, Bartlett PF. The adult mouse hippocampal progenitor is neurogenic but not a stem cell. J Neurosci. 2005;25:10815&#x2013;10821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725873</ArticleId><ArticleId IdType="pubmed">16306394</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, Martino G, Schwartz M. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci. 2006;31:149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297637</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacci E, Ajmone-Cat MA, Anelli T, Biagioni S, Minghetti L. In vitro neuronal and glial differentiation from embryonic or adult neural precursor cells are differently affected by chronic or acute activation of microglia. Glia. 2008;56:412&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">18186084</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Huang D, Sasse ME, Ransohoff RM. Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc. 2006;1:1947&#x2013;1951.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487181</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson ME, Conboy IM. Regulating the Notch pathway in embryonic, adult and old stem cells. Current opinion in pharmacology. 2007;7:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">17475556</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active gamma- Secretase Complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Edman LC, Mira H, Arenas E. The beta-chemokines CCL2 and CCL7 are two novel differentiation factors for midbrain dopaminergic precursors and neurons. Exp Cell Res. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18420193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehninger D, Kempermann G. Regional effects of wheel running and environmental enrichment on cell genesis and microglia proliferation in the adult murine neocortex. Cereb Cortex. 2003;13:845&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">12853371</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray MJ, Poljakovic M, Kepka-Lenhart D, Morris SM., Jr. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene. 2005;353:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922518</ArticleId></ArticleIdList></Reference><Reference><Citation>Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development. 2000;127:2593&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821758</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, Bernstein A, van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 2002;16:846&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186324</ArticleId><ArticleId IdType="pubmed">11937492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. J Neurosci. 1999;19:4229&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782616</ArticleId><ArticleId IdType="pubmed">10341227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H, Koo EH. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell. 2002;110:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002;52:135&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997;386:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. Experience-induced neurogenesis in the senescent dentate gyrus. J Neurosci. 1998;18:3206&#x2013;3212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792643</ArticleId><ArticleId IdType="pubmed">9547229</ArticleId></ArticleIdList></Reference><Reference><Citation>Krathwohl MD, Kaiser JL. Chemokines promote quiescence and survival of human neural progenitor cells. Stem Cells. 2004;22:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">14688397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, et al. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med. 1997;3:756&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437:1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, Song H, Colamarino SA, Ming GL, Gage FH. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol. 2004;44:399&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Huang R, Cao X, Wang SM, Shi Q, Huang RP. Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate. Clin Chem Lab Med. 2003;41:139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666998</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A. 2002;99:8025&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem (Tokyo) 2001;130:169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481032</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi M, Niidome T, Matsuda S, Akaike A, Kihara T, Sugimoto H. Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur J Neurosci. 2007;25:649&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">17328769</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima K, Taga T. Mechanisms underlying cytokine-mediated cell-fate regulation in the nervous system. Mol Neurobiol. 2002;25:233&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12109873</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba T, Mochizuki H, Onodera M, Namiki H, Seki T. Postnatal neurogenesis in hippocampal slice cultures: early in vitro labeling of neural precursor cells leads to efficient neuronal production. J Neurosci Res. 2007;85:1704&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">17455308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, Murray PJ. Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol. 2004;172:7565&#x2013;7573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187136</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Martinez L, Jaworski DM. Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci. 2005;25:4917&#x2013;4929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1282460</ArticleId><ArticleId IdType="pubmed">15901773</ArticleId></ArticleIdList></Reference><Reference><Citation>Raineteau O, Rietschin L, Gradwohl G, Guillemot F, Gahwiler BH. Neurogenesis in hippocampal slice cultures. Mol Cell Neurosci. 2004;26:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207849</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaberg RM, van der Kooy D. Adult rodent neurogenic regions: the ventricular subependyma contains neural stem cells, but the dentate gyrus contains restricted progenitors. J Neurosci. 2002;22:1784&#x2013;1793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758891</ArticleId><ArticleId IdType="pubmed">11880507</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T, Arai Y. Age-related production of new granule cells in the adult dentate gyrus. Neuroreport. 1995;6:2479&#x2013;2482.</Citation><ArticleIdList><ArticleId IdType="pubmed">8741746</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science. 2004;304:1338&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15060285</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature. 2002;417:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986659</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci U S A. 1999;96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Kreutzberg GW. Lectin binding by resting and reactive microglia. J Neurocytol. 1987;16:249&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">3625239</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tozuka Y, Fukuda S, Namba T, Seki T, Hisatsune T. GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells. Neuron. 2005;47:803&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157276</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran PB, Ren D, Veldhouse TJ, Miller RJ. Chemokine receptors are expressed widely by embryonic and adult neural progenitor cells. J Neurosci Res. 2004;76:20&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048927</ArticleId></ArticleIdList></Reference><Reference><Citation>Trejo JL, Carro E, Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci. 2001;21:1628&#x2013;1634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762955</ArticleId><ArticleId IdType="pubmed">11222653</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropepe V, Craig CG, Morshead CM, van der Kooy D. Transforming growth factor-alpha null and senescent mice show decreased neural progenitor cell proliferation in the forebrain subependyma. J Neurosci. 1997;17:7850&#x2013;7859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793925</ArticleId><ArticleId IdType="pubmed">9315905</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallieres L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci. 2002;22:486&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758670</ArticleId><ArticleId IdType="pubmed">11784794</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H. Neurogenesis and exercise: past and future directions. Neuromolecular medicine. 2008;10:128&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18286389</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci. 1999;2:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton NM, Sutter BM, Laywell ED, Levkoff LH, Kearns SM, Marshall GP, 2nd, Scheffler B, Steindler DA. Microglia instruct subventricular zone neurogenesis. Glia. 2006;54:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">16977605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, Younkin LH, DeGasperi R, Gama Sosa MA, Robakis NK, et al. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004;188:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynes MW, Riches DW. Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol. 2003;171:3550&#x2013;3559.</Citation><ArticleIdList><ArticleId IdType="pubmed">14500651</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Moats-Staats BM, Ye P, D'Ercole AJ. Expression of insulin-like growth factor system genes during the early postnatal neurogenesis in the mouse hippocampus. J Neurosci Res. 2007;85:1618&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2302789</ArticleId><ArticleId IdType="pubmed">17455296</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, et al. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, Cohen H, Kipnis J, Schwartz M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci. 2006;9:268&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21115843</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>50</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Activation and intrinsic gamma-secretase activity of presenilin 1.</ArticleTitle><Pagination><StartPage>21435</StartPage><EndPage>21440</EndPage><MedlinePgn>21435-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1013246107</ELocationID><Abstract><AbstractText>A complex composed of presenilin (PS), nicastrin, PEN-2, and APH-1 is absolutely required for &#x3b3;-secretase activity in vivo. Evidence has emerged to suggest a role for PS as the catalytic subunit of &#x3b3;-secretase, but it has not been established that PS is catalytically active in the absence of associated subunits. We now report that bacterially synthesized, recombinant PS (rPS) reconstituted into liposomes exhibits &#x3b3;-secretase activity. Moreover, an rPS mutant that lacks a catalytic aspartate residue neither exhibits reconstituted &#x3b3;-secretase activity nor interacts with a transition-state &#x3b3;-secretase inhibitor. Importantly, we demonstrate that rPS harboring mutations that cause early onset familial Alzheimer's disease (FAD) lead to elevations in the ratio of A&#x3b2;42 to A&#x3b2;40 peptides produced from a wild-type APP substrate and that rPS enhances the A&#x3b2;42/A&#x3b2;40 peptide ratio from FAD-linked mutant APP substrates, findings that are entirely consistent with the results obtained in in vivo settings. Thus, &#x3b3;-secretase cleavage specificity is an inherent property of the polypeptide. Finally, we demonstrate that PEN2 is sufficient to promote the endoproteolysis of PS1 to generate the active form of &#x3b3;-secretase. Thus, we conclusively establish that activated PS is catalytically competent and the bimolecular interaction of PS1 and PEN2 can convert the PS1 zymogen to an active protease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Kwangwook</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xulun</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Gilchrist</LastName><ForeName>M Lane</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA062948</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469349">PSENEN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011510">Proteolipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C020485">proteoliposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21236-7. doi: 10.1073/pnas.1016284108.</RefSource><PMID Version="1">21135249</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011510" MajorTopicYN="N">Proteolipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21115843</ArticleId><ArticleId IdType="pmc">PMC3003001</ArticleId><ArticleId IdType="doi">10.1073/pnas.1013246107</ArticleId><ArticleId IdType="pii">1013246107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo WJ, et al. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem. 2003;278:7850&#x2013;7854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, et al. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. J Biol Chem. 2005;280:17020&#x2013;17026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201533</ArticleId><ArticleId IdType="pubmed">15711015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Ikeuchi T, Yu C, Sisodia SS. Regulated hyperaccumulation of presenilin-1 and the &#x201c;gamma-secretase&#x201d; complex. Evidence for differential intramembranous processing of transmembrane subatrates. J Biol Chem. 2003;278:33992&#x2013;34002.</Citation><ArticleIdList><ArticleId IdType="pubmed">12821663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, et al. Glu(332) in the Nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity. J Biol Chem. 2008;283:20096&#x2013;20105.</Citation><ArticleIdList><ArticleId IdType="pubmed">18502756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G, Liu Z, Ilagan MX, Kopan R. Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin. J Neurosci. 2010;30:1648&#x2013;1656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853942</ArticleId><ArticleId IdType="pubmed">20130175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumori A, Fluhrer R, Steiner H, Haass C. Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis. J Neurosci. 2010;30:7853&#x2013;7862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632680</ArticleId><ArticleId IdType="pubmed">20534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell WA, Reed ML, Strahle J, Wolfe MS, Xia W. Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase. J Neurochem. 2003;85:1563&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787075</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyabi O, et al. Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and nicastrin glycosylation but remain catalytically inactive in the absence of wild type presenilin. J Biol Chem. 2003;278:43430&#x2013;43436.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885769</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse S, et al. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron. 1998;21:1213&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856475</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol. 2000;2:428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878808</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Ahn K, Zhu L, Ubarretxena-Belandia I, Li YM. Soluble oligomers of the intramembrane serine protease YqgP are catalytically active in the absence of detergents. Biochemistry. 2008;47:11920&#x2013;11929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643057</ArticleId><ArticleId IdType="pubmed">18937501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi T, Dolios G, Kim SH, Wang R, Sisodia SS. Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of &#x201c;gamma-secretase&#x201d;. J Biol Chem. 2003;278:7010&#x2013;7018.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493731</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, et al. The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem. 1999;274:7615&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton CC, Tian Y, Frattini MG, Li YM. An exo-cell assay for examining real-time gamma-secretase activity and inhibition. Mol Neurodegener. 2009;4:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224971</ArticleId><ArticleId IdType="pubmed">19490610</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Crump CJ, Li YM. Dual role of {alpha}-secretase cleavage in the regulation of {gamma}-secretase activity for amyloid production. J Biol Chem. 2010;285:32549&#x2013;32556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952257</ArticleId><ArticleId IdType="pubmed">20675367</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearman MS, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry. 2000;39:8698&#x2013;8704.</Citation><ArticleIdList><ArticleId IdType="pubmed">10913280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun J, Yin YI, Yang G, Tarassishin L, Li YM. Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors. J Org Chem. 2004;69:7344&#x2013;7347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15471490</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton CC, et al. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci USA. 2009;106:20228&#x2013;20233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787169</ArticleId><ArticleId IdType="pubmed">19906985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Bassit B, Chau D, Li YM. An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production. Nat Struct Mol Biol. 2010;17:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">20062056</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L, Zhu L, Li YM. Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS ONE. 2009;4:e5088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661375</ArticleId><ArticleId IdType="pubmed">19352431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayerl TM, Bloom M. Physical properties of single phospholipid bilayers adsorbed to micro glass beads. A new vesicular model system studied by 2H-nuclear magnetic resonance. Biophys J. 1990;58:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1280977</ArticleId><ArticleId IdType="pubmed">2207243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006;27:686&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol. 2000;2:848&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">11056541</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA. 2002;99:8025&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, et al. Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis. 1998;5:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9746908</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan D, et al. PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling. Proc Natl Acad Sci USA. 2001;98:12186&#x2013;12190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59789</ArticleId><ArticleId IdType="pubmed">11593035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, et al. Modulation of &#x3b3;-secretase reduces &#x3b2;-amyloid deposition in a transgenic mouse model of Alzheimer&#x2019;s disease. Neuron. 2010;67:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin YI, et al. {gamma}-secretase substrate concentration modulates the Abeta42/Abeta40 ratio: Implications for Alzheimer disease. J Biol Chem. 2007;282:23639&#x2013;23644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, et al. Mechanism of the cleavage specificity of Alzheimer&#x2019;s disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA. 1999;96:3053&#x2013;3058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15893</ArticleId><ArticleId IdType="pubmed">10077635</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, et al. Amyloidogenic function of the Alzheimer&#x2019;s disease-associated presenilin 1 in the absence of endoproteolysis. Biochemistry. 1999;38:14600&#x2013;14605.</Citation><ArticleIdList><ArticleId IdType="pubmed">10545183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Sisoda SS. Evidence that the &#x201c;NF&#x201d; mofit in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2. J Biol Chem. 2005;280:41953&#x2013;41966.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234243</ArticleId></ArticleIdList></Reference><Reference><Citation>Knappenberger KS, et al. Mechanism of gamma-secretase cleavage activation: Is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry. 2004;43:6208&#x2013;6218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147205</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, et al. Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation. Proc Natl Acad Sci USA. 2000;97:9299&#x2013;9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16862</ArticleId><ArticleId IdType="pubmed">10922078</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19828817</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>41</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment.</ArticleTitle><Pagination><StartPage>13042</StartPage><EndPage>13052</EndPage><MedlinePgn>13042-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2362-09.2009</ELocationID><Abstract><AbstractText>Amyloid beta protein (Abeta), a pathogenic molecule associated with Alzheimer's disease, is produced by gamma-secretase, which cleaves the beta-carboxyl terminal fragment (betaCTF) of beta-amyloid precursor protein in the middle of its transmembrane domain. How the cleavage proceeds within the membrane has long been enigmatic. We hypothesized previously that betaCTF is cleaved first at the membrane-cytoplasm boundary, producing two long Abetas, Abeta(48) and Abeta(49), which are processed further by releasing three residues at each step to produce Abeta(42) and Abeta(40), respectively. To test this hypothesis, we used liquid chromatography tandem mass spectrometry (LC-MS/MS) to quantify the specific tripeptides that are postulated to be released. Using CHAPSO (3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxyl-1-propanesulfonate)-reconstituted gamma-secretase system, we confirmed that Abeta(49) is converted to Abeta(43/40) by successively releasing two or three tripeptides and that Abeta(48) is converted to Abeta(42/38) by successively releasing two tripeptides or these plus an additional tetrapeptide. Most unexpectedly, LC-MS/MS quantification revealed an induction period, 3-4 min, in the generation of peptides. When extrapolated, each time line for each tripeptide appears to intercept the same point on the x-axis. According to numerical simulation based on the successive reaction kinetics, the induction period exists. These results strongly suggest that Abeta is generated through the stepwise processing of betaCTF by gamma-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takami</LastName><ForeName>Mako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Faculty of Life and Medical Sciences, Doshisha University, Kizugawa 619-0225, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagashima</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Seiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Morishima-Kawashima</LastName><ForeName>Maho</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Funamoto</LastName><ForeName>Satoru</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002793">Cholic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>82473-24-3</RegistryNumber><NameOfSubstance UI="C048531">chapso</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002793" MajorTopicYN="N">Cholic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19828817</ArticleId><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2362-09.2009</ArticleId><ArticleId IdType="pii">29/41/13042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beher D, Wrigley JD, Owens AP, Shearman MS. Generation of C-terminally truncated amyloid-&#x3b2; peptides is dependent on &#x3b3;-secretase activity. J Neurochem. 2002;82:563&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">12153480</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target &#x3b3;-secretase and lower A&#x3b2; 42 in vivo. J Clin Invest. 2003;112:440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166298</ArticleId><ArticleId IdType="pubmed">12897211</ArticleId></ArticleIdList></Reference><Reference><Citation>Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, Ihara Y. Truncated carboxyl-terminal fragments of &#x3b2;-amyloid precursor protein are processed to amyloid &#x3b2;-proteins 40 and 42. Biochemistry. 2004;43:13532&#x2013;13540.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491160</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A&#x3b2; 42(43) and A&#x3b2; 40 in senile plaques with end-specific A&#x3b2; monoclonals: evidence that an initially deposited species is A&#x3b2; 42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, Ihara Y. Equimolar production of amyloid &#x3b2;-protein and amyloid precursor protein intracellular domain from &#x3b2;-carboxyl-terminal fragment by &#x3b3;-secretase. J Biol Chem. 2006;281:14776&#x2013;14786.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting A&#x3b2;42 production. Nat Med. 2005;11:545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. Electron microscopic structure of purified, active &#x3b3;-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A. 2006;103:6889&#x2013;6894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Beher D, Grimm HS, Wang R, Shearman MS, Masters CL, Beyreuther K. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc Natl Acad Sci U S A. 2002;99:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122196</ArticleId><ArticleId IdType="pubmed">11805291</ArticleId></ArticleIdList></Reference><Reference><Citation>Osawa S, Funamoto S, Nobuhara M, Wada-Kakuda S, Shimojo M, Yagishita S, Ihara Y. Phosphoinositides suppress &#x3b3;-secretase in both the detergent-soluble and -insoluble states. J Biol Chem. 2008;283:19283&#x2013;19292.</Citation><ArticleIdList><ArticleId IdType="pubmed">18480063</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Li H, Ye W, Li D, Aeschbach L, Fraering PC, Wolfe MS, Selkoe DJ, Li H. Cryoelectron microscopy structure of purified &#x3b3;-secretase at 12 A resolution. J Mol Biol. 2009;385:642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y. Longer forms of amyloid &#x3b2;-protein: implications for the mechanism of intramembrane cleavage by &#x3b3;-secretase. J Neurosci. 2005;25:436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama H, Koo EH, Haass C, Takio K, Morishima-Kawashima M, Ishiura S, Ihara Y. Potential link between amyloid &#x3b2;-protein 42 and C-terminal fragment &#x3b3; 49-99 of &#x3b2;-amyloid precursor protein. J Biol Chem. 2003;278:24294&#x2013;24301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707272</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic A&#x3b2;42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagishita S, Morishima-Kawashima M, Tanimura Y, Ishiura S, Ihara Y. DAPT-induced intracellular accumulations of longer amyloid &#x3b2;-proteins: further implications for the mechanism of intramembrane cleavage by &#x3b3;-secretase. Biochemistry. 2006;45:3952&#x2013;3960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16548522</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagishita S, Morishima-Kawashima M, Ishiura S, Ihara Y. A&#x3b2;46 is processed to A&#x3b2;40 and A&#x3b2;43, but not to A&#x3b2;42, in the low density membrane domains. J Biol Chem. 2008;283:733&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">18024430</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16959576</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>126</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations.</ArticleTitle><Pagination><StartPage>981</StartPage><EndPage>993</EndPage><MedlinePgn>981-93</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder. Mutations in presenilins 1 and 2 (PS1 and PS2) account for approximately 40% of familial AD (FAD) cases. FAD mutations and genetic deletions of presenilins have been associated with calcium (Ca(2+)) signaling abnormalities. We demonstrate that wild-type presenilins, but not PS1-M146V and PS2-N141I FAD mutants, can form low-conductance divalent-cation-permeable ion channels in planar lipid bilayers. In experiments with PS1/2 double knockout (DKO) mouse embryonic fibroblasts (MEFs), we find that presenilins account for approximately 80% of passive Ca(2+) leak from the endoplasmic reticulum. Deficient Ca(2+) signaling in DKO MEFs can be rescued by expression of wild-type PS1 or PS2 but not by expression of PS1-M146V or PS2-N141I mutants. The ER Ca(2+) leak function of presenilins is independent of their gamma-secretase activity. Our data suggest a Ca(2+) signaling function for presenilins and provide support for the "Ca(2+) hypothesis of AD."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Huiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Bezprozvanny</LastName><ForeName>Arseny</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhengnan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sheu-Fen</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Yi-Heng</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Serneels</LastName><ForeName>Lutgarde</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bezprozvanny</LastName><ForeName>Ilya</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS038082</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023104</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS38082</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008051" MajorTopicYN="N">Lipid Bilayers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16959576</ArticleId><ArticleId IdType="mid">NIHMS334090</ArticleId><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2006.06.059</ArticleId><ArticleId IdType="pii">S0092-8674(06)01025-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop PS, Cordell B, Fraser P, De Strooper B. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol. 1999;147:277&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA. 1993;90:567&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45704</ArticleId><ArticleId IdType="pubmed">8380642</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley JG, Duan W, Chan S, Duff K, Mattson MP. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J Neurochem. 1999;72:1030&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037474</ArticleId></ArticleIdList></Reference><Reference><Citation>Camello C, Lomax R, Petersen OH, Tepikin AV. Calcium leak from intracellular stores-the enigma of calcium signalling. Cell Calcium. 2002;32:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedazo-Minguez A, Popescu BO, Ankarcrona M, Nishimura T, Cowburn RF. The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations. J Biol Chem. 2002;277:36646&#x2013;36655.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121968</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Schneider I, Dewachter I, Caluwaerts N, Kretzschmar H, Van Leuven F. Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J Biol Chem. 2003;278:2484&#x2013;2489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12431992</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol. 2000;2:461&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofer AM. Measurement of free [Ca2+] changes in agonist-sensitive internal stores using compartmentalized fluorescent indicators. Methods Mol Biol. 1999;114:249&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10081023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, Alkon DL. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA. 1994;91:534&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42983</ArticleId><ArticleId IdType="pubmed">8290560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasri NN, Kocks SL, Verbert L, Hebert SS, Callewaert G, Parys JB, Missiaen L, De Smedt H. Up-regulation of inositol 1,4,5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca(2+) content in presenilin double knock-out cells. Cell Calcium. 2006;40:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675011</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989;568:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2629579</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudon H, Hansson EM, Melen K, Bergman A, Farmery MR, Winblad B, Lendahl U, von Heijne G, Naslund J. A nine-transmembrane domain topology for presenilin 1. J Biol Chem. 2005;280:35352&#x2013;35360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046406</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. J Biol Chem. 1999a;274:32535&#x2013;32538.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551803</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J Neurochem. 1999b;72:1061&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037477</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, LaFerla FM, Callamaras N, Parker I. Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. Neurobiol Dis. 2001;8:469&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442355</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Muller U, Saftig P, De Strooper B, et al. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci USA. 2002;99:4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123710</ArticleId><ArticleId IdType="pubmed">11917117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomax RB, Camello C, Van Coppenolle F, Petersen OH, Tepikin AV. Basal and physiological Ca(2+) leak from the endoplasmic reticulum of pancreatic acinar cells. Second messenger-activated channels and translocons. J Biol Chem. 2002;277:26479&#x2013;26485.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2000;23:222&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782128</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, Van Broeckhoven C, Merchiers P, Spittaels K, Annaert W, De Strooper B. Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J Biol Chem. 2003;278:43430&#x2013;43436.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885769</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, Pozzan T, Korsmeyer SJ. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci USA. 2005;102:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544078</ArticleId><ArticleId IdType="pubmed">15613488</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinton P, Ferrari D, Magalhaes P, Schulze-Osthoff K, Di Virgilio F, Pozzan T, Rizzuto R. Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J Cell Biol. 2000;148:857&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174537</ArticleId><ArticleId IdType="pubmed">10704437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ris L, Dewachter I, Reverse D, Godaux E, Van Leuven F. Capacitative calcium entry induces hippocampal long term potentiation in the absence of presenilin-1. J Biol Chem. 2003;278:44393&#x2013;44399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12902342</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, III, Kandel ER, Duff K, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, et al. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem. 2001;276:11539&#x2013;11544.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278803</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M, Martens G, Zwijsen A, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA. 2005;102:1719&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547495</ArticleId><ArticleId IdType="pubmed">15665098</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, LaPlant Q, Ball H, Dann CE, III, Sudhof T, Yu G. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium. 2005;38:427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125228</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006;26:5180&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T, Asahi M, Yamaguchi O, Hikoso S, Nakayama H, Kusakari Y, Kawai M, Hongo K, Higuchi Y, Kashiwase K, et al. Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling. FASEB J. 2005;19:2069&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon A, Fraser P. The presenilins. Genome Biol. 2002;3 reviews3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC244923</ArticleId><ArticleId IdType="pubmed">12429067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 2003;39:227&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220623</ArticleId><ArticleId IdType="pubmed">12873381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Wang Z, Bezprozvanny I. Modulation of mammalian inositol 1,4,5-trisphosphate receptor isoforms by calcium: a role of calcium sensor region. Biophys J. 2005a;88:1056&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1305112</ArticleId><ArticleId IdType="pubmed">15531634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Wang Z, Nosyreva E, De Smedt H, Bezprozvanny I. Functional characterization of mammalian inositol 1,4,5-trisphosphate receptor isoforms. Biophys J. 2005b;88:1046&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1305111</ArticleId><ArticleId IdType="pubmed">15533917</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Coppenolle F, Vanden Abeele F, Slomianny C, Flourakis M, Hesketh J, Dewailly E, Prevarskaya N. Ribosome-translocon complex mediates calcium leakage from endoplasmic reticulum stores. J Cell Sci. 2004;117:4135&#x2013;4142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15280427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodbury DJ, Miller C. Nystatin-induced liposome fusion: a versatile approach to ion channel reconstitution into planar bilayers. Biophys J. 1990;58:833&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1281030</ArticleId><ArticleId IdType="pubmed">1701101</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, et al. Presenilin-mediated modulation of capacitative calcium entry. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweifach A, Lewis RS. The mitogen-regulated calcium current of T lymphocytes is activated by depletion of intracellular calcium stores. Proc Natl Acad Sci USA. 1993;90:6295&#x2013;6299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46915</ArticleId><ArticleId IdType="pubmed">8392195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21385716</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>331</Volume><Issue>6021</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Enhancement of consolidated long-term memory by overexpression of protein kinase Mzeta in the neocortex.</ArticleTitle><Pagination><StartPage>1207</StartPage><EndPage>1210</EndPage><MedlinePgn>1207-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1200215</ELocationID><Abstract><AbstractText>Memories are more easily disrupted than improved. Many agents can impair memories during encoding and consolidation. In contrast, the armamentarium of potential memory enhancers is so far rather modest. Moreover, the effect of the latter appears to be limited to enhancing new memories during encoding and the initial period of cellular consolidation, which can last from a few minutes to hours after learning. Here, we report that overexpression in the rat neocortex of the protein kinase C isozyme protein kinase M&#x3b6; (PKM&#x3b6;) enhances long-term memory, whereas a dominant negative PKM&#x3b6; disrupts memory, even long after memory has been formed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shema</LastName><ForeName>Reut</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haramati</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ron</LastName><ForeName>Shiri</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hazvi</LastName><ForeName>Shoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Alon</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sacktor</LastName><ForeName>Todd Charlton</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Dudai</LastName><ForeName>Yadin</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH57068</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH53576</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="C504730">protein kinase M zeta, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="Y">Memory, Long-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21385716</ArticleId><ArticleId IdType="doi">10.1126/science.1200215</ArticleId><ArticleId IdType="pii">331/6021/1207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12815136</PMID><DateCompleted><Year>2003</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>348</Volume><Issue>25</Issue><PubDate><Year>2003</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Leisure activities and the risk of dementia in the elderly.</ArticleTitle><Pagination><StartPage>2508</StartPage><EndPage>2516</EndPage><MedlinePgn>2508-16</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Participation in leisure activities has been associated with a lower risk of dementia. It is unclear whether increased participation in leisure activities lowers the risk of dementia or participation in leisure activities declines during the preclinical phase of dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined the relation between leisure activities and the risk of dementia in a prospective cohort of 469 subjects older than 75 years of age who resided in the community and did not have dementia at base line. We examined the frequency of participation in leisure activities at enrollment and derived cognitive-activity and physical-activity scales in which the units of measure were activity-days per week. Cox proportional-hazards analysis was used to evaluate the risk of dementia according to the base-line level of participation in leisure activities, with adjustment for age, sex, educational level, presence or absence of chronic medical illnesses, and base-line cognitive status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over a median follow-up period of 5.1 years, dementia developed in 124 subjects (Alzheimer's disease in 61 subjects, vascular dementia in 30, mixed dementia in 25, and other types of dementia in 8). Among leisure activities, reading, playing board games, playing musical instruments, and dancing were associated with a reduced risk of dementia. A one-point increment in the cognitive-activity score was significantly associated with a reduced risk of dementia (hazard ratio, 0.93 [95 percent confidence interval, 0.90 to 0.97]), but a one-point increment in the physical-activity score was not (hazard ratio, 1.00). The association with the cognitive-activity score persisted after the exclusion of the subjects with possible preclinical dementia at base line. Results were similar for Alzheimer's disease and vascular dementia. In linear mixed models, increased participation in cognitive activities at base line was associated with reduced rates of decline in memory.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Participation in leisure activities is associated with a reduced risk of dementia, even after adjustment for base-line cognitive status and after the exclusion of subjects with possible preclinical dementia. Controlled trials are needed to assess the protective effect of cognitive leisure activities on the risk of dementia.</AbstractText><CopyrightInformation>Copyright 2003 Massachusetts Medical Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verghese</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Einstein Aging Study, Albert Einstein College of Medicine, Bronx, NY 10461, USA. jverghes@aecom.yu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Mindy J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Derby</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Kuslansky</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ambrose</LastName><ForeName>Anne F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Sliwinski</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Buschke</LastName><ForeName>Herman</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AGO3949-15</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2003 Jun 19;348(25):2489-90. doi: 10.1056/NEJMp030051.</RefSource><PMID Version="1">12815133</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2003 Sep 25;349(13):1290-2; author reply 1290-2. doi: 10.1056/NEJM200309253491316.</RefSource><PMID Version="1">14507956</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2003 Sep 25;349(13):1290-2; author reply 1290-2.</RefSource><PMID Version="1">14510017</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003615" MajorTopicYN="N">Dancing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007899" MajorTopicYN="Y">Leisure Activities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009146" MajorTopicYN="N">Music</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010988" MajorTopicYN="N">Play and Playthings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011932" MajorTopicYN="N">Reading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013177" MajorTopicYN="N">Sports</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa022252</ArticleId><ArticleId IdType="pii">348/25/2508</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11756603</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>12</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Influence of leisure activity on the incidence of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>2236</StartPage><EndPage>2242</EndPage><MedlinePgn>2236-42</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether leisure activities modify the risk for incident dementia.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although high educational and occupational attainments have been associated with reduced risk of incident dementia, the relation between leisure activities and dementia risk has not been adequately investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 1,772 nondemented individuals aged 65 years or older, living in northern Manhattan, New York, were identified and followed longitudinally in a community-based cohort incidence study. Subjects' leisure activities at baseline were assessed, annual examinations with the same standardized neurologic and neuropsychological measures were performed for up to 7 years (mean 2.9 years), and incident dementia was assessed as the main outcome measure. Cox proportional hazards models, adjusting for age, ethnic group, education, and occupation, were used to estimate the relative risk (RR) of incident dementia associated with high leisure activities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1,772 subjects, 207 became demented. The risk of dementia was decreased in subjects with high leisure activities (RR, 0.62; 95% CI 0.46 to 0.83). The association of high leisure with decreased RR of incident dementia was present even when baseline cognitive performance, health limitations interfering with desired leisure activities, cerebrovascular disease, and depression were considered.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The data suggest that engagement in leisure activities may reduce the risk of incident dementia, possibly by providing a reserve that delays the onset of clinical manifestations of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scarmeas</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience Division of the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>M X</ForeName><Initials>MX</Initials></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01 RR000645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007899" MajorTopicYN="Y">Leisure Activities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>13</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11756603</ArticleId><ArticleId IdType="mid">NIHMS262616</ArticleId><ArticleId IdType="pmc">PMC3025284</ArticleId><ArticleId IdType="doi">10.1212/wnl.57.12.2236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dartigues JF, Gagnon M, Michel P, et al. The Paquid research program on the epidemiology of dementia. Methods and initial results. Rev Neurol. 1991;147:225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">2063070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaiuto S, Rocca W, Lippi A. Impact of education and occupation on prevalence of Alzheimer&#x2019;s disease (AD) and multiinfarct dementia (MID) in Appignano, Macerata Province, Italy. Neurology. 1990;40(suppl 1):346.</Citation><ArticleIdList><ArticleId IdType="pubmed">2320236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MY, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer&#x2019;s disease in Shanghai, China: impact of age, gender, and education. Ann Neurol. 1990;27:428&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">2353798</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer&#x2019;s disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology. 1991;41:1886&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pubmed">1745343</ArticleId></ArticleIdList></Reference><Reference><Citation>Korczyn A, Kahana E, Galper Y. Epidemiology of dementia in Ashkelon, Israel. Neuroepidemiology. 1991;10:100.</Citation></Reference><Reference><Citation>Sulkava R, Wikstrom J, Aromaa A, et al. Prevalence of severe dementia in Finland. Neurology. 1985;35:1025&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">4010941</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland RP. Epidemiology, education, and the ecology of Alzheimer&#x2019;s disease. Neurology. 1993;43:246&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">8437687</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittner SJ, White LR, Farmer ME, et al. Methodological issues in screening for dementia: the problem of education adjustment. J Chronic Dis. 1986;39:163&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">3949940</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R. Education and the prevalence of dementia and Alzheimer&#x2019;s disease. Neurology. 1993;43:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer J. Do psychosocial risk factors contribute to Alzheimer&#x2019;s disease? In: Henderson AS, Henderson JH, editors. Etiology of dementia of Alzheimer&#x2019;s type. John Wiley &amp; Sons; New York, NY: 1988. pp. 39&#x2013;52.</Citation></Reference><Reference><Citation>Gurland B. The borderlands of dementia: the influence of sociocultural characteristics on rates of dementia occurring in the senium. Aging. 1981;15:61&#x2013;84.</Citation></Reference><Reference><Citation>Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology. 1993;7:273&#x2013;295.</Citation></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer&#x2019;s disease. JAMA. 1994;271:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickel H, Cooper B. Incidence and relative risk of dementia in an urban elderly population: findings of a prospective field study. Psychol Med. 1994;24:179&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">8208883</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrigoule C, Letenneur L, Dartigues JF, Zarrouk M, Commenges D, Barberger&#x2013;Gateau P. Social and leisure activities and risk of dementia: a prospective longitudinal study. J Am Geriatr Soc. 1995;43:485&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">7730528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurland B, Golden RR, Teresi JA, Challop J. The SHORT-CARE. An efficient instrument for the assessment of depression, dementia and disability. J Gerontol. 1984;39:166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">6699370</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49:453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580806</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24:1019&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">4473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton A. The Visual Retention Test. The Psychological Corp; New York, NY: 1955.</Citation></Reference><Reference><Citation>Wechsler D. Wechler Adult Intelligence Scale. The Psychological Corp; New York, NY: 1981. Revised.</Citation></Reference><Reference><Citation>Mattis S. Mental Status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, editors. Geriatric psychiatry. Grune &amp; Stratton; New York, NY: 1976.</Citation></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Lea &amp; Febiger; Philadelphia, PA: 1983.</Citation></Reference><Reference><Citation>Benton A, Hamsher A. Multiligual Aphasia Examination. University of Iowa; Iowa City: 1976.</Citation></Reference><Reference><Citation>Goodglass H, Kaplan D. The assessment of aphasia and related disorders. 2nd ed. Lea &amp; Febiger; Philadelphia, PA: 1983.</Citation></Reference><Reference><Citation>Rosen W. The Rosen Drawing Test. Veterans Administration Medical Center; Bronx, NY: 1981.</Citation></Reference><Reference><Citation>Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140:734&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">6846631</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab J, England A. Projection technique for evaluating surgery in Parkinson&#x2019;s disease. In: Gillinghan FS, Donaldson MN, editors. Third Symposium on Parkinson&#x2019;s Disease; Edinburg, Scotland: E &amp; S Livingstone; 1969. pp. 152&#x2013;157.</Citation></Reference><Reference><Citation>Spitzer R, Williams J. Structured clinical interview for DSM III-R&#x2013;Hamilton version. New York State Psychiatric Institute; New York: 1986.</Citation></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">3395203</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association CoNaS . Diagnostic and Statistical Manual of Mental Disorders. Third Edition. American Psychiatric Association; Washington, DC: 1987. Revised.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawless J. Statistical model and methods for lifetime data. John Wiley &amp; Sons; New York, NY: 1982.</Citation></Reference><Reference><Citation>Rothman K. Modern epidemiology. Little Brown &amp; Co; Boston, MA: 1986. pp. 311&#x2013;326.</Citation></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with &#x201c;reversible dementia&#x201d;: a controlled study. Am J Psychiatry. 1993;150:1693&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105707</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassuk SS, Berkman LF, Wypij D. Depressive symptomatology and incident cognitive decline in an elderly community sample. Arch Gen Psychiatry. 1998;55:1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862549</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer&#x2019;s disease in the elderly living in the community. Arch Gen Psychiatry. 1996;53:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8629893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultsch DF, Hertzog C, Small BJ, Dixon RA. Use it or lose it: engaged lifestyle as a buffer of cognitive decline in aging? Psychol Aging. 1999;14:245&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">10403712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold DP, Andres D, Etezadi J, Arbuckle T, Schwartzman A, Chaikelson J. Structural equation model of intellectual change and continuity and predictors of intelligence in older men. Psychol Aging. 1995;10:294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7662188</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaie K. Midlife influences upon intellectual functioning in old age. International J Behavioral Development. 1984;7:463&#x2013;478.</Citation></Reference><Reference><Citation>Kondo K, Niino M, Shido K. A case-control study of Alzheimer&#x2019;s disease in Japan&#x2013;significance of life-styles. Dementia. 1994;5:314&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">7866485</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland R, Fritsch T, Smyth K, et al. Patients with Alzheimer&#x2019; disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci USA. 2001;98:3440&#x2013;3445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30672</ArticleId><ArticleId IdType="pubmed">11248097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. Genetic influence on neurogenesis in the dentate gyrus of adult mice. Proc Natl Acad Sci USA. 1997;94:10409&#x2013;10414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23376</ArticleId><ArticleId IdType="pubmed">9294224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature. 1997;386:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci. 1999;2:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Reeves AJ, Graziano MS, Gross CG. Neurogenesis in the neocortex of adult primates. Science. 1999;286:548&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521353</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bjork&#x2013;Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer&#x2019;s disease. Ann Neurol. 1992;32:371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">1416806</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Alexander GE, Prohovnik I, et al. Relationship between lifetime occupation and parietal flow: implications for a reserve against Alzheimer&#x2019;s disease pathology. Neurology. 1995;45:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824135</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Zarahn E, Anderson KE, et al. Association of leisure activities with regional cerebral blood flow (RCBF) in Alzheimer&#x2019;s disease (AD): implications for the cognitive reserve hypothesis; Presented at: the Society for Neuroscience 31st Annual Meeting; San Diego, CA. November 10&#x2013;15, 2001.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22090477</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>46</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Robust central reduction of amyloid-&#x3b2; in humans with an orally available, non-peptidic &#x3b2;-secretase inhibitor.</ArticleTitle><Pagination><StartPage>16507</StartPage><EndPage>16516</EndPage><MedlinePgn>16507-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3647-11.2011</ELocationID><Abstract><AbstractText>According to the amyloid cascade hypothesis, cerebral deposition of amyloid-&#x3b2; peptide (A&#x3b2;) is critical for Alzheimer's disease (AD) pathogenesis. A&#x3b2; generation is initiated when &#x3b2;-secretase (BACE1) cleaves the amyloid precursor protein. For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD. However, development of such agents has turned out to be extremely challenging, with major hurdles in cell penetration, oral bioavailability/metabolic clearance, and brain access. Using a fragment-based chemistry strategy, we have generated LY2811376 [(S)-4-(2,4-difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]thiazin-2-ylamine], the first orally available non-peptidic BACE1 inhibitor that produces profound A&#x3b2;-lowering effects in animals. The biomarker changes obtained in preclinical animal models translate into man at doses of LY2811376 that were safe and well tolerated in healthy volunteers. Prominent and long-lasting A&#x3b2; reductions in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376. This represents the first translation of BACE1-driven biomarker changes in CNS from preclinical animal models to man. Because of toxicology findings identified in longer-term preclinical studies, this compound is no longer progressing in clinical development. However, BACE1 remains a viable target because the adverse effects reported here were recapitulated in LY2811376-treated BACE1 KO mice and thus are unrelated to BACE1 inhibition. The magnitude and duration of central A&#x3b2; reduction obtainable with BACE1 inhibition positions this protease as a tractable small-molecule target through which to test the amyloid hypothesis in man.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly &amp; Co., Indianapolis, Indiana 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Martenyi</LastName><ForeName>Ferenc</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sheehan</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Boggs</LastName><ForeName>Leonard N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Monk</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Mathes</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Mergott</LastName><ForeName>Dustin J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Stout</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Timm</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Smith Labell</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Celedon R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Masako</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jhee</LastName><ForeName>Stanford S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ereshefsky</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lindstrom</LastName><ForeName>Terry D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Calligaro</LastName><ForeName>David O</ForeName><Initials>DO</Initials></Author><Author ValidYN="Y"><LastName>Cocke</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Greg Hall</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Audia</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569204">LY2811376</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013843">Thiazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.45</RegistryNumber><NameOfSubstance UI="C509284">BACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003461" MajorTopicYN="N">Crystallography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008956" MajorTopicYN="N">Models, Chemical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013843" MajorTopicYN="N">Thiazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22090477</ArticleId><ArticleId IdType="pmc">PMC6633289</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3647-11.2011</ArticleId><ArticleId IdType="pii">31/46/16507</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-&#x3b2; levels. Neurology. 2007;68:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Brackenbury WJ, Isom LL. Voltage-gated Na+ channels: potential for &#x3b2; subunits as therapeutic targets. Expert Opin Ther Targets. 2008;12:1191&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376311</ArticleId><ArticleId IdType="pubmed">18694383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the &#x3b2;-amyloid precursor protein in familial Alzheimer's disease increases &#x3b2;-protein production. Nature. 1992;360:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50:760&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlanson DA, McDowell RS, O'Brien T. Fragment-based drug discovery. J Med Chem. 2004;47:3463&#x2013;3482.</Citation><ArticleIdList><ArticleId IdType="pubmed">15214773</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res. 2003;74:386&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598315</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R. BACE1&#x2212;/&#x2212; mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener. 2010;5:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933677</ArticleId><ArticleId IdType="pubmed">20731874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science. 2000;290:150&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">11021803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today. 2004;9:430&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">15109945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD, Yan R. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J. 2008;22:2970&#x2013;2980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493455</ArticleId><ArticleId IdType="pubmed">18413858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999;14:419&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem. 2007;100:802&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">17156133</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, Kovacs DM. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA. 2000;97:1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamas MS, Robichaud A, Erdei J, Quagliato D, Solvibile W, Zhou P, Morris K, Turner J, Wagner E, Fan K, Olland A, Jacobsen S, Reinhart P, Riddell D, Pangalos M. Design and synthesis of aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett. 2010;20:6597&#x2013;6605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20880704</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE, Jr, Thompson LA, Toyn JH, Marcin L, Barten DM, Marcinkeviciene J, Kopcho L, Kim Y, Lin A, Guss V, Burton C, Iben L, Polson C, Cantone J, Ford M, Drexler D, Fiedler T, Lentz KA, Grace JE, Jr, Kolb J, et al. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. J Pharmacol Exp Ther. 2008;326:502&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">18499745</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004;304:700&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi K, Osuga J, Tozawa R, Kitamine T, Yagyu H, Sekiya M, Tomita S, Okazaki H, Tamura Y, Yahagi N, Iizuka Y, Harada K, Gotoda T, Shimano H, Yamada N, Ishibashi S. Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene. J Biol Chem. 2003;278:42936&#x2013;42941.</Citation><ArticleIdList><ArticleId IdType="pubmed">12920113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Kn&#xf6;lker HJ, Simons K. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science. 2008;320:520&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">18436784</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001;10:1317&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther. 2008;324:957&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">18156464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328:131&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18854490</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma KK, Ralhan NK, Narang KS. Pyrimidobenzothiazine derivatives. II. The condensation of isothiocyano ketones and aryl amines. J Org Chem. 1963;28:740&#x2013;742.</Citation></Reference><Reference><Citation>Simmons J. The $10 billion pill. Fortune magazine. 2003 Jan 20;</Citation><ArticleIdList><ArticleId IdType="pubmed">12602122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel SJ. Progress toward the development of a viable BACE-1 inhibitor. Drug Dev Res. 2009;70:101&#x2013;110.</Citation></Reference><Reference><Citation>Strobel G. Keystone drug news: CoMentis BACE inhibitor debuts. Alzheimer's Research Forum. 2008.  Available at  http://www.alzforum.org/new/detail.asp?id=1790.</Citation></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N. &#x3b2; subunits of voltage-gated sodium channels are novel substrates of &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE1) and &#x3b3;-secretase. J Biol Chem. 2005;280:23009&#x2013;23017.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HC, Chai X, Mosior M, Kohn W, Boggs LN, Erickson JA, McClure DB, Yeh WK, Zhang L, Gonzalez-DeWhitt P, Mayer JP, Martin JA, Hu J, Chen SH, Bueno AB, Little SP, McCarthy JR, May PC. Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta&#x2032;-cleavage sites by human and murine BACE1. J Neurochem. 2004;91:1249&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584902</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol. 1995;37:287&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Xiao K, Ma L, Xiong B, Fu Y, Yu H, Wang W, Wang X, Hu D, Peng H, Li J, Gong Q, Chai Q, Tang X, Zhang H, Li J, Shen J. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg Med Chem. 2009;17:1600&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22286308</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.</ArticleTitle><Pagination><StartPage>291</StartPage><EndPage>295</EndPage><MedlinePgn>291-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.2613</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau has risk alleles for both Alzheimer's disease and Parkinson's disease and mutations that cause brain degenerative diseases termed tauopathies. Aggregated tau forms neurofibrillary tangles in these pathologies, but little is certain about the function of tau or its mode of involvement in pathogenesis. Neuronal iron accumulation has been observed pathologically in the cortex in Alzheimer's disease, the substantia nigra (SN) in Parkinson's disease and various brain regions in the tauopathies. Here we report that tau-knockout mice develop age-dependent brain atrophy, iron accumulation and SN neuronal loss, with concomitant cognitive deficits and parkinsonism. These changes are prevented by oral treatment with a moderate iron chelator, clioquinol. Amyloid precursor protein (APP) ferroxidase activity couples with surface ferroportin to export iron, but its activity is inhibited in Alzheimer's disease, thereby causing neuronal iron accumulation. In primary neuronal culture, we found loss of tau also causes iron retention, by decreasing surface trafficking of APP. Soluble tau levels fall in affected brain regions in Alzheimer's disease and tauopathies, and we found a similar decrease of soluble tau in the SN in both Parkinson's disease and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model. These data suggest that the loss of soluble tau could contribute to toxic neuronal iron accumulation in Alzheimer's disease, Parkinson's disease and tauopathies, and that it can be rescued pharmacologically.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mental Health Research Institute, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayton</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Finkelstein</LastName><ForeName>David I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Spoerri</LastName><ForeName>Loredana</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ciccotosto</LastName><ForeName>Giuseppe D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>David K</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bruce X W</ForeName><Initials>BX</Initials></Author><Author ValidYN="Y"><LastName>Adlard</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Cherny</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Linh Q</ForeName><Initials>LQ</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Blaine R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Volitakis</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Egan</LastName><ForeName>Gary F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Duce</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.16.3.1</RegistryNumber><NameOfSubstance UI="D002570">Ceruloplasmin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2012 Feb 06;18(2):197-8. doi: 10.1038/nm.2668.</RefSource><PMID Version="1">22310680</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2012 Jun;27(7):816. doi: 10.1002/mds.25045.</RefSource><PMID Version="1">22912976</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2013 Apr;28(4):439. doi: 10.1002/mds.25411.</RefSource><PMID Version="1">23568842</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002570" MajorTopicYN="N">Ceruloplasmin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22286308</ArticleId><ArticleId IdType="doi">10.1038/nm.2613</ArticleId><ArticleId IdType="pii">nm.2613</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 2002 Nov 22;277(47):45518-28</Citation><ArticleIdList><ArticleId IdType="pubmed">12198135</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15997-6002</Citation><ArticleIdList><ArticleId IdType="pubmed">18832465</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 Jun 19;43(7):699-705</Citation><ArticleIdList><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1988 Jun 15;263(17):7948-53</Citation><ArticleIdList><ArticleId IdType="pubmed">3131334</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2007 May 22;68(21):1820-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17515544</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2010 Nov;42(11):1775-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20678581</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Nov 16;25(46):10637-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2001 Mar;114(Pt 6):1179-87</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2002 Sep;17(5):917-27</Citation><ArticleIdList><ArticleId IdType="pubmed">12360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1992;32 Suppl:S94-100</Citation><ArticleIdList><ArticleId IdType="pubmed">1510387</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Sep 11;39(6):889-909</Citation><ArticleIdList><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 May;12(5):510-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17179995</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2000 Feb 4;279(3):129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10688046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1994 Jun 9;369(6480):488-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8202139</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2001;24:1121-59</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 2005;74:29-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15952880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1995 Apr;1(4):365-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7585068</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosignals. 2005;14(1-2):46-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15956814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2004 Nov;5(11):863-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15496864</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2008 Aug;29(8):1276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17386961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2002 Mar 18;156(6):1051-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1994 Aug 29;351(1):80-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8076698</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9866-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9275217</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2003 May;105(5):469-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12677447</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Sep 17;142(6):857-67</Citation><ArticleIdList><ArticleId IdType="pubmed">20817278</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 May 4;316(5825):750-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Mar 27;37(6):899-909</Citation><ArticleIdList><ArticleId IdType="pubmed">12670420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Aug 6;142(3):387-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2001 Mar;76(5):1265-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11238711</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Imaging. 1999 Feb;17(2):213-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10215476</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2001 Nov 1;125(1-2):109-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11682102</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2000 Aug;25(4):402-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2012 Apr;33(4):814-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20619503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16306400</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>47</Issue><PubDate><Year>2005</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.</ArticleTitle><Pagination><StartPage>10874</StartPage><EndPage>10883</EndPage><MedlinePgn>10874-83</MedlinePgn></Pagination><Abstract><AbstractText>Beta-secretase [beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the beta-amyloid (Abeta) peptide involved in the pathogenesis of Alzheimer's disease (AD). BACE1 levels and activity are increased in AD brain and are likely to drive Abeta overproduction, but the cause of BACE1 elevation in AD is unknown. Interestingly, cerebral glucose metabolism and blood flow are both reduced in preclinical AD, suggesting that impaired energy production may be an early pathologic event in AD. To determine whether reduced energy metabolism would cause BACE1 elevation, we used pharmacological agents (insulin, 2-deoxyglucose, 3-nitropropionic acid, and kainic acid) to induce acute energy inhibition in C57/B6 wild-type and amyloid precursor protein (APP) transgenic (Tg2576) mice. Four hours after treatment, we observed that reduced energy production caused a approximately 150% increase of cerebral BACE1 levels compared with control. Although this was a modest increase, the effect was long-lasting, because levels of the BACE1 enzyme remained elevated for at least 7 d after a single dose of energy inhibitor. In Tg2576 mice, levels of the BACE1-cleaved APP ectodomain APPsbeta were also elevated and paralleled the BACE1 increase in both relative amount and duration. Importantly, cerebral Abeta40 levels in Tg2576 were increased to approximately 200% of control at 7 d after injection, demonstrating that energy inhibition was potentially amyloidogenic. These results support the hypothesis that impaired energy production in the brain may drive AD pathogenesis by elevating BACE1 levels and activity, which, in turn, lead to Abeta overproduction. This process may represent one of the earliest pathogenic events in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Velliquette</LastName><ForeName>Rodney A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2006 Feb 15;26(7):2140-2</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="Y">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>5</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16306400</ArticleId><ArticleId IdType="pmc">PMC6725876</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2350-05.2005</ArticleId><ArticleId IdType="pii">25/47/10874</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Auer RN, Wieloch T, Olsson Y, Siesjo BK (1984) The distribution of hypoglycemic brain damage. Acta Neuropathol (Berl) 64: 177-191.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496035</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay L, Zemcov A, Blass JP, McDowell FH (1984) Rapid rate of decline in cerebral blood flow in progressive dementias. Monogr Neural Sci 11: 107-110.</Citation><ArticleIdList><ArticleId IdType="pubmed">6738542</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R (2004) Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm 111: 523-536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057522</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM (2000) Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21: 153-160.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867200</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell AL, Chen YI, Yu M, Wang X, Dedeoglu A, Cicchetti F, Jenkins BG, Beal MF (2004) 3-Nitropropionic acid-induced neurotoxicity&#x2014;assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy. J Neurochem 89: 1206-1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147513</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672-674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens MJ, Bommer UA (1999) Translational control: the cancer connection. Int J Biochem Cell Biol 31: 1-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10216939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R (2005) Statins cause intracellular accumulation of APP, beta-secretase cleaved fragments, and Abeta via an isoprenoid-dependent mechanism. J Biol Chem 280: 18755-18770.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718241</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler NR, Haxby JV, Duara R, Grady CL, Moore AM, Parisi JE, White J, Heston L, Margolin RM, Rapoport SI (1985) Brain metabolism as measured with positron emission tomography: serial assessment in a patient with familial Alzheimer's disease. Neurology 35: 1556-1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">3877253</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC (1999) Critical threshold cerebral hypoperfusion causes Alzheimer's disease? Acta Neuropathol (Berl) 98: 1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412794</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980533</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Ferris SH, George AE, Reisberg B, Christman DR, Kricheff II, Wolf AP (1983a) Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab 3: 391-394.</Citation><ArticleIdList><ArticleId IdType="pubmed">6603463</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Ferris SH, George AE, Christman DR, Fowler JS, Gentes C, Reisberg B, Gee B, Emmerich M, Yonekura Y, Brodie J, Kricheff II, Wolf AP (1983b) Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol 4: 568-571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8334899</ArticleId><ArticleId IdType="pubmed">6410799</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pietri Tonelli D, Mihailovich M, Di Cesare A, Codazzi F, Grohovaz F, Zacchetti D (2004) Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res 32: 1808-1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390341</ArticleId><ArticleId IdType="pubmed">15034149</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22: 529-539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445252</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K (2004) The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem 279: 18146-18156.</Citation><ArticleIdList><ArticleId IdType="pubmed">14970212</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Wolfe MS (2001) A portrait of Alzheimer secretases&#x2014;new features and familiar faces. Science 293: 1449-1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520976</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269: 13623-13628.</Citation><ArticleIdList><ArticleId IdType="pubmed">8175797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, Govoni S (1997) Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231: 113-117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Benussi L, Bianchetti A, Binetti G, Curti D, Govoni S, Moraschi S, Racchi M, Trabucchi M (1999) Energy metabolism inhibition impairs amyloid precursor protein secretion from Alzheimer's fibroblasts. Neurosci Lett 263: 197-200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213169</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, Bennett BD, Kahn S, Ross S, Burgess T, Katta V, Rogers G, Vassar R, Citron M (2000) Characterization of Alzheimer's beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem 275: 21099-21106.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, Muller U (2004) Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J 23: 4106-4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 29: 177-185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783-786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112088</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Kukull W, Mayeux R (2005) Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurol 64: 494-500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW (2000) Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem 275: 33729-33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14: 419-427.</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Strickland D, Rebeck GW (2000) Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch Neurol 57: 646-650.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibach B, Poljansky S, Marienhagen J, Sommer M, Manner P, Hajak G (2004) Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease. NeuroImage 23: 739-743.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG, Roher AE (2004) Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 26: 525-539.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37: 925-937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y (2001) Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyl-transferase. Proc Natl Acad Sci USA 98: 13554-13559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Kotani N, Ogawa K, Suzuki M, Dohmae N, Takio K, Saido TC, Hashimoto Y (2003) Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta-secretase (BACE1). J Biol Chem 278: 14865-14871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Nakagawa K, Oka R, Tachida Y, Ogawa K, Luo Y, Citron M, Shitara H, Taya C, Yonekawa H, Paulson JC, Miyoshi E, Taniguchi N, Hashimoto Y (2005) In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. J Biol Chem 280: 8589-8595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from A&#x3b2;1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Schobel S, Zimmer AK, Lichtenthaler SF, Haass C (2004) Expression of the Alzheimer protease BACE1 is suppressed via its 5&#x2032;-untranslated region. EMBO Rep 5: 620-625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299076</ArticleId><ArticleId IdType="pubmed">15167888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Sudhof TC (2004) Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279: 10542-10550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101: 3632-3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713-48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97: 1456-1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Little AR, O'Callaghan JP (2001) Astrogliosis in the adult and developing CNS: is there a role for proinflammatory cytokines? Neurotoxicology 22: 607-618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770882</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4: 231-232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82: 4245-4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda H (2001) Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 15: 85-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11448080</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda H, Kanetaka H, Ohnishi T, Asada T, Imabayashi E, Nakano S, Katoh A, Tanaka F (2002) Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 29: 1502-1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397471</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Wenzel HJ, Robbins CA, Sosunov AA, Schwartzkroin PA (2003) Mouse strain differences in kainic acid sensitivity, seizure behavior, mortality, and hippocampal pathology. Neuroscience 122: 551-561.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614919</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier-Ruge W, Bertoni-Freddari C, Iwangoff P (1994) Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 40: 246-252.</Citation><ArticleIdList><ArticleId IdType="pubmed">7959080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32: 486-510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63: 2332-2340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623696</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1: 345-347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA 100: 12444-12449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218777</ArticleId><ArticleId IdType="pubmed">14523244</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in the Tg2576 mouse model of Alzheimer's disease. Neuron 41: 27-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Panegyres PK (2001) The functions of the amyloid precursor protein gene. Rev Neurosci 12: 1-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236063</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, Paganetti P, Mathews PM, Harroch S, Buxbaum JD (2004) BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25: 642-649.</Citation><ArticleIdList><ArticleId IdType="pubmed">15080893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI (1999) In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249 [Suppl 3]: 46-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654100</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI, Horwitz B, Grady CL, Haxby JV, DeCarli C, Schapiro MB (1991) Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography. Adv Exp Med Biol 291: 231-248.</Citation><ArticleIdList><ArticleId IdType="pubmed">1927686</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334: 752-758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers Jr GW, Edelman GM, Mauro VP (2004) Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci USA 101: 2794-2799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365699</ArticleId><ArticleId IdType="pubmed">14981268</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG (2003) Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 23: 2055-2062.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512367</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62: 1148-1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079015</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361: 260-263.</Citation><ArticleIdList><ArticleId IdType="pubmed">7678698</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Perry G, Smith MA, Friedland RP (2000) Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 21: 357-361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, et al. (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537-540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Kim SH, Thinakaran G (1999) Function and dysfunction of the presenilins. Am J Hum Genet 65: 7-12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1378068</ArticleId><ArticleId IdType="pubmed">10364510</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97: 6037-6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter O-C, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J (2002) Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 33: 1986-1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154250</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10: 279-288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Guglielmotto M, Bardini P, Santoro G, Davit A, Di Simone D, Danni O, Tabaton M (2003) Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol Dis 14: 291-301.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572450</ArticleId></ArticleIdList></Reference><Reference><Citation>Textor S (2004) Ischemic nephropathy: where are we now? J Am Soc Nephrol 15: 1974-1982.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284283</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, Song W (2005) Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 112: 455-469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15614428</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ (2002) Alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299: 373-376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT (2005) The LDL-receptor related protein (LRP) is a novel beta-secretase (BACE 1) substrate. J Biol Chem 280: 17777-17785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H (2005) Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J Neurosci 25: 1219-1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster MT, Pearce BR, Bowen DM, Francis PT (1998) The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm 105: 839-853.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW (2004) Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009: 1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120577</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22: 1858-1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N (2005) Beta subunits of voltagegated sodium channels are novel substrates of BACE1 and gamma-secretase. J Biol Chem 280: 23009-23017.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533-537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA (2005) APOE, vascular pathology, and the AD brain. Neurol 65: 259-265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043796</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG (1998) The role of A beta 42 in Alzheimer's disease. J Physiol (Paris) 92: 289-292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9789825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19109907</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.</ArticleTitle><Pagination><StartPage>988</StartPage><EndPage>1009</EndPage><MedlinePgn>988-1009</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.10.047</ELocationID><Abstract><AbstractText>beta-site APP cleaving enzyme-1 (BACE1), the rate-limiting enzyme for beta-amyloid (Abeta) production, is elevated in Alzheimer's disease (AD). Here, we show that energy deprivation induces phosphorylation of the translation initiation factor eIF2alpha (eIF2alpha-P), which increases the translation of BACE1. Salubrinal, an inhibitor of eIF2alpha-P phosphatase PP1c, directly increases BACE1 and elevates Abeta production in primary neurons. Preventing eIF2alpha phosphorylation by transfection with constitutively active PP1c regulatory subunit, dominant-negative eIF2alpha kinase PERK, or PERK inhibitor P58(IPK) blocks the energy-deprivation-induced BACE1 increase. Furthermore, chronic treatment of aged Tg2576 mice with energy inhibitors increases levels of eIF2alpha-P, BACE1, Abeta, and amyloid plaques. Importantly, eIF2alpha-P and BACE1 are elevated in aggressive plaque-forming 5XFAD transgenic mice, and BACE1, eIF2alpha-P, and amyloid load are correlated in humans with AD. These results strongly suggest that eIF2alpha phosphorylation increases BACE1 levels and causes Abeta overproduction, which could be an early, initiating molecular mechanism in sporadic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadleir</LastName><ForeName>Katherine R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Maus</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Velliquette</LastName><ForeName>Rodney A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Eimer</LastName><ForeName>William A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Hitt</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bembinster</LastName><ForeName>Leslie A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Lammich</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>S&#xe9;bastien S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31 AG030965-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG022560</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG020506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022560</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32 AG000260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32 AG020506-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG030965</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000963">Antimetabolites</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003292">Convulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009574">Nitro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011422">Propionates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011500">Protein Synthesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>181233-60-3</RegistryNumber><NameOfSubstance UI="C101003">ELF2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>1CC1JFE158</RegistryNumber><NameOfSubstance UI="D003609">Dactinomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9G2MP84A8W</RegistryNumber><NameOfSubstance UI="D003847">Deoxyglucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C117035">PERK kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>QY4L0FOX0D</RegistryNumber><NameOfSubstance UI="C015392">3-nitropropionic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2008 Dec 26;60(6):941-3. doi: 10.1016/j.neuron.2008.12.010.</RefSource><PMID Version="1">19109900</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000963" MajorTopicYN="N">Antimetabolites</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003292" MajorTopicYN="N">Convulsants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003609" MajorTopicYN="N">Dactinomycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003847" MajorTopicYN="N">Deoxyglucose</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009574" MajorTopicYN="N">Nitro Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011422" MajorTopicYN="N">Propionates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011500" MajorTopicYN="N">Protein Synthesis Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019892" MajorTopicYN="N">eIF-2 Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19109907</ArticleId><ArticleId IdType="mid">NIHMS85025</ArticleId><ArticleId IdType="pmc">PMC2667382</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.10.047</ArticleId><ArticleId IdType="pii">S0896-6273(08)00947-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992;31:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">1349466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer&#x2019;s disease beta-secretase (BACE-1) J Neural Transm. 2004;111:523&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem. 2002;80:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948243</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 2005;307:935&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705855</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, R&#xfc;b U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64:1404&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851731</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down&#x2019;s syndrome. Neuron. 2002;33:677&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnevalli LS, Pereira CM, Jaqueta CB, Alves VS, Paiva VN, Vattem KM, Wek RC, Mello LE, Castilho BA. Phosphorylation of the alpha subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus. Biochem J. 2006;397:187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479748</ArticleId><ArticleId IdType="pubmed">16492139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B, Mattson MP. PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways. J Neurosci. 1995;15:7095&#x2013;7104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578094</ArticleId><ArticleId IdType="pubmed">7472464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiocco MJ, Kulnane LS, Younkin L, Younkin S, Evin G, Lamb BT. Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice. J Biol Chem. 2004;279:52535&#x2013;52542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659546</ArticleId><ArticleId IdType="pubmed">15452128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiocco MJ, Lamb BT. Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice. Neurobiol Aging. 2007;28:75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659539</ArticleId><ArticleId IdType="pubmed">16387391</ArticleId></ArticleIdList></Reference><Reference><Citation>Cigan AM, Bushman JL, Boal TR, Hinnebusch AG. A protein complex of translational regulators of GCN4 mRNA is the guanine nucleotide-exchange factor for translation initiation factor 2 in yeast. Proc Natl Acad Sci U S A. 1993;90:5350&#x2013;5354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46714</ArticleId><ArticleId IdType="pubmed">8506384</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the beta-amyloid precursor protein in familial Alzheimer&#x2019;s disease increases beta-protein production. Nature. 1992;360:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens MJ. Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis. Prog Mol Subcell Biol. 2001;27:57&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11575161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. Linking vascular disorders and Alzheimer&#x2019;s disease: Potential involvement of BACE1. Neurobiology of aging 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490488</ArticleId><ArticleId IdType="pubmed">18289733</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Gobert D, Harding H, Herdy B, Azzi M, Bruno M, Bidinosti M, Ben Mamou C, Marcinkiewicz E, Yoshida M, et al. Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature. 2005;436:1166&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464117</ArticleId><ArticleId IdType="pubmed">16121183</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Gobert D, Stern E, Gamache K, Colina R, Cuello C, Sossin W, Kaufman R, Pelletier J, Rosenblum K, et al. eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell. 2007;129:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149214</ArticleId><ArticleId IdType="pubmed">17418795</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980532</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Ferris SH, George AE, Christman DR, Fowler JS, Gentes C, Reisberg B, Gee B, Emmerich M, Yonekura Y, et al. Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol. 1983;4:568&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8334899</ArticleId><ArticleId IdType="pubmed">6410799</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer&#x2019;s disease. Annals of the New York Academy of Sciences. 2007;1097:114&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413016</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pietri Tonelli D, Mihailovich M, Di Cesare A, Codazzi F, Grohovaz F, Zacchetti D. Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res. 2004;32:1808&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390341</ArticleId><ArticleId IdType="pubmed">15034149</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Decarli C. Vascular factors in dementia: an overview. J Neurol Sci. 2004;226:19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537513</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitatzis A, Carroll K, Majeed AW, Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004;45:1613&#x2013;1622.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, Govoni S. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett. 1997;231:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietzen DW, Ross CM, Hao S, Sharp JW. Phosphorylation of eIF2alpha is involved in the signaling of indispensable amino acid deficiency in the anterior piriform cortex of the brain in rats. J Nutr. 2004;134:717&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">15051816</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, Bennett BD, Kahn S, Ross S, Burgess T, et al. Characterization of Alzheimer&#x2019;s beta -secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem. 2000;275:21099&#x2013;21106.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887202</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, Ron D. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/-mice reveals a role for translational control in secretory cell survival. Molecular cell. 2001;7:1153&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430819</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature. 1999;397:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930704</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer&#x2019;s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008;105:6415&#x2013;6420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359789</ArticleId><ArticleId IdType="pubmed">18434550</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol. 2005;6:318&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803138</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer&#x2019;s disease. Ann Neurol. 2002;51:783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer A, Bardenheuer HJ, Martin E, Plaschke K. Amyloid precursor protein (APP) and its derivatives change after cellular energy depletion. An in vitro-study. J Neural Transm. 2005;112:239&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15657641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490:115&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer&#x2019;s disease beta-secretase. J Biol Chem. 2000;275:33729&#x2013;33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999;14:419&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jousse C, Oyadomari S, Novoa I, Lu P, Zhang Y, Harding HP, Ron D. Inhibition of a constitutive translation initiation factor 2alpha phosphatase, CReP, promotes survival of stressed cells. J Cell Biol. 2003;163:767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173671</ArticleId><ArticleId IdType="pubmed">14638860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann E, Antion MD, Banko JL, Hou L. Synaptic plasticity and translation initiation. Learn Mem. 2004;11:365&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254214</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem. 2005;280:32499&#x2013;32504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033761</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Schobel S, Zimmer AK, Lichtenthaler SF, Haass C. Expression of the Alzheimer protease BACE1 is suppressed via its 5&#x2019;-untranslated region. EMBO Rep. 2004;5:620&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299076</ArticleId><ArticleId IdType="pubmed">15167888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends in biochemical sciences. 2001;26:504&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">11504627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski JQ, Lee VM. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol. 2005;168:291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer&#x2019;s disease patients. Proc Natl Acad Sci U S A. 2004;101:3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 2000;97:1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. Mice deficient in BACE1, the Alzheimer&#x2019;s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994;87:504&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">8059603</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Seminars in cell &amp; developmental biology. 2007;18:716&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706143</ArticleId><ArticleId IdType="pubmed">18023214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihailovich M, Thermann R, Grohovaz F, Hentze MW, Zacchetti D. Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5&#x2019; untranslated region. Nucleic Acids Res 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888809</ArticleId><ArticleId IdType="pubmed">17439957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell SL. Extrapyramidal features in Alzheimer&#x2019;s disease. Age Ageing. 1999;28:401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">10459796</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri MH, Saini KD, Nitsch RM. Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. J Neural Transm. 2004;111:413&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer&#x2019;s disease using neuroimaging. Experimental gerontology. 2007;42:129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839732</ArticleId></ArticleIdList></Reference><Reference><Citation>Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001;153:1011&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174339</ArticleId><ArticleId IdType="pubmed">11381086</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Temporal memory deficits in Alzheimer&#x2019;s mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006;23:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer&#x2019;s disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ, Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741373</ArticleId><ArticleId IdType="pubmed">16931765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozmen L, Woolley M, Albientz A, Miss MT, Nelboeck P, Malherbe P, Czech C, Gruninger-Leitch F, Brockhaus M, Ballard T, Jacobsen H. BACE/APPV717F double-transgenic mice develop cerebral amyloidosis and inflammation. Neurodegener Dis. 2005;2:284&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909011</ArticleId></ArticleIdList></Reference><Reference><Citation>Paschen W, Mengesdorf T. Cellular abnormalities linked to endoplasmic reticulum dysfunction in cerebrovascular disease--therapeutic potential. Pharmacol Ther. 2005;108:362&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16140387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavitt GD. eIF2B, a mediator of general and gene-specific translational control. Biochem Soc Trans. 2005;33:1487&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246152</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel AL, Bredesen DE. Activation of the cell stress kinase PKR in Alzheimer&#x2019;s disease and human amyloid precursor protein transgenic mice. Neurobiol Dis. 2003;14:52&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678666</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak P, Oren A, Ben-Dror I, Steinberg D, Sapoznik S, Arditi-Duvdevany A, Vardimon L. The cytoskeletal network controls c-Jun translation in a UTR-dependent manner. Oncogene. 2006;25:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247475</ArticleId></ArticleIdList></Reference><Reference><Citation>Proud CG. Regulation of eukaryotic initiation factor eIF2B. Prog Mol Subcell Biol. 2001;26:95&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">11575168</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W. Degradation of BACE by the ubiquitin-proteasome pathway. Faseb J. 2004;18:1571&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289451</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao GN. Oxidant stress stimulates phosphorylation of eIF4E without an effect on global protein synthesis in smooth muscle cells. Lack of evidence for a role of H202 in angiotensin II-induced hypertrophy. J Biol Chem. 2000;275:16993&#x2013;16999.</Citation><ArticleIdList><ArticleId IdType="pubmed">10828072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI. Functional brain imaging in the resting state and during activation in Alzheimer&#x2019;s disease. Implications for disease mechanisms involving oxidative phosphorylation. Ann N Y Acad Sci. 1999a;893:138&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer&#x2019;s disease. Eur Arch Psychiatry Clin Neurosci. 1999b;249(Suppl 3):46&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10654100</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers GW, Jr, Edelman GM, Mauro VP. Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci U S A. 2004;101:2794&#x2013;2799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365699</ArticleId><ArticleId IdType="pubmed">14981268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK. Gene structure and organization of the human beta-secretase (BACE) promoter. Faseb J. 2004;18:1034&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059975</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S, Kaufman RJ. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Molecular cell. 2001;7:1165&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430820</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder M, Kaufman RJ. Divergent roles of IRE1alpha and PERK in the unfolded protein response. Curr Mol Med. 2006;6:5&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennvik K, Bogdanovic N, Volkmann I, Fastbom J, Benedikz E. Beta-secretase-cleaved amyloid precursor protein in Alzheimer brain: a morphologic study. J Cell Mol Med. 2004;8:127&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740108</ArticleId><ArticleId IdType="pubmed">15090268</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005;8:1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer&#x2019;s disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Soane L, Kahraman S, Kristian T, Fiskum G. Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J Neurosci Res. 2007;85:3407&#x2013;3415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570316</ArticleId><ArticleId IdType="pubmed">17847081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood R, Porter AC, Olsen DA, Cavener DR, Wek RC. A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2alpha. Genetics. 2000;154:787&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1460965</ArticleId><ArticleId IdType="pubmed">10655230</ArticleId></ArticleIdList></Reference><Reference><Citation>Spruill LS, Baicu CF, Zile MR, McDermott PJ. Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload. J Mol Cell Cardiol. 2008;44:69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246077</ArticleId><ArticleId IdType="pubmed">18036610</ArticleId></ArticleIdList></Reference><Reference><Citation>Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer&#x2019;s disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7:63&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750215</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl K. The DNA-binding domains of the jun oncoprotein and the yeast GCN4 transcriptional activator protein are functionally homologous. Cell. 1987;50:841&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">3040261</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczygielski J, Mautes A, Steudel WI, Falkai P, Bayer TA, Wirths OJ. Traumatic brain injury: cause or risk of Alzheimer&#x2019;s disease? A review of experimental studies. Neural Transm. 2005;112:1547&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem. 2005;92:628&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanahashi H, Tabira T. Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production. Neurosci Lett. 2001;307:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner PR, O&#x2019;Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003;70:1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. alpha- and beta-secretase: profound changes in Alzheimer&#x2019;s disease. Biochem Biophys Res Commun. 2002;299:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardimon L, Ben-Dror I, Oren A, Polak P. Cytoskeletal and cell contact control of the glucocorticoid pathway. Mol Cell Endocrinol. 2006;252:142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez de Aldana CR, Dever TE, Hinnebusch AG. Mutations in the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2 alpha) that overcome the inhibitory effect of eIF-2 alpha phosphorylation on translation initiation. Proc Natl Acad Sci U S A. 1993;90:7215&#x2013;7219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47107</ArticleId><ArticleId IdType="pubmed">8102207</ArticleId></ArticleIdList></Reference><Reference><Citation>Velliquette RA, O&#x2019;Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer&#x2019;s disease pathogenesis. J Neurosci. 2005;25:10874&#x2013;10883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725876</ArticleId><ArticleId IdType="pubmed">16306400</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt PK, Bos TJ, Doolittle RF. Homology between the DNA-binding domain of the GCN4 regulatory protein of yeast and the carboxyl-terminal region of a protein coded for by the oncogene jun. Proc Natl Acad Sci U S A. 1987;84:3316&#x2013;3319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304860</ArticleId><ArticleId IdType="pubmed">3554236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT. The expression of microRNA miR-107 decreases early in Alzheimer&#x2019;s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28:1213&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837363</ArticleId><ArticleId IdType="pubmed">18234899</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster MT, Pearce BR, Bowen DM, Francis PT. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm. 1998;105:839&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 2004;1009:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120577</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Yu WH, Maloney B, Bailey J, Ma J, Marie I, Maurin T, Wang L, Figueroa H, Herman M, et al. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008;57:680&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329816</ArticleId><ArticleId IdType="pubmed">18341989</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Dewachter I, Smyth N, Van Dooren T, Borghgraef P, Haass C, Van Leuven F. beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am J Pathol. 2004;165:1621&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618675</ArticleId><ArticleId IdType="pubmed">15509532</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:52&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, et al. Membrane-anchored aspartyl protease with Alzheimer&#x2019;s disease beta-secretase activity. Nature. 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W, Frank CL, Korth MJ, Sopher BL, Novoa I, Ron D, Katze MG. Control of PERK eIF2alpha kinase activity by the endoplasmic reticulum stress-induced molecular chaperone P58IPK. Proc Natl Acad Sci U S A. 2002;99:15920&#x2013;15925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC138540</ArticleId><ArticleId IdType="pubmed">12446838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG. The role of A beta 42 in Alzheimer&#x2019;s disease. J Physiol Paris. 1998;92:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9789825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology. 2006;66:S102&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O&#x2019;Connor T, Logan S, Maus E, Citron M, Berry R, et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer&#x2019;s disease pathogenesis. J Neurosci. 2007;27:3639&#x2013;3649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Song W. Leaky scanning and reinitiation regulate BACE1 gene expression. Mol Cell Biol. 2006;26:3353&#x2013;3364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1447409</ArticleId><ArticleId IdType="pubmed">16611980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10072051</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.</ArticleTitle><Pagination><StartPage>358</StartPage><EndPage>368</EndPage><MedlinePgn>358-68</MedlinePgn></Pagination><Abstract><AbstractText>The distribution and density of neurofibrillary tangles and amyloid plaques was studied in a unique series of cases whose premortem cognitive status had been assessed with the Clinical Dementia Rating (CDR), including 39 nondemented cases (CDR = 0; age, 51-88 years), 15 very mildly demented cases (CDR = 0.5), and 8 severely demented (CDR = 3) cases. The initial formation of tangles and plaques in healthy aging appeared to be independent of each other. Tangles were found in all the nondemented cases, especially in hippocampal and parahippocampal areas; the average tangle concentration increased exponentially with age. In contrast, plaques were absent in some brains up to age 88, and the earliest plaque formation in other cases occurred in the neocortex, in patches of diffuse plaques. Widely distributed neuritic as well as diffuse plaques throughout neocortex and limbic structures characterized a further group of nondemented cases. In these cases there was also a substantial increase over other nondemented cases, both in the number of tangles and in the rate of increase in tangles with age, suggesting an interaction between amyloid and neurofibrillary change at this stage. Such cases closely resemble CDR = 0.5 cases, and it is proposed they represent "preclinical" Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Price</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId><ArticleId IdType="doi">10.1002/1531-8249(199903)45:3&lt;358::aid-ana12&gt;3.0.co;2-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23137949</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Florbetapir PET analysis of amyloid-&#x3b2; deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.</ArticleTitle><Pagination><StartPage>1057</StartPage><EndPage>1065</EndPage><MedlinePgn>1057-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(12)70227-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(12)70227-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Fibrillar amyloid-&#x3b2; (A&#x3b2;) is thought to begin accumulating in the brain many years before the onset of clinical impairment in patients with Alzheimer's disease. By assessing the accumulation of A&#x3b2; in people at risk of genetic forms of Alzheimer's disease, we can identify how early preclinical changes start in individuals certain to develop dementia later in life. We sought to characterise the age-related accumulation of A&#x3b2; deposition in presenilin 1 (PSEN1) E280A mutation carriers across the spectrum of preclinical disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between Aug 1 and Dec 6, 2011, members of the familial Alzheimer's disease Colombian kindred aged 18-60 years were recruited from the Alzheimer's Prevention Initiative's registry at the University of Antioquia, Medell&#xed;n, Colombia. Cross-sectional assessment using florbetapir PET was done in symptomatic mutation carriers with mild cognitive impairment or mild dementia, asymptomatic carriers, and asymptomatic non-carriers. These assessments were done at the Banner Alzheimer's Institute in Phoenix, AZ, USA. A cortical grey matter mask consisting of six predefined regions.was used to measure mean cortical florbetapir PET binding. Cortical-to-pontine standard-uptake value ratios were used to characterise the cross-sectional accumulation of fibrillar A&#x3b2; deposition in carriers and non-carriers with regression analysis and to estimate the trajectories of fibrillar A&#x3b2; deposition.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We enrolled a cohort of 11 symptomatic individuals, 19 presymptomatic mutation carriers, and 20 asymptomatic non-carriers, ranging in age from 20 to 56 years. There was greater florbetapir binding in asymptomatic PSEN1 E280A mutation carriers than in age matched non-carriers. Fibrillar A&#x3b2; began to accumulate in PSEN 1E280A mutation carriers at a mean age of 28&#xb7;2 years (95% CI 27&#xb7;3-33&#xb7;4), about 16 years and 21 years before the predicted median ages at mild cognitive impairment and dementia onset, respectively. (18)F florbetapir binding rose steeply over the next 9&#xb7;4 years and plateaued at a mean age of 37&#xb7;6 years (95% CI 35&#xb7;3-40&#xb7;2), about 6 and 11 years before the expected respective median ages at mild cognitive impairment and dementia onset. Prominent florbetapir binding was seen in the anterior and posterior cingulate, precuneus, and parietotemporal and frontal grey matter, as well as in the basal ganglia. Binding in the basal ganglia was not seen earlier or more prominently than in other regions.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings contribute to the understanding of preclinical familial Alzheimer's disease and help set the stage for assessment of amyloid-modifying treatments in the prevention of familial Alzheimer's disease.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Avid Radiopharmaceuticals, Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Colciencias, National Institute on Aging, and the State of Arizona.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA. adam.fleisher@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Jakimovich</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Madelyn Gutierrez</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Langois</LastName><ForeName>Carolyn M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Ayutyanont</LastName><ForeName>Napatkamon</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Roontiva</LastName><ForeName>Auttawut</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thiyyagura</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Acosta-Baena</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Margarita</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2012 Dec;11(12):1018-20. doi: 10.1016/S1474-4422(12)70255-7.</RefSource><PMID Version="1">23137951</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2013 Jan;9(1):4. doi: 10.1038/nrneurol.2012.243.</RefSource><PMID Version="1">23165336</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. ASF served as a consultant to Eli Lilly and Avid Radiopharmaceuticals and received grant funding from Avid Radiopharmaceuticals. The Banner Alzheimer&#x2019;s Foundation has received compensation for undertaking educational programs for Avid Radiopharmaceuticals and Eli Lilly staff, which ASF contributed time towards. KSK serves as a scientific adviser to Amgen, Genentech, iPierian, and Noscira; serves on the board of Minerva Biotechnologies; and has had research contracts with the NIA and the California Institute for Regenerative Medicine. PNT has received consulting fees from Abbott Laboratories, AC Immune, Adamas, Allergan, Avanir, Boehringer-Ingelheim, Chase Pharmaceuticals, Chiesi, Eisai, Elan, Medavante, Merz, Neuroptix, Novartis, Otsuka, Sanofi-Aventis, Schering-Plough, and Worldwide Clinical Trials; consulting fees and research support from AstraZeneca, Avid Radiopharmaceuticals, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Medivation, Merck and Company, Pfizer, Roche, Toyama, and Wyeth Laboratories; research support from Baxter Healthcare, Functional Neuromodulation, GE Healthcare, and Targacept; and other research support from NIA, National Institute of Mental Health, Alzheimer&#x2019;s Association, and Arizona Department of Health Services. PNT also has stock options in Medavante and Adamas and holds a patent for biomarkers of Alzheimer&#x2019;s disease. EMR has received research funding from Avid Radiopharmaceuticals and holds a paid consultation role for Eli Lilly. KC, YTQ, LJJ, MGG, CML, JBSL, NA, AR, PT, WL, HM, LL, SM, NA-B, MG, GG, RAR, MJH, and FL declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23137949</ArticleId><ArticleId IdType="mid">NIHMS421955</ArticleId><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70227-2</ArticleId><ArticleId IdType="pii">S1474-4422(12)70227-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr. 1997;9 (suppl 1):257&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17:101&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque-Castano A, Roldan MI, Arango-Viana JC, Arcos-Burgos M, Cubillo H, Lopera F. Neuropathological findings in early-onset Alzheimer&#x2019;s disease (E280a-PS1 mutation) Rev Neurol. 1999;29:1&#x2013;6. [Spanish]</Citation><ArticleIdList><ArticleId IdType="pubmed">10528300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Tariot PN. Alzheimer&#x2019;s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010;4:3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850446</ArticleId><ArticleId IdType="pubmed">20383319</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Houston WS, Eyler LT, et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol. 2005;62:1881&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344346</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2009;106:6820&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol. 2011;10:213&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, Almkvist O, Axelman K, et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging. 2011;32:1388&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">19796846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115:1449&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137006</ArticleId><ArticleId IdType="pubmed">15931380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277:793&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012 published online Nov 6.  http://dx.doi.org/10.1016/S1474-4422(12)70228-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70228-4</ArticleId><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43:1467&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh JI, Yesavage JA. Geriatric depression scale (GDS): recent evidence and development of a shorter version. In: Brink TL, editor. Clinical gerontology: a guide to assessment and intervention. New York: The Haworth Press; 1986. pp. 165&#x2013;73.</Citation></Reference><Reference><Citation>Reisberg B. Functional assessment staging (FAST) Psychopharmacol Bull. 1988;24:653&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249767</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. APOE4 and age effects on florbetapir PET in healthy aging and Alzheimer disease. Neurobiol Aging. 2012 doi: 10.1016/j.neurobiolaging.2012.04.017. published online May 28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.04.017</ArticleId><ArticleId IdType="pubmed">22633529</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer&#x2019;s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">22628162</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Hinz R, Ramlackhansingh A, et al. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PiB brain scans? Neuroimage. 2012;60:1716&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">22306804</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Zhou Y, An Y, et al. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol. 2011;68:644&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136195</ArticleId><ArticleId IdType="pubmed">21555640</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Cantwell MN, Greer PJ, et al. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med. 2000;41:1842&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079492</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohka J, Zijdenbos A, Evans A. Fast and robust parameter estimation for statistical partial volume models in brain MRI. Neuroimage. 2004;23:84&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15325355</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J, Verkkoniemi A, Aalto S, et al. PET amyloid ligand [11C] PIB uptake shows predominantly striatal increase in variant Alzheimer&#x2019;s disease. Brain. 2008;131:1845&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18583368</ArticleId></ArticleIdList></Reference><Reference><Citation>Remes AM, Laru L, Tuominen H, et al. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol. 2008;65:540&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18413480</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Alzheimer&#x2019;s disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol. 1990;49:215&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">1692337</ArticleId></ArticleIdList></Reference><Reference><Citation>Suenaga T, Hirano A, Llena JF, Yen SH, Dickson DW. Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer&#x2019;s disease. Acta Neuropathol. 1990;80:280&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">1698005</ArticleId></ArticleIdList></Reference><Reference><Citation>Brilliant MJ, Elble RJ, Ghobrial M, Struble RG. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol. 1997;23:322&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9292871</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065020</ArticleId><ArticleId IdType="pubmed">19837759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23137948</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.</ArticleTitle><Pagination><StartPage>1048</StartPage><EndPage>1056</EndPage><MedlinePgn>1048-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(12)70228-4</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(12)70228-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medell&#xed;n Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF A&#x3b2;(1-42), total tau and phospho-tau(181) concentrations, and plasma A&#x3b2;(1-42) concentrations and A&#x3b2;(1-42):A&#x3b2;(1-40) ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) &#x25b;4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0&#xb7;001 and p&lt;0&#xb7;014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p&lt;0&#xb7;010 after correction), and less grey matter in several parietal regions (all p&lt;0&#xb7;002 uncorrected and corrected p=0&#xb7;009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF A&#x3b2;(1-42) concentrations (p=0&#xb7;008) and plasma A&#x3b2;(1-42) concentrations (p=0&#xb7;01) than non-carriers.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with A&#x3b2;(1-42) overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA. eric.reiman@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Velez-Pardo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jimenez-Del-Rio</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Arbelaez</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Margarita</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Acosta-Baena</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Chantal E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Tirado</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025526</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG041705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS078786</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG041705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31-NS078786</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2012 Dec;11(12):1017-8. doi: 10.1016/S1474-4422(12)70256-9.</RefSource><PMID Version="1">23137950</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2013 Jan;9(1):4. doi: 10.1038/nrneurol.2012.243.</RefSource><PMID Version="1">23165336</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="Y">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23137948</ArticleId><ArticleId IdType="mid">NIHMS421823</ArticleId><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70228-4</ArticleId><ArticleId IdType="pii">S1474-4422(12)70228-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Association workgroup. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci U S A. 2004;101(1):284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Valla J, Yaari R, Wolf AB, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer&#x2019;s susceptibility gene. J Alzheimers Dis. 2010;22(1):307&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124564</ArticleId><ArticleId IdType="pubmed">20847408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P, Lerch JP, Pruessner JC, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007;6(6):494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106(17):7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2011;2(6):35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71(2):85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31(10):2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. N Engl J Med. 2012 epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277(10):793&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Budson AE, Celone K, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer&#x2019;s disease. Ann Neurol. 2010;68(6):865&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175143</ArticleId><ArticleId IdType="pubmed">21194156</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz Y, Stern C, Reiman EM, et al. Cortical signature of Alzheimer&#x2019;s disease-related thinning in presymptomatic presenilin-1 mutation carriers. Alzheimers Dement. 2011;7(4):S220.</Citation></Reference><Reference><Citation>Mondadori CR, Buchmann A, Mustovic H, et al. Enhanced brain activity may precede the diagnosis of Alzheimer&#x2019;s disease by 30 years. Brain. 2006;129(Pt 11):2908&#x2013;2922.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012294</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, Fox NC. Acceleration of cortical thinning in familial Alzheimer&#x2019;s disease. Neurobiol Aging. 2011;32(10):1765&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">20005601</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer&#x2019;s disease: an independent component analysis. J Neurosci. 2006;26(40):10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, et al. The Cortical Signature of Alzheimer&#x2019;s Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals. Cerebral Cortex. 2009;19(3):497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Age-associated fibrillar amyloid-&#x3b2; deposition in individuals from the presenilin 1 E280A autosomal-dominant Alzheimer&#x2019;s disease kindred. Lancet Neurol. Submitted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Acevedo DC, Gomez RD, Moreno S, et al. Validity and reliability of the CERAD-Col neuropsychological battery. Rev Neurol. 2007;45(11):655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18050096</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/&#x3b2;- amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Coppola G, Elashoff D, et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2012;33(1):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696356</ArticleId><ArticleId IdType="pubmed">22343824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi T, Dolios G, Kim SH, Wang R, Sisodia SS. Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of &#x201c;gamma-secretase&#x201d;. J Biol Chem. 2003;278(9):7010&#x2013;7018.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493731</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the &#x3b5;4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Vaishnavi SN, Couture L, et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta ) deposition. Proc Natl Acad Sci U S A. 2010;107(41):17763&#x2013;17767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955133</ArticleId><ArticleId IdType="pubmed">20837517</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13(2):190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14(6):750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer&#x2019;s disease. J Nucl Med. 2006;47(11):1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS, Tariot PN. Alzheimer&#x2019;s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers in Medicine. 2010;4(1):3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850446</ArticleId><ArticleId IdType="pubmed">20383319</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme Medical Publishers; New York: 1988.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12506200</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.</ArticleTitle><Pagination><StartPage>330</StartPage><EndPage>335</EndPage><MedlinePgn>330-5</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid beta-protein (Abeta) is linked to neuronal injury and death in Alzheimer's disease (AD). Of particular relevance for elucidating the role of Abeta in AD is new evidence that oligomeric forms of Abeta are potent neurotoxins that play a major role in neurodegeneration and the strong association of the 42-residue form of Abeta, Abeta42, with the disease. Detailed knowledge of the structure and assembly dynamics of Abeta thus is important for the development of properly targeted AD therapeutics. Recently, we have shown that Abeta oligomers can be cross-linked efficiently, and their relative abundances quantified, by using the technique of photo-induced cross-linking of unmodified proteins (PICUP). Here, PICUP, size-exclusion chromatography, dynamic light scattering, circular dichroism spectroscopy, and electron microscopy have been combined to elucidate fundamental features of the early assembly of Abeta40 and Abeta42. Carefully prepared aggregate-free Abeta40 existed as monomers, dimers, trimers, and tetramers, in rapid equilibrium. In contrast, Abeta42 preferentially formed pentamerhexamer units (paranuclei) that assembled further to form beaded superstructures similar to early protofibrils. Addition of Ile-41 to Abeta40 was sufficient to induce formation of paranuclei, but the presence of Ala-42 was required for their further association. These data demonstrate that Abeta42 assembly involves formation of several distinct transient structures that gradually rearrange into protofibrils. The strong etiologic association of Abeta42 with AD may thus be a result of assemblies formed at the earliest stages of peptide oligomerization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bitan</LastName><ForeName>Gal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkitadze</LastName><ForeName>Marina D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Lomakin</LastName><ForeName>Aleksey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vollers</LastName><ForeName>Sabrina S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Benedek</LastName><ForeName>George B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Teplow</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG14366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18921</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018921</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38328</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS038328</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2002</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>12</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>22</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>12</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2003</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12506200</ArticleId><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="doi">10.1073/pnas.222681699</ArticleId><ArticleId IdType="pii">222681699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J A, Higgins G A. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. J Neuropathol Exp Neurol. 1994;53:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. Proc Natl Acad Sci USA. 1997;94:2095&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33655</ArticleId><ArticleId IdType="pubmed">9122152</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner G G, Wong C W. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters C L, Simms G, Weinman N A, Multhaup G, McDonald B L, Beyreuther K. Proc Natl Acad Sci USA. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein W L, Krafft G A, Finch C E. Trends Neurosci. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G Q, Mallory M, Rockenstein E M, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper J D, Wong S S, Lieber C M, Lansbury P T. Chem Biol. 1997;4:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190286</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D M, Lomakin A, Benedek G B, Condron M M, Teplow D B. J Biol Chem. 1997;272:22364&#x2013;22372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Wals P, Osterburg H H, Johnson S A, Pasinetti G M, Morgan T E, Rozovsky I, Stine W B, Snyder S W, Holzman T F, et al. Exp Neurol. 1995;136:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">7589331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert M P, Barlow A K, Chromy B A, Edwards C, Freed R, Liosatos M, Morgan T E, Rozovsky I, Trommer B, Viola K L, et al. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D M, Hartley D M, Kusumoto Y, Fezoui Y, Condron M M, Lomakin A, Benedek G B, Selkoe D J, Teplow D B. J Biol Chem. 1999;274:25945&#x2013;25952.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley D M, Walsh D M, Ye C P P, Diehl T, Vasquez S, Vassilev P M, Teplow D B, Selkoe D J. J Neurosci. 1999;19:8876&#x2013;8884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, Westlind-Danielsson A, Eckman C B, Condron M M, Axelman K, Forsell C, Stenh C, Luthman J, Teplow D B, Younkin S G, et al. Nat Neurosci. 2001;4:887&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D M, Klyubin I, Fadeeva J V, Cullen W K, Anwyl R, Wolfe M S, Rowan M J, Selkoe D J. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung T T, Cai X-D, Odaka A, Otvos L, Jr, Eckman C, Golde T E, Younkin S G. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina S A, Ho L B, Eckman C B, Long K E, Otvos L, Jr, Younkin L H, Suzuki N, Younkin S G. J Biol Chem. 1995;270:7013&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706234</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T D, Hardy J, Hutton M, Kukull W, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T E, Eckman C B, Younkin S G. Biochim Biophys Acta Mol Basis Dis. 2000;1502:172&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen J L, Das P, Sagi S A, Wang R, Pietrzik C U, Findlay K A, Smith T W, Murphy M P, Butler T, et al. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin S G. Ann Neurol. 1995;37:287&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695227</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. Nature. 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren K N, Manelli A M, Stine W B, Baker L K, Krafft G A, LaDu M J. J Biol Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett J T, Berger E P, Lansbury P T., Jr Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow D B. Int J Exp Clin Invest. 1998;5:121&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">9686307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Lomakin A, Teplow D B. J Biol Chem. 2001;276:35176&#x2013;35184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fezoui Y, Hartley D M, Harper J D, Khurana R, Walsh D M, Condron M M, Selkoe D J, Lansbury P T, Fink A L, Teplow D B. Int J Exp Clin Invest. 2000;7:166&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11019857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A, Benedek G B, Teplow D B. Methods Enzymol. 1999;309:429&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A, Chung D S, Benedek G B, Kirschner D A, Teplow D B. Proc Natl Acad Sci USA. 1996;93:1125&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40042</ArticleId><ArticleId IdType="pubmed">8577726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkitadze M D, Condron M M, Teplow D B. J Mol Biol. 2001;312:1103&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">11580253</ArticleId></ArticleIdList></Reference><Reference><Citation>Fancy D A, Kodadek T. Proc Natl Acad Sci USA. 1999;96:6020&#x2013;6024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26828</ArticleId><ArticleId IdType="pubmed">10339534</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell L C. Biochim Biophys Acta. 2000;1502:16&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nybo M, Svehag S E, Nielsen E H. Scand J Immunol. 1999;49:219&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102637</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio T R, Cashikar A G, Kowal A S, Sawicki G J, Moslehi J J, Serpell L, Arnsdorf M F, Lindquist S L. Science. 2000;289:1317&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958771</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S H, Bevis B, Arnsdorf M F. Biophys J. 2001;81:446&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301524</ArticleId><ArticleId IdType="pubmed">11423427</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackley H K L, Sanders G H W, Davies M C, Roberts C J, Tendler S J B, Wilkinson M J. J Mol Biol. 2000;298:833&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A, Teplow D B, Kirschner D A, Benedek G B. Proc Natl Acad Sci USA. 1997;94:7942&#x2013;7947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21534</ArticleId><ArticleId IdType="pubmed">9223292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11932745</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>416</Volume><Issue>6880</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.</ArticleTitle><Pagination><StartPage>535</StartPage><EndPage>539</EndPage><MedlinePgn>535-9</MedlinePgn></Pagination><Abstract><AbstractText>Although extensive data support a central pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, the amyloid hypothesis remains controversial, in part because a specific neurotoxic species of Abeta and the nature of its effects on synaptic function have not been defined in vivo. Here we report that natural oligomers of human Abeta are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell. Cerebral microinjection of cell medium containing these oligomers and abundant Abeta monomers but no amyloid fibrils markedly inhibited hippocampal long-term potentiation (LTP) in rats in vivo. Immunodepletion from the medium of all Abeta species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Abeta monomers but not oligomers, did not prevent the inhibition of LTP. Therefore, Abeta oligomers, in the absence of monomers and amyloid fibrils, disrupted synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid. Finally, treatment of cells with gamma-secretase inhibitors prevented oligomer formation at doses that allowed appreciable monomer production, and such medium no longer disrupted LTP, indicating that synaptotoxic Abeta oligomers can be targeted therapeutically.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klyubin</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Fadeeva</LastName><ForeName>Julia V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>William K</ForeName><Initials>WK</Initials></Author><Author ValidYN="Y"><LastName>Anwyl</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Rowan</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.56</RegistryNumber><NameOfSubstance UI="D007339">Insulysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2002 Apr 4;416(6880):483-4. doi: 10.1038/416483a.</RefSource><PMID Version="1">11932723</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007339" MajorTopicYN="N">Insulysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008861" MajorTopicYN="N">Microsomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pii">416535a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19242475</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>457</Volume><Issue>7233</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.</ArticleTitle><Pagination><StartPage>1128</StartPage><EndPage>1132</EndPage><MedlinePgn>1128-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature07761</ELocationID><Abstract><AbstractText>A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laur&#xe9;n</LastName><ForeName>Juha</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Yale University School of Medicine, New Haven, Connecticut 06536, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimbel</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Haakon B</ForeName><Initials>HB</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS033020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DA018343</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32GN07205</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2009 Feb 26;457(7233):1090-1. doi: 10.1038/4571090a.</RefSource><PMID Version="1">19242462</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2010 Aug 12;466(7308):E3-4; discussion E4-5. doi: 10.1038/nature09217.</RefSource><PMID Version="1">20703260</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="Y">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19242475</ArticleId><ArticleId IdType="mid">NIHMS102739</ArticleId><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="doi">10.1038/nature07761</ArticleId><ArticleId IdType="pii">nature07761</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440(7082):352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy BA, et al. Self-assembly of Abeta(1&#x2013;42) into globular neurotoxins. Biochemistry. 2003;42(44):12749&#x2013;12760.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer&#x2019;s disease. J Neurosci. 2007;27(4):796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Synaptic targeting by Alzheimer&#x2019;s-related amyloid beta oligomers. J Neurosci. 2004;24(45):10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27(11):2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler RW, et al. Solution State Characterization of Amyloid &#x3b2;-Derived Diffusible Ligands. Biochemistry. 2006;45(51):15157&#x2013;15167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95(11):6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer&#x2019;s disease. Nature. 1996;382(6593):685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, et al. beta-Amyloid(1&#x2013;42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem. 2000;275(8):5626&#x2013;5632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>Viles JH, et al. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc Natl Acad Sci U S A. 1999;96(5):2042&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26733</ArticleId><ArticleId IdType="pubmed">10051591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GS, et al. Location and properties of metal-binding sites on the human prion protein. Proceedings of the National Academy of Sciences of the United states of America. 2001;98(15):8531&#x2013;8535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37470</ArticleId><ArticleId IdType="pubmed">11438695</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. Embo J. 2007;26(2):538&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783444</ArticleId><ArticleId IdType="pubmed">17245436</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, et al. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105&#x2013;125. Embo J. 2007;26(2):548&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783448</ArticleId><ArticleId IdType="pubmed">17245437</ArticleId></ArticleIdList></Reference><Reference><Citation>Riek R, et al. NMR structure of the mouse prion protein domain PrP(121&#x2013;321) Nature. 1996;382(6587):180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8700211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueler H, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356(6370):577&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373228</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JC, et al. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Molecular neurobiology. 1994;8((2&#x2013;3)):121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7999308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lledo PM, Tremblay P, DeArmond SJ, Prusiner SB, Nicoll RA. Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus. Proc Natl Acad Sci U S A. 1996;93(6):2403&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39809</ArticleId><ArticleId IdType="pubmed">8637886</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis J, Errington M, Bliss T, Voss K, MacLeod N. Age-dependent loss of PTP and LTP in the hippocampus of PrP-null mice. Neurobiology of disease. 2003;13(1):55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12758067</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemenschneider M, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology. 2004;63(2):364&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277640</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, et al. The prion gene is associated with human long-term memory. Human molecular genetics. 2005;14(15):2241&#x2013;2246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987701</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehiely F, et al. Identification of candidate proteins binding to prion protein. Neurobiology of disease. 1997;3(4):339&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173930</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt-Ulms G, et al. Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nature biotechnology. 2004;22(6):724&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">15146195</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkitaramani DV, et al. Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci. 2007;27(44):11832&#x2013;11837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671021</ArticleId><ArticleId IdType="pubmed">17978019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52(5):831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravani H, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. The Journal of cell biology. 2008;181(3):551&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364707</ArticleId><ArticleId IdType="pubmed">18443219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8849730</PMID><DateCompleted><Year>1996</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>383</Volume><Issue>6600</Issue><PubDate><Year>1996</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans.</ArticleTitle><Pagination><StartPage>550</StartPage><EndPage>553</EndPage><MedlinePgn>550-3</MedlinePgn></Pagination><Abstract><AbstractText>The paired helical filament (PHF) is the major component of the neurofibrillary deposits that form a defining neuropathological characteristic of Alzheimer's disease. PHFs are composed of microtubule-associated protein tau, in a hyperphosphorylated state. Hyperphosphorylation of tau results in its inability to bind to microtubules and is believed to precede PHF assembly. However, it is unclear whether hyperphosphorylation of tau is either necessary or sufficient for PHF formation. Here we show that non-phosphorylated recombinant tau isoforms with three microtubule-binding repeats form paired helical-like filaments under physiological conditions in vitro, when incubated with sulphated glycosaminoglycans such as heparin or heparan sulphate. Furthermore, heparin prevents tau from binding to microtubules and promotes microtubule disassembly. Finally, we show that heparan sulphate and hyperphosphorylated tau coexist in nerve cells of the Alzheimer's disease brain at the earliest known stages of neurofibrillary pathology. These findings, with previous studies which show that heparin stimulates tau phosphorylation by a number of protein kinases, indicate that sulphated glycosaminoglycans may be a key factor in the formation of the neurofibrillary lesions of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakes</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Spillantini</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 1996 Oct 10;383(6600):476-7. doi: 10.1038/383476a0.</RefSource><PMID Version="1">8849716</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId><ArticleId IdType="doi">10.1038/383550a0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21325519</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant.</ArticleTitle><Pagination><StartPage>2511</StartPage><EndPage>2525</EndPage><MedlinePgn>2511-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5245-10.2011</ELocationID><Abstract><AbstractText>This report describes the behavioral and electrophysiological analysis of regulatable transgenic mice expressing mutant repeat domains of human Tau (Tau(RD)). Mice were generated to express Tau(RD) in two forms, differing in their propensity for &#x3b2;-structure and thus in their tendency for aggregation ("pro-aggregant" or "anti-aggregant") (Mocanu et al., 2008). Only pro-aggregant mice show pronounced changes typical for Tau pathology in Alzheimer's disease (aggregation, missorting, hyperphosphorylation, synaptic and neuronal loss), indicating that the &#x3b2;-propensity and hence the ability to aggregate is a key factor in the disease. We now tested the mice with regard to neuromotor parameters, behavior, learning and memory, and synaptic plasticity and correlated this with histological and biochemical parameters in different stages of switching Tau(RD) on or off. The mice are normal in neuromotor tests. However, pro-aggregant Tau(RD) mice are strongly impaired in memory and show pronounced loss of long-term potentiation (LTP), suggesting that Tau aggregation specifically perturbs these brain functions. Remarkably, when the expression of human pro-aggregant Tau(RD) is switched on for &#x223c; 10 months and off for &#x223c; 4 months, memory and LTP recover, whereas aggregates decrease moderately and change their composition from mixed human plus mouse Tau to mouse Tau only. Neuronal loss persists, but synapses are partially rescued. This argues that continuous presence of amyloidogenic pro-aggregant Tau(RD) constitutes the main toxic insult for memory and LTP, rather than the aggregates as such.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max Planck Unit for Structural Molecular Biology, c/o DESY, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Jeugd</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Tariq</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Balschun</LastName><ForeName>Detlef</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Petrova</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Drexler</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lepu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rune</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>D'Hooge</LastName><ForeName>Rudi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Alzheimer</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21325519</ArticleId><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5245-10.2011</ArticleId><ArticleId IdType="pii">31/7/2511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, Lewis J, Leighty R, McGowan E, Cracchiolo JR, Hutton M, Garcia MF. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res. 2004;1012:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15158158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Balschun D, Wolfer DP, Bertocchini F, Barone V, Conti A, Zuschratter W, Missiaen L, Lipp HP, Frey JU, Sorrentino V. Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning. EMBO J. 1999;18:5264&#x2013;5273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171597</ArticleId><ArticleId IdType="pubmed">10508160</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Zheng-Fischh&#xf6;fer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11714&#x2013;11721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar K, Yen S, Lee G. Disease-related modifications in tau affect the interaction between fyn and tau. J Biol Chem. 2005;280:35119&#x2013;35125.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115884</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal A&#x3b2; causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991;1:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS. The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule. J Neurosci. 2009;29:2151&#x2013;2161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768429</ArticleId><ArticleId IdType="pubmed">19228967</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman CA, Perez Y, Lacaille JC. Effects of GABA(A) inhibition on the expression of long-term potentiation in CA1 pyramidal cells are dependent on tetanization parameters. Hippocampus. 1998;8:289&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Tonegawa S. Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Annu Rev Neurosci. 1997;20:157&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">9056711</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Figueroa YH, Wang L, Tonuva G, Chang E, Kuret J, Conrad C, Duff KE. Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem. 2009;284:20830&#x2013;20839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742848</ArticleId><ArticleId IdType="pubmed">19478088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Denk F, Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging. 2009;30:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806682</ArticleId><ArticleId IdType="pubmed">17590238</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Hooge R, L&#xfc;llmann-Rauch R, Beckers T, Balschun D, Schwake M, Reiss K, von Figura K, Saftig P. Neurocognitive and psychotiform behavioral alterations and enhanced hippocampal long-term potentiation in transgenic mice displaying neuropathological features of human &#x3b1;-mannosidosis. J Neurosci. 2005;25:6539&#x2013;6549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725435</ArticleId><ArticleId IdType="pubmed">16014715</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS, Jr, Hutton M, Burrows F, Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007;117:648&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794119</ArticleId><ArticleId IdType="pubmed">17304350</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodt H, Eder M, Frick A, Zieglg&#xe4;nsberger W. Precisely localized LTD in the neocortex revealed by infrared-guided laser stimulation. Science. 1999;286:110&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">10506556</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Sch&#xf6;nig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of Alzheimer tauopathy. J Biol Chem. 2007;282:31755&#x2013;31765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode BL, Feinstein SC. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol. 1994;124:769&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119949</ArticleId><ArticleId IdType="pubmed">8120098</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode BL, Chau M, Denis PE, Feinstein SC. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease. J Biol Chem. 2000;275:38182&#x2013;38189.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gossen M, Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu Rev Genet. 2002;36:153&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429690</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Probst A, Spillantini MG, Sch&#xe4;fer T, Jakes R, B&#xfc;rki K, Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995;14:1304&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Graziano A, Petrosini L, Bartoletti A. Automatic recognition of explorative strategies in the Morris water maze. J Neurosci Methods. 2003;130:33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">14583402</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry. 1994;33:9511&#x2013;9522.</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenraad CC, Bradke F. Control of neuronal polarity and plasticity&#x2014;a renaissance for microtubules? Trends Cell Biol. 2009;19:669&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">19801190</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Viesselmann C, Nam S, Merriam E, Dent EW. Activity-dependent dynamic microtubule invasion of dendritic spines. J Neurosci. 2008;28:13094&#x2013;13105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671621</ArticleId><ArticleId IdType="pubmed">19052200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H, Ishiguro K, Hasegawa M, Yen SH, Chishti MA, Harigaya Y, Abe K, Okamoto K, George-Hyslop PS, Westaway D. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol. 2005;166:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602315</ArticleId><ArticleId IdType="pubmed">15681835</ArticleId></ArticleIdList></Reference><Reference><Citation>Impey S, Smith DM, Obrietan K, Donahue R, Wade C, Storm DR. Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning. Nat Neurosci. 1998;1:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VMY. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, Grigoriev I, Camera P, Spangler SA, Di Stefano P, Demmers J, Krugers H, Defilippi P, Akhmanova A, Hoogenraad CC. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron. 2009;61:85&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146815</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, Dewachter I, Seymour CM, Borghgraef P, Devijver H, K&#xfc;gler S, Van Leuven F. Alzheimer's disease: old problem, new views from transgenic and viral models. Biochim Biophys Acta. 2010;1802:808&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">20332023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996;399:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Pangalos M, Geerts H, Wiech H, Mandelkow E. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. FEBS Lett. 1999;451:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10356980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y, Takemura R, Oshima T, Mori H, Ihara Y, Yanagisawa M, Masaki T, Hirokawa N. Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. J Cell Biol. 1989;109:1173&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115758</ArticleId><ArticleId IdType="pubmed">2504728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel ER. Neuroscience&#x2014;the molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">11691980</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246844</ArticleId></ArticleIdList></Reference><Reference><Citation>Klausnitzer J, Manahan-Vaughan D. Frequency facilitation at mossy fiber-CA3 synapses of freely behaving rats is regulated by adenosine A1 receptors. J Neurosci. 2008;28:4836&#x2013;4840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670436</ArticleId><ArticleId IdType="pubmed">18448660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretz O, Fester L, Wehrenberg U, Zhou L, Brauckmann S, Zhao S, Prange-Kiel J, Naumann T, Jarry H, Frotscher M, Rune GM. Hippocampal synapses depend on hippocampal estrogen synthesis. J Neurosci. 2004;24:5913&#x2013;5921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729232</ArticleId><ArticleId IdType="pubmed">15229239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, Goedert M, Amos LA, Spillantini MG. Interaction of tau protein with the dynactin complex. EMBO J. 2007;26:4546&#x2013;4554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063488</ArticleId><ArticleId IdType="pubmed">17932487</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006;22:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567017</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Sch&#xf6;nig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The potential for &#x3b2;-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissette DA, Parachikova A, Green KN, LaFerla FM. Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem. 2009;284:6033&#x2013;6037.</Citation><ArticleIdList><ArticleId IdType="pubmed">18948253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashiba T, Young JZ, McHugh TJ, Buhl DL, Tonegawa S. Transgenic inhibition of synaptic transmission reveals role of CA3 output in hippocampal learning. Science. 2008;319:1260&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">18218862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci. 2004;5:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll RA, Schmitz D. Synaptic plasticity at hippocampal mossy fibre synapses. Nat Rev Neurosci. 2005;6:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">16261180</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Am J Pathol. 2008;173:762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527075</ArticleId><ArticleId IdType="pubmed">18669616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekkala S, Albert ML, Spiro A, III, Erkinjuntti T. Perseveration in Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;25:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">18075249</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, Schmidt B, Mandelkow E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry. 2007;46:10016&#x2013;10023.</Citation><ArticleIdList><ArticleId IdType="pubmed">17685560</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB, Nelson RB, Lau LF, Duff KE. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007;27:3090&#x2013;3097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672474</ArticleId><ArticleId IdType="pubmed">17376970</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741&#x2013;10749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Prange-Kiel J, Rune GM, Leranth C. Median raphe mediates estrogenic effects to the hippocampus in female rats. Eur J Neurosci. 2004;19:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">14725625</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss U, Biernat J, Mandelkow EM, Mandelkow E. The &#x201c;jaws&#x201d; model of tau-microtubule interaction examined in CHO cells. J Cell Sci. 1997;110:789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9099953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol. 2008;212:71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18490011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci. 2003;358:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693153</ArticleId><ArticleId IdType="pubmed">12740129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Maeda S, Takashima A. Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res. 2008;5:591&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">19075586</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar M, Kuret J, Lee G. Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone. J Neurosci Res. 2008;86:2763&#x2013;2773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271846</ArticleId><ArticleId IdType="pubmed">18500754</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics. 2008;5:443&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084246</ArticleId><ArticleId IdType="pubmed">18625456</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook GR, Ray WJ, Shearman M, Hutton M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol Interv. 2007;7:261&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">17932415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL, 3rd, Mumby MC, Bloom GS. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem. 1999;274:25490&#x2013;25498.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464280</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, de Calignon A, Matsui T, Zehr C, Pitstick R, Wu HY, Osetek JD, Jones PB, Bacskai BJ, Feany MB, Carlson GA, Ashe KH, Lewis J, Hyman BT. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci. 2008;28:862&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670992</ArticleId><ArticleId IdType="pubmed">18216194</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol. 1999;155:2153&#x2013;2165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland RJ, McDonald RJ. Hippocampus, amygdala, and memory deficits in rats. Behav Brain Res. 1990;37:57&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2310495</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki K, Fujiwara M, Tanemura K, Murayama M, Ishiguro K, Planel E, Sato S, Hashikawa T, Takashima A. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A. 2002;99:13896&#x2013;13901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129794</ArticleId><ArticleId IdType="pubmed">12368474</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by MARK2/Par-1. J Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Traykov L, Baudic S, Raoux N, Latour F, Rieu D, Smagghe A, Rigaud AS. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. J Neurol Sci. 2005;230:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760623</ArticleId></ArticleIdList></Reference><Reference><Citation>van Swieten JC, Bronner IF, Azmani A, Severijnen LA, Kamphorst W, Ravid R, Rizzu P, Willemsen R, Heutink P. The DeltaK280 mutation in MAP tau favors exon 10 skipping in vivo. J Neuropathol Exp Neurol. 2007;66:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204933</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow E-M, Mandelkow E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta structure. J Biol Chem. 2001;276:48165&#x2013;48174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Martinez-Vicente M, Kr&#xfc;ger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18:4153&#x2013;4170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MJ, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilsch VW, Behnisch T, Jager T, Reymann KG, Balschun D. When are class I metabotropic glutamate receptors necessary for long- term potentiation? J Neurosci. 1998;18:6071&#x2013;6080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793202</ArticleId><ArticleId IdType="pubmed">9698302</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci. 2004;24:4657&#x2013;4667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729383</ArticleId><ArticleId IdType="pubmed">15140937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker RS. Short-term synaptic plasticity. Annu Rev Neurosci. 1989;12:13&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">2648947</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3132715</PMID><DateCompleted><Year>1988</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>12</Issue><PubDate><Year>1988</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease.</ArticleTitle><Pagination><StartPage>4506</StartPage><EndPage>4510</EndPage><MedlinePgn>4506-10</MedlinePgn></Pagination><Abstract><AbstractText>A substantially enriched preparation of Alzheimer paired helical filaments (PHFs) has been used as a starting point for biochemical studies. Pronase treatment, which strips off adhering proteins, leaves a resistant core that is structurally intact. This has been used to raise a monoclonal antibody that decorates the filament core. The antibody has been used to follow the extraction of two peptide fragments (9.5 and 12 kDa) by immunoblotting. The link between the PHF as a morphological entity and these peptides has been established independently by photoaffinity labeling with a chemical ligand to the PHF core. Sequence analysis of these peptides was used to design oligonucleotide probes for cloning a cognate cDNA, which leads to its identification as human microtubule-associated tau protein. The sequencing of the 9.5- and 12-kDa peptides shows they are derived from a conserved region of tau containing three repeating segments. Since these fragments have been copurified with the Pronase-resistant core and are only released by subsequent steps, the corresponding part of the tau molecule must be tightly bound in the PHF core.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wischik</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Th&#xf8;gersen</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Runswick</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Jakes</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Milstein</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Klug</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1988</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3132715</ArticleId><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="doi">10.1073/pnas.85.12.4506</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Cell Biol. 1981 Jun;89(3):653-65</Citation><ArticleIdList><ArticleId IdType="pubmed">6166621</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1964 Jun;87:307-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14188276</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1981;73(Pt B):3-46</Citation><ArticleIdList><ArticleId IdType="pubmed">7300683</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1982 Jan;2(1):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7033478</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1982 Jul 1;298(5869):84-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6178036</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1985 Jun;100(6):1905-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2581978</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(11):3916-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3889918</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Dec 30;4(13B):3661-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2419127</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med Bull. 1986 Jan;42(1):51-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3513893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1986 May 5;261(13):6084-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1986 Feb;5(2):269-76</Citation><ArticleIdList><ArticleId IdType="pubmed">2423324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem. 1986 May;99(5):1541-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2423512</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(11):4040-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(11):4044-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Mar 27;235(4796):1641-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3029875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1987 Jul 25;262(21):10035-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3611052</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jan 15;239(4837):285-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3122323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem. 1987 Dec;102(6):1415-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3129414</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1963 Jan 12;197:192-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1981 Jul;104(1):77-89</Citation><ArticleIdList><ArticleId IdType="pubmed">7020426</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19503072</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Transmission and spreading of tauopathy in transgenic mouse brain.</ArticleTitle><Pagination><StartPage>909</StartPage><EndPage>913</EndPage><MedlinePgn>909-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb1901</ELocationID><Abstract><AbstractText>Hyperphosphorylated tau makes up the filamentous intracellular inclusions of several neurodegenerative diseases, including Alzheimer's disease. In the disease process, neuronal tau inclusions first appear in the transentorhinal cortex from where they seem to spread to the hippocampal formation and neocortex. Cognitive impairment becomes manifest when inclusions reach the hippocampus, with abundant neocortical tau inclusions and extracellular beta-amyloid deposits being the defining pathological hallmarks of Alzheimer's disease. An abundance of tau inclusions, in the absence of beta-amyloid deposits, defines Pick's disease, progressive supranuclear palsy, corticobasal degeneration and other diseases. Tau mutations cause familial forms of frontotemporal dementia, establishing that tau protein dysfunction is sufficient to cause neurodegeneration and dementia. Thus, transgenic mice expressing mutant (for example, P301S) human tau in nerve cells show the essential features of tauopathies, including neurodegeneration and abundant filaments made of hyperphosphorylated tau protein. By contrast, mouse lines expressing single isoforms of wild-type human tau do not produce tau filaments or show neurodegeneration. Here we have used tau-expressing lines to investigate whether experimental tauopathy can be transmitted. We show that injection of brain extract from mutant P301S tau-expressing mice into the brain of transgenic wild-type tau-expressing animals induces assembly of wild-type human tau into filaments and spreading of pathology from the site of injection to neighbouring brain regions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clavaguera</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Pathology, University of Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>Tristan</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>R Anthony</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Abramowski</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Probst</LastName><ForeName>Alphonse</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Stalder</LastName><ForeName>Anna K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Beibel</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tolnay</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105184319</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U.1051.02.002(78792)</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">UKMS5225</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19503072</ArticleId><ArticleId IdType="mid">UKMS5225</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pii">ncb1901</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA. 1998;95:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. 2000;99:469&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805089</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, Clavaguera F, Tolnay M. Tauopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115:39&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17786456</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989;3:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 1971;19:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Ohm T, Bohl J. Silver impregnation of Alzheimer's neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol. 1988;63:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">2464205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM-Y, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Goedert M. Abnormal tau-containing filaments in neurodegenerative diseases. J. Struct. Biol. 2000;130:271&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940231</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prions. Proc. Natl. Acad. Sci. USA. 1998;95:13363&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, et al. Synthetic mammalian prions. Science. 2004;305:673&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, et al. Evidence for seeding of &#x3b2;-amyloid by intracerebral infusion of Alzheimer brain extracts in &#x3b2;&#x304;amyloid precursor protein-transgenic mice. J. Neurosci. 2000;15:3606&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral beta-amyloidosis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, et al. Induction of tau pathology by intracerebral infusion of amyloid-&#x3b2;-containing brain extract and by amyloid-&#x3b2; deposition in APP X tau transgenic mice. Am. J. Pathol. 2007;171:2012&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111123</ArticleId><ArticleId IdType="pubmed">18055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y, et al. Transmission of mouse senile amyloidosis. Lab. Invest. 2001;81:493&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">11304568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundmark K, et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc. Natl. Acad. Sci. USA. 2002;99:6979&#x2013;6984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124514</ArticleId><ArticleId IdType="pubmed">12011456</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, LeVine H, III, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci. 2006;29:438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725716</ArticleId><ArticleId IdType="pubmed">16806508</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout, et al. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol. Dis. 2004;15:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751770</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nature Neurosci. 2006;9:108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Li J-Y, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nature Rev. Neurosci. 2008;9:741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">18769444</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P, et al. Human spongiform encephalopathy: The National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 1994;35:513&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">8179297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, et al. Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J. Neurochem. 1992;58:548&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">1729400</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995;189:167&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, Goedert M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38&#x3b4; or JNK2 in the presence of heparin generates the AT100 epitope. J. Neurochem. 2006;99:154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, et al. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron. 1988;1:817&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">2483104</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl. Acad. Sci. USA. 1991;88:2288&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. Academic Press; New York: 2001.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22699906</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>24</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Gender modulates the APOE &#x3b5;4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels.</ArticleTitle><Pagination><StartPage>8254</StartPage><EndPage>8262</EndPage><MedlinePgn>8254-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0305-12.2012</ELocationID><Abstract><AbstractText>We examined whether the effect of the apolipoprotein E (APOE) genotype on functional brain connectivity is modulated by gender in healthy older human adults. Our results confirm significantly decreased connectivity in the default mode network in healthy older APOE &#x3b5;4 carriers compared with &#x3b5;3 homozygotes. More important, further testing revealed a significant interaction between APOE genotype and gender in the precuneus, a major default mode hub. Female &#x3b5;4 carriers showed significantly reduced default mode connectivity compared with either female &#x3b5;3 homozygotes or male &#x3b5;4 carriers, whereas male &#x3b5;4 carriers differed minimally from male &#x3b5;3 homozygotes. An additional analysis in an independent sample of healthy elderly using an independent marker of Alzheimer's disease, i.e., spinal fluid levels of tau, provided corresponding evidence for this gender-by-APOE interaction. Together, these results converge with previous work showing a higher prevalence of the &#x3b5;4 allele among women with Alzheimer's disease and, critically, demonstrate that this interaction between APOE genotype and gender is detectable in the preclinical period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damoiseaux</LastName><ForeName>Jessica S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA. jeske@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shirer</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000117</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073498</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS073498</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036421" MajorTopicYN="N">Nerve Fibers, Unmyelinated</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>Aliza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bwayo</LastName><ForeName>Salome K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosp</LastName><ForeName>Hartford</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22699906</ArticleId><ArticleId IdType="mid">NIHMS385647</ArticleId><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0305-12.2012</ArticleId><ArticleId IdType="pii">32/24/8254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen EA, Erhardt EB, Damaraju E, Gruner W, Segall JM, Silva RF, Havlicek M, Rachakonda S, Fries J, Kalyanam R, Michael AM, Caprihan A, Turner JA, Eichele T, Adelsheim S, Bryan AD, Bustillo J, Clark VP, Feldstein Ewing SW, Filbey F, et al. A baseline for the multivariate comparison of resting state networks. Front Syst Neurosci. 2011;5:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051178</ArticleId><ArticleId IdType="pubmed">21442040</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, Reidler JS, Sepulcre J, Poulin R, Buckner RL. Functional-anatomic fractionation of the brain's default network. Neuron. 2010;65:550&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848443</ArticleId><ArticleId IdType="pubmed">20188659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry&#x2013;the methods. Neuroimage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Watson DR, Shi Y, Wang Y, Yue C, YuhuanTeng, Wu D, Yuan Y, Zhang Z. Specifically progressive deficits of brain functional marker in amnestic type mild cognitive impairment. PLoS One. 2011;6:e24271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174167</ArticleId><ArticleId IdType="pubmed">21935394</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, Beckmann CF, Adelstein JS, Buckner RL, Colcombe S, Dogonowski AM, Ernst M, Fair D, Hampson M, Hoptman MJ, Hyde JS, Kiviniemi VJ, K&#xf6;tter R, Li SJ, Lin CP, et al. Toward discovery science of human brain function. Proc Natl Acad Sci U S A. 2010;107:4734&#x2013;4739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842060</ArticleId><ArticleId IdType="pubmed">20176931</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD, Finch CE, Henderson VW. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609670</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004;1019:24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246987</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging. 2011;33:828.e19&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218226</ArticleId><ArticleId IdType="pubmed">21840627</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi M, Valsasina P, Misci P, Falini A, Comi G, Rocca MA. The organization of intrinsic brain activity differs between genders: a resting state fMRI study in a large cohort of young healthy subjects. Hum Brain Mapp. 2012 doi: 10.1002/hbm.21514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.21514</ArticleId><ArticleId IdType="pmc">PMC6870508</ArticleId><ArticleId IdType="pubmed">22359372</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A, Grundman M, Jack CR, Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005;62:953&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956166</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009;19:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson VW. Aging, estrogens, and episodic memory in women. Cogn Behav Neurol. 2009;22:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791907</ArticleId><ArticleId IdType="pubmed">19996872</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS, Alzheimer's Disease Neuroimaging Initiative Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68:1526&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging. 2010 doi: 10.1016/j.neurobiolaging.2010.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.10.007</ArticleId><ArticleId IdType="pmc">PMC3483632</ArticleId><ArticleId IdType="pubmed">21122949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, Refsum H, Nurk E, Warden DR, Tell GS, Vollset SE, Engedal K, Nygaard HA, Smith AD. Apolipoprotein E epsilon4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. J Neurol Neurosurg Psychiatry. 2006;77:902&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077621</ArticleId><ArticleId IdType="pubmed">16595618</ArticleId></ArticleIdList></Reference><Reference><Citation>Littow H, Elseoud AA, Haapea M, Isohanni M, Moilanen I, Mankinen K, Nikkinen J, Rahko J, Rantala H, Remes J, Starck T, Tervonen O, Veijola J, Beckmann C, Kiviniemi VJ. Age-related differences in functional nodes of the brain cortex&#x2013;a high model order group ICA study. Front Syst Neurosci. 2010;4:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955419</ArticleId><ArticleId IdType="pubmed">20953235</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Stufflebeam SM, Sepulcre J, Hedden T, Buckner RL. Evidence from intrinsic activity that asymmetry of the human brain is controlled by multiple factors. Proc Natl Acad Sci U S A. 2009;106:20499&#x2013;20503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2777963</ArticleId><ArticleId IdType="pubmed">19918055</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Jones DT, Vemuri P, McDade E, Avula R, Przybelski S, Boeve BF, Knopman DS, Petersen RC, Jack CR., Jr Effect of APOE &#x3b5;4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol. 2011;68:1131&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392960</ArticleId><ArticleId IdType="pubmed">21555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002;15:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes TR, Fox AS, Johnstone T, Chung MK, Kalin N, Davidson RJ. Integrating VBM into the general linear model with voxelwise anatomical covariates. Neuroimage. 2007;34:500&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586764</ArticleId><ArticleId IdType="pubmed">17113790</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu CE, Wijsman EM, Heston LL, Litt M, Schellenberg GD. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet. 1996;58:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914663</ArticleId><ArticleId IdType="pubmed">8644745</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin P, Liu Y, Shi J, Wang Y, Duncan N, Gong Q, Weng X, Northoff G. Dissociation between anterior and posterior cortical regions during self-specificity and familiarity: a combined fMRI-meta-analytic study. Hum Brain Mapp. 2012;33:154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6869961</ArticleId><ArticleId IdType="pubmed">21391261</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18:712&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10534053</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott WK, Saunders AM, Gaskell PC, Locke PA, Growdon JH, Farrer LA, Auerbach SA, Roses AD, Haines JL, Pericak-Vance MA. Apolipoprotein E epsilon2 does not increase risk of early-onset sporadic Alzheimer's disease. Ann Neurol. 1997;42:376&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">9307262</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, Liu C, Dixit S, Benzinger T, Fagan A, Goate A, Mintun MA. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci. 2010;30:17035&#x2013;17040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="pubmed">21159973</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, Women's Health Initiative Memory Study Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947&#x2013;2958.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213206</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">18501637</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl 1):S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, M&#xfc;hlau M, Calhoun VD, Eichele T, L&#xe4;er L, Drzezga A, F&#xf6;rstl H, Kurz A, Zimmer C, Wohlschl&#xe4;ger AM. Selective changes of resting state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer's disease. Neuropharmacology. 2010;59:310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913164</ArticleId><ArticleId IdType="pubmed">20394760</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg AJ, Filippini N, Ebmeier KP, Smith SM, Karpe F, Mackay CE. The effects of APOE on the functional architecture of the resting brain. Neuroimage. 2012;59:565&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">21851856</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin LQ, Kelly AM, Biswal BB, Xavier Castellanos F, Milham MP. Functional connectivity of default mode network components: correlation, anticorrelation, and causality. Hum Brain Mapp. 2009;30:625&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654104</ArticleId><ArticleId IdType="pubmed">18219617</ArticleId></ArticleIdList></Reference><Reference><Citation>Veer IM, Beckmann CF, van Tol MJ, Ferrarini L, Milles J, Veltman DJ, Aleman A, van Buchem MA, van der Wee NJ, Rombouts SA. Whole brain resting state analysis reveals decreased functional connectivity in major depression. Front Syst Neurosci. 2010;4:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950744</ArticleId><ArticleId IdType="pubmed">20941370</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Liang M, Wang L, Tian L, Zhang X, Li K, Jiang T. Altered functional connectivity in early Alzheimer's disease: a resting state fMRI study. Hum Brain Mapp. 2007;28:967&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871392</ArticleId><ArticleId IdType="pubmed">17133390</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman-Fogel I, Moayedi M, Taylor KS, Pope G, Davis KD. Cognitive and default-mode resting state networks: do male and female brains &#x201c;rest&#x201d; differently? Hum Brain Mapp. 2010;31:1713&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870948</ArticleId><ArticleId IdType="pubmed">20725910</ArticleId></ArticleIdList></Reference><Reference><Citation>Westlye ET, Lundervold A, Rootwelt H, Lundervold AJ, Westlye LT. Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE epsilon4 carriers: relationships with memory performance. J Neurosci. 2011;31:7775&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633142</ArticleId><ArticleId IdType="pubmed">21613490</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitfield-Gabrieli S, Moran JM, Nieto-Casta&#xf1;&#xf3;n A, Triantafyllou C, Saxe R, Gabrieli JD. Associations and dissociations between default and self-reference networks in the human brain. Neuroimage. 2011;55:225&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">21111832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000;54:1949&#x2013;1954.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HY, Wang SJ, Xing J, Liu B, Ma ZL, Yang M, Zhang ZJ, Teng GJ. Detection of PCC functional connectivity characteristics in resting state fMRI in mild Alzheimer's disease. Behav Brain Res. 2009;197:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786570</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22279231</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing.</ArticleTitle><Pagination><StartPage>1467</StartPage><EndPage>1480</EndPage><MedlinePgn>1467-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2272-11.2012</ELocationID><Abstract><AbstractText>sorLA is a sorting receptor for amyloid precursor protein (APP) genetically linked to Alzheimer's disease (AD). Retromer, an adaptor complex in the endosome-to-Golgi retrieval pathway, has been implicated in APP transport because retromer deficiency leads to aberrant APP sorting and processing and levels of retromer proteins are altered in AD. Here we report that sorLA and retromer functionally interact in neurons to control trafficking and amyloidogenic processing of APP. We have identified a sequence (FANSHY) in the cytoplasmic domain of sorLA that is recognized by the VPS26 subunit of the retromer complex. Accordingly, we characterized the interaction between the retromer complex and sorLA and determined the role of retromer on sorLA-dependent sorting and processing of APP. Mutations in the VPS26 binding site resulted in receptor redistribution to the endosomal network, similar to the situation seen in cells with VPS26 knockdown. The sorLA mutant retained APP-binding activity but, as opposed to the wild-type receptor, misdirected APP into a distinct non-Golgi compartment, resulting in increased amyloid processing. In conclusion, our data provide a molecular link between reduced retromer expression and increased amyloidogenesis as seen in patients with sporadic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fjorback</LastName><ForeName>Anja W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>The Lundbeck Foundation Research Centre MIND, Department of Biomedicine, Aarhus University, and MIND Centre, Stereology and Electron Microscopy Laboratory, Centre for Stochastic Geometry and Advanced Bioimaging, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seaman</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gustafsen</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mehmedbasic</LastName><ForeName>Arnela</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gokool</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chengbiao</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Militz</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Peder</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nyengaard</LastName><ForeName>Jens R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Willnow</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Erik Ils&#xf8;</ForeName><Initials>EI</Initials></Author><Author ValidYN="Y"><LastName>Mobley</LastName><ForeName>William B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Nykj&#xe6;r</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Olav M</ForeName><Initials>OM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0700750</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046188" MajorTopicYN="N">Protein Modification, Translational</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors disclose no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22279231</ArticleId><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2272-11.2012</ArticleId><ArticleId IdType="pii">32/4/1467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen OM, Christensen LL, Christensen PA, S&#xf8;rensen ES, Jacobsen C, Moestrup SK, Etzerodt M, Thogersen HC. Identification of the minimal functional unit in the low density lipoprotein receptor-related protein for binding the receptor-associated protein (RAP) J Biol Chem. 2000;275:21017&#x2013;21024.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747921</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE. SorLA/LR11, a neuronal sorting receptor that regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE. Molecular dissection of the interaction between APP and its neuronal trafficking receptor SorLA/LR11. Biochemistry. 2006;45:2618&#x2013;2628.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489755</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol. 2004;165:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172094</ArticleId><ArticleId IdType="pubmed">15078903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol. 2008;20:427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833274</ArticleId><ArticleId IdType="pubmed">18472259</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7:568&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936697</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuel M, Lefrancois S, Zeng J, Morales CR. AP-1 and retromer play opposite roles in the trafficking of sortilin between the Golgi apparatus and the lysosomes. Biochem Biophys Res Commun. 2008;366:724&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">18078806</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlton JG, Bujny MV, Peter BJ, Oorschot VM, Rutherford A, Arkell RS, Klumperman J, McMahon HT, Cullen PJ. Sorting nexin-2 is associated with tubular elements of the early endosome, but is not essential for retromer-mediated endosome-to-TGN transport. J Cell Sci. 2005;118:4527&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904489</ArticleId><ArticleId IdType="pubmed">16179610</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlton J, Bujny M, Peter BJ, Oorschot VM, Rutherford A, Mellor H, Klumperman J, McMahon HT, Cullen PJ. Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high-curvature membranes and 3-phosphoinositides. Curr Biol. 2004;14:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">15498486</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins BM. The structure and function of the retromer protein complex. Traffic. 2008;9:1811&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541005</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins BM, Norwood SJ, Kerr MC, Mahony D, Seaman MN, Teasdale RD, Owen DJ. Structure of Vps26B and mapping of its interaction with the retromer protein complex. Traffic. 2008;9:366&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">18088321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer JF, Gustafsen C, Behrens MA, Oliveira CL, Pedersen JS, Madsen P, Petersen CM, Thirup SS. GGA autoinhibition revisited. Traffic. 2010;11:259&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">20015111</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, Lehrman MA, Russell DW, Anderson RG, Brown MS, Goldstein JL. The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell. 1986;45:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">3955657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression Is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci. 2008;28:12877&#x2013;12886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampe W, Riedel IB, Lintzel J, Bader CO, Franke I, Schaller HC. Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. J Cell Sci. 2000;113:4475&#x2013;4485.</Citation><ArticleIdList><ArticleId IdType="pubmed">11082041</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbour ME, Breusegem SY, Antrobus R, Freeman C, Reid E, Seaman MN. The cargo-selective retromer complex is a recruiting hub for protein complexes that regulate endosomal tubule dynamics. J Cell Sci. 2010;123:3703&#x2013;3717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964111</ArticleId><ArticleId IdType="pubmed">20923837</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Li F, Chang WP, Tang J. GGA proteins mediate the recycling pathway of memapsin 2 (BACE) J Biol Chem. 2005;280:11696&#x2013;11703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-&#x3b2; metabolism: evidence for involvement of SORL1 and the retromer complex. J Neurosci. 2010;30:13110&#x2013;13115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274732</ArticleId><ArticleId IdType="pubmed">20881129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JJ, Radice G, Perkins CP, Costantini F. Identification and characterization of a novel, evolutionarily conserved gene disrupted by the murine Hb58 embryonic lethal transgene insertion. Development. 1992;115:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">1638986</ArticleId></ArticleIdList></Reference><Reference><Citation>Motoi Y, Aizawa T, Haga S, Nakamura S, Namba Y, Ikeda K. Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain. Brain Res. 1999;833:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">10375696</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L, Kreber R, Honig LS, Ganetzky B, Duff K, Arancio O, Small SA. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and A&#x3b2; accumulation. Proc Natl Acad Sci USA. 2008;105:7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Madsen P, Christensen EI, Nykjaer A, Gliemann J, Kasper D, Pohlmann R, Petersen CM. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001;20:2180&#x2013;2190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125444</ArticleId><ArticleId IdType="pubmed">11331584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes A, Petersen CM. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol Cell Biol. 2007;27:6842&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099242</ArticleId><ArticleId IdType="pubmed">17646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nothwehr SF, Ha SA, Bruinsma P. Sorting of yeast membrane proteins into an endosome-to-Golgi pathway involves direct interaction of their cytosolic domains with Vps35p. J Cell Biol. 2000;151:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192648</ArticleId><ArticleId IdType="pubmed">11038177</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. The lipoprotein receptor LR11 regulates amyloid &#x3b2; production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Popoff V, Mardones GA, Tenza D, Rojas R, Lamaze C, Bonifacino JS, Raposo G, Johannes L. The retromer complex and clathrin define an early endosomal retrograde exit site. J Cell Sci. 2007;120:2022&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pubmed">17550971</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiche J, Theilig F, Rafiqi FH, Carlo AS, Militz D, Mutig K, Todiras M, Christensen EI, Ellison DH, Bader M, Nykjaer A, Bachmann S, Alessi D, Willnow TE. SORLA/SORL1 functionally interacts with SPAK to control renal activation of Na+-K+-Cl&#x2212; cotransporter 2. Mol Cell Biol. 2010;30:3027&#x2013;3037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876682</ArticleId><ArticleId IdType="pubmed">20385770</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M, Carlo AS, Breyhan H, Sporbert A, Militz D, Schmidt V, Wozny C, Harmeier A, Erdmann B, Bales KR, Wolf S, Kempermann G, Paul SM, Schmitz D, Bayer TA, Willnow TE, Andersen OM. Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J Biol Chem. 2008;283:14826&#x2013;14834.</Citation><ArticleIdList><ArticleId IdType="pubmed">18362153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sannerud R, Annaert W. Trafficking, a key player in regulated intramembrane proteolysis. Semin Cell Dev Biol. 2009;20:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056506</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. ApoE receptor LR11 in Alzheimer's disease: Gene profiling of lymphoblasts mirrors changes in the brain. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, Willnow TE. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem. 2007;282:32956&#x2013;32964.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855360</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz DG, Griffin CT, Schneider EA, Yee D, Magnuson T. Genetic analysis of sorting nexins 1 and 2 reveals a redundant and essential function in mice. Mol Biol Cell. 2002;13:3588&#x2013;3600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129968</ArticleId><ArticleId IdType="pubmed">12388759</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. J Cell Biol. 2004;165:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172078</ArticleId><ArticleId IdType="pubmed">15078902</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;15:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Identification of a novel conserved sorting motif required for retromer-mediated endosome-to-TGN retrieval. J Cell Sci. 2007;120:2378&#x2013;2389.</Citation><ArticleIdList><ArticleId IdType="pubmed">17606993</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Endosome protein sorting: motifs and machinery. Cell Mol Life Sci. 2008;65:2842&#x2013;2858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131859</ArticleId><ArticleId IdType="pubmed">18726175</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, Marcusson EG, Cereghino JL, Emr SD. Endosome to Golgi retrieval of the vacuolar protein sorting receptor, Vps10p, requires the function of the VPS29, VPS30, and VPS35 gene products. J Cell Biol. 1997;137:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139870</ArticleId><ArticleId IdType="pubmed">9105038</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, McCaffery JM, Emr SD. A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J Cell Biol. 1998;142:665&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148169</ArticleId><ArticleId IdType="pubmed">9700157</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Rojas R, Bonifacino JS, Hurley JH. The retromer subunit Vps26 has an arrestin fold and binds Vps35 through its C-terminal domain. Nat Struct Mol Biol. 2006;13:540&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1584284</ArticleId><ArticleId IdType="pubmed">16732284</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner CF, Seaman MN. The role of retromer in neurodegenerative disease. In: St. George-Hyslop P, editor. Intracellular traffic and neurodegenerative disorders. Heidelberg: Springer; 2009. pp. 125&#x2013;140.</Citation></Reference><Reference><Citation>Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derberg O, Gullberg M, Jarvius M, Ridderstr&#xe5;le K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3:995&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabuchi M, Yanatori I, Kawai Y, Kishi F. Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1. J Cell Sci. 2010;123:756&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA, Gandy S, da Cruz ESEF, da Cruz E Silva OA. Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener. 2010;5:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2994555</ArticleId><ArticleId IdType="pubmed">20937087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassmer T, Attar N, Bujny MV, Oakley J, Traer CJ, Cullen PJ. A loss-of-function screen reveals SNX5 and SNX6 as potential components of the mammalian retromer. J Cell Sci. 2007;120:45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148574</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Petersen CM, Nykjaer A. VPS10P-domain receptors: regulators of neuronal viability and function. Nat Rev Neurosci. 2008;9:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">19002190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22699908</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>24</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies.</ArticleTitle><Pagination><StartPage>8270</StartPage><EndPage>8283</EndPage><MedlinePgn>8270-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1592-12.2012</ELocationID><Abstract><AbstractText>Stress induces aggregation of RNA-binding proteins to form inclusions, termed stress granules (SGs). Recent evidence suggests that SG proteins also colocalize with neuropathological structures, but whether this occurs in Alzheimer's disease is unknown. We examined the relationship between SG proteins and neuropathology in brain tissue from P301L Tau transgenic mice, as well as in cases of Alzheimer's disease and FTDP-17. The pattern of SG pathology differs dramatically based on the RNA-binding protein examined. SGs positive for T-cell intracellular antigen-1 (TIA-1) or tristetraprolin (TTP) initially do not colocalize with tau pathology, but then merge with tau inclusions as disease severity increases. In contrast, G3BP (ras GAP-binding protein) identifies a novel type of molecular pathology that shows increasing accumulation in neurons with increasing disease severity, but often is not associated with classic markers of tau pathology. TIA-1 and TTP both bind phospho-tau, and TIA-1 overexpression induces formation of inclusions containing phospho-tau. These data suggest that SG formation might stimulate tau pathophysiology. Thus, study of RNA-binding proteins and SG biology highlights novel pathways interacting with the pathophysiology of AD, providing potentially new avenues for identifying diseased neurons and potentially novel mechanisms regulating tau biology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vanderweyde</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118-2526, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Haung</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Varnum</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liu-Yesucevitz</LastName><ForeName>Liqun</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Citro</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wolozin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ES15567</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS066108</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS073679</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG042213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS073679</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG042213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS066108</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020395</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008541</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES015567</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS060872</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039102">Poly(A)-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075223">Poly-ADP-Ribose Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067776">RNA Recognition Motif Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074019">T-Cell Intracellular Antigen-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C071558">TIA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051816">Tristetraprolin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.12</RegistryNumber><NameOfSubstance UI="C116070">G3BP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.12</RegistryNumber><NameOfSubstance UI="C492055">G3bp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039102" MajorTopicYN="N">Poly(A)-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075223" MajorTopicYN="N">Poly-ADP-Ribose Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067776" MajorTopicYN="N">RNA Recognition Motif Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074019" MajorTopicYN="N">T-Cell Intracellular Antigen-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051816" MajorTopicYN="N">Tristetraprolin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22699908</ArticleId><ArticleId IdType="mid">NIHMS385787</ArticleId><ArticleId IdType="pmc">PMC3402380</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1592-12.2012</ArticleId><ArticleId IdType="pii">32/24/8270</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291657</ArticleId></ArticleIdList></Reference><Reference><Citation>Atlas R, Behar L, Elliott E, Ginzburg I. The insulin-like growth factor mRNA binding-protein IMP-1 and the Ras-regulatory protein G3BP associate with tau mRNA and HuD protein in differentiated P19 neuronal cells. J Neurochem. 2004;89:613&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">15086518</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair IP, Williams KL, Warraich ST, Durnall JC, Thoeng AD, Manavis J, Blumbergs PC, Vucic S, Kiernan MC, Nicholson GA. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81:639&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965854</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol Cell. 2009;36:932&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813218</ArticleId><ArticleId IdType="pubmed">20064460</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, Nicholson GA, Auer-Grumbach M, Wagner K, De Jonghe P, Griffin JW, Fischbeck KH, Timmerman V, Cornblath DR, Chance PF. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4) Am J Hum Genet. 2004;74:1128&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182077</ArticleId><ArticleId IdType="pubmed">15106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernov KG, Barbet A, Hamon L, Ovchinnikov LP, Curmi PA, Pastr&#xe9; D. Role of microtubules in stress granule assembly: microtubule dynamical instability favors the formation of micrometric stress granules in cells. J Biol Chem. 2009;284:36569&#x2013;36580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794772</ArticleId><ArticleId IdType="pubmed">19843517</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, Stutz F, Dargemont C. Deubiquitination, a new player in Golgi to endoplasmic reticulum retrograde transport. J Biol Chem. 2003a;278:51989&#x2013;51992.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593109</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, Stutz F, Belgareh N, Haguenauer-Tsapis R, Dargemont C. Ubp3 requires a cofactor, Bre5, to specifically deubiquitinate the COPII protein, Sec23. Nat Cell Biol. 2003b;5:661&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">12778054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cok SJ, Acton SJ, Morrison AR. The proximal region of the 3&#x2032;-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U. J Biol Chem. 2003;278:36157&#x2013;36162.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855701</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L, Mazzini L, Oggioni GD, Luciano B, Godi M, Brusco A, D'Alfonso S. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet. 2011;130:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">21537950</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, R&#xfc;b U, Auburger G, Trojanowski JQ, Lee VM, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, Dember LM, Anderson P. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell. 2004;15:5383&#x2013;5398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC532018</ArticleId><ArticleId IdType="pubmed">15371533</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodzik L, de Santi S, Tsui WH, Mosconi L, Zinkowski R, Pirraglia E, Wang HY, Li Y, Rich KE, Zetterberg H, Blennow K, Mehta P, de Leon MJ. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging. 2011;32:2131&#x2013;2141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179835</ArticleId><ArticleId IdType="pubmed">20133017</ArticleId></ArticleIdList></Reference><Reference><Citation>Goggin K, Beaudoin S, Grenier C, Brown AA, Roucou X. Prion protein aggresomes are poly(A)+ ribonucleoprotein complexes that induce a PKR-mediated deficient cell stress response. Biochim Biophys Acta. 2008;1783:479&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023289</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Patterson V, Swingler R, Kieran D, Prehn J, Morrison KE, Green A, Acharya KR, Brown RH, Jr, Hardiman O. ANG mutations segregate with familial and &#x2018;sporadic&#x2019; amyotrophic lateral sclerosis. Nat Genet. 2006;38:411&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">16501576</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohmann K, Schuelke M, Diers A, Hoffmann K, Lucke B, Adams C, Bertini E, Leonhardt-Horti H, Muntoni F, Ouvrier R, Pfeufer A, Rossi R, Van Maldergem L, Wilmshurst JM, Wienker TF, Sendtner M, Rudnik-Sch&#xf6;neborn S, Zerres K, H&#xfc;bner C. Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet. 2001;29:75&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528396</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, Weber C, Mandel JL, Cancel G, Abbas N, D&#xfc;rr A, Didierjean O, Stevanin G, Agid Y, Brice A. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine K, Stirling R, Hume D, Kennedy D. Rasputin, more promiscuous than ever: a review of G3BP. Int J Dev Biol. 2004;48:1065&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">15602692</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski J, Psujek M, Bartosik-Psujek H. Total-tau and phospho-tau(181Thr) in cerebrospinal fluid of neurologically intact population increase with age. Folia Biol (Praha) 2009;55:126&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">19691919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996;399:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans. 2002;30:963&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Anderson P. Mammalian stress granules and processing bodies. Methods Enzymol. 2007;431:61&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N, Golan DE, Anderson P. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol. 2000;151:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190599</ArticleId><ArticleId IdType="pubmed">11121440</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFalpha regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res. 2010;29:610&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">20813201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19:R46&#x2013;R64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, Gispert S, Bonini NM, Andersen PM, Gitler AD. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011;20:1697&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071667</ArticleId><ArticleId IdType="pubmed">21292779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre S, B&#xfc;rglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">7813012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One. 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, Warren ST, Wolozin B. Local RNA translation at the synapse and in disease. J Neurosci. 2011;31:16086&#x2013;16093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241995</ArticleId><ArticleId IdType="pubmed">22072660</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, Rouleau GA, Vande Velde C. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B, Chen S, Gueydan C, Kruys V, Streuli M, Anderson P. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 2000;19:4154&#x2013;4163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC306595</ArticleId><ArticleId IdType="pubmed">10921895</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002;21:5691&#x2013;5700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131065</ArticleId><ArticleId IdType="pubmed">12411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronkina N, Menon MB, Schwermann J, Tiedje C, Hitti E, Kotlyarov A, Gaestel M. MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol. 2010;80:1915&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, DeJesus-Hernandez M, Adamson J, Li M, Volkening K, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Woodruff BK, Knopman DS, White CL, 3rd, Van Gerpen JA, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011;20:3207&#x2013;3212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140823</ArticleId><ArticleId IdType="pubmed">21610160</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Soncini C, Berdo I, Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene. 2001;20:3869&#x2013;3879.</Citation><ArticleIdList><ArticleId IdType="pubmed">11439350</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas MG, Loschi M, Desbats MA, Boccaccio GL. RNA granules: the good, the bad and the ugly. Cell Signal. 2011;23:324&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001194</ArticleId><ArticleId IdType="pubmed">20813183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai NP, Tsui YC, Wei LN. Dynein motor contributes to stress granule dynamics in primary neurons. Neuroscience. 2009;159:647&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650738</ArticleId><ArticleId IdType="pubmed">19171178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, Thijs V, Dubois B, Matthijs G, van den Berg LH, Robberecht W. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011;76:2066&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pubmed">21562247</ArticleId></ArticleIdList></Reference><Reference><Citation>Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell. 2001;12:1393&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34592</ArticleId><ArticleId IdType="pubmed">11359930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekri L, Chebli K, Tourri&#xe8;re H, Nielsen FC, Hansen TV, Rami A, Tazi J. Control of fetal growth and neonatal survival by the RasGAP-associated endoribonuclease G3BP. Mol Cell Biol. 2005;25:8703&#x2013;8716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265751</ArticleId><ArticleId IdType="pubmed">16166649</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22674261</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>23</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-&#x3b2;1-42 oligomers are revealed in vivo by using a novel animal model.</ArticleTitle><Pagination><StartPage>7852</StartPage><EndPage>7861</EndPage><MedlinePgn>7852-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5901-11.2012</ELocationID><Abstract><AbstractText>Neuronal and synaptic degeneration are the best pathological correlates for memory decline in Alzheimer's disease (AD). Although the accumulation of soluble low-molecular-weight amyloid-&#x3b2; (A&#x3b2;) oligomers has been suggested to trigger neurodegeneration in AD, animal models overexpressing or infused with A&#x3b2; lack neuronal loss at the onset of memory deficits. Using a novel in vivo approach, we found that repeated hippocampal injections of small soluble A&#x3b2;(1-42) oligomers in awake, freely moving mice were able to induce marked neuronal loss, tau hyperphosphorylation, and deficits in hippocampus-dependent memory. The neurotoxicity of small A&#x3b2;(1-42) species was observed in vivo as well as in vitro in association with increased caspase-3 activity and reduced levels of the NMDA receptor subunit NR2B. We found that the sequestering agent transthyretin is able to bind the toxic A&#x3b2;(1-42) species and attenuated the loss of neurons and memory deficits. Our novel mouse model provides evidence that small, soluble A&#x3b2;(1-42) oligomers are able to induce extensive neuronal loss in vivo and initiate a cascade of events that mimic the key neuropathological hallmarks of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brouillette</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>INSERM, UMR837, Alzheimer and Tauopathies, 59045 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caillierez</LastName><ForeName>Rapha&#xeb;lle</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zommer</LastName><ForeName>Nad&#xe8;ge</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Alves-Pires</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Benilova</LastName><ForeName>Iryna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005561">Formates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0YIW783RG1</RegistryNumber><NameOfSubstance UI="C030544">formic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005561" MajorTopicYN="N">Formates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007536" MajorTopicYN="N">Isomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22674261</ArticleId><ArticleId IdType="pmc">PMC6620963</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5901-11.2012</ArticleId><ArticleId IdType="pii">32/23/7852</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AbdAlla S, Lother H, el Missiry A, Langer A, Sergeev P, el Faramawy Y, Quitterer U. Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem. 2009;284:6554&#x2013;6565.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074441</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009;118:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390859</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi SL, Tran T, Liu C, Lin S, Li Y, Keller JM, Eckenhoff RG, Eckenhoff MF. Brain and behavior changes in 12-month-old Tg2576 and nontransgenic mice exposed to anesthetics. Neurobiol Aging. 2008;29:1002&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4899817</ArticleId><ArticleId IdType="pubmed">17346857</ArticleId></ArticleIdList></Reference><Reference><Citation>Broersen K, Jonckheere W, Rozenski J, Vandersteen A, Pauwels K, Pastore A, Rousseau F, Schymkowitz J. A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease. Protein Eng Des Sel. 2011;24:743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">21565831</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillette J, Quirion R. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging. 2008;29:1721&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512093</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A. 2008;105:2681&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268196</ArticleId><ArticleId IdType="pubmed">18272491</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002;8:1390&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin) J Neurosci. 2007;27:7006&#x2013;7010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672232</ArticleId><ArticleId IdType="pubmed">17596449</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet. 2010;19:R12&#x2013;R20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875049</ArticleId><ArticleId IdType="pubmed">20413653</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie H, Cecconi F. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci. 2011;14:69&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>Doggui S, Brouillette J, Chabot JG, Farso M, Quirion R. Possible involvement of transthyretin in hippocampal beta-amyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8) Neurodegener Dis. 2010;7:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">20173334</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty JJ, Wu J, Nichols RA. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003;23:6740&#x2013;6747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740736</ArticleId><ArticleId IdType="pubmed">12890766</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J, Murphy RM. Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry. 2010;49:8276&#x2013;8289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943652</ArticleId><ArticleId IdType="pubmed">20795734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology. 2004;101:703&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999;97:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry. 2006;45:15157&#x2013;15167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950&#x2013;11958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671645</ArticleId><ArticleId IdType="pubmed">19005060</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji C, Song C, Zuo P. The mechanism of memory impairment induced by Abeta chronic administration involves imbalance between cytokines and neurotrophins in the rat hippocampus. Curr Alzheimer Res. 2011;8:410&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">21244354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010;29:3408&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Freche H, Brouillette J, Fernandez-Gomez FJ, Patin P, Caillierez R, Zommer N, Sergeant N, Bu&#xe9;e-Scherrer V, Lebuffe G, Blum D, Bu&#xe9;e L. Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology. 2012;116:779&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">22343471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368&#x2013;9372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40986</ArticleId><ArticleId IdType="pubmed">7568134</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm T, Ort M, T&#xe4;htivaara L, Jukarainen N, Goldsteins G, Puoliv&#xe4;li J, Nurmi A, Pussinen R, Ahtoniemi T, Miettinen TK, Kanninen K, Leskinen S, Vartiainen N, Yrj&#xe4;nheikki J, Laatikainen R, Harris-White ME, Koistinaho M, Frautschy SA, Bures J, Koistinaho J. beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proc Natl Acad Sci U S A. 2006;103:8852&#x2013;8857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482667</ArticleId><ArticleId IdType="pubmed">16723396</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008;27:224&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206134</ArticleId><ArticleId IdType="pubmed">18059472</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AM, Piazza A, Martin DS, Walsh M, Mandel A, Bolton AE, Lynch MA. The deficit in long-term potentiation induced by chronic administration of amyloid-beta is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025. Exp Gerontol. 2009;44:300&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">19121379</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A. 2009;106:14745&#x2013;14750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736424</ArticleId><ArticleId IdType="pubmed">19706468</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Ed 5. Burlington, MA: Elsevier Academic; 2005.</Citation></Reference><Reference><Citation>Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB, Nelson RB, Lau LF, Duff KE. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007;27:3090&#x2013;3097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672474</ArticleId><ArticleId IdType="pubmed">17376970</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010;66:739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000;874:123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10960596</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Peters&#xe9;n A. Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur J Neurol. 2010;17:456&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922456</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994;91:8368&#x2013;8372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44607</ArticleId><ArticleId IdType="pubmed">8078889</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Soura V, Stewart-Parker M, Williams TL, Ratnayaka A, Atherton J, Gorringe K, Tuffin J, Darwent E, Rambaran R, Klein W, Lacor P, Staras K, Thorpe J, Serpell LC. Visualization of co-localization in Abeta42-administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death. Biochem J. 2012;441:579&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">21955321</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380&#x2013;7388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758007</ArticleId><ArticleId IdType="pubmed">12196559</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci. 2004;24:7707&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729623</ArticleId><ArticleId IdType="pubmed">15342738</ArticleId></ArticleIdList></Reference><Reference><Citation>Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem. 2005;280:13355&#x2013;13363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668252</ArticleId></ArticleIdList></Reference><Reference><Citation>Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637173</ArticleId><ArticleId IdType="pubmed">22272619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, Kubota T, Harigaya Y, Shoji M, Maeda S. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Brain Pathol. 2009;19:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094645</ArticleId><ArticleId IdType="pubmed">18429966</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington RA, Vir&#xe1;g L, Marcouiller F, Papon MA, El Khoury NB, Julien C, Morin F, Emala CW, Planel E. Propofol directly increases tau phosphorylation. PLoS One. 2011;6:e16648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031597</ArticleId><ArticleId IdType="pubmed">21304998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22654059</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>336</Volume><Issue>6085</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol.</ArticleTitle><Pagination><StartPage>1168</StartPage><EndPage>1171</EndPage><MedlinePgn>1168-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1219988</ELocationID><Abstract><AbstractText>C99 is the transmembrane carboxyl-terminal domain of the amyloid precursor protein that is cleaved by &#x3b3;-secretase to release the amyloid-&#x3b2; polypeptides, which are associated with Alzheimer's disease. Nuclear magnetic resonance and electron paramagnetic resonance spectroscopy show that the extracellular amino terminus of C99 includes a surface-embedded "N-helix" followed by a short "N-loop" connecting to the transmembrane domain (TMD). The TMD is a flexibly curved &#x3b1; helix, making it well suited for processive cleavage by &#x3b3;-secretase. Titration of C99 reveals a binding site for cholesterol, providing mechanistic insight into how cholesterol promotes amyloidogenesis. Membrane-buried GXXXG motifs (G, Gly; X, any amino acid), which have an established role in oligomerization, were also shown to play a key role in cholesterol binding. The structure and cholesterol binding properties of C99 may aid in the design of Alzheimer's therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Center for Structural Biology and Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, TN 37232 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuanli</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Van Horn</LastName><ForeName>Wade D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Hustedt</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>Johanna M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Hadziselimovic</LastName><ForeName>Arina</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Beel</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Charles R</ForeName><Initials>CR</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2LP1</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>F31 NS077681</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 GM080513</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008320</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM08320</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008823">Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C543304">amyloid beta-protein precursor C-terminal fragment beta, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004578" MajorTopicYN="N">Electron Spin Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22654059</ArticleId><ArticleId IdType="mid">NIHMS427173</ArticleId><ArticleId IdType="pmc">PMC3528355</ArticleId><ArticleId IdType="doi">10.1126/science.1219988</ArticleId><ArticleId IdType="pii">336/6085/1168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O&#x2019;Brien RJ, Wong PC. Annu. Rev. Neurosci. 2011;34:185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174086</ArticleId><ArticleId IdType="pubmed">21456963</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Nat. Rev. Mol. Cell Biol. 2007;8:101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca AC, Resende R, Oliveira CR, Pereira CM. Exp. Neurol. 2010;223:282.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782682</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, et al. Proc. Natl. Acad. Sci. U.S.A. 1998;95:6460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S, et al. Neurobiol. Dis. 2002;9:11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11848681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, et al. J. Biol. Chem. 2011;286:39804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220543</ArticleId><ArticleId IdType="pubmed">21868378</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, et al. J. Neurosci. 2009;29:13042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, Yau WM, Tycko R. Biophys. J. 2011;100:711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030151</ArticleId><ArticleId IdType="pubmed">21281586</ArticleId></ArticleIdList></Reference><Reference><Citation>Botev A, et al. Biochemistry. 2011;50:828.</Citation><ArticleIdList><ArticleId IdType="pubmed">21186781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadezhdin KD, Bocharova OV, Bocharov EV, Arseniev AS. Acta Naturae. 2011;2010:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347594</ArticleId><ArticleId IdType="pubmed">22649674</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, et al. Biochemistry. 2008;47:9428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572687</ArticleId><ArticleId IdType="pubmed">18702528</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, et al. Proc. Natl. Acad. Sci. U.S.A. 2009;106:1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienlen-Campard P, et al. J. Biol. Chem. 2008;283:7733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702479</ArticleId><ArticleId IdType="pubmed">18201969</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. EMBO J. 2007;26:1702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita N, Straub JE, Thirumalai D. J. Am. Chem. Soc. 2009;131:17843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791510</ArticleId><ArticleId IdType="pubmed">19995075</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. J. Mol. Biol. 2009;385:642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzi F, et al. J. Biol. Chem. 2011;286:21440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122203</ArticleId><ArticleId IdType="pubmed">21454611</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban S. Biochem. J. 2010;425:501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131108</ArticleId><ArticleId IdType="pubmed">20070259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Chem. Rev. 2009;109:1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667872</ArticleId><ArticleId IdType="pubmed">19226105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Crook R. Alzheimer Research Forum. 2012  www.alzforum.org/res/com/mut/app/</Citation></Reference><Reference><Citation>van Meer G, Voelker DR, Feigenson GW. Nat. Rev.Mol. Cell Biol. 2008;9:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2642958</ArticleId><ArticleId IdType="pubmed">18216768</ArticleId></ArticleIdList></Reference><Reference><Citation>Epand RM. Biochim. Biophys. Acta. 2008;1778:1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">18423371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmon MA, et al. J. Biol. Chem. 1992;267:7683.</Citation><ArticleIdList><ArticleId IdType="pubmed">1560003</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie KR, Prestegard JH, Engelman DM. Science. 1997;276:131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9082985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, et al. Proc. Natl. Acad. Sci. U.S.A. 2005;102:14278.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, et al. Nature. 2008;453:925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagi SA, et al. J. Biol. Chem. 2011;286:39794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220583</ArticleId><ArticleId IdType="pubmed">21868380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. J. Cell Biol. 2003;160:113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, et al. Nat. Med. 1998;4:730.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623986</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. J. Biol. Chem. 2008;283:22529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504869</ArticleId><ArticleId IdType="pubmed">18539594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodovitz S, Klein WL. J. Biol. Chem. 1996;271:4436.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Proc. Natl. Acad. Sci. U.S.A. 2001;98:5815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33296</ArticleId><ArticleId IdType="pubmed">11309494</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa K. Subcell. Biochem. 2005;38:179.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709479</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, et al. Mol. Biol. Cell. 2007;18:3591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951756</ArticleId><ArticleId IdType="pubmed">17626163</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Delaglio F, Cornilescu G, Bax A. J. Biomol. NMR. 2009;44:213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726990</ArticleId><ArticleId IdType="pubmed">19548092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Sykes BD. Methods Enzymol. 1994;239:363.</Citation><ArticleIdList><ArticleId IdType="pubmed">7830591</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA. Methods Mol. Biol. 2004;278:313.</Citation><ArticleIdList><ArticleId IdType="pubmed">15318002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Tjandra N. J. Biomol. NMR. 2007;38:303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17593526</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F, et al. J. Biomol. NMR. 1995;6:277.</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>Battiste JL, Wagner G. Biochemistry. 2000;39:5355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820006</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Delaglio F, Cornilescu G, Bax A. J. Biomol. NMR. 2009;44:213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726990</ArticleId><ArticleId IdType="pubmed">19548092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM. J. Magn Reson. 2003;160:65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12565051</ArticleId></ArticleIdList></Reference><Reference><Citation>Altenbach C, Greenhalgh DA, Khorana HG, Hubbell WL. Proc. Natl. Acad. Sci. U.S. A. 1994;91:1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43224</ArticleId><ArticleId IdType="pubmed">8127863</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke G. Annu. Rev. Phys. Chem. 2012;63:419.</Citation><ArticleIdList><ArticleId IdType="pubmed">22404592</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22677258</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety, tolerability, and antibody response of active A&#x3b2; immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.</ArticleTitle><Pagination><StartPage>597</StartPage><EndPage>604</EndPage><MedlinePgn>597-604</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(12)70140-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunotherapy targeting the amyloid &#x3b2; (A&#x3b2;) peptide is a potential strategy to slow the progression of Alzheimer's disease. We aimed to assess the safety and tolerability of CAD106, a novel active A&#x3b2; immunotherapy for patients with Alzheimer's disease, designed to induce N-terminal A&#x3b2;-specific antibodies without an A&#x3b2;-specific T-cell response.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We did a phase 1, double-blind, placebo-controlled, 52-week study in two centres in Sweden. Participants, aged 50-80 years, with mild-to-moderate Alzheimer's disease were entered into one of two cohorts according to time of study entry and then randomly allocated (by use of a computer-generated randomisation sequence) to receive either CAD106 or placebo (4:1; cohort one received CAD106 50 &#x3bc;g or placebo, cohort two received CAD106 150 &#x3bc;g or placebo). Each patient received three subcutaneous injections. All patients, caregivers, and investigators were masked to treatment allocation throughout the study. Primary objectives were to assess the safety and tolerability of CAD106 and to identify the A&#x3b2;-specific antibody response. Safety assessment was done by recording of all adverse events, assessment of MRI scans, physical and neurological examinations, vital signs, electrocardiography, electroencephalography, and laboratory analysis of blood and CSF. Patients with A&#x3b2;-IgG serum titres higher than 16 units at least once during the study were classified as responders. This study is registered with ClinicalTrials.gov, number NCT00411580.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between August, 2005, and March, 2007, we randomly allocated 31 patients into cohort one (24 patients to CAD106 treatment and seven to placebo) and 27 patients into cohort two (22 patients to CAD106 treatment and five to placebo). 56 of 58 patients reported adverse events. In cohort one, nasopharyngitis was the most commonly reported adverse event (10 of 24 CAD106-treated patients). In cohort two, injection site erythema was the most commonly reported adverse event (14 of 22 CAD106-treated patients). Overall, nine patients reported serious adverse events--none was thought to be related to the study drug. We recorded no clinical or subclinical cases of meningoencephalitis. 16 of 24 (67%) CAD106-treated patients in cohort one and 18 of 22 (82%) in cohort two developed A&#x3b2; antibody response meeting pre-specified responder threshold. One of 12 placebo-treated patients (8%) had A&#x3b2;-IgG concentrations that qualified them as a responder.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings suggest that CAD106 has a favourable safety profile and acceptable antibody response in patients with Alzheimer's disease. Larger trials with additional dose investigations are needed to confirm the safety and establish the efficacy of CAD106.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Novartis Pharma AG.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Karolinska Institutet Alzheimer Disease Research Centre and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden. bengt.winblad@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasen</LastName><ForeName>Niels</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Floesser</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Imbert</LastName><ForeName>Georges</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dumortier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>R Paul</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lundmark</LastName><ForeName>Joens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Orgogozo</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00411580</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2012 Jul;11(7):571-2. doi: 10.1016/S1474-4422(12)70136-9.</RefSource><PMID Version="1">22677257</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2012 Aug;8(8):414. doi: 10.1038/nrneurol.2012.128.</RefSource><PMID Version="1">22777243</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22677258</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70140-0</ArticleId><ArticleId IdType="pii">S1474-4422(12)70140-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22464332</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>232</StartPage><EndPage>244</EndPage><MedlinePgn>232-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2012.02.016</ELocationID><Abstract><AbstractText>cis-trans isomerization of proteins phosphorylated by proline-directed kinases is proposed to control numerous signaling molecules and is implicated in the pathogenesis of Alzheimer's and other diseases. However, there is no direct evidence for the existence of cis-trans protein isomers in&#xa0;vivo or for their conformation-specific function or regulation. Here we develop peptide chemistries that allow the generation of cis- and trans-specific antibodies and use them to raise antibodies specific for isomers of phosphorylated tau. cis, but not trans, p-tau appears early&#xa0;in the brains of humans with mild cognitive impairment, accumulates exclusively in degenerated neurons, and localizes to dystrophic neurites during Alzheimer's progression. Unlike trans p-tau, the cis isomer cannot promote microtubule assembly, is more resistant to dephosphorylation and degradation, and is more prone to aggregation. Pin1 converts cis to trans p-tau to prevent Alzheimer's tau pathology. Isomer-specific antibodies and vaccines may therefore have value for the early diagnosis and treatment of Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwood</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Lester</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Denial</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiao Zhen</ForeName><Initials>XZ</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kun Ping</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA167677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM058556</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017870</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA167677</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG13854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG039405</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG029385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17870</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA122434</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG039405</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL111430</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA122434</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072340">NIMA-Interacting Peptidylprolyl Isomerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.8</RegistryNumber><NameOfSubstance UI="C000606846">PIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.8</RegistryNumber><NameOfSubstance UI="D019696">Peptidylprolyl Isomerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.8</RegistryNumber><NameOfSubstance UI="C000606850">Pin1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007536" MajorTopicYN="N">Isomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072340" MajorTopicYN="N">NIMA-Interacting Peptidylprolyl Isomerase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019696" MajorTopicYN="N">Peptidylprolyl Isomerase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22464332</ArticleId><ArticleId IdType="mid">NIHMS448565</ArticleId><ArticleId IdType="pmc">PMC3601591</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2012.02.016</ArticleId><ArticleId IdType="pii">S0092-8674(12)00216-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>An SAA, Lester CC, Peng JL, et al. Retention of the cis proline conformation in tripeptide fragments of bovine pancreatic ribonucleaase A containing a non-natural proline analogues: 5,5-dimethylproline. J Am Chem Soc. 1999;121:11558&#x2013;11566.</Citation></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11357143</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224:472&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118:658&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30:16559&#x2013;16566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135981</ArticleId><ArticleId IdType="pubmed">21147995</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown NR, Noble ME, Endicott JA, Johnson LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol. 1999;1:438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559988</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R. Pin1 in Alzheimer's disease. J Neurochem. 2006;98:1697&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">16945100</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2004;10:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350898</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci. 1987;78:151&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P. Characterization and Use of Monoclonal Antibodies to Tau and Paired Helical Filament Tau. Alzheimer's disease: Methods in Molecular Medicine. 2000;32:361&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">21318532</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan PJ, Johnson GV. The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel. 2010;13:595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941661</ArticleId><ArticleId IdType="pubmed">20812151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, Bouwman FH, Schonknecht P, Schoonenboom NS, Andreasen N, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology. 2007;69:2205&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071141</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011;20:79&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">21741598</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamdane M, Dourlen P, Bretteville A, Sambo AV, Ferreira S, Ando K, Kerdraon O, Begard S, Geay L, Lippens G, et al. Pin1 allows for differential Tau dephosphorylation in neuronal cells. Mol Cell Neurosci. 2006;32:155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI, Davies P. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol. 2001;49:545&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">11310639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Lane E, Vincent I, Otvos L, Jr, Hoffmann R, Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem. 1997;69:2087&#x2013;2095.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Chen CH, Suizu F, Huang P, Schiene-Fischer C, Daum S, Zhang YJ, Goate A, Chen RW, Lu KP. Death associated protein kinase 1 phosphoylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell. 2011a;22:147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088080</ArticleId><ArticleId IdType="pubmed">21497122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Pastorino L, Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in aging, cancer and Alzheimer's disease. Expet Rev Mol Med. 2011b;13:e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21682951</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, et al. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet. 2006;15:2560&#x2013;2568.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Balastik M, Lee TH, Liou YC, Sun A, Finn G, Pastorino L, Lee VM-Y, Lu KP. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest. 2008;118:1877&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323189</ArticleId><ArticleId IdType="pubmed">18431510</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou Y-C, Sun A, Ryo A, Zhou XZ, Yu Z-X, Huang H-K, Bronson R, Bing G, Li X, Hunter T, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891359</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou YC, Zhou XZ, Lu KP. The prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci. 2011;36:501&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185210</ArticleId><ArticleId IdType="pubmed">21852138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KP, Finn G, Lee TH, Nicholson LK. Prolyl cis-trans isomerization as a molecular timer. Nature Chem Biol. 2007;3:619&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">17876319</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 1996;380:544&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">8606777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KP, Liou YC, Zhou XZ. Pinning down the proline-directed phosphorylation signaling. Trends Cell Biol. 2002;12:164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11978535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu KP, Zhou XZ. The prolyl isomerase Pin1: a pivotal new twist in phosphorylation signalling and human disease. Nat Rev Mol Cell Biol. 2007;8:904&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">17878917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature. 1999a;399:784&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu PJ, Zhou XZ, Shen M, Lu KP. A function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science. 1999b;283:1325&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lummis SC, Beene DL, Lee LW, Lester HA, Broadhurst RW, Dougherty DA. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature. 2005;438:248&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">16281040</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis. 2007;12:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SL, Pastorino L, Zhou XZ, Lu KP. Pin1 promotes APP protein turnover by inhibiting GSK3&#x3b2; kinase activity - A novel mechanism for Pin1 to protect against Alzheimer&#x2019;s disease. J Biol Chem. 2011 (Accepted)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293570</ArticleId><ArticleId IdType="pubmed">22184106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SL, Tang NLS, Tam CWC, Lui VWC, Lam LCW, Chiu HFK, Driver JA, Pastorino L, Lu KP. A functional polymorphism in Pin1 that prevents its suppression by AP4 Is associated with delayed onset of Alzheimer&#x2019;s disease. Neurobiol Aging. 2010 Jun 24; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988914</ArticleId><ArticleId IdType="pubmed">20580132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M, Zhou XZ, Kishi S, Kosugi I, Tsutsui Y, Lu KP. A specific interaction between the telomeric protein Pin2/TRF1 and the mitotic spindle. Curr Biol. 2001;11:1512&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11413462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH, Li X, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature. 2006;440:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic peptidyl-prolyl isomerase Pin1 suggests that substrate recognition is phosphorylation dependent. Cell. 1997;89:875&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">9200606</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging. 1990;11:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">2325814</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen M, Stukenberg PT, Kirschner MW, Lu KP. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev. 1998;12:706&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316589</ArticleId><ArticleId IdType="pubmed">9499405</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009;32:150&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162340</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuerkorn M, Fischer G, Schiene-Fischer C. Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol. 2011;11:281&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">21497135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun-Kyi A, Finn G, Greenwood A, Nowak M, Lee TH, Asara JM, Tsokos GC, Fitzgerald K, Israel E, Li X, et al. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nature Immunol. 2011;12:733&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298750</ArticleId><ArticleId IdType="pubmed">21743479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wintjens R, Wieruszeski JM, Drobecq H, Rousselot-Pailley P, Buee L, Lippens G, Landrieu I. 1H NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides. J Biol Chem. 2001;276:25150&#x2013;25156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11313338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld J, Xu J, Kuang J, Kirschner MW, Fischer G, et al. Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism. Science. 1997;278:1957&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395400</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011;20:214&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yukawa K, Tanaka T, Bai T, Li L, Tsubota Y, Owada-Makabe K, Maeda M, Hoshino K, Akira S, Iso H. Deletion of the kinase domain from death-associated protein kinase enhances spatial memory in mice. Int J Mol Med. 2006;17:869&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">16596273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, K&#xfc;llertz G, Stark M, Fischer G, Lu KP. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell. 2000;6:873&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou XZ, Lu PJ, Wulf G, Lu KP. Phosphorylation-dependent prolyl isomerization: A novel signaling regulatory mechanism. Cell Mol Life Sci. 1999;56:788&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11147038</ArticleId><ArticleId IdType="pubmed">11212339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23102935</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population.</ArticleTitle><Pagination><StartPage>1518.e1</StartPage><EndPage>1518.e15183</EndPage><MedlinePgn>1518.e1-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2012.09.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(12)00487-3</ELocationID><Abstract><AbstractText>Pathogenic mutations of the APP gene, leading to early-onset Alzheimer's disease (AD) have been known for more than 20 years. Recently, it was discovered that APP mutations might also be protective. A rare variant A673T reportedly protects against AD and age-related cognitive impairment and might functionally inhibit proteolytic cleavage at the &#x3b2;-secretase site of APP. We sequenced APP exon 16 in a population-based sample of 515 Finnish subjects aged 85 or older. Neuropathologic data were available in 274. We found the A673T variant in 1 subject (0.2%), who lived until age 104.8 years (second highest age-at-death in the cohort). Neuropathologic analysis showed little beta-amyloid pathology (Consortium to Establish a Registry for Alzheimer's Disease score 0). Some vascular amyloid was detected in meningeal arteries suggesting that vascular &#x3b2;-amyloid accumulation might be less inhibited than the parenchymal. She was demented at the age of 104, most likely because of hippocampal sclerosis. The low amount of parenchymal &#x3b2;-amyloid pathology at the age of 104.8 years supports the concept that the A673T variant protects the brain against &#x3b2;-amyloid pathology and AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kero</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Helsinki and HUSLAB, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paetau</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Polvikoski</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tanskanen</LastName><ForeName>Maarit</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sulkava</LastName><ForeName>Raimo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jansson</LastName><ForeName>Lilja</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Myllykangas</LastName><ForeName>Liisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23102935</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.09.017</ArticleId><ArticleId IdType="pii">S0197-4580(12)00487-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21813677</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>31</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>11159</StartPage><EndPage>11171</EndPage><MedlinePgn>11159-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6209-10.2011</ELocationID><Abstract><AbstractText>Mononuclear phagocytes are important modulators of Alzheimer's disease (AD), but the specific functions of resident microglia, bone marrow-derived mononuclear cells, and perivascular macrophages have not been resolved. To elucidate the spatiotemporal roles of mononuclear phagocytes during disease, we targeted myeloid cell subsets from different compartments and examined disease pathogenesis in three different mouse models of AD (APP(swe/PS1), APP(swe), and APP23 mice). We identified chemokine receptor 2 (CCR2)-expressing myeloid cells as the population that was preferentially recruited to &#x3b2;-amyloid (A&#x3b2;) deposits. Unexpectedly, AD brains with dysfunctional microglia and devoid of parenchymal bone marrow-derived phagocytes did not show overt changes in plaque pathology and A&#x3b2; load. In contrast, restriction of CCR2 deficiency to perivascular myeloid cells drastically impaired &#x3b2;-amyloid clearance and amplified vascular A&#x3b2; deposition, while parenchymal plaque deposition remained unaffected. Together, our data advocate selective functions of CCR2-expressing myeloid subsets, which could be targeted specifically to modify disease burden in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mildner</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University of Freiburg, D-79106 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlevogt</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kierdorf</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>B&#xf6;ttcher</LastName><ForeName>Chotima</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Erny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Br&#xfc;ck</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Bechmann</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039481">CD11b Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515335">Ccr2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054390">Receptors, CCR2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="N">Bone Marrow Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039481" MajorTopicYN="N">CD11b Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042282" MajorTopicYN="N">Microdissection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054390" MajorTopicYN="N">Receptors, CCR2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014916" MajorTopicYN="N">Whole-Body Irradiation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21813677</ArticleId><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6209-10.2011</ArticleId><ArticleId IdType="pii">31/31/11159</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Algotsson A, Winblad B. The integrity of the blood&#x2013;brain barrier in Alzheimer's disease. Acta Neurol Scand. 2007;115:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">17511849</ArticleId></ArticleIdList></Reference><Reference><Citation>Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res. 1999;117:145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann I, Kwidzinski E, Kovac AD, Simb&#xfc;rger E, Horvath T, Gimsa U, Dirnagl U, Priller J, Nitsch R. Turnover of rat brain perivascular cells. Exp Neurol. 2001;168:242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259112</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I, Sessa M, Fasano S, Brambilla R, Marchesini S, Bordignon C, Naldini L. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest. 2004;113:1118&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC385395</ArticleId><ArticleId IdType="pubmed">15085191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood&#x2013;brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68:1809&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668699</ArticleId><ArticleId IdType="pubmed">17515542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefr&#xe8;re F, Blanche S, Audit M, Payen E, Leboulch P, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">19892975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem. 1999;274:32301&#x2013;32308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542270</ArticleId></ArticleIdList></Reference><Reference><Citation>Diserbo M, Agin A, Lamproglou I, Mauris J, Staali F, Multon E, Amourette C. Blood&#x2013;brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Can J Physiol Pharmacol. 2002;80:670&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">12182325</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak J, Potempska A, LeVine H, Haske T, Dickson D, Mazur-Kolecka B. Extracellular deposits of A beta produced in cultures of Alzheimer disease brain vascular smooth muscle cells. J Neuropathol Exp Neurol. 2005;64:82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois S, Bensidhoum M, Mouiseddine M, Mazurier C, Allenet B, Semont A, Frick J, Sach&#xe9; A, Bouchet S, Thierry D, Gourmelon P, Gorin NC, Chapel A. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells. 2006;24:1020&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T. Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm. 2010;117:961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917548</ArticleId><ArticleId IdType="pubmed">20517700</ArticleId></ArticleIdList></Reference><Reference><Citation>Getts DR, Terry RL, Getts MT, M&#xfc;ller M, Rana S, Shrestha B, Radford J, Van Rooijen N, Campbell IL, King NJ. Ly6c+ &#x201c;inflammatory monocytes&#x201d; are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J Exp Med. 2008;205:2319&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556789</ArticleId><ArticleId IdType="pubmed">18779347</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, K&#xe4;lin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2009;106:1261&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey WF, Vass K, Lassmann H. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J Neuropathol Exp Neurol. 1992;51:246&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">1583531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci. 1997;51:135&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225377</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation. 2005;2:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276812</ArticleId><ArticleId IdType="pubmed">16232318</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22:2246&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758281</ArticleId><ArticleId IdType="pubmed">11896164</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Koistinaho J. Interactions between Alzheimer's disease and cerebral ischemia&#x2014;focus on inflammation. Brain Res Brain Res Rev. 2005;48:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokovay E, Cunningham LA. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol Dis. 2005;19:471&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci. 2010;30:9651&#x2013;9658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929651</ArticleId><ArticleId IdType="pubmed">20660248</ArticleId></ArticleIdList></Reference><Reference><Citation>Linard C, Marquette C, Mathieu J, Pennequin A, Claren&#xe7;on D, Math&#xe9; D. Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: effect of an NF-kappaB inhibitor. Int J Radiat Oncol Biol Phys. 2004;58:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751512</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm TM, Koistinaho M, P&#xe4;repalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis. 2005;18:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649704</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Br&#xfc;ck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Djukic M, Garbe D, Wellmer A, Kuziel WA, Mack M, Nau R, Prinz M. Ly-6G+CCR2&#x2212; myeloid cells rather than Ly-6ChighCCR2+ monocytes are required for the control of bacterial infection in the central nervous system. J Immunol. 2008;181:2713&#x2013;2722.</Citation><ArticleIdList><ArticleId IdType="pubmed">18684962</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Mack M, Schmidt H, Br&#xfc;ck W, Djukic M, Zabel MD, Hille A, Priller J, Prinz M. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain. 2009;132:2487&#x2013;2500.</Citation><ArticleIdList><ArticleId IdType="pubmed">19531531</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L. Neuroscience: Alzheimer's disease. Nature. 2009;461:895&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">19829367</ArticleId></ArticleIdList></Reference><Reference><Citation>Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2011;31:6208&#x2013;6220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632958</ArticleId><ArticleId IdType="pubmed">21508244</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller J, Fl&#xfc;gel A, Wehner T, Boentert M, Haas CA, Prinz M, Fern&#xe1;ndez-Klett F, Prass K, Bechmann I, de Boer BA, Frotscher M, Kreutzberg GW, Persons DA, Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med. 2001;7:1356&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11726978</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller J, Prinz M, Heikenwalder M, Zeller N, Schwarz P, Heppner FL, Aguzzi A. Early and rapid engraftment of bone marrow-derived microglia in scrapie. J Neurosci. 2006;26:11753&#x2013;11762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674798</ArticleId><ArticleId IdType="pubmed">17093096</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia. 2011;59:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">21125659</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. Tickets to the brain: role of CCR2 and CX(3)CR1 in myeloid cell entry in the CNS. J Neuroimmunol. 2010;224:80&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20554025</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, Piesche M, Schroers R, Weiss E, Kirschning CJ, Rochford CD, Br&#xfc;ck W, Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest. 2006;116:456&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350999</ArticleId><ArticleId IdType="pubmed">16440059</ArticleId></ArticleIdList></Reference><Reference><Citation>Raasch J, Zeller N, van Loo G, Merkler D, Mildner A, Erny D, Knobeloch KP, Bethea JR, Waisman A, Knust M, Del Turco D, Deller T, Blank T, Priller J, Br&#xfc;ck W, Pasparakis M, Prinz M. I{kappa}B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-{kappa}B in the central nervous system. Brain. 2011;134:1184&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055835</ArticleId><ArticleId IdType="pubmed">21310728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006;7:311&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16462739</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2009;19:392&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094842</ArticleId><ArticleId IdType="pubmed">18637012</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, Coomaraswamy J, Staufenbiel M, Landmann R, Jucker M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci. 2005;25:11125&#x2013;11132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725647</ArticleId><ArticleId IdType="pubmed">16319312</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 1999;286:2352&#x2013;2355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600748</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci. 2002;5:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Wegiel J, Wang KC, Kujawa M, Lach B. Ultrastructural studies of the cells forming amyloid fibers in classical plaques. Can J Neurol Sci. 1989;16:535&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">2553231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Barcikowska M, Kida E. Phagocytosis of beta/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol. 1991;81:588&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">1858487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol. 2005;166:1475&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606401</ArticleId><ArticleId IdType="pubmed">15855647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, Gaber MW, McColgan T, Naimark MD, Kiani MF, Merchant TE. Radiation-induced permeability and leukocyte adhesion in the rat blood&#x2013;brain barrier: modulation with anti-ICAM-1 antibodies. Brain Res. 2003;969:59&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">12676365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23254930</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>493</Volume><Issue>7434</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>31</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.</ArticleTitle><Pagination><StartPage>674</StartPage><EndPage>678</EndPage><MedlinePgn>674-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature11729</ELocationID><Abstract><AbstractText>Alzheimer's disease is the world's most common dementing illness. Deposition of amyloid-&#x3b2; peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-&#x3b2; activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1&#x3b2; maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer's disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer's disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3(-/-) or Casp1(-/-) mice carrying mutations associated with familial Alzheimer's disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer's disease, and demonstrated reduced brain caspase-1 and interleukin-1&#x3b2; activation as well as enhanced amyloid-&#x3b2; clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-&#x3b2; in the APP/PS1 model of Alzheimer's disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer's disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Clinical Neuroscience Unit, Department of Neurology, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany. michael.Heneka@ukb.uni-bonn.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Stutz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Delekate</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vieira-Saecker</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Griep</LastName><ForeName>Angelika</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Axt</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Remus</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tzeng</LastName><ForeName>Te-Chen</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Halle</LastName><ForeName>Annett</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Korte</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Eicke</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Golenbock</LastName><ForeName>Douglas T</ForeName><Initials>DT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI083713</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM054060</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL093262</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI084048</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Immunol. 2013 Feb;13(2):69. doi: 10.1038/nri3392.</RefSource><PMID Version="1">23334247</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23254930</ArticleId><ArticleId IdType="mid">NIHMS418619</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pii">nature11729</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011;14:1227&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009;64:110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834890</ArticleId><ArticleId IdType="pubmed">19840553</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008;9:857&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009;27:229&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho VM, Lee J-A, Martin KC. The cell biology of synaptic plasticity. Science. 2011;334:623&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286636</ArticleId><ArticleId IdType="pubmed">22053042</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JM, et al. Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer&#x2019;s disease. Behav. Brain Res. 2011;222:169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">21443906</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O&#x2019;Banion MK. Inflammatory processes in Alzheimer&#x2019;s disease. J. Neuroimmunol. 2007;184:69&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010;117:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbantoglu J, et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997;387:500&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J. Neurosci. 1998;18:2974&#x2013;2981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792583</ArticleId><ArticleId IdType="pubmed">9526014</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 2003;23:2665&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742111</ArticleId><ArticleId IdType="pubmed">12684452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, Khoury JE. Microglial dysfunction and defective &#x3b2;-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Locus ceruleus controls Alzheimer&#x2019;s disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U.S.A. 2010;107:6058&#x2013;6063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851853</ArticleId><ArticleId IdType="pubmed">20231476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, et al. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 2007;117:1595&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, et al. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 2007;27:9301&#x2013;9309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673122</ArticleId><ArticleId IdType="pubmed">17728444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer&#x2019;s disease. J. Neurosci. 2011;31:11159&#x2013;11171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Malito E, Hulse RE, Tang W-J. Amyloid &#x3b2;-degrading cryptidases: insulin degrading enzyme, neprilysin, and presequence peptidase. Cell Mol Life Sci. 2008;65:2574&#x2013;2585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756532</ArticleId><ArticleId IdType="pubmed">18470479</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, et al. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Raes G, et al. FIZZ1 and Ym as tools to discriminate between differentially activated macrophages. Dev. Immunol. 2002;9:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276098</ArticleId><ArticleId IdType="pubmed">12892049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, et al. Nitration of tyrosine 10 critically enhances amyloid &#x3b2; aggregation and plaque formation. Neuron. 2011;71:833&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">21903077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 2004;24:6049&#x2013;6056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729673</ArticleId><ArticleId IdType="pubmed">15240796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanneganti T-D, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature. 2006;440:233&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell. 1995;80:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">7859282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study &#x2018;recognition memory&#x2019;. Nat Protoc. 2006;1:1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406415</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger S, et al. alpha-secretase mediated conversion of the Amyloid Precursor Protein derived membrane stub C99 to C83 limits Abeta generation. J. Neurochem. 2009;111:1369&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">19804379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19738171</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Systemic inflammation and disease progression in Alzheimer disease.</ArticleTitle><Pagination><StartPage>768</StartPage><EndPage>774</EndPage><MedlinePgn>768-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181b6bb95</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute and chronic systemic inflammation are characterized by the systemic production of the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) that plays a role in immune to brain communication. Previous preclinical research shows that acute systemic inflammation contributes to an exacerbation of neurodegeneration by activation of primed microglial cells.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether acute episodes of systemic inflammation associated with increased TNF-alpha would be associated with long-term cognitive decline in a prospective cohort study of subjects with Alzheimer disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three hundred community-dwelling subjects with mild to severe Alzheimer disease were cognitively assessed, and a blood sample was taken for systemic inflammatory markers. Each subject's main caregiver was interviewed to assess the presence of incident systemic inflammatory events. Assessments of both patient and caregiver were repeated at 2, 4, and 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Acute systemic inflammatory events, found in around half of all subjects, were associated with an increase in the serum levels of proinflammatory cytokine TNF-alpha and a 2-fold increase in the rate of cognitive decline over a 6-month period. High baseline levels of TNF-alpha were associated with a 4-fold increase in the rate of cognitive decline. Subjects who had low levels of serum TNF-alpha throughout the study showed no cognitive decline over the 6-month period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both acute and chronic systemic inflammation, associated with increases in serum tumor necrosis factor alpha, is associated with an increase in cognitive decline in Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Neurosciences Division, University of Southampton, UK. ch4@soton.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zotova</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Woolford</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Culliford</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>V H</ForeName><Initials>VH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>078300</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2010 Apr 6;74(14):1157; author reply 1157-8. doi: 10.1212/WNL.0b013e3181d5df7f.</RefSource><PMID Version="1">20368640</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19738171</ArticleId><ArticleId IdType="pmc">PMC2848584</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bb95</ArticleId><ArticleId IdType="pii">73/10/768</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15536110</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsland AE, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008;64:484&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562462</ArticleId><ArticleId IdType="pubmed">18514163</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004 May;61:668&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148142</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2008;70:1222&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo P, Martin-Aragon S, Benedi J, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer&#x2019;s disease. Immunol Lett 2008;117:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer&#x2019;s disease patients. J Immunol 2008;193:183&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">18037502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signalling proteins. Nat Med 2007;13:1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry 2003;74:788&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738504</ArticleId><ArticleId IdType="pubmed">12754353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 1998;12:215&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9772027</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17220915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005;25:9275&#x2013;9284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009;65:304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633437</ArticleId><ArticleId IdType="pubmed">18801476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Mrak RE, Griffin WS. Neuritic plaque evolution in Alzheimer&#x2019;s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol (Berl) 1997;94:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224523</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis K. A new rating scale for Alzheimer&#x2019;s Disease. Am J Psychiatry 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method: a new method for detection of delirium. Ann Intern Med 1990;113:941&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">2240918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice&#x2014;a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;108:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">12551878</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007;28:533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001;8:131&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">11303144</ArticleId></ArticleIdList></Reference><Reference><Citation>Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer&#x2019;s disease. Expert Rev Neurother 2008;8:743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ. Alzheimer&#x2019;s disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J Alzheimers Dis 2008;13:437&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">18487851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008;29:494&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528851</ArticleId><ArticleId IdType="pubmed">18436709</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, De RD, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007;20:380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551353</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer&#x2019;s disease: an epidemiological perspective. Eur J Pharmacol 2008;585:119&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474785</ArticleId><ArticleId IdType="pubmed">18384771</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh P, Woodward M, Rumley A, Lowe G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol 2008;141:852&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">18371109</ArticleId></ArticleIdList></Reference><Reference><Citation>Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer&#x2019;s disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000;103:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer&#x2019;s disease or vascular dementia. J Psychiatr Res 2008;41:686&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600299</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson&#x2019;s disease. Brain 2008;131:1880&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442423</ArticleId><ArticleId IdType="pubmed">18504291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, D&#x2019;Aigle T, Gowing G, Julien JP, Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 2004;24:1340&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730331</ArticleId><ArticleId IdType="pubmed">14960605</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization; 1992.</Citation></Reference><Reference><Citation>McCusker J, Cole M, Dendukuri N, Belzile E, Primeau F. Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study. CMAJ 2001;165:575&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC81415</ArticleId><ArticleId IdType="pubmed">11563209</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 2003;132:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808682</ArticleId><ArticleId IdType="pubmed">12653832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering M, Cumiskey D, O&#x2019;Conner JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2008;90:663&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944202</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Bausano B, Pike BR, et al. TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. J Neurosci Res 2001;64:121&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">11288141</ArticleId></ArticleIdList></Reference><Reference><Citation>Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNF&#x3b1;. Science 2002;295:2285.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910117</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005;25:3219&#x2013;3228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725093</ArticleId><ArticleId IdType="pubmed">15788779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12714745</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>300</Volume><Issue>5619</Issue><PubDate><Year>2003</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Initiation and synergistic fibrillization of tau and alpha-synuclein.</ArticleTitle><Pagination><StartPage>636</StartPage><EndPage>640</EndPage><MedlinePgn>636-40</MedlinePgn></Pagination><Abstract><AbstractText>Alpha-synuclein (alpha-syn) and tau polymerize into amyloid fibrils and form intraneuronal filamentous inclusions characteristic of neurodegenerative diseases. We demonstrate that alpha-syn induces fibrillization of tau and that coincubation of tau and alpha-syn synergistically promotes fibrillization of both proteins. The in vivo relevance of these findings is grounded in the co-occurrence of alpha-syn and tau filamentous amyloid inclusions in humans, in single transgenic mice that express A53T human alpha-syn in neurons, and in oligodendrocytes of bigenic mice that express wild-type human alpha-syn plus P301L mutant tau. This suggests that interactions between alpha-syn and tau can promote their fibrillization and drive the formation of pathological inclusions in human neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>Benoit I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forman</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Golbe</LastName><ForeName>Lawrence I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Kotzbauer</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId><ArticleId IdType="doi">10.1126/science.1082324</ArticleId><ArticleId IdType="pii">300/5619/636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21460840</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>429</StartPage><EndPage>435</EndPage><MedlinePgn>429-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.803</ELocationID><Abstract><AbstractText>We sought to identify new susceptibility loci for Alzheimer's disease through a staged association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease Genetic Consortium (ADGC) in a companion paper. We undertook a combined analysis of four genome-wide association datasets (stage 1) and identified ten newly associated variants with P &#x2264; 1 &#xd7; 10(-5). We tested these variants for association in an independent sample (stage 2). Three SNPs at two loci replicated and showed evidence for association in a further sample (stage 3). Meta-analyses of all data provided compelling evidence that ABCA7 (rs3764650, meta P = 4.5 &#xd7; 10(-17); including ADGC data, meta P = 5.0 &#xd7; 10(-21)) and the MS4A gene cluster (rs610932, meta P = 1.8 &#xd7; 10(-14); including ADGC data, meta P = 1.2 &#xd7; 10(-16)) are new Alzheimer's disease susceptibility loci. We also found independent evidence for association for three loci reported by the ADGC, which, when combined, showed genome-wide significance: CD2AP (GERAD+, P = 8.0 &#xd7; 10(-4); including ADGC data, meta P = 8.6 &#xd7; 10(-9)), CD33 (GERAD+, P = 2.2 &#xd7; 10(-4); including ADGC data, meta P = 1.6 &#xd7; 10(-9)) and EPHA1 (GERAD+, P = 3.4 &#xd7; 10(-4); including ADGC data, meta P = 6.0 &#xd7; 10(-10)).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Neurosciences and Mental Health Research Institute, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gerrish</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hamshere</LastName><ForeName>Marian L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Jaspreet Singh</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Moskvina</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dowzell</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Stretton</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ivanov</LastName><ForeName>Dobril</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Widdowson</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Jade</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>A David</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Beaumont</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Warden</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Nigel M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Vardy</LastName><ForeName>Emma R L C</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>R&#xfc;ther</LastName><ForeName>Eckart</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xfc;rmann</LastName><ForeName>Britta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Heun</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>K&#xf6;lsch</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>van den Bussche</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Heuser</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gallacher</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Giegling</LastName><ForeName>Ina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bettens</LastName><ForeName>Karolien</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Gurling</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McQuillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gwilliam</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;hleisen</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>J&#xf6;ckel</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Klopp</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>H-Erich</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Aasly</LastName><ForeName>Jan O</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Barcikowska</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Breteler</LastName><ForeName>Monique M B</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Annette L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><CollectiveName>CHARGE consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Tzourio</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alp&#xe9;rovitch</LastName><ForeName>Annick</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>EADI1 consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Feulner</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Riehle</LastName><ForeName>Caterina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Krawczak</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mayhaus</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nicolhaus</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wagenpfeil</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Snaedal</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bj&#xf6;rnsson</LastName><ForeName>Sigurbj&#xf6;rn</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Chouraki</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Genier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Combarros</LastName><ForeName>Onofre</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Zelenika</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Delepine</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bullido</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mateo</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Frank-Garcia</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Porcellini</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hanon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Coto</LastName><ForeName>Eliecer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Siciliano</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mancuso</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Panza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Boss&#xf9;</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Piccardi</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Arosio</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Annoni</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Licastro</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Thorlakur</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Riemenschneider</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0801306</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9810900</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0802189</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>082604</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411895">ABCA7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114545">CD2-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C571163">CD33 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C436715">MS4A4E protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063268">Sialic Acid Binding Ig-like Lectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036082">Receptor, EphA1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015214" MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005810" MajorTopicYN="N">Multigene Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036082" MajorTopicYN="N">Receptor, EphA1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063268" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 3</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">UKMS34702</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21460840</ArticleId><ArticleId IdType="mid">UKMS34702</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pii">ng.803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43:1467&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1088&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1094&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux JJ, et al. Association of CR1, CLU and PICALM with Alzheimer&#x2019;s disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19:3295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908469</ArticleId><ArticleId IdType="pubmed">20534741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, et al. Complement receptor 1 polymorphisms and risk of late onset Alzheimer&#x2019;s disease. Brain Res. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20558149</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol. 2010;67:961&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919638</ArticleId><ArticleId IdType="pubmed">20554627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, et al. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch Neurol. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, et al. Association of CLU and PICALM variants with Alzheimer&#x2019;s disease. Neurobiol Aging. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010357</ArticleId><ArticleId IdType="pubmed">20570404</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67:677&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC. Common variants in MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. (In Press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. GAB2 alleles modify Alzheimer&#x2019;s risk in APOE epsilon4 carriers. Neuron. 2007;54:713&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#x2019;er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genome-wide association studies of nearly all common variants. Genet Epidemiol. 2008;32:381&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18348202</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1:e78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1315281</ArticleId><ArticleId IdType="pubmed">16362079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, et al. Abundant quantitative trait Loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6:e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83:623&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Weickert CS, Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem. 2008;104:1145&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, et al. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J Biol Chem. 2005;280:3989&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B. Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport. 2006;17:891&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16738483</ArticleId></ArticleIdList></Reference><Reference><Citation>Jehle AW, et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol. 2006;174:547&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064260</ArticleId><ArticleId IdType="pubmed">16908670</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF. Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics. 2001;53:357&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11486273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinet JP, et al. Isolation and characterization of cDNAs coding for the beta subunit of the high-affinity receptor for immunoglobulin E. Proc Natl Acad Sci U S A. 1988;85:6483&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281997</ArticleId><ArticleId IdType="pubmed">2970642</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17380156</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateno H, et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol. 2007;27:5699&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952126</ArticleId><ArticleId IdType="pubmed">17562860</ArticleId></ArticleIdList></Reference><Reference><Citation>Dustin ML, et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998;94:667&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9741631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch DK, et al. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem. 2003;278:21805&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672817</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A, Soriano E. Functions of ephrin/Eph interactions in the development of the nervous system: emphasis on the hippocampal system. Brain Res Brain Res Rev. 2005;49:211&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai KO, Ip NY. Synapse development and plasticity: roles of ephrin/Eph receptor signaling. Curr Opin Neurobiol. 2009;19:275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19497733</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulthard MG, et al. Characterization of the Epha1 receptor tyrosine kinase: expression in epithelial tissues. Growth Factors. 2001;18:303&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">11519828</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, et al. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci. 2009;122:243&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118217</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy SL, et al. Generation and characterization of EphA1 receptor tyrosine kinase reporter knockout mice. Genesis. 2008;46:553&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov AI, Romanovsky AA. Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life. 2006;58:389&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801213</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39:1494&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20953194</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.</ArticleTitle><Pagination><StartPage>1396</StartPage><EndPage>1403</EndPage><MedlinePgn>1396-403</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2660</ELocationID><Abstract><AbstractText>Many mutations confer one or more toxic function(s) on copper/zinc superoxide dismutase 1 (SOD1) that impair motor neuron viability and cause familial amyotrophic lateral sclerosis (FALS). Using a conformation-specific antibody that detects misfolded SOD1 (C4F6), we found that oxidized wild-type SOD1 and mutant SOD1 share a conformational epitope that is not present in normal wild-type SOD1. In a subset of human sporadic ALS (SALS) cases, motor neurons in the lumbosacral spinal cord were markedly C4F6 immunoreactive, indicating that an aberrant wild-type SOD1 species was present. Recombinant, oxidized wild-type SOD1 and wild-type SOD1 immunopurified from SALS tissues inhibited kinesin-based fast axonal transport in a manner similar to that of FALS-linked mutant SOD1. Our findings suggest that wild-type SOD1 can be pathogenic in SALS and identify an SOD1-dependent pathogenic mechanism common to FALS and SALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Daryl A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical Center, Worcester, Massachusetts, USA. daryl.bosco@umassmed.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morfini</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Karabacak</LastName><ForeName>N Murat</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuyu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Gros-Louis</LastName><ForeName>Francois</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pasinelli</LastName><ForeName>Piera</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Goolsby</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Lemay</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>McKenna-Yasek</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Agar</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>1RC1NS068391-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS067206-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS05225-03</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS050557-05</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS067206</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RC2NS070342-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000888">Antibodies, Anti-Idiotypic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2010 Nov;13(11):1303-4. doi: 10.1038/nn1110-1303.</RefSource><PMID Version="1">20975748</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2010 Dec;6(12):645. doi: 10.1038/nrneurol.2010.169.</RefSource><PMID Version="1">21188749</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000888" MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20953194</ArticleId><ArticleId IdType="mid">NIHMS236199</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pii">nn.2660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol. 1985;18:271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">4051456</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis PN, Daoud H, Dion PA, Rouleau GA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2009;9:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">19348708</ArticleId></ArticleIdList></Reference><Reference><Citation>Selverstone Valentine J, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem. 2005;74:563&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">15952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay M, Valentine JS. Aggregation of Copper-Zinc Superoxide Dismutase in Familial and Sporadic ALS. Antioxid Redox Signal. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842589</ArticleId><ArticleId IdType="pubmed">19271992</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Fu R, Deng HX, Siddique T, O'Halloran TV. Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice. Proc Natl Acad Sci U S A. 2006;103:7148&#x2013;7153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1447524</ArticleId><ArticleId IdType="pubmed">16636274</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar KS, et al. A common property of amyotrophic lateral sclerosis-associated variants: Destabilization of the Cu/Zn superoxide dismutase electrostatic loop. J Biol Chem. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781497</ArticleId><ArticleId IdType="pubmed">19635794</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Hart PJ, Borchelt DR, Andersen PM. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet. 2009;18:3217&#x2013;3226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Johnson JL, Agar NY, Agar JN. Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol. 2008;6:e170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486295</ArticleId><ArticleId IdType="pubmed">18666828</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, et al. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009;29:12776&#x2013;12786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801051</ArticleId><ArticleId IdType="pubmed">19828789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102:170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruzman A, et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007;104:12524&#x2013;12529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941502</ArticleId><ArticleId IdType="pubmed">17636119</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman JS, Estevez AG, Crow JP, Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci. 2001;24:S15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11881740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredesen DE, Ellerby LM, Hart PJ, Wiedau-Pazos M, Valentine JS. Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? Ann Neurol. 1997;42:135&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">9266721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol. 2007;62:553&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">18074357</ArticleId></ArticleIdList></Reference><Reference><Citation>Durazo A, et al. Metal-free superoxide dismutase-1 and three different ALS variants share a similar partially unfolded {beta}-barrel at physiological temperature. J Biol Chem. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797206</ArticleId><ArticleId IdType="pubmed">19805550</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez AG, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science. 1999;286:2498&#x2013;2500.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617463</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277:47551&#x2013;47556.</Citation><ArticleIdList><ArticleId IdType="pubmed">12356748</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L, et al. Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: a possible general mechanism for familial ALS. Proc Natl Acad Sci U S A. 2007;104:11263&#x2013;11267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1899188</ArticleId><ArticleId IdType="pubmed">17592131</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007;104:2495&#x2013;2500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Lasek RJ, Allen RD. Fast axonal transport in extruded axoplasm from squid giant axon. Science. 1982;218:1129&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">6183745</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20345765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara N, et al. Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. J Biol Chem. 2007;282:35933&#x2013;35944.</Citation><ArticleIdList><ArticleId IdType="pubmed">17913710</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari A, et al. Metal deficiency increases aberrant hydrophobicity of mutant superoxide dismutases that cause amyotrophic lateral sclerosis. J Biol Chem. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785702</ArticleId><ArticleId IdType="pubmed">19651777</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R, et al. Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem. 2004;279:15499&#x2013;15504.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734542</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson AK, Bilsel O, Kondrashkina E, Zitzewitz JA, Matthews CR. Mapping the folding free energy surface for metal-free human Cu,Zn superoxide dismutase. J Mol Biol. 2006;364:1084&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046019</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Lasek RJ, Allen RD. Video microscopy of fast axonal transport in extrudedaxoplasm: a new model for study of molecular mechanisms. Cell Motil. 1985;5:81&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">2580632</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002;21:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci. 2006;9:907&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751763</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, et al. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci. 2009;12:864&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739046</ArticleId><ArticleId IdType="pubmed">19525941</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15711537</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz L, et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation. 2007;4:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014744</ArticleId><ArticleId IdType="pubmed">17784957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerman A, et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20111867</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HN, et al. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann Neurol. 2009;66:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19670443</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Asayama K, Hirano A, Kobayashi M. Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev Neurosci. 1996;18:492&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940623</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, et al. Cu/Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis. Neurosci Lett. 1994;179:149&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845611</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis. 2001;8:933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R, et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med. 2007;13:754&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">17486090</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43:19&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233914</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. 2006;9:108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci U S A. 2008;105:4022&#x2013;4027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268797</ArticleId><ArticleId IdType="pubmed">18296640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg MJ, Normark J, Holmgren A, Oliveberg M. Folding of human superoxide dismutase: disulfide reduction prevents dimerization and produces marginally stable monomers. Proc Natl Acad Sci U S A. 2004;101:15893&#x2013;15898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528748</ArticleId><ArticleId IdType="pubmed">15522970</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci. 2008;31:151&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558852</ArticleId></ArticleIdList></Reference><Reference><Citation>Strom AL, et al. Retrograde axonal transport and motor neuron disease. J Neurochem. 2008;106:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477783</ArticleId><ArticleId IdType="pubmed">18384644</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard JF, Cote F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature. 1995;375:61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">7536898</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999;2:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Glass JD. Axonal degeneration in motor neuron disease. Neurodegener Dis. 2007;4:431&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934327</ArticleId></ArticleIdList></Reference><Reference><Citation>Strange RW, et al. Variable metallation of human superoxide dismutase: atomic resolution crystal structures of Cu-Zn, Zn-Zn and as-isolated wild-type enzymes. J Mol Biol. 2006;356:1152&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward LJ, et al. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem. 2002;277:15923&#x2013;15931.</Citation><ArticleIdList><ArticleId IdType="pubmed">11854284</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse. Hum Mol Genet. 2009;18:1642&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667291</ArticleId><ArticleId IdType="pubmed">19233858</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23332364</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>216</EndPage><MedlinePgn>207-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(12)70291-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(12)70291-0</ELocationID><Abstract><AbstractText>In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD). The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical symptoms. Since then, evidence has accumulated that supports the major assumptions of this model. Evidence has also appeared that challenges some of our assumptions, which has allowed us to modify our original model. Refinements to our model include indexing of individuals by time rather than clinical symptom severity; incorporation of interindividual variability in cognitive impairment associated with progression of AD pathophysiology; modifications of the specific temporal ordering of some biomarkers; and recognition that the two major proteinopathies underlying AD biomarker changes, amyloid &#x3b2; (A&#x3b2;) and tau, might be initiated independently in sporadic AD, in which we hypothesise that an incident A&#x3b2; pathophysiology can accelerate antecedent limbic and brainstem tauopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. jack.clifford@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wiste</LastName><ForeName>Heather J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Lesnick</LastName><ForeName>Timothy G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Vernon S</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2013 Feb;12(2):126-8. doi: 10.1016/S1474-4422(12)70305-8.</RefSource><PMID Version="1">23332358</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017711" MajorTopicYN="Y">Nonlinear Dynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b><u>Conflicts of interest</u></b>. Dr. Jack serves on scientific advisory boards for Elan/Janssen AI, Bristol Meyer Squibb, Eli Lilly &amp; Company, GE Healthcare, Siemens, and Eisai Inc.; receives research support from Baxter International Inc., Allon Therapeutics, Inc., the NIH/NIA, and the Alexander Family Alzheimer&#x2019;s Disease Research Professorship of the Mayo Foundation; and holds stock in Johnson &amp; Johnson. Dr. Knopman serves as Deputy Editor for Neurology&#xae;; served on a data safety monitoring board for Eli Lilly and Company; served as a consultant for Elan/Janssen. Dr. Jagust served as a consultant to GE Healthcare, which manufactures flutemetamol, and collaborates with Avid Radiopharmaceuticals, which manufactures florbetapir, through the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Dr. Weiner serves on the advisory boards for Elan/Wyeth, Novartis, Banner, Lilly, VACO, Biogen Idec, Araclon and Pfizer; serves as a consultant to Elan/Wyeth, Novartis, Forest, Ispen, Daiichi Sankyo, Inc., Astra Zeneca, Araclon, Pfizer, TauRx Therapeutics LTD, Bayer, Biogen Idec, Exonhit Therapeutics, Servier, Synarc; received honoraria from American Academy of Neurology, ipsen, NeuroVigil, Inc., and Insitut Catala de Neurociencies Aplicades; receives research funding from Merck and Avid; owns stock in Synarc and Elan; and serves on the editorial advisory board for Alzheimer&#x2019;s and Dementia, and MRI. Dr. Aisen serves on a scientific advisory board for NeuroPhage; serves as a consultant to Elan Corporation, Wyeth, Eisai Inc., Bristol-Myers Squibb, Eli Lilly and Company, NeuroPhage, Merck &amp; Co., Roche, Amgen, Abbott, Pfizer Inc., Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen and Medivation Inc.; receives research support from Pfizer Inc., and Baxter International Inc.; and has received stock options from Medivation Inc., and NeuroPhage. Dr. Petersen serves on scientific advisory boards for the Alzheimer&#x2019;s Association, the National Advisory Council on Aging (NIA), Elan/Janssen AI, Pfizer Inc (Wyeth), and GE Healthcare; receives royalties from publishing Mild Cognitive Impairment (Oxford University Press, 2003); serves as a consultant for Elan/Janssen AI and GE Healthcare; and receives research support from the NIH/NIA. Dr. Shaw serves on the technical advisory board for Saladax Biomedical. Dr. Vemuri, Ms. Wiste, Mr. Weigand, Mr. Lesnick, and Dr. Pankratz report no disclosures. Dr. Trojanowski serves as an Associate Editor of Alzheimer&#x2019;s &amp; Dementia; may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is co-Inventor and he received revenue from the sale of Avid to Eli Lily as co-inventor on imaging related patents submitted by the University of Pennsylvania; receives research support from the NIH, Bristol Myer Squib, AstraZenica and several non-profits. Dr. Donohue has served as consultant to Bristol-Meyers Squibb.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23332364</ArticleId><ArticleId IdType="mid">NIHMS437127</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pii">S1474-4422(12)70291-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012;78:84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466670</ArticleId><ArticleId IdType="pubmed">22189451</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations. Neurology. 2009;73:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715210</ArticleId><ArticleId IdType="pubmed">19636048</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer&#x2019;s disease. Brain. 2009;132:2048&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714061</ArticleId><ArticleId IdType="pubmed">19460794</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Frisoni GB, Clark CM, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210817</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Sencakova D, Jack CR, Jr, et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002;19:23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A, Grundman M, Jack CR, Jr, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005;62:953&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956166</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR., Jr Measuring progression of AD with imaging: Outcome measures for trials. ICAD 2009; 2009; Vienna, Austria. 2009. pp. S1&#x2013;03.</Citation></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Yang C, Schneider JA, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging. 2010;33:878&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026854</ArticleId><ArticleId IdType="pubmed">20961664</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011;68:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082956</ArticleId><ArticleId IdType="pubmed">21320990</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal Fluid Levels of beta-Amyloid 1&#x2013;42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry. 2012;69:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO Mol Med. 2009;1:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer&#x2019;s disease. Neuroscience. 2000;95:721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Vinters HV, Ellis WG, et al. Correlates of hippocampal neuron number in Alzheimer&#x2019;s disease and ischemic vascular dementia. Ann Neurol. 2005;57:896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851673</ArticleId><ArticleId IdType="pubmed">15929035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage. 2008;42:559&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097053</ArticleId><ArticleId IdType="pubmed">18572417</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer&#x2019;s disease: a case-control study. Lancet Neurol. 2012;11:868&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490201</ArticleId><ArticleId IdType="pubmed">22951070</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735194</ArticleId><ArticleId IdType="pubmed">17894374</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli CS, Atack JR, Ball MJ, et al. Postmortem regional neurofibrillary tangle densities, but not senile plaque densities, are related to regional cerebral metabolic rates for glucose during life in Alzheimer&#x2019;s disease. Neurodegeneration. 1992;1:113&#x2013;121.</Citation></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68:1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482918</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999;52:1687&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724764</ArticleId><ArticleId IdType="pubmed">10953178</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648510</ArticleId><ArticleId IdType="pubmed">18991338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8:389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517915</ArticleId><ArticleId IdType="pubmed">22285638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: a serial MRI study. Lancet Neurol. 2006;5:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology. 2008;70:1740&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734477</ArticleId><ArticleId IdType="pubmed">18032747</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, et al. Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons. Brain Pathol. 2010;20:66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864342</ArticleId><ArticleId IdType="pubmed">19021630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, et al. Evidence for Ordering of Alzheimer Disease Biomarkers. Arch Neurol. 2011;68:1526&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal Change of Biomarkers in Cognitive Decline. Arch Neurol. 2011;68:1257&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604752</ArticleId><ArticleId IdType="pubmed">21670386</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer&#x2019;s disease follows amyloid deposition with temporal delay. Biol Psychiatry. 2012;71:792&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679929</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitutdinal cognitive decline. Accepted for publication in Annals of Neurology. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Quiroz Y, Jakimovich L, et al. Age-associated trajectories of biomarkers in early-onset Alzheimer&#x2019;s disease, for the Alzheimer&#x2019;s Prevention Initiative. Alzheimer&#x2019;s Association International Conference; 2012; Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Association; 2012.</Citation></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Frisoni GB. The dynamics of Alzheimer&#x2019;s disease biomarkers in the Alzheimer&#x2019;s Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010;31:1263&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467365</ArticleId><ArticleId IdType="pubmed">20538373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Desikan RS, Sepulcre J, et al. The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease. Arch Neurol. 2011;68:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248949</ArticleId><ArticleId IdType="pubmed">21825241</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Tosun D, Insel PS, et al. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. 2012;33:845&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032014</ArticleId><ArticleId IdType="pubmed">20855131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, et al. Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Arch Neurol. 2012;69:856&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595157</ArticleId><ArticleId IdType="pubmed">22409939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Lesnick T, et al. Brain beta amyloid load approaches a plateau. Accepted for publication in Neurology. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurfjell L, Lundqvist R, Villemagne VL, Rowe CC. A data-derived A&#x3b2; biomarker model computed using longitudinal PiB data from AIBL. Alzheimer&#x2019;s Association International Conference; 2012; Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Associaton; 2012.</Citation></Reference><Reference><Citation>Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun. 2007;358:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646256</ArticleId><ArticleId IdType="pubmed">17482143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr Seeding &#x201c;one-dimensional crystallization&#x201d; of amyloid: a pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. Arch Neurol. 2011;68:1049&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218566</ArticleId><ArticleId IdType="pubmed">21825242</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O&#x2019;Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol. 2008;64:168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694129</ArticleId><ArticleId IdType="pubmed">18496870</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18:713&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661625</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta neuropathologica. 2012;124:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551449</ArticleId><ArticleId IdType="pubmed">22526019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measure and magnetic resonance imaging atophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2010;133:3336&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Cohen A, Bi W, et al. Why we need two cutoffs for amyloid-imaging: Early versus Alzheimer&#x2019;s-like amyloid-positivity. Alzheimer&#x2019;s Association International Conference; 2012; Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Associaton; 2012.</Citation></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739591</ArticleId><ArticleId IdType="pubmed">19467352</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Weigand SD, Przybelski SA, et al. Cognitive reserve and Alzheimer&#x2019;s disease biomarkers are independent determinants of cognition. Brain. 2011;134:1479&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097887</ArticleId><ArticleId IdType="pubmed">21478184</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed BR, Mungas D, Farias ST, et al. Measuring cognitive reserve based on the decomposition of episodic memory variance. Brain. 2010;133:2196&#x2013;2209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139935</ArticleId><ArticleId IdType="pubmed">20591858</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Mintun MA, D&#x2019;Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008;65:1467&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752218</ArticleId><ArticleId IdType="pubmed">19001165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick T, przybelski S, et al. Effect of lifestyle activities on AD biomarkers and cognition. Accepted for publication in Annals of Neurology. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R. Dominantly inherited Alzheimer network clinical trials: A model for prevention trials. AAIC; 2011 July 16&#x2013;21; Paris, France: Alzheimer&#x2019;s &amp; Dementia; 2011. p. S680.</Citation></Reference><Reference><Citation>Donohue M, Aisen PS, Dartigues J, Jacqmin-Gadda H, Gamst A, Le Gogg M. Validating Alzheimer&#x2019;s pathological cascade by merging ADNI with PAQUID. Alzheimer&#x2019;s Assoication International Conference; 2012; Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Association; 2012.</Citation></Reference><Reference><Citation>Jedynak BM, Liu B, Lang A, et al. Sample size comparisons in ADNI: A case for the Alzheimer&#x2019;s disease progression scale. Alzheimer&#x2019;s Association International Conference; 2012; Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Association; 2012.</Citation></Reference><Reference><Citation>Mungas D, Jones R, Tommet D. Sequencing of CSF abeta and tau, Brain Structure and Function, and Cognition in Alzheimer&#x2019;s Disease. American Academy of Neurology Annual Meeting; 2012; New Orleans. Louisiana: Neurology; 2012. p. PD1.0003.</Citation></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta Neuropathol. 2011;121:171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer&#x2019;s disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Neuroplasticity failure in Alzheimer&#x2019;s disease: bridging the gap between plaques and tangles. Neuron. 1999;24:521&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol. 2011;121:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">21225273</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Habeck CG, Stern Y, Anderson KE. APOE genotype and cerebral blood flow in healthy young individuals. JAMA. 2003;290:1581&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026566</ArticleId><ArticleId IdType="pubmed">14506116</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67:308&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G. Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanis SB, Tesoriero JA, Babus LW, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29:15317&#x2013;15322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846754</ArticleId><ArticleId IdType="pubmed">19955384</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer&#x2019;s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer&#x2019;s disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Machulda MM, vemuri P, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011;77:1524&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198977</ArticleId><ArticleId IdType="pubmed">21975202</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Smiljic A, Hayenga AO, et al. Relationships between Beta-Amyloid and Functional Connectivity in Different Components of the Default Mode Network in Aging. Cereb Cortex. 2011;21:2399&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169663</ArticleId><ArticleId IdType="pubmed">21383234</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Jones DT, Vemuri P, et al. Effect of APOE e4 Status on Intrinsic Network Connectivity in Cognitively Normal Elderly Subjects. Arch Neurol. 2011;68:1131&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392960</ArticleId><ArticleId IdType="pubmed">21555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O&#x2019;Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Morris JC, Snyder AZ, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci. 2010;30:17035&#x2013;17040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="pubmed">21159973</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal J, Schultz A, Johnson K, et al. Disrupted functional connectivity in autosomal dominant Alzheimer&#x2019;s Disease: Preliminary findings from the DIAN study. Alzheimer&#x2019;s Assoication International Conference; 2012; Vancouver, British Columbia, Canada: Alzheimer&#x2019;s Association; 2012.</Citation></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Mormino EC. Lifespan brain activity, beta-amyloid, and Alzheimer&#x2019;s disease. Trends Cogn Sci. 2011;15:520&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206968</ArticleId><ArticleId IdType="pubmed">21983147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer&#x2019;s disease. Brain. 2011;134:1089&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">21436112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425844</ArticleId><ArticleId IdType="pubmed">22855860</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2007;130:1777&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752411</ArticleId><ArticleId IdType="pubmed">17533169</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer&#x2019;s disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage. 2008;39:1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390889</ArticleId><ArticleId IdType="pubmed">18054253</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906178</ArticleId><ArticleId IdType="pubmed">20592257</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Fouquet M, Baron JC, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer&#x2019;s disease. Brain. 2010;133:3301&#x2013;3314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291528</ArticleId><ArticleId IdType="pubmed">20688814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Villemagne VL, Pike KE, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer&#x2019;s disease. Neurodegener Dis. 2012;10:141&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">22301812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17088211</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking.</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>459</EndPage><MedlinePgn>445-59</MedlinePgn></Pagination><Abstract><AbstractText>Arc/Arg3.1 is an immediate-early gene whose mRNA is rapidly transcribed and targeted to dendrites of neurons as they engage in information processing and storage. Moreover, Arc/Arg3.1 is known to be required for durable forms of synaptic plasticity and learning. Despite these intriguing links to plasticity, Arc/Arg3.1's molecular function remains enigmatic. Here, we demonstrate that Arc/Arg3.1 protein interacts with dynamin and specific isoforms of endophilin to enhance receptor endocytosis. Arc/Arg3.1 selectively modulates trafficking of AMPA-type glutamate receptors (AMPARs) in neurons by accelerating endocytosis and reducing surface expression. The Arc/Arg3.1-endocytosis pathway appears to regulate basal AMPAR levels since Arc/Arg3.1 KO neurons exhibit markedly reduced endocytosis and increased steady-state surface levels. These findings reveal a novel molecular pathway that is regulated by Arc/Arg3.1 and likely contributes to late-phase synaptic plasticity and memory consolidation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Shoaib</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Okuno</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lyford</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Petralia</LastName><ForeName>Ronald S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Plath</LastName><ForeName>Niels</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kuhl</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Huganir</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Worley</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 MH068830</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH053608</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092069">activity regulated cytoskeletal-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.-</RegistryNumber><NameOfSubstance UI="D000217">Acyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034281">Dynamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000217" MajorTopicYN="N">Acyltransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020798" MajorTopicYN="N">Two-Hybrid System Techniques</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17088211</ArticleId><ArticleId IdType="mid">NIHMS13792</ArticleId><ArticleId IdType="pmc">PMC1784006</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.08.033</ArticleId><ArticleId IdType="pii">S0896-6273(06)00682-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977;126:397&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">861729</ArticleId></ArticleIdList></Reference><Reference><Citation>Barik S. Megaprimer PCR. Methods Mol Biol. 2002;192:189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">12494651</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpied TA, Scott DB, Ehlers MD. Dynamics and regulation of clathrin coats at specialized endocytic zones of dendrites and spines. Neuron. 2002;36:435&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">12408846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock J, Thode C, Hannemann O, Braun K, Darlison MG. Early socio-emotional experience induces expression of the immediate-early gene Arc/arg3.1 (activity-regulated cytoskeleton-associated protein/activity-regulated gene) in learning-relevant brain regions of the newborn chick. Neuroscience. 2005;133:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">15908132</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm J, Malinow R. AMPA receptor phosphorylation during synaptic plasticity. Biochem Soc Trans. 2005;33:1354&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246117</ArticleId></ArticleIdList></Reference><Reference><Citation>Brakeman PR, Lanahan AA, O&#x2019;Brien R, Roche K, Barnes CA, Huganir RL, Worley PF. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature. 1997;386:284&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">9069287</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TC, Tran IC, Backos DS, Esteban JA. NMDA receptor-dependent activation of the small GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD. Neuron. 2005;45:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629704</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke SN, Chawla MK, Penner MR, Crowell BE, Worley PF, Barnes CA, McNaughton BL. Differential encoding of behavior and spatial context in deep and superficial layers of the neocortex. Neuron. 2005;45:667&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748843</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RC, Beattie EC, von Zastrow M, Malenka RC. Role of AMPA receptor endocytosis in synaptic plasticity. Nat Rev Neurosci. 2001;2:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11331915</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RC, Beattie EC, Xia H, Luscher C, Altschuler Y, Nicoll RA, Malenka RC, von Zastrow M. Dynamin-dependent endocytosis of ionotropic glutamate receptors. Proc Natl Acad Sci U S A. 1999;96:14112&#x2013;14117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24199</ArticleId><ArticleId IdType="pubmed">10570207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MS, Obar RA, Schroeder CC, Austin TW, Poodry CA, Wadsworth SC, Vallee RB. Multiple forms of dynamin are encoded by shibire, a Drosophila gene involved in endocytosis. Nature. 1991;351:583&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">1828536</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Deng L, Maeno-Hikichi Y, Lai M, Chang S, Chen G, Zhang JF. Formation of an endophilin-Ca2+ channel complex is critical for clathrin-mediated synaptic vesicle endocytosis. Cell. 2003;115:37&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">14532001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung HJ, Steinberg JP, Huganir RL, Linden DJ. Requirement of AMPA receptor GluR2 phosphorylation for cerebellar long-term depression. Science. 2003;300:1751&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">12805550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottrell JR, Borok E, Horvath TL, Nedivi E. CPG2: a brain- and synapse-specific protein that regulates the endocytosis of glutamate receptors. Neuron. 2004;44:677&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065105</ArticleId><ArticleId IdType="pubmed">15541315</ArticleId></ArticleIdList></Reference><Reference><Citation>Darstein M, Petralia RS, Swanson GT, Wenthold RJ, Heinemann SF. Distribution of kainate receptor subunits at hippocampal mossy fiber synapses. J Neurosci. 2003;23:8013&#x2013;8019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740495</ArticleId><ArticleId IdType="pubmed">12954862</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HP, Squire LR. Protein synthesis and memory: a review. Psychol Bull. 1984;96:518&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">6096908</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, O&#x2019;Brien RJ, Fung ET, Lanahan AA, Worley PF, Huganir RL. GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature. 1997;386:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9069286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca R, Nagerl UV, Morris RG, Bonhoeffer T. Competing for memory: hippocampal LTP under regimes of reduced protein synthesis. Neuron. 2004;44:1011&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gad H, Ringstad N, Low P, Kjaerulff O, Gustafsson J, Wenk M, Di Paolo G, Nemoto Y, Crun J, Ellisman MH, et al. Fission and uncoating of synaptic clathrin-coated vesicles are perturbed by disruption of interactions with the SH3 domain of endophilin. Neuron. 2000;27:301&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">10985350</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabs D, Slepnev VI, Songyang Z, David C, Lynch M, Cantley LC, De Camilli P. The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence. J Biol Chem. 1997;272:13419&#x2013;13425.</Citation><ArticleIdList><ArticleId IdType="pubmed">9148966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray NW, Fourgeaud L, Huang B, Chen J, Cao H, Oswald BJ, Hemar A, McNiven MA. Dynamin 3 is a component of the postsynapse, where it interacts with mGluR5 and Homer. Curr Biol. 2003;13:510&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646135</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzowski JF, Lyford GL, Stevenson GD, Houston FP, McGaugh JL, Worley PF, Barnes CA. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci. 2000;20:3993&#x2013;4001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772617</ArticleId><ArticleId IdType="pubmed">10818134</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzowski JF, McNaughton BL, Barnes CA, Worley PF. Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles. Nat Neurosci. 1999;2:1120&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10570490</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard L, Nelson KK, Maciewicz RA, Blobel CP. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1. J Biol Chem. 1999;274:31693&#x2013;31699.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531379</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Kayser MS, Bear MF. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science. 2000;288:1254&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818003</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttner WB, Schiebler W, Greengard P, De Camilli P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol. 1983;96:1374&#x2013;1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112660</ArticleId><ArticleId IdType="pubmed">6404912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Kim YS, Yuan JP, Petralia RS, Worley PF, Linden DJ. Activation of the TRPC1 cation channel by metabotropic glutamate receptor mGluR1. Nature. 2003;426:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka T, Ikeda K. Possible temperature-dependent blockage of synaptic vesicle recycling induced by a single gene mutation in Drosophila. J Neurobiol. 1983;14:207&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">6304244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanahan A, Worley P. Immediate-early genes and synaptic function. Neurobiol Learn Mem. 1998;70:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9753585</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6:112&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687999</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Simonetta A, Sheng M. Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons. Neuron. 2004;43:221&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260958</ArticleId></ArticleIdList></Reference><Reference><Citation>Link W, Konietzko U, Kauselmann G, Krug M, Schwanke B, Frey U, Kuhl D. Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci U S A. 1995;92:5734&#x2013;5738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41771</ArticleId><ArticleId IdType="pubmed">7777577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, Gilbert DJ, Jenkins NA, Lanahan AA, Worley PF. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 1995;14:433&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857651</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R. AMPA receptor trafficking and long-term potentiation. Philos Trans R Soc Lond B Biol Sci. 2003;358:707&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693162</ArticleId><ArticleId IdType="pubmed">12740116</ArticleId></ArticleIdList></Reference><Reference><Citation>Man HY, Lin JW, Ju WH, Ahmadian G, Liu L, Becker LE, Sheng M, Wang YT. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron. 2000;25:649&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774732</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M, Yoshida-Matsuoka J, Yamagata K, Sugiura H, Ichikawa M, Norita M. Rapid induction of Arc is observed in the granule cell dendrites in the accessory olfactory bulb after mating. Brain Res. 2003;975:189&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">12763607</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson PS, Garcia EP, Slepnev VI, David C, Zhang X, Grabs D, Sossin WS, Bauerfeind R, Nemoto Y, De Camilli P. A presynaptic inositol-5-phosphatase. Nature. 1996;379:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">8552192</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, Kay BK, McPherson PS. Synaptojanin forms two separate complexes in the nerve terminal. Interactions with endophilin and amphiphysin. J Biol Chem. 1997;272:27239&#x2013;27245.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341169</ArticleId></ArticleIdList></Reference><Reference><Citation>Moga DE, Calhoun ME, Chowdhury A, Worley P, Morrison JH, Shapiro ML. Activity-regulated cytoskeletal-associated protein is localized to recently activated excitatory synapses. Neuroscience. 2004;125:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15051140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousavi SA, Malerod L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J. 2004;377:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1223844</ArticleId><ArticleId IdType="pubmed">14505490</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PV, Kandel ER. A macromolecular synthesis-dependent late phase of long-term potentiation requiring cAMP in the medial perforant pathway of rat hippocampal slices. J Neurosci. 1996;16:3189&#x2013;3198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579127</ArticleId><ArticleId IdType="pubmed">8627357</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto PM, Gamby C, Wells D, Fallon J, Vallee RB. Dynamin isoform-specific interaction with the shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton. J Biol Chem. 2001;276:48458&#x2013;48465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715172</ArticleId><ArticleId IdType="pubmed">11583995</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani S, Abraham WC. Inhibition of protein synthesis in the dentate gyrus, but not the entorhinal cortex, blocks maintenance of long-term potentiation in rats. Neurosci Lett. 1989;106:175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">2586822</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Penick EC, Edwards JG, Kauer JA, Ehlers MD. Recycling endosomes supply AMPA receptors for LTP. Science. 2004;305:1972&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448273</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter BJ, Kent HM, Mills IG, Vallis Y, Butler PJ, Evans PR, McMahon HT. BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. Science. 2004;303:495&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645856</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature. 2002;416:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11894096</ArticleId></ArticleIdList></Reference><Reference><Citation>Plath N, Ohana O, Dammerman B, Errington ML, Gross C, Mao X, Engelsberg A, Mahlke C, Welzl H, Kobalz U, et al. Arg3.1/Arc is essential for the consolidation of synaptic plasticity and memories. Neuron. 2006 In Press.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088210</ArticleId></ArticleIdList></Reference><Reference><Citation>Poodry CA, Hall L, Suzuki DT. Developmental properties of Shibire: a pleiotropic mutation affecting larval and adult locomotion and development. Dev Biol. 1973;32:373&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">4208027</ArticleId></ArticleIdList></Reference><Reference><Citation>Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol. 2004;5:133&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15040446</ArticleId></ArticleIdList></Reference><Reference><Citation>Qualmann B, Roos J, DiGregorio PJ, Kelly RB. Syndapin I, a synaptic dynamin-binding protein that associates with the neural Wiskott-Aldrich syndrome protein. Mol Biol Cell. 1999;10:501&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25183</ArticleId><ArticleId IdType="pubmed">9950691</ArticleId></ArticleIdList></Reference><Reference><Citation>Racz B, Blanpied TA, Ehlers MD, Weinberg RJ. Lateral organization of endocytic machinery in dendritic spines. Nat Neurosci. 2004;7:917&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Amaya V, Vazdarjanova A, Mikhael D, Rosi S, Worley PF, Barnes CA. Spatial exploration-induced Arc mRNA and protein expression: evidence for selective, network-specific reactivation. J Neurosci. 2005;25:1761&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725922</ArticleId><ArticleId IdType="pubmed">15716412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringstad N, Gad H, Low P, Di Paolo G, Brodin L, Shupliakov O, De Camilli P. Endophilin/SH3p4 is required for the transition from early to late stages in clathrin-mediated synaptic vesicle endocytosis. Neuron. 1999;24:143&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">10677033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringstad N, Nemoto Y, De Camilli P. The SH3p4/Sh3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. Proc Natl Acad Sci U S A. 1997;94:8569&#x2013;8574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23017</ArticleId><ArticleId IdType="pubmed">9238017</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux A, Uyhazi K, Frost A, De Camilli P. GTP-dependent twisting of dynamin implicates constriction and tension in membrane fission. Nature. 2006;441:528&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16648839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumbaugh G, Adams JP, Kim JH, Huganir RL. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. Proc Natl Acad Sci U S A. 2006;103:4344&#x2013;4351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450173</ArticleId><ArticleId IdType="pubmed">16537406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumbaugh G, Sia GM, Garner CC, Huganir RL. Synapse-associated protein-97 isoform-specific regulation of surface AMPA receptors and synaptic function in cultured neurons. J Neurosci. 2003;23:4567&#x2013;4576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740810</ArticleId><ArticleId IdType="pubmed">12805297</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuske KR, Richmond JE, Matthies DS, Davis WS, Runz S, Rube DA, van der Bliek AM, Jorgensen EM. Endophilin is required for synaptic vesicle endocytosis by localizing synaptojanin. Neuron. 2003;40:749&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622579</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd JD, Rumbaugh G, Wu J, Chowdhury S, Plath N, Kuhl D, Huganir RL, Worley PF. Arc mediates synaptic scaling of AMPA receptors. Neuron. 2006 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764219</ArticleId><ArticleId IdType="pubmed">17088213</ArticleId></ArticleIdList></Reference><Reference><Citation>Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature. 2002;416:183&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11894095</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg JP, Takamiya K, Shen Y, Xia J, Rubio ME, Yu S, Jin W, Thomas GM, Linden DJ, Huganir RL. Targeted in vivo mutations of the AMPA receptor subunit GluR2 and its interacting protein PICK1 eliminate cerebellar long-term depression. Neuron. 2006;49:845&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">16543133</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward O, Wallace CS, Lyford GL, Worley PF. Synaptic activation causes the mRNA for the IEG Arc to localize selectively near activated postsynaptic sites on dendrites. Neuron. 1998;21:741&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808461</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward O, Worley P. Local synthesis of proteins at synaptic sites on dendrites: role in synaptic plasticity and memory consolidation? Neurobiol Learn Mem. 2002;78:508&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagawa Y, Kanold PO, Majdan M, Shatz CJ. Multiple periods of functional ocular dominance plasticity in mouse visual cortex. Nat Neurosci. 2005;8:380&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15723060</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui CC, Copeland NG, Gilbert DJ, Jenkins NA, Barnes C, Worley PF. Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. J Neurosci. 1996;16:2463&#x2013;2478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578758</ArticleId><ArticleId IdType="pubmed">8786423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu J`C, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, Linden DJ, Worley PF. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron. 1998;21:717&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808459</ArticleId></ArticleIdList></Reference><Reference><Citation>Velho TA, Pinaud R, Rodrigues PV, Mello CV. Co-induction of activity-dependent genes in songbirds. Eur J Neurosci. 2005;22:1667&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16197507</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde ER, Lee-Osbourne J, Worley PF, Malinow R, Cline HT. Increased Expression of the Immediate-early Gene Arc Reduces AMPA Receptor-mediated Synaptic Transmission. Neuron. 2006 This Issue.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951199</ArticleId><ArticleId IdType="pubmed">17088212</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstreken P, Kjaerulff O, Lloyd TE, Atkinson R, Zhou Y, Meinertzhagen IA, Bellen HJ. Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter release. Cell. 2002;109:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955450</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstreken P, Koh TW, Schulze KL, Zhai RG, Hiesinger PR, Zhou Y, Mehta SQ, Cao Y, Roos J, Bellen HJ. Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron. 2003;40:733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622578</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science. 1996;274:2086&#x2013;2089.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YT, Linden DJ. Expression of cerebellar long-term depression requires postsynaptic clathrin-mediated endocytosis. Neuron. 2000;25:635&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774731</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissenhorn W. Crystal structure of the endophilin-A1 BAR domain. J Mol Biol. 2005;351:653&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023669</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Zhang X, Staudinger J, Huganir RL. Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1. Neuron. 1999;22:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Cahill SM, Lemmon MA, Fushman D, Schlessinger J, Cowburn D. Identification of the binding site for acidic phospholipids on the pH domain of dynamin: implications for stimulation of GTPase activity. J Mol Biol. 1996;255:14&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell. 2002;110:443&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z, Buck LB. Combinatorial effects of odorant mixes in olfactory cortex. Science. 2006;311:1477&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pubmed">16527983</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22673115</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Identification of Alzheimer disease-associated variants in genes that regulate retromer function.</ArticleTitle><Pagination><StartPage>2231.e15</StartPage><EndPage>2231.e30</EndPage><MedlinePgn>2231.e15-2231.e30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2012.04.020</ELocationID><Abstract><AbstractText>The proteolytic processing of amyloid precursor protein (APP) to generate the neurotoxic amyloid &#x3b2; (A&#x3b2;) peptide is central to the pathogenesis of Alzheimer disease (AD). The endocytic system mediates the processing of APP by controlling its access to secretases that cleave APP. A key mediator of APP localization is SorL1-a membrane protein that has been genetically linked to AD. The retromer complex is a conserved protein complex required for endosome-to-Golgi retrieval of a number of physiologically important membrane proteins including SorL1. Based on the prior suggestion that endocytosis and retromer sorting pathways might be involved, we hypothesized that variants in other genes in this pathway might also modulate AD risk. Genetic association of AD with 451 polymorphisms in 15 genes encoding retromer or retromer-associated proteins was tested in a Caucasian sample of 8309 AD cases and 7366 cognitively normal elders using individual single nucleotide polymorphism (SNP)- and gene-based tests. We obtained significant evidence of association with KIAA1033 (VEGAS p = 0.025), SNX1 (VEGAS p = 0.035), SNX3 (p = 0.0057), and RAB7A (VEGAS p = 0.018). Ten KIAA1033 SNPs were also significantly associated with AD in a group of African Americans (513 AD cases, 504 control subjects). Findings with four significant SNX3 SNPs in the discovery sample were replicated in a community-based sample of Israeli-Arabs (124 AD cases, 142 control subjects). We show that Snx3 and Rab7A proteins interact with the cargo-selective retromer complex through independent mechanisms to regulate the membrane association of retromer and thereby are key mediators of retromer function. These data implicate additional AD risk genes in the retromer pathway and formally demonstrate a direct link between the activity of the retromer complex and the pathogenesis of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruesegem</LastName><ForeName>Sophia Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Harbour</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Inzelberg</LastName><ForeName>Rivka</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Seaman</LastName><ForeName>Matthew N J</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01-AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701444</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG33193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>100140</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01-AG17173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513978">SNX1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513980">SNX3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058305">Sorting Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498296">VPS26A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090802">rab7 GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurobiol Aging. 2013 Jul;34(7):1923</RefSource><Note>Inzelberg, Rivka [added]; Friedland, Robert [added]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058305" MajorTopicYN="N">Sorting Nexins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090802" MajorTopicYN="N">rab7 GTP-Binding Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosure Statement</b>. The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22673115</ArticleId><ArticleId IdType="mid">NIHMS376099</ArticleId><ArticleId IdType="pmc">PMC3391348</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.04.020</ArticleId><ArticleId IdType="pii">S0197-4580(12)00271-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102(38):13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry. 2006;45(8):2618&#x2013;2628.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489755</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RG, Goldstein JL, Brown MS. A mutation that impairs the ability of lipoprotein receptors to localise in coated pits on the cell surface of human fibroblasts. Nature. 1977;270(5639):695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">201867</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol. 2004;165(1):123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172094</ArticleId><ArticleId IdType="pubmed">15078903</ArticleId></ArticleIdList></Reference><Reference><Citation>Balderhaar HJ, Arlt H, Ostrowicz C, Brocker C, Sundermann F, Brandt R, Babst M, Ungermann C. The Rab GTPase Ypt7 is linked to retromer-mediated receptor recycling and fusion at the yeast late endosome. J Cell Sci. 123(Pt 23):4085&#x2013;4094.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008;29(5):769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun V, Wong A, Landekic M, Hong WJ, Grinstein S, Brumell JH. Sorting nexin 3 (SNX3) is a component of a tubular endosomal network induced by Salmonella and involved in maturation of the Salmonella-containing vacuole. Cell Microbiol. 12(9):1352&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pubmed">20482551</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd CG. Physiology and pathology of endosome-to-Golgi retrograde sorting. Traffic. 12(8):948&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3133849</ArticleId><ArticleId IdType="pubmed">21382144</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuel M, Lefrancois S, Zeng J, Morales CR. AP-1 and retromer play opposite roles in the trafficking of sortilin between the Golgi apparatus and the lysosomes. Biochem Biophys Res Commun. 2008;366(3):724&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">18078806</ArticleId></ArticleIdList></Reference><Reference><Citation>Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell. 1999;3(1):11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10024875</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol. 8(1) e1000294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811148</ArticleId><ArticleId IdType="pubmed">20126254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci. 2008;28(48):12877&#x2013;12886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton S. Retromer retrieves wntless. Dev Cell. 2008;14(1):4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18194646</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback AW, Seaman M, Gustafsen C, Mehmedbasic A, Gokool S, Wu C, Militz D, Schmidt V, Madsen P, Nyengaard JR, Willnow TE, Christensen EI, Mobley WB, Nykj&#xe6;r A, Andersen OM. Retromer Binds the FANSHY Sorting Motif in SorLA to Regulate Amyloid Precursor Protein Sorting and Processing. J Neuroscience. 2012;32(4):1467&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="pubmed">22279231</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokool S, Tattersall D, Seaman MN. EHD1 interacts with retromer to stabilize SNX1 tubules and facilitate endosome-to-Golgi retrieval. Traffic. 2007;8(12):1873&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868075</ArticleId></ArticleIdList></Reference><Reference><Citation>Haft CR, de la Luz Sierra M, Bafford R, Lesniak MA, Barr VA, Taylor SI. Human orthologs of yeast vacuolar protein sorting proteins Vps26, 29, and 35: assembly into multimeric complexes. Mol Biol Cell. 2000;11(12):4105&#x2013;4116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15060</ArticleId><ArticleId IdType="pubmed">11102511</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbour ME, Breusegem SY, Antrobus R, Freeman C, Reid E, Seaman MN. The cargo-selective retromer complex is a recruiting hub for protein complexes that regulate endosomal tubule dynamics. J Cell Sci. 123(Pt 21):3703&#x2013;3717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964111</ArticleId><ArticleId IdType="pubmed">20923837</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Harterink M, Port F, Lorenowicz MJ, McGough IJ, Silhankova M, Betist MC, van Weering JR, van Heesbeen RG, Middelkoop TC, Basler K, Cullen PJ, Korswagen HC. A SNX3-dependent retromer pathway mediates retrograde transport of the Wnt sorting receptor Wntless and is required for Wnt secretion. Nat Cell Biol. 13(8):914&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4052212</ArticleId><ArticleId IdType="pubmed">21725319</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. Meta-analysis confirms CR1, CLU, PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 67(12):1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Yamamoto M, Morihara T, Akatsu H, Kudo T, Kamino K, Takeda M. SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett. 2009;461(2):177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19539718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, Kornhuber J, Frolich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den Bussche H, Hull M, Kurz A, Ruther E, Henn FA, Maier W. Association of SORL1 gene variants with Alzheimer's disease. Brain Res. 2009;1264:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19368828</ArticleId></ArticleIdList></Reference><Reference><Citation>Koumandou VL, Klute MJ, Herman EK, Nunez-Miguel R, Dacks JB, Field MC. Evolutionary reconstruction of the retromer complex and its function in Trypanosoma brucei. J Cell Sci. 124(Pt 9):1496&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078816</ArticleId><ArticleId IdType="pubmed">21502137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci. 2010;30(39):13110&#x2013;13115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274732</ArticleId><ArticleId IdType="pubmed">20881129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Barral S, Reitz C. The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease. Curr Neurol Neurosci Rep. 2008;8(5):384&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694663</ArticleId><ArticleId IdType="pubmed">18713574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Honig LS, Vonsattel JP, Clark L, Mayeux R. Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. Neurology. 2008;70(11):887&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634845</ArticleId><ArticleId IdType="pubmed">17978276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y, Rogaeva E, Wakutani Y, Farrer L, St George-Hyslop P, Mayeux R. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol. 2007;64(4):501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="pubmed">17420311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Shibata N, Cheng R, Mayeux R. Possible association between SORL1 and Alzheimer disease? Reanalysing the data of Shibata et al. Dement Geriatr Cogn Disord. 2008;26(5):482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703707</ArticleId><ArticleId IdType="pubmed">18984959</ArticleId></ArticleIdList></Reference><Reference><Citation>Leprince C, Romero F, Cussac D, Vayssiere B, Berger R, Tavitian A, Camonis JH. A new member of the amphiphysin family connecting endocytosis and signal transduction pathways. J Biol Chem. 1997;272(24):15101&#x2013;15105.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182529</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95(3):221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16077740</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rowland C, Catanese J, Morris J, Lovestone S, O'Donovan MC, Goate A, Owen M, Williams J, Grupe A. SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis. 2008;29(2):293&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323581</ArticleId><ArticleId IdType="pubmed">17949987</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, Hayward NK, Montgomery GW, Visscher PM, Martin NG, Macgregor S. A versatile gene-based test for genome-wide association studies. Am J Hum Genet. 87(1):139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896770</ArticleId><ArticleId IdType="pubmed">20598278</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RCP, Griffith P, Akomolafe A, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA. Genetic Variants at Multiple Loci Influence Alzheimer Disease Risk in African Americans. Arch Neurol. 2011 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356921</ArticleId><ArticleId IdType="pubmed">22159054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Monzo P, Gauthier NC, Keslair F, Loubat A, Field CM, Le Marchand-Brustel Y, Cormont M. Clues to CD2-associated protein involvement in cytokinesis. Mol Biol Cell. 2005;16(6):2891&#x2013;2902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142433</ArticleId><ArticleId IdType="pubmed">15800069</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L, Kreber R, Honig LS, Ganetzky B, Duff K, Arancio O, Small SA. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A. 2008;105(20):7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakada-Tsukui K, Saito-Nakano Y, Ali V, Nozaki T. A retromerlike complex is a novel Rab7 effector that is involved in the transport of the virulence factor cysteine protease in the enteric protozoan parasite Entamoeba histolytica. Mol Biol Cell. 2005;16(11):5294&#x2013;5303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266427</ArticleId><ArticleId IdType="pubmed">16120649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes A, Petersen CM. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol Cell Biol. 2007;27(19):6842&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099242</ArticleId><ArticleId IdType="pubmed">17646382</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26(5):1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C. Genetic variants in SORCS2, SORCS3 and SORT1 affect amyloid processing and the risk of Alzheimer's disease. Submitted.</Citation></Reference><Reference><Citation>Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, Zou F, Bettens K, Sleegers K, Tan K, Kimura R, Shibata N, Arai H, Kamboh MI, Prince JA, Maier W, Riemenschneider M, Owen M, Harold D, Hollingworth P, Cellini E, Sorbi S, Nacmias B, Takeda M, Pericak-Vance MA, Haines JL, Younkin S, Williams J, van Broeckhoven C, Farrer LA, St George-Hyslop PH, Mayeux R. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 68(1):99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086666</ArticleId><ArticleId IdType="pubmed">21220680</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN, Palotas A, Lantigua R, Medrano M, I ZJ-V, Vardarajan B, Simkin I, Haines JL, Pericak-Vance MA, Farrer LA, Lee JH, Rogaeva E, George-Hyslop PS, Mayeux R. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol. 69(1):47&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086759</ArticleId><ArticleId IdType="pubmed">21280075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas R, van Vlijmen T, Mardones GA, Prabhu Y, Rojas AL, Mohammed S, Heck AJ, Raposo G, van der Sluijs P, Bonifacino JS. Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7. J Cell Biol. 2008;183(3):513&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575791</ArticleId><ArticleId IdType="pubmed">18981234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudinskiy N, Grishchuk Y, Vaslin A, Puyal J, Delacourte A, Hirling H, Clarke PG, Luthi-Carter R. Calpain hydrolysis of alpha- and beta2-adaptins decreases clathrin-dependent endocytosis and may promote neurodegeneration. J Biol Chem. 2009;284(18):12447&#x2013;12458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673311</ArticleId><ArticleId IdType="pubmed">19240038</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61(8):1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MNJ. Identification of a novel conserved sorting motif necessary for retromer-mediated endosome-to-Golgi retrieval. J Cell Sci. 2007;120:2378&#x2013;2389.</Citation><ArticleIdList><ArticleId IdType="pubmed">17606993</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. J Cell Biol. 2004;165(1):111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172078</ArticleId><ArticleId IdType="pubmed">15078902</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, Harbour ME, Tattersall D, Read E, Bright N. Membrane recruitment of the cargo-selective retromer subcomplex is catalysed by the small GTPase Rab7 and inhibited by the Rab-GAP TBC1D5. J Cell Sci. 2009;122(Pt 14):2371&#x2013;2382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704877</ArticleId><ArticleId IdType="pubmed">19531583</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, McCaffery JM, Emr SD. A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J Cell Biol. 1998;142(3):665&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148169</ArticleId><ArticleId IdType="pubmed">9700157</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM. Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama. 303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherva R, Baldwin CT, Inzelberg R, Vardarajan B, Cupples LA, Lunetta K, Bowirrat A, Naj A, Pericak-Vance M, Friedland RP, Farrer LA. Identification of novel candidate genes for Alzheimer's disease by autozygosity mapping using genome wide SNP data. J Alzheimers Dis. 23(2):349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819807</ArticleId><ArticleId IdType="pubmed">21098978</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA. Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease. Arch Neurol. 2008;65(3):323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726781</ArticleId><ArticleId IdType="pubmed">18332244</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005;58(6):909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci. 2006;26(2):418&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="pubmed">16407538</ArticleId></ArticleIdList></Reference><Reference><Citation>Strochlic TI, Schmiedekamp BC, Lee J, Katzmann DJ, Burd CG. Opposing activities of the Snx3-retromer complex and ESCRT proteins mediate regulated cargo sorting at a common endosome. Mol Biol Cell. 2008;19(11):4694&#x2013;4706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575174</ArticleId><ArticleId IdType="pubmed">18768754</ArticleId></ArticleIdList></Reference><Reference><Citation>Strochlic TI, Setty TG, Sitaram A, Burd CG. Grd19/Snx3p functions as a cargo-specific adapter for retromer-dependent endocytic recycling. J Cell Biol. 2007;177(1):115&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064116</ArticleId><ArticleId IdType="pubmed">17420293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan CP, Jay AG, Stack EC, Pakaluk M, Wadlinger E, Fine RE, Wells JM, Morin PJ. Retromer disruption promotes amyloidogenic APP processing. Neurobiol Dis. 2011;43(2):338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114192</ArticleId><ArticleId IdType="pubmed">21515373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabuchi M, Yanatori I, Kawai Y, Kishi F. Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1. J Cell Sci. 123(Pt 5):756&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164305</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL. SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging. 2009;30(7):1048&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063222</ArticleId></ArticleIdList></Reference><Reference><Citation>Viklund IM, Aspenstrom P, Meas-Yedid V, Zhang B, Kopec J, Agren D, Schneider G, D'Amato M, Olivo-Marin JC, Sansonetti P, Van Nhieu GT, Pettersson S. WAFL, a new protein involved in regulation of early endocytic transport at the intersection of actin and microtubule dynamics. Exp Cell Res. 2009;315(6):1040&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">19121306</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ. VPS35 mutations in Parkinson disease. Am J Hum Genet. 89(1):162&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135796</ArticleId><ArticleId IdType="pubmed">21763482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassmer T, Attar N, Bujny MV, Oakley J, Traer CJ, Cullen PJ. A loss-of-function screen reveals SNX5 and SNX6 as potential components of the mammalian retromer. J Cell Sci. 2007;120(Pt 1):45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brucke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 89(1):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135812</ArticleId><ArticleId IdType="pubmed">21763483</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22516235</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>134</EndPage><MedlinePgn>126-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2012.03.030</ELocationID><Abstract><AbstractText>The retromer complex plays an important role in intracellular transport, is highly expressed in the hippocampus, and has been implicated in the trafficking of the amyloid precursor protein (APP). Nevertheless, the trafficking routes of the neuronal retromer and the role it plays in APP transport in neuronal processes remain unknown. Here we use hippocampal neuronal cultures to address these issues. Using fluorescence microscopy, we find that Vps35, the core element of the retromer complex, is in dendrites and axons, is enriched in endosomes and trans-Golgi network, and is found in APP-positive vesicles. Next, to identify the role the neuronal retromer plays in cargo transport, we infected hippocampal neurons with a lentivirus expressing shRNA to silence Vps35. By live fluorescence imaging, Vps35 deficiency was found to reduce the frequency, but not the kinetics, of long-range APP transport within neuronal processes. Supporting the interpretation that retromer promotes long-range transport, Vps35 deficiency led to increased APP in the early endosomes, in processes but not the soma. Finally, Vps35 deficiency was associated with increased levels of A&#x3b2;, a cleaved product of APP, increased colocalization of APP with its cleaving enzyme BACE1 in processes, and caused an enlargement of early endosomes. Taken together, our studies clarify the function of the neuronal retromer, and suggest specific mechanisms for how retromer dysfunction observed in Alzheimer's disease affects APP transport and processing.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhalla</LastName><ForeName>Akhil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University College of Physicians and Surgeons, New York NY10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vetanovetz</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Morel</LastName><ForeName>Etienne</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chamoun</LastName><ForeName>Zeina</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS056049</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056049</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419573">VPS35 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021601" MajorTopicYN="N">trans-Golgi Network</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22516235</ArticleId><ArticleId IdType="mid">NIHMS368956</ArticleId><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2012.03.030</ArticleId><ArticleId IdType="pii">S0969-9961(12)00119-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol. 2004;165:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172094</ArticleId><ArticleId IdType="pubmed">15078903</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya TY, Wu Y, Tang X, Zhou B, Cheng L, Sharma YV, Yan D, Selva EM, Lin X. The retromer complex influences Wnt secretion by recycling wntless from endosomes to the trans-Golgi network. Dev Cell. 2008;14:120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">18160348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol. 2008;20:427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833274</ArticleId><ArticleId IdType="pubmed">18472259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunholz S, Sisodia S, Lorenzo A, Deyts C, Kins S, Morfini G. Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp Brain Res. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670699</ArticleId><ArticleId IdType="pubmed">21960299</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A, Rebeck GW, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C, van Duijn C, Cras P, Bogdanovic N, Bird T, Peterhoff C, Nixon R. Endocytic disturbances distinguish among subtypes of Alzheimer&#x2019;s disease and related disorders. Ann Neurol. 2001;50:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706973</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006;52:293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046692</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Haft CR, de la Luz Sierra M, Bafford R, Lesniak MA, Barr VA, Taylor SI. Human orthologs of yeast vacuolar protein sorting proteins Vps26, 29, and 35: assembly into multimeric complexes. Mol Biol Cell. 2000;11:4105&#x2013;4116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15060</ArticleId><ArticleId IdType="pubmed">11102511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonen E, Parton RG, Hunziker W, Simons K, Dotti CG. Transcytosis of the polymeric immunoglobulin receptor in cultured hippocampal neurons. Curr Biol. 1993;3:635&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">15335854</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Skehel P, Dotti CG. Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell. 2000;11:1213&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14842</ArticleId><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci. 2003;116:3339&#x2013;3346.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829747</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A. 1990;87:1561&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="pubmed">1689489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S. Diabetes-associated SorCS1 regulates Alzheimer&#x2019;s amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci. 2010;30:13110&#x2013;13115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274732</ArticleId><ArticleId IdType="pubmed">20881129</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L, Kreber R, Honig LS, Ganetzky B, Duff K, Arancio O, Small SA. Retromer deficiency observed in Alzheimer&#x2019;s disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A. 2008;105:7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L, Aubry L, Vanti WB, Moreno H, Abeliovich A. Directed conversion of Alzheimer&#x2019;s disease patient skin fibroblasts into functional neurons. Cell. 2011;146:359&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151530</ArticleId><ArticleId IdType="pubmed">21816272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer&#x2019;s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172&#x2013;11177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN, Palotas A, Lantigua R, Medrano M, I ZJ-V, Vardarajan B, Simkin I, Haines JL, Pericak-Vance MA, Farrer LA, Lee JH, Rogaeva E, George-Hyslop PS, Mayeux R. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer&#x2019;s disease risk. Ann Neurol. 2011;69:47&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086759</ArticleId><ArticleId IdType="pubmed">21280075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;15:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA. Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease. Arch Neurol. 2008;65:323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726781</ArticleId><ArticleId IdType="pubmed">18332244</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Gandy S. Sorting through the cell biology of Alzheimer&#x2019;s disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan CP, Jay AG, Stack EC, Pakaluk M, Wadlinger E, Fine RE, Wells JM, Morin PJ. Retromer disruption promotes amyloidogenic APP processing. Neurobiol Dis. 2011;43:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114192</ArticleId><ArticleId IdType="pubmed">21515373</ArticleId></ArticleIdList></Reference><Reference><Citation>Verges M, Luton F, Gruber C, Tiemann F, Reinders LG, Huang L, Burlingame AL, Haft CR, Mostov KE. The mammalian retromer regulates transcytosis of the polymeric immunoglobulin receptor. Nat Cell Biol. 2004;6:763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247922</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira SI, Rebelo S, Esselmann H, Wiltfang J, Lah J, Lane R, Small SA, Gandy S, da Cruz ESEF, da Cruz ESOA. Retrieval of the Alzheimer&#x2019;s amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener. 2010;5:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2994555</ArticleId><ArticleId IdType="pubmed">20937087</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89:162&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135796</ArticleId><ArticleId IdType="pubmed">21763482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89:168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135812</ArticleId><ArticleId IdType="pubmed">21763483</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22691495</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>25</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Loss of functional GABA(A) receptors in the Alzheimer diseased brain.</ArticleTitle><Pagination><StartPage>10071</StartPage><EndPage>10076</EndPage><MedlinePgn>10071-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1204606109</ELocationID><Abstract><AbstractText>The cholinergic and glutamatergic neurotransmission systems are known to be severely disrupted in Alzheimer's disease (AD). GABAergic neurotransmission, in contrast, is generally thought to be well preserved. Evidence from animal models and human postmortem tissue suggest GABAergic remodeling in the AD brain. Nevertheless, there is no information on changes, if any, in the electrophysiological properties of human native GABA receptors as a consequence of AD. To gain such information, we have microtransplanted cell membranes, isolated from temporal cortices of control and AD brains, into Xenopus oocytes, and recorded the electrophysiological activity of the transplanted GABA receptors. We found an age-dependent reduction of GABA currents in the AD brain. This reduction was larger when the AD membranes were obtained from younger subjects. We also found that GABA currents from AD brains have a faster rate of desensitization than those from non-AD brains. Furthermore, GABA receptors from AD brains were slightly, but significantly, less sensitive to GABA than receptors from non-AD brains. The reduction of GABA currents in AD was associated with reductions of mRNA and protein of the principal GABA receptor subunits normally present in the temporal cortex. Pairwise analysis of the transcripts within control and AD groups and analyses of the proportion of GABA receptor subunits revealed down-regulation of &#x3b1;1 and &#x3b3;2 subunits in AD. In contrast, the proportions of &#x3b1;2, &#x3b2;1, and &#x3b3;1 transcripts were up-regulated in the AD brains. Our data support a functional remodeling of GABAergic neurotransmission in the human AD brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Limon</LastName><ForeName>Agenor</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Neurobiology, Department of Neurobiology and Behavior, University of California, Irvine, CA 92697, USA. alimonru@uci.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes-Ruiz</LastName><ForeName>Jorge Mauricio</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Miledi</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22691495</ArticleId><ArticleId IdType="pmc">PMC3382476</ArticleId><ArticleId IdType="doi">10.1073/pnas.1204606109</ArticleId><ArticleId IdType="pii">1204606109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Mobley WC. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J Neurochem. 2011;117:613&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127285</ArticleId><ArticleId IdType="pubmed">21388375</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchetti S, Huitinga I, Swaab DF. Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. Neuroscience. 2011;191:6&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21514366</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: Classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev. 2008;60:243&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847512</ArticleId><ArticleId IdType="pubmed">18790874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanct&#xf4;t KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: Evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49:439&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">15362248</ArticleId></ArticleIdList></Reference><Reference><Citation>McEnery MW. The mitochondrial benzodiazepine receptor: Evidence for association with the voltage-dependent anion channel (VDAC) J Bioenerg Biomembr. 1992;24:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">1380506</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarf AM, Ittner LM, Kassiou M. The translocator protein (18 kDa): central nervous system disease and drug design. J Med Chem. 2009;52:581&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">19133775</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosenza-Nashat M, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35:306&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693902</ArticleId><ArticleId IdType="pubmed">19077109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizukami K, Grayson DR, Ikonomovic MD, Sheffield R, Armstrong DM. GABAA receptor &#x3b2; 2 and &#x3b2; 3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimer-related neuropathology. Brain Res Mol Brain Res. 1998;56:268&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">9602147</ArticleId></ArticleIdList></Reference><Reference><Citation>Miledi R, Due&#xf1;as Z, Martinez-Torres A, Kawas CH, Eusebi F. Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes. Proc Natl Acad Sci USA. 2004;101:1760&#x2013;1763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC341849</ArticleId><ArticleId IdType="pubmed">14749517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernareggi A, Due&#xf1;as Z, Reyes-Ruiz JM, Ruzzier F, Miledi R. Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proc Natl Acad Sci USA. 2007;104:2956&#x2013;2960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1815288</ArticleId><ArticleId IdType="pubmed">17301224</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennisi G, et al. Motor cortex excitability in Alzheimer disease: One year follow-up study. Neurosci Lett. 2002;329:293&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12183034</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lazzaro V, et al. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:555&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739006</ArticleId><ArticleId IdType="pubmed">15026495</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcade M, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008;106:392&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">18397369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschy JM, Harvey RJ, Schwarz G. Gephyrin: Where do we stand, where do we go? Trends Neurosci. 2008;31:257&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403029</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesse S, et al. Glial fibrillary acidic protein and protein S-100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis. 2009;17:541&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433893</ArticleId></ArticleIdList></Reference><Reference><Citation>Russek SJ. Evolution of GABA(A) receptor diversity in the human genome. Gene. 1999;227:213&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023064</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PJ, et al. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann N Y Acad Sci. 1999;868:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">10414349</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden WH, Peugh LD, Jansen LA. Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex. Neurosci Lett. 2010;483:167&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233535</ArticleId><ArticleId IdType="pubmed">20692323</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong DM, Ikonomovic MD, Sheffield R, Wenthold RJ. AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease. Brain Res. 1994;639:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">8205474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Lippa CF, Zhu J, Lin Q, Rosso AL. Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Brain Res. 2009;1292:191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745956</ArticleId><ArticleId IdType="pubmed">19635471</ArticleId></ArticleIdList></Reference><Reference><Citation>Partin KM, Patneau DK, Winters CA, Mayer ML, Buonanno A. Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin A. Neuron. 1993;11:1069&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">7506043</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E, et al. Phosphatase inhibitors remove the run-down of gamma-aminobutyric acid type A receptors in the human epileptic brain. Proc Natl Acad Sci USA. 2004;101:10183&#x2013;10188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC454185</ArticleId><ArticleId IdType="pubmed">15218107</ArticleId></ArticleIdList></Reference><Reference><Citation>Barish ME. A transient calcium-dependent chloride current in the immature Xenopus oocyte. J Physiol. 1983;342:309&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1193960</ArticleId><ArticleId IdType="pubmed">6313909</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson SA, et al. Salicylidene salicylhydrazide, a selective inhibitor of beta 1-containing GABAA receptors. Br J Pharmacol. 2004;142:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574914</ArticleId><ArticleId IdType="pubmed">15100159</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SJ, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neurochem. 1983;41:256&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">6134787</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen F, Poulter M, Waddington JL, Mashal RD, Crow TJ. [3H]R05-4864 and [3H]flunitrazepam binding in kainate-lesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res. 1983;278:373&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">6640329</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging. 1987;8:521&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">3323927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Morrison JH. The aging brain: Morphomolecular senescence of cortical circuits. Trends Neurosci. 2004;27:607&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">15374672</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein DL, et al. Changes in the structural complexity of the aged brain. Aging Cell. 2007;6:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441530</ArticleId><ArticleId IdType="pubmed">17465981</ArticleId></ArticleIdList></Reference><Reference><Citation>Loerch PM, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE. 2008;3:e3329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553198</ArticleId><ArticleId IdType="pubmed">18830410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwood CC, et al. Aging of the cerebral cortex differs between humans and chimpanzees. Proc Natl Acad Sci USA. 2011;108:13029&#x2013;13034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156199</ArticleId><ArticleId IdType="pubmed">21788499</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain. 2010;133:512&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858015</ArticleId><ArticleId IdType="pubmed">20080878</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007;20:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341768</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Marin V, et al. Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques. Front Neuroanat. 2009;3:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784678</ArticleId><ArticleId IdType="pubmed">19949482</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakiri M, et al. An immunohistochemical study of GABAA receptor gamma subunits in Alzheimer's disease hippocampus: Relationship to neurofibrillary tangle progression. Neuropathology. 2009;29:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078755</ArticleId><ArticleId IdType="pubmed">19019179</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Tannenberg RK, Dodd PR. Reduced expression of the inhibitory synapse scaffolding protein gephyrin in Alzheimer's disease. J Alzheimers Dis. 2008;14:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">18599957</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser DD, et al. GABAA/benzodiazepine receptors in acutely isolated hippocampal astrocytes. J Neurosci. 1995;15:2720&#x2013;2732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577765</ArticleId><ArticleId IdType="pubmed">7722625</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnert TP, et al. &#x3b8;, a novel gamma-aminobutyric acid type A receptor subunit. Proc Natl Acad Sci USA. 1999;96:9891&#x2013;9896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22306</ArticleId><ArticleId IdType="pubmed">10449790</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntsman MM, Huguenard JR. Fast IPSCs in rat thalamic reticular nucleus require the GABAA receptor beta1 subunit. J Physiol. 2006;572:459&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779681</ArticleId><ArticleId IdType="pubmed">16469775</ArticleId></ArticleIdList></Reference><Reference><Citation>Khom S, et al. Pharmacological properties of GABAA receptors containing gamma1 subunits. Mol Pharmacol. 2006;69:640&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">16272224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallacher J, et al. Benzodiazepine use and risk of dementia: Evidence from the Caerphilly Prospective Study (CaPS) J Epidemiol Community Health. 2011 doi: 10.1136/jech-2011-200314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2011-200314</ArticleId><ArticleId IdType="pubmed">22034632</ArticleId></ArticleIdList></Reference><Reference><Citation>Liepert J, B&#xe4;r KJ, Meske U, Weiller C. Motor cortex disinhibition in Alzheimer's disease. Clin Neurophysiol. 2001;112:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459683</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-&#x394; &#x394; C(T)) Method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan JS, Reed A, Chen F, Stewart CN., Jr Statistical analysis of real-time PCR data. BMC Bioinformatics. 2006;7:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1395339</ArticleId><ArticleId IdType="pubmed">16504059</ArticleId></ArticleIdList></Reference><Reference><Citation>Limon A, Reyes-Ruiz JM, Miledi R. Microtransplantation of neurotransmitter receptors from postmortem autistic brains to Xenopus oocytes. Proc Natl Acad Sci USA. 2008;105:10973&#x2013;10977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504813</ArticleId><ArticleId IdType="pubmed">18645182</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22685416</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants.</ArticleTitle><Pagination><StartPage>e1002707</StartPage><MedlinePgn>e1002707</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002707</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1002707</ELocationID><Abstract><AbstractText>Genetic variants that modify brain gene expression may also influence risk for human diseases. We measured expression levels of 24,526 transcripts in brain samples from the cerebellum and temporal cortex of autopsied subjects with Alzheimer's disease (AD, cerebellar n=197, temporal cortex n=202) and with other brain pathologies (non-AD, cerebellar n=177, temporal cortex n=197). We conducted an expression genome-wide association study (eGWAS) using 213,528 cisSNPs within &#xb1; 100 kb of the tested transcripts. We identified 2,980 cerebellar cisSNP/transcript level associations (2,596 unique cisSNPs) significant in both ADs and non-ADs (q&lt;0.05, p=7.70 &#xd7; 10(-5)-1.67 &#xd7; 10(-82)). Of these, 2,089 were also significant in the temporal cortex (p=1.85 &#xd7; 10(-5)-1.70 &#xd7; 10(-141)). The top cerebellar cisSNPs had 2.4-fold enrichment for human disease-associated variants (p&lt;10(-6)). We identified novel cisSNP/transcript associations for human disease-associated variants, including progressive supranuclear palsy SLCO1A2/rs11568563, Parkinson's disease (PD) MMRN1/rs6532197, Paget's disease OPTN/rs1561570; and we confirmed others, including PD MAPT/rs242557, systemic lupus erythematosus and ulcerative colitis IRF5/rs4728142, and type 1 diabetes mellitus RPS26/rs1701704. In our eGWAS, there was 2.9-3.3 fold enrichment (p&lt;10(-6)) of significant cisSNPs with suggestive AD-risk association (p&lt;10(-3)) in the Alzheimer's Disease Genetics Consortium GWAS. These results demonstrate the significant contributions of genetic factors to human brain gene expression, which are reliably detected across different brain regions and pathologies. The significant enrichment of brain cisSNPs among disease-associated variants advocates gene expression changes as a mechanism for many central nervous system (CNS) and non-CNS diseases. Combined assessment of expression and disease GWAS may provide complementary information in discovery of human disease variants with functional implications. Our findings have implications for the design and interpretation of eGWAS in general and the use of brain expression quantitative trait loci in the study of human disease genetics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Fanggeng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>High Seng</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Curtis S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Mariet</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Rowley</LastName><ForeName>Christopher N</ForeName><Initials>CN</Initials></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Asha A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Middha</LastName><ForeName>Sumit</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Maharjan</LastName><ForeName>Sooraj</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thuy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Malphrus</LastName><ForeName>Kimberly G</ForeName><Initials>KG</Initials></Author><Author ValidYN="Y"><LastName>Palusak</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lincoln</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bisceglio</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Georgescu</LastName><ForeName>Constantin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kouri</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kolbert</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Jen</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Genetics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nil&#xfc;fer</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000117</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH060451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA137788</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006375</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007754</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG034550</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG02213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR029893</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016575</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS039764</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080295</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024151</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG08051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA132378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1 AG06781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA129769</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG1961</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG30146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MO1RR00096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS059873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR02777</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="Y">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>NR Graff-Radford has served as a consultant to Codman and received grant support from Elan Pharmaceutical Research, Pfizer Pharmaceuticals, Medivation, and Forrest. RC Petersen has been a consultant to GE Healthcare and Elan Pharmaceuticals, has served on a data safety monitoring committee for Pfizer and Janssen Alzheimer Immunotherapy, and has provided a CME lecture for Novartis. ADGC Authors: T.D.B. received licensing fees from and is on the speaker's bureau of Athena Diagnostics. M.R.F. receives research funding from BristolMyersSquibb Company, Danone Research, Elan Pharmaceuticals, Eli Lilly, Novartis Pharmaceuticals, OctaPharma AG, Pfizer, and Sonexa Therapeutics; receives honoraria as scientific consultant from Accera, Astellas Pharma US Inc., Baxter, Bayer Pharmaceuticals Corporation, BristolMyersSquibb, Eisai Medical Research, GE Healthcare, Medavante, Medivation, Merck, Novartis Pharmaceuticals, Pfizer, Prana Biotechnology, QR Pharma, The sanofi-aventis Group, and Toyama Chemical; and is speaker for Eisai Medical Research, Forest Laboratories, Pfizer, and Novartis Pharmaceuticals. A.M.G. has research funding from AstraZeneca, Pfizer and Genentech, and has received remuneration for giving talks at Pfizer and Genentech. R.C.P. is on the Safety Monitory Committee of Pfizer (Wyeth) and a consultant to the Safety Monitoring Committee at Janssen Alzheimer's Immunotherapy Program (Elan), to Elan Pharmaceuticals, and to GE Healthcare. R.E.T. is a consultant to Eisai, Japan, in the area of Alzheimer's genetics and a shareholder in, and consultant to, Pathway Genomics, San Diego, CA.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barmada</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buros</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>Chris S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corneveaux</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demirci</LastName><ForeName>F Yesim</ForeName><Initials>FY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dombroski</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellis</LastName><ForeName>William G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallins</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilman</LastName><ForeName>Sid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordani</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamboh</LastName><ForeName>Ilyas</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mack</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perl</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajbhandary</LastName><ForeName>Ruchita A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shelanski</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slifer</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>Peter St</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri Narayan</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22685416</ArticleId><ArticleId IdType="pmc">PMC3369937</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1002707</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ertekin-Taner N. Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. Mol Neurodegener. 2011;6:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3113300</ArticleId><ArticleId IdType="pubmed">21569597</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy A, Chu JH, Xu M, Carey VJ, Lazarus R, et al. Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes. Hum Mol Genet. 2010;19:4745&#x2013;4757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972694</ArticleId><ArticleId IdType="pubmed">20833654</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, et al.  Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010;6:e1000888. doi: 10.1371/journal.pgen.1000888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000888</ArticleId><ArticleId IdType="pmc">PMC2848547</ArticleId><ArticleId IdType="pubmed">20369019</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, et al. Genetics of gene expression surveyed in maize, mouse and man. Nature. 2003;422:297&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646919</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet. 2003;33:422&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">12567189</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, et al. Genetic analysis of genome-wide variation in human gene expression. Nature. 2004;430:743&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966974</ArticleId><ArticleId IdType="pubmed">15269782</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks SA, Leonardson A, Zhu H, Cundiff P, Pietrusiak P, et al. Genetic inheritance of gene expression in human cell lines. Am J Hum Genet. 2004;75:1094&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182144</ArticleId><ArticleId IdType="pubmed">15514893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, et al. Mapping determinants of human gene expression by regional and genome-wide association. Nature. 2005;437:1365&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005311</ArticleId><ArticleId IdType="pubmed">16251966</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, et al.  Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1:e78. doi: 10.1371/journal.pgen.0010078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.0010078</ArticleId><ArticleId IdType="pmc">PMC1315281</ArticleId><ArticleId IdType="pubmed">16362079</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. Population genomics of human gene expression. Nat Genet. 2007;39:1217&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683249</ArticleId><ArticleId IdType="pubmed">17873874</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007;315:848&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665772</ArticleId><ArticleId IdType="pubmed">17289997</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, et al. A genome-wide association study of global gene expression. Nat Genet. 2007;39:1202&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">17873877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, et al. Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics. 1990;6:575&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">2184120</ArticleId></ArticleIdList></Reference><Reference><Citation>A haplotype map of the human genome. Nature. 2005;437:1299&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, et al.  Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1:e78. doi: 10.1371/journal.pgen.0010078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.0010078</ArticleId><ArticleId IdType="pmc">PMC1315281</ArticleId><ArticleId IdType="pubmed">16362079</ArticleId></ArticleIdList></Reference><Reference><Citation>Goring HH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, et al. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat Genet. 2007;39:1208&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotival M, Zeller T, Wild PS, Maouche S, Szymczak S, et al.  Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans. PLoS Genet. 2011;7:e1002367. doi: 10.1371/journal.pgen.1002367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002367</ArticleId><ArticleId IdType="pmc">PMC3228821</ArticleId><ArticleId IdType="pubmed">22144904</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science. 2009;325:1246&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867218</ArticleId><ArticleId IdType="pubmed">19644074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Gudjonsson JE, Liang L, Stuart PE, Li Y, et al. Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals. Am J Hum Genet. 2010;87:779&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997368</ArticleId><ArticleId IdType="pubmed">21129726</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">18344981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong H, Beaulaurier J, Lum PY, Molony C, Yang X, et al.  Liver and adipose expression associated SNPs are enriched for association to type 2 diabetes. PLoS Genet. 2010;6:e1000932. doi: 10.1371/journal.pgen.1000932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000932</ArticleId><ArticleId IdType="pmc">PMC2865508</ArticleId><ArticleId IdType="pubmed">20463879</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundberg E, Adoue V, Kwan T, Ge B, Duan QL, et al.  Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet. 2011;7:e1001279. doi: 10.1371/journal.ppat.1001279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001279</ArticleId><ArticleId IdType="pmc">PMC3024267</ArticleId><ArticleId IdType="pubmed">21283786</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al.  Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 2008;6:e107. doi: 10.1371/journal.pbio.0060107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060107</ArticleId><ArticleId IdType="pmc">PMC2365981</ArticleId><ArticleId IdType="pubmed">18462017</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39:1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106:9362&#x2013;9367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687147</ArticleId><ArticleId IdType="pubmed">19474294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009;41:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100:9440&#x2013;9445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol. 2010;28:2198&#x2013;2206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860437</ArticleId><ArticleId IdType="pubmed">20368555</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007;68:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251522</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853717</ArticleId><ArticleId IdType="pubmed">20070850</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41:1234&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19838193</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006;38:550&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">16642019</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 2007;104:6758&#x2013;6763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847749</ArticleId><ArticleId IdType="pubmed">17412832</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084597</ArticleId><ArticleId IdType="pubmed">21297633</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007;54:713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaksovirta H, Peuralinna T, Schymick JC, Scholz SW, Lai SL, et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 2010;9:978&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965392</ArticleId><ArticleId IdType="pubmed">20801718</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem. 2005;280:9610&#x2013;9617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15632119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Zou F, Chai HS, Younkin CS, Crook J, et al. Novel late-onset Alzheimer's disease loci variants associate with brain gene expression. Neurology. 2012 in-press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398432</ArticleId><ArticleId IdType="pubmed">22722634</ArticleId></ArticleIdList></Reference><Reference><Citation>Atz M, Walsh D, Cartagena P, Li J, Evans S, et al. Methodological considerations for gene expression profiling of human brain. J Neurosci Methods. 2007;163:295&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835340</ArticleId><ArticleId IdType="pubmed">17512057</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Caffrey TM, Joachim C, Paracchini S, Esiri MM, Wade-Martins R. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet. 2006;15:3529&#x2013;3537.</Citation><ArticleIdList><ArticleId IdType="pubmed">17085483</ArticleId></ArticleIdList></Reference><Reference><Citation>Caffrey TM, Joachim C, Wade-Martins R. Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus. Neurobiol Aging. 2008;29:1923&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801070</ArticleId><ArticleId IdType="pubmed">17602795</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Pittman AM, Zhao AS, Rohrer K, Kaleem M, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174556</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24:1547&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pubmed">18467348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res. 2008;36:e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2241869</ArticleId><ArticleId IdType="pubmed">18178591</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Westfall PH, Zaykin DV, Young SS. Multiple tests for genetic effects in association studies. Methods Mol Biol. 2002;184:143&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">11889711</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22688190</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Active vaccination with ankyrin G reduces &#x3b2;-amyloid pathology in APP transgenic mice.</ArticleTitle><Pagination><StartPage>358</StartPage><EndPage>368</EndPage><MedlinePgn>358-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2012.70</ELocationID><Abstract><AbstractText>Serum antibodies against amyloid-&#x3b2; peptide (A&#x3b2;) in humans with or without diagnosis of Alzheimer's disease (AD) indicate the possibility of immune responses against brain antigens. In an unbiased screening for antibodies directed against brain proteins, we found in AD patients high serum levels of antibodies against the neuronal cytoskeletal protein ankyrin G (ankG); these correlated with slower rates of cognitive decline. Neuronal expression of ankG was higher in AD brains than in nondemented age-matched healthy control subjects. AnkG was present in exosomal vesicles, and it accumulated in &#x3b2;-amyloid plaques. Active immunization with ankG of arcA&#x3b2; transgenic mice reduced brain &#x3b2;-amyloid pathology and increased brain levels of soluble A&#x3b2;(42). AnkG immunization induced a reduction in &#x3b2;-amyloid pathology, also in Swedish transgenic mice(.) Anti-ankG monoclonal antibodies reduced A&#x3b2;-induced loss of dendritic spines in hippocampal ArcA&#x3b2; organotypic cultures. Together, these data established a role for ankG in the human adaptive immune response against resident brain proteins, and they show that ankG immunization reduces brain &#x3b2;-amyloid and its related neuropathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santuccione</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Division of Psychiatry Research, University of Zurich, Zurich, Switzerland. antonella.santuccione@bli.uzh.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlini</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tackenberg</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bali</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ferretti</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>McAfoose</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kulic</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bernreuther</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Welt</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Glatzel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rajendran</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hock</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nitsch</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490613">ANK3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017487">Ankyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017487" MajorTopicYN="N">Ankyrins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22688190</ArticleId><ArticleId IdType="doi">10.1038/mp.2012.70</ArticleId><ArticleId IdType="pii">mp201270</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22692213</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>287</Volume><Issue>31</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo.</ArticleTitle><Pagination><StartPage>25927</StartPage><EndPage>25940</EndPage><MedlinePgn>25927-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M112.377465</ELocationID><Abstract><AbstractText>The &#x3b2;-site amyloid precursor protein-cleaving enzyme BACE1 is a prime drug target for Alzheimer disease. However, the function and the physiological substrates of BACE1 remain largely unknown. In this work, we took a quantitative proteomic approach to analyze the secretome of primary neurons after acute BACE1 inhibition, and we identified several novel substrate candidates for BACE1. Many of these molecules are involved in neuronal network formation in the developing nervous system. We selected the adhesion molecules L1 and CHL1, which are crucial for axonal guidance and maintenance of neural circuits, for further validation as BACE1 substrates. Using both genetic BACE1 knock-out and acute pharmacological BACE1 inhibition in mice and cell cultures, we show that L1 and CHL1 are cleaved by BACE1 under physiological conditions. The BACE1 cleavage sites at the membrane-proximal regions of L1 (between Tyr(1086) and Glu(1087)) and CHL1 (between Gln(1061) and Asp(1062)) were determined by mass spectrometry. This work provides molecular insights into the function and the pathways in which BACE1 is involved, and it will help to predict or interpret possible side effects of BACE1 inhibitor drugs in current clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lujia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KULeuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar&#xe3;o</LastName><ForeName>Soraia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Laga</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bockstael</LastName><ForeName>Katrijn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Borgers</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gijsen</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Moechars</LastName><ForeName>Diederik</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gevaert</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490649">Chl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039842">Neural Cell Adhesion Molecule L1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Biol Chem. 2012 Sep 28;287(40):33719</RefSource><Note>Gevaer, Kris [corrected to Gevaert, Kris]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015815" MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039842" MajorTopicYN="N">Neural Cell Adhesion Molecule L1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22692213</ArticleId><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="doi">10.1074/jbc.M112.377465</ArticleId><ArticleId IdType="pii">S0021-9258(20)73604-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M. A., Biere A. L., Curran E., Burgess T., Louis J. C., Collins F., Treanor J., Rogers G., Citron M. (1999) &#x3b2;-Secretase cleavage of Alzheimer amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735&#x2013;741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Anderson J. P., Barbour R., Basi G. S., Caccavello R., Davis D., Doan M., Dovey H. F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S. M., Wang S., Walker D., Zhao J., McConlog L., John V. (1999) Purification and cloning of amyloid precursor protein &#x3b2;-secretase from human brain. Nature 402, 537&#x2013;540</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I., Powell D., Howlett D. R., Tew D. G., Meek T. D., Chapman C., Gloger I. S., Murphy K. E., Southan C. D., Ryan D. M., Smith T. S., Simmons D. L., Walsh F. S., Dingwall C., Christie G. (1999) Identification of a novel aspartic protease (Asp-2) as &#x3b2;-secretase. Mol. Cell. Neurosci. 14, 419&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">10656250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Bienkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., Brashier J. R., Stratman N. C., Mathews W. R., Buhl A. E., Carter D. B., Tomasselli A. G., Parodi L. A., Heinrikson R. L., Gurney M. E. (1999) Membrane-anchored aspartyl protease with Alzheimer disease &#x3b2;-secretase activity. Nature 402, 533&#x2013;537</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. (2000) Human aspartic protease memapsin 2 cleaves the &#x3b2;-secretase site of &#x3b2;-amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 97, 1456&#x2013;1460</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Vassar R., Golde T. (2010) The secretases. Enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O., Marr R. A., Rockenstein E., Crews L., Coufal N. G., Gage F. H., Verma I. M., Masliah E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 1343&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlog L., Buttini M., Anderson J. P., Brigham E. F., Chen K. S., Freedman S. B., Games D., Johnson-Wood K., Lee M., Zeller M., Liu W., Motter R., Sinha S. (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282, 26326&#x2013;26334</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Bolon B., Kahn S., Bennett B. D., Babu-Khan S., Denis P., Fan W., Kha H., Zhang J., Gong Y., Martin L., Louis J. C., Yan Q., Richards W. G., Citron M., Vassar R. (2001) Mice deficient in BACE1, the Alzheimer &#x3b2;-secretase, have normal phenotype and abolished &#x3b2;-amyloid generation. Nat. Neurosci. 4, 231&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird F. M., Cai H., Savonenko A. V., Farah M. H., He K., Melnikova T., Wen H., Chiang H. C., Xu G., Koliatsos V. E., Borchelt D. R., Price D. L., Lee H. K., Wong P. C. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11693&#x2013;11709</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M., Garratt A. N., Novak B., Citron M., Kaufmann S., Rittger A., DeStrooper B., Saftig P., Birchmeier C., Haass C. (2006) Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science 314, 664&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi D., Zeller M., Cole T., Buttini M., McConlog L., Sinha S., Freedman S., Morris R. G., Chen K. S. (2008) BACE1 gene deletion. Impact on behavioral function in a model of Alzheimer disease. Neurobiol. Aging 29, 861&#x2013;873</Citation><ArticleIdList><ArticleId IdType="pubmed">17331621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M., Chang L., Tseng W., Oakley H., Citron M., Klein W. L., Vassar R., Disterhoft J. F. (2006) Temporal memory deficits in Alzheimer mouse models. Rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23, 251&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M., Sametsky E. A., Younkin L. H., Oakley H., Younkin S. G., Citron M., Vassar R., Disterhoft J. F. (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer disease. Neuron 41, 27&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Song L., Laird F., Wong P. C., Lee H. K. (2008) BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J. Neurosci. 28, 8677&#x2013;8681</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728626</ArticleId><ArticleId IdType="pubmed">18753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison S. M., Harper A. J., Hawkins J., Duddy G., Grau E., Pugh P. L., Winter P. H., Shilliam C. S., Hughes Z. A., Dawson L. A., Gonzalez M. I., Upton N., Pangalos M. N., Dingwall C. (2003) BACE1 (&#x3b2;-secretase) transgenic and knock-out mice. Identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 24, 646&#x2013;655</Citation><ArticleIdList><ArticleId IdType="pubmed">14664815</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D., Tournoy J., Hartmann D., Huth T., Cryns K., Deforce S., Serneels L., Camacho I. E., Marjaux E., Craessaerts K., Roebroek A. J., Schwake M., D'Hooge R., Bach P., Kalinke U., Moechars D., Alzheimer C., Reiss K., Saftig P., De Strooper B. (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J. Biol. Chem. 280, 30797&#x2013;30806</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Hicks C. W., He W., Wong P., Macklin W. B., Trapp B. D., Yan R. (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9, 1520&#x2013;1525</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Zhou X., He W., Yang J., Xiong W., Wong P., Wilson C. G., Yan R. (2010) BACE1 deficiency causes altered neuronal activity and neurodegeneration. J. Neurosci. 30, 8819&#x2013;8829</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A. V., Melnikova T., Laird F. M., Stewart K. A., Price D. L., Wong P. C. (2008) Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. U.S.A. 105, 5585&#x2013;5590</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B. D., Jaramillo T. C., Chetkovich D. M., Vassar R. (2010) BACE1&#x2212;/&#x2212; mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol. Neurodegener. 5, 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933677</ArticleId><ArticleId IdType="pubmed">20731874</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H. K., Sakurai T., Oyama F., Kaneko K., Wada K., Miyazaki H., Kurosawa M., De Strooper B., Saftig P., Nukina N. (2005) &#x3b2;-Subunits of voltage-gated sodium channels are novel substrates of &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE1) and &#x3b3;-secretase. J. Biol. Chem. 280, 23009&#x2013;23017</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D. Y., Carey B. W., Wang H., Ingano L. A., Binshtok A. M., Wertz M. H., Pettingell W. H., He P., Lee V. M., Woolf C. J., Kovacs D. M. (2007) BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 9, 755&#x2013;764</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S., Tachida Y., Oka R., Shirotani K., Saido T. C., Hashimoto Y. (2001) Alzheimer &#x3b2;-secretase, &#x3b2;-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. U.S.A. 98, 13554&#x2013;13559</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler S. F., Dominguez D. I., Westmeyer G. G., Reiss K., Haass C., Saftig P., De Strooper B., Seed B. (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278, 48713&#x2013;48719</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn P. H., Marjaux E., Imhof A., De Strooper B., Haass C., Lichtenthaler S. F. (2007) Regulated intramembrane proteolysis of the interleukin-1 receptor II by &#x3b1;-, &#x3b2;-, and &#x3b3;-secretase. J. Biol. Chem. 282, 11982&#x2013;11995</Citation><ArticleIdList><ArticleId IdType="pubmed">17307738</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim C. A., Kinoshita A., Peltan I. D., Tangredi M. M., Herl L., Lee B. M., Spoelgen R., Hshieh T. T., Ranganathan S., Battey F. D., Liu C. X., Bacskai B. J., Sever S., Irizarry M. C., Strickland D. K., Hyman B. T. (2005) The low density lipoprotein receptor-related protein (LRP) is a novel &#x3b2;-secretase (BACE1) substrate. J. Biol. Chem. 280, 17777&#x2013;17785</Citation><ArticleIdList><ArticleId IdType="pubmed">15749709</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., S&#xfc;dhof T. C. (2004) Cleavage of amyloid-&#x3b2; precursor protein and amyloid-&#x3b2; precursor-like protein by BACE 1. J. Biol. Chem. 279, 10542&#x2013;10550</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L., Ikin A. F., Lamprianou S., Vacaresse N., Revelli J. P., Platt K., Paganetti P., Mathews P. M., Harroch S., Buxbaum J. D. (2004) BACE (&#x3b2;-secretase) modulates the processing of APLP2 in vivo. Mol. Cell. Neurosci. 25, 642&#x2013;649</Citation><ArticleIdList><ArticleId IdType="pubmed">15080893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming M. L., Elias J. E., Gygi S. P., Selkoe D. J. (2009) Identification of &#x3b2;-secretase (BACE1) substrates using quantitative proteomics. PLoS One 4, e8477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Maness P. F., Schachner M. (2007) Neural recognition molecules of the immunoglobulin superfamily. Signaling transducers of axon guidance and neuronal migration. Nat. Neurosci. 10, 19&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pubmed">17189949</ArticleId></ArticleIdList></Reference><Reference><Citation>Irintchev A., Schachner M. (2011) The injured and regenerating nervous system. Immunoglobulin superfamily members as key players. Neuroscientist 1.73858411419047</Citation><ArticleIdList><ArticleId IdType="pubmed">21903634</ArticleId></ArticleIdList></Reference><Reference><Citation>Montag-Sallaz M., Schachner M., Montag D. (2002) Misguided axonal projections, neural cell adhesion molecule 180 mRNA up-regulation, and altered behavior in mice deficient for the close homolog of L1. Mol. Cell. Biol. 22, 7967&#x2013;7981</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134725</ArticleId><ArticleId IdType="pubmed">12391163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratte M., Rougon G., Schachner M., Jamon M. (2003) Mice deficient for the close homolog of the neural adhesion cell L1 (CHL1) display alterations in emotional reactivity and motor coordination. Behav. Brain Res. 147, 31&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">14659567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenwrick S., Watkins A., De Angelis E. (2000) Neural cell recognition molecule L1. Relating biological complexity to human disease mutations. Hum. Mol. Genet. 9, 879&#x2013;886</Citation><ArticleIdList><ArticleId IdType="pubmed">10767310</ArticleId></ArticleIdList></Reference><Reference><Citation>Frints S. G., Marynen P., Hartmann D., Fryns J. P., Steyaert J., Schachner M., Rolf B., Craessaerts K., Snellinx A., Hollanders K., D'Hooge R., De Deyn P. P., Froyen G. (2003) CALL interrupted in a patient with nonspecific mental retardation. Gene dosage-dependent alteration of murine brain development and behavior. Hum. Mol. Genet. 12, 1463&#x2013;1474</Citation><ArticleIdList><ArticleId IdType="pubmed">12812975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurumaji A., Nomoto H., Okano T., Toru M. (2001) An association study between polymorphism of L1CAM gene and schizophrenia in a Japanese sample. Am. J. Med. Genet. 105, 99&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">11425011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai K., Migita O., Toru M., Arinami T. (2002) An association between a missense polymorphism in the close homolog of L1 (CHL1, CALL) gene and schizophrenia. Mol. Psychiatry 7, 412&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pubmed">11986985</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W. G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., George-Hyslop P. S., Cordell B., Fraser P., De Strooper B. (1999) Presenilin 1 controls &#x3b3;-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. J. Cell Biol. 147, 277&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghesquiere B., Jonckheere V., Colaert N., Van Durme J., Timmerman E., Goethals M., Schymkowitz J., Rousseau F., Vandekerckhove J., Gevaert K. (2011) Redox proteomics of protein-bound methionine oxidation. Mol. Cell. Proteomics M110.006866-1-12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098596</ArticleId><ArticleId IdType="pubmed">21406390</ArticleId></ArticleIdList></Reference><Reference><Citation>Colaert N., Helsens K., Impens F., Vandekerckhove J., Gevaert K. (2010) Rover. A tool to visualize and validate quantitative proteomics data from different sources. Proteomics 10, 1226&#x2013;1229</Citation><ArticleIdList><ArticleId IdType="pubmed">20058247</ArticleId></ArticleIdList></Reference><Reference><Citation>Helsens K., Colaert N., Barsnes H., Muth T., Flikka K., Staes A., Timmerman E., Wortelkamp S., Sickmann A., Vandekerckhove J., Gevaert K., Martens L. (2010) ms_lims, a simple yet powerful open source laboratory information management system for MS-driven proteomics. Proteomics 10, 1261&#x2013;1264</Citation><ArticleIdList><ArticleId IdType="pubmed">20058248</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe4;ll L., Storey J. D., MacCoss M. J., Noble W. S. (2008) Assigning significance to peptides identified by tandem mass spectrometry using decoy databases. J. Proteome Res. 7, 29&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">18067246</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer S., Oleszewski M., Gutwein P., Geiger C., Altevogt P. (1999) Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J. Cell Sci. 112, 2667&#x2013;2675</Citation><ArticleIdList><ArticleId IdType="pubmed">10413675</ArticleId></ArticleIdList></Reference><Reference><Citation>Maretzky T., Schulte M., Ludwig A., Rose-John S., Blobel C., Hartmann D., Altevogt P., Saftig P., Reiss K. (2005) L1 is sequentially processed by two differently activated metalloproteases and presenilin/&#x3b3;-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol. Cell. Biol. 25, 9040&#x2013;9053</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265787</ArticleId><ArticleId IdType="pubmed">16199880</ArticleId></ArticleIdList></Reference><Reference><Citation>Esterh&#xe1;zy D., St&#xfc;tzer I., Wang H., Rechsteiner M. P., Beauchamp J., D&#xf6;beli H., Hilpert H., Matile H., Prummer M., Schmidt A., Lieske N., Boehm B., Marselli L., Bosco D., Kerr-Conte J., Aebersold R., Spinas G. A., Moch H., Migliorini C., Stoffel M. (2011) Bace2 is a &#x3b2; cell-enriched protease that regulates pancreatic &#x3b2; cell function and mass. Cell Metab. 14, 365&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pubmed">21907142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi N. J., Ueda K., Itoh N., Suzuki S., Sakaguchi G., Kato A., Yukimasa A., Hori A., Koriyama Y., Haraguchi H., Yasui K., Kanda Y. (May 3, 2007) International Patent Application WO2007/049532, Japan</Citation></Reference><Reference><Citation>Lopes L. V., Cunha R. A., Ribeiro J. A. (1999) Cross-talk between A1 and A2A adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 82, 3196&#x2013;3203</Citation><ArticleIdList><ArticleId IdType="pubmed">10601453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy A., Delgado-Escueta A. V. (1984) Rapid preparation of synaptosomes from mammalian brain using nontoxic isoosmotic gradient material (Percoll). J. Neurochem. 43, 1114&#x2013;1123</Citation><ArticleIdList><ArticleId IdType="pubmed">6088694</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttner W. B., Schiebler W., Greengard P., De Camilli P. (1983) Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J. Cell Biol. 96, 1374&#x2013;1388</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112660</ArticleId><ArticleId IdType="pubmed">6404912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Ch&#xe1;vez-Guti&#xe9;rrez L., Bockstael K., Sannerud R., Annaert W., May P. C., Karran E., De Strooper B. (2011) Inhibition of &#x3b2;-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J. Biol. Chem. 286, 8677&#x2013;8687</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048749</ArticleId><ArticleId IdType="pubmed">21209097</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel S. J., Coburn C. A., Steele T. G., Jones K. G., Loutzenhiser E. F., Gregro A. R., Rajapakse H. A., Lai M. T., Crouthamel M. C., Xu M., Tugusheva K., Lineberger J. E., Pietrak B. L., Espeseth A. S., Shi X. P., Chen-Dodson E., Holloway M. K., Munshi S., Simon A. J., Kuo L., Vacca J. P. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human &#x3b2;-secretase (BACE-1). J. Med. Chem. 47, 6447&#x2013;6450</Citation><ArticleIdList><ArticleId IdType="pubmed">15588077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Brouwers N., Benilova I., Vandersteen A., Mercken M., Van Laere K., Van Damme P., Demedts D., Van Leuven F., Sleegers K., Broersen K., Van Broeckhoven C., Vandenberghe R., De Strooper B. (2011) Amyloid precursor protein mutation E682K at the alternative &#x3b2;-secretase cleavage &#x3b2;&#x2032;-site increases A&#x3b2; generation. EMBO Mol. Med. 3, 291&#x2013;302</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377078</ArticleId><ArticleId IdType="pubmed">21500352</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton P. A., Mitchell K. J., Goodrich L. V., Lu X., Pinson K., Scherz P., Skarnes W. C., Tessier-Lavigne M. (2001) Defining brain wiring patterns and mechanisms through gene trapping in mice. Nature 410, 174&#x2013;179</Citation><ArticleIdList><ArticleId IdType="pubmed">11242070</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S. F., Summerhurst K., R&#xfc;nker A. E., Kerjan G., Friedel R. H., Ch&#xe9;dotal A., Murphy P., Mitchell K. J. (2007) Expression of Plxdc2/TEM7R in the developing nervous system of the mouse. Gene Expr. Patterns 7, 635&#x2013;644</Citation><ArticleIdList><ArticleId IdType="pubmed">17280871</ArticleId></ArticleIdList></Reference><Reference><Citation>Steegmaier M., Levinovitz A., Isenmann S., Borges E., Lenter M., Kocher H. P., Kleuser B., Vestweber D. (1995) The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 373, 615&#x2013;620</Citation><ArticleIdList><ArticleId IdType="pubmed">7531823</ArticleId></ArticleIdList></Reference><Reference><Citation>Leshchyns'ka I., Sytnyk V., Richter M., Andreyeva A., Puchkov D., Schachner M. (2006) The adhesion molecule CHL1 regulates uncoating of clathrin-coated synaptic vesicles. Neuron 52, 1011&#x2013;1025</Citation><ArticleIdList><ArticleId IdType="pubmed">17178404</ArticleId></ArticleIdList></Reference><Reference><Citation>Persohn E., Schachner M. (1990) Immunohistological localization of the neural adhesion molecules L1 and N-CAM in the developing hippocampus of the mouse. J. Neurocytol. 19, 807&#x2013;819</Citation><ArticleIdList><ArticleId IdType="pubmed">2292714</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Rickenbacher G. T., Rodriguez S., Moulia T. W., Albers M. W. (2012) The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci. Rep. 2, 231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262176</ArticleId><ArticleId IdType="pubmed">22355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Fu Y., Yasvoina M., Shao P., Hitt B., O'Connor T., Logan S., Maus E., Citron M., Berry R., Binder L., Vassar R. (2007) &#x3b2;-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques. Implications for Alzheimer disease pathogenesis. J. Neurosci. 27, 3639&#x2013;3649</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Kovacs D. M., Yan R., Wong P. C. (2009) The &#x3b2;-secretase enzyme BACE in health and Alzheimer disease. Regulation, cell biology, function, and therapeutic potential. J. Neurosci. 29, 12787&#x2013;12794</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner R. T., 3rd, Koelsch G., Hong L., Castanheira P., Ermolieff J., Ghosh A. K., Tang J. (2001) Subsite specificity of memapsin 2 (&#x3b2;-secretase). Implications for inhibitor design. Biochemistry 40, 10001&#x2013;10006</Citation><ArticleIdList><ArticleId IdType="pubmed">11513577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillenbrand R., Molthagen M., Montag D., Schachner M. (1999) The close homolog of the neural adhesion molecule L1 (CHL1). Patterns of expression and promotion of neurite outgrowth by heterophilic interactions. Eur. J. Neurosci. 11, 813&#x2013;826</Citation><ArticleIdList><ArticleId IdType="pubmed">10103075</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda T., Saitoh H., Masuko M., Katagiri-Abe T., Tominaga K., Kozakai I., Kobayashi K., Kumanishi T., Watanabe Y. G., Odani S., Kuwano R. (2000) The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res. Mol. Brain Res. 77, 19&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">10814828</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoda Y., Watanabe K. (2009) Contactins. Emerging key roles in the development and function of the nervous system. Cell Adh. Migr. 3, 64&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675151</ArticleId><ArticleId IdType="pubmed">19262165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandai K., Guo T., St Hillaire C., Meabon J. S., Kanning K. C., Bothwell M., Ginty D. D. (2009) LIG family receptor tyrosine kinase-associated proteins modulate growth factor signals during neural development. Neuron 63, 614&#x2013;627</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758028</ArticleId><ArticleId IdType="pubmed">19755105</ArticleId></ArticleIdList></Reference><Reference><Citation>Falls D. L. (2003) Neuregulins. Functions, forms, and signaling strategies. Exp. Cell Res. 284, 14&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pubmed">12648463</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvais C., D'Auria L., Tyteca D., Perrot G., Lemoine P., Troeberg L., Dedieu S., No&#xeb;l A., Nagase H., Henriet P., Courtoy P. J., Marbaix E., Emonard H. (2011) Cell cholesterol modulates metalloproteinase-dependent shedding of low density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J. 25, 2770&#x2013;2781</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470721</ArticleId><ArticleId IdType="pubmed">21518850</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagogeos D. (2003) Neural GPI-anchored cell adhesion molecules. Front. Biosci. 8, s1304&#x2013;s1320</Citation><ArticleIdList><ArticleId IdType="pubmed">12957835</ArticleId></ArticleIdList></Reference><Reference><Citation>Suetterlin P., Marler K. M., Drescher U. (2012) Axonal ephrinA/EphA interactions, and the emergence of order in topographic projections. Semin. Cell Dev. Biol. 23, 1&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">22040913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajapaksha T. W., Eimer W. A., Bozza T. C., Vassar R. (2011) The Alzheimer &#x3b2;-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol. Neurodegener. 6, 88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269394</ArticleId><ArticleId IdType="pubmed">22204380</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka H., Kobayashi K., Okubo M., Fukuoka T., Noguchi K. (2011) Increase of close homolog of cell adhesion molecule L1 in primary afferent by nerve injury and the contribution to neuropathic pain. J. Comp. Neurol. 519, 1597&#x2013;1615</Citation><ArticleIdList><ArticleId IdType="pubmed">21452236</ArticleId></ArticleIdList></Reference><Reference><Citation>Naus S., Richter M., Wildeboer D., Moss M., Schachner M., Bartsch J. W. (2004) Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J. Biol. Chem. 279, 16083&#x2013;16090</Citation><ArticleIdList><ArticleId IdType="pubmed">14761956</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlomann U., Rathke-Hartlieb S., Yamamoto S., Jockusch H., Bartsch J. W. (2000) Tumor necrosis factor &#x3b1; induces a metalloprotease-disintegrin, ADAM8 (CD 156). Implications for neuron-glia interactions during neurodegeneration. J. Neurosci. 20, 7964&#x2013;7971</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772711</ArticleId><ArticleId IdType="pubmed">11050116</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahme M., Bartsch U., Martini R., Anliker B., Schachner M., Mantei N. (1997) Disruption of the mouse L1 gene leads to malformations of the nervous system. Nat. Genet. 17, 346&#x2013;349</Citation><ArticleIdList><ArticleId IdType="pubmed">9354804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen N. R., Taylor J. S., Scott L. B., Guillery R. W., Soriano P., Furley A. J. (1998) Errors in corticospinal axon guidance in mice lacking the neural cell adhesion molecule L1. Curr. Biol. 8, 26&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">9427628</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyanenko G. P., Tsai A. Y., Maness P. F. (1999) Abnormalities in neuronal process extension, hippocampal development, and the ventricular system of L1 knockout mice. J. Neurosci. 19, 4907&#x2013;4920</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782672</ArticleId><ArticleId IdType="pubmed">10366625</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyanenko G. P., Maness P. F. (2003) The L1 cell adhesion molecule is essential for topographic mapping of retinal axons. J. Neurosci. 23, 530&#x2013;538</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741870</ArticleId><ArticleId IdType="pubmed">12533613</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhusi M., Schlatter M. C., Demyanenko G. P., Thresher R., Maness P. F. (2008) L1 interaction with ankyrin regulates mediolateral topography in the retinocollicular projection. J. Neurosci. 28, 177&#x2013;188</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671135</ArticleId><ArticleId IdType="pubmed">18171935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A. G., Demyanenko G. P., Powell A., Schachner M., Enriquez-Barreto L., Tran T. S., Polleux F., Maness P. F. (2007) Close homolog of L1 and neuropilin 1 mediates guidance of thalamocortical axons at the ventral telencephalon. J. Neurosci. 27, 13667&#x2013;13679</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673613</ArticleId><ArticleId IdType="pubmed">18077678</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyanenko G. P., Siesser P. F., Wright A. G., Brennaman L. H., Bartsch U., Schachner M., Maness P. F. (2011) L1 and CHL1 cooperate in thalamocortical axon targeting. Cereb. Cortex 21, 401&#x2013;412</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020587</ArticleId><ArticleId IdType="pubmed">20576928</ArticleId></ArticleIdList></Reference><Reference><Citation>Demyanenko G. P., Schachner M., Anton E., Schmid R., Feng G., Sanes J., Maness P. F. (2004) Close homolog of L1 modulates area-specific neuronal positioning and dendrite orientation in the cerebral cortex. Neuron 44, 423&#x2013;437</Citation><ArticleIdList><ArticleId IdType="pubmed">15504324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Bo X., Schoepfer R., Holtmaat A. J., Verhaagen J., Emson P. C., Lieberman A. R., Anderson P. N. (2005) Growth-associated protein GAP-43 and L1 act synergistically to promote regenerative growth of Purkinje cell axons in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 14883&#x2013;14888</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1253563</ArticleId><ArticleId IdType="pubmed">16195382</ArticleId></ArticleIdList></Reference><Reference><Citation>Roonprapunt C., Huang W., Grill R., Friedlander D., Grumet M., Chen S., Schachner M., Young W. (2003) Soluble cell adhesion molecule L1-Fc promotes locomotor recovery in rats after spinal cord injury. J. Neurotrauma. 20, 871&#x2013;882</Citation><ArticleIdList><ArticleId IdType="pubmed">14577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G., Nie D. Y., Wang W. Z., Zhang P. H., Shen J., Ang B. T., Liu G. H., Luo X. G., Chen N. L., Xiao Z. C. (2004) Optic nerve regeneration in polyglycolic acid-chitosan conduits coated with recombinant L1-Fc. Neuroreport. 15, 2167&#x2013;2172</Citation><ArticleIdList><ArticleId IdType="pubmed">15371726</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakovcevski I., Wu J., Karl N., Leshchyns'ka I., Sytnyk V., Chen J., Irintchev A., Schachner M. (2007) Glial scar expression of CHL1, the close homolog of the adhesion molecule L1, limits recovery after spinal cord injury. J. Neurosci. 27, 7222&#x2013;7233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794588</ArticleId><ArticleId IdType="pubmed">17611275</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah M. H., Pan B. H., Hoffman P. N., Ferraris D., Tsukamoto T., Nguyen T., Wong P. C., Price D. L., Slusher B. S., Griffin J. W. (2011) Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J. Neurosci. 31, 5744&#x2013;5754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302726</ArticleId><ArticleId IdType="pubmed">21490216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22700814</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.</ArticleTitle><Pagination><StartPage>229</StartPage><EndPage>236</EndPage><MedlinePgn>229-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e31825fdf18</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the particular pathology of the Arctic APP (APParc) early-onset familial Alzheimer disease (eoFAD) mutation for the first time in vivo with PET in comparison with other eoFAD mutations and sporadic Alzheimer disease (sAD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined 2 APParc mutation carriers together with 5 noncarrier siblings cross-sectionally with (11)C-labeled Pittsburgh compound B (PiB) and (18)F-fluorodeoxyglucose (FDG) PET, as well as MRI, CSF biomarkers, and neuropsychological tests. Likewise, we examined 7 patients with sAD, 1 carrier of a presenilin 1 (PSEN1) mutation, 1 carrier of the Swedish APP (APPswe) mutation, and 7 healthy controls (HCs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cortical PiB retention was very low in the APParc mutation carriers while cerebral glucose metabolism and CSF levels of A&#x3b2;(1-42), total and phosphorylated tau were clearly pathologic. This was in contrast to the PSEN1 and APPswe mutation carriers revealing high PiB retention in the cortex and the striatum in combination with abnormal glucose metabolism and CSF biomarkers, and the patients with sAD who showed typically high cortical PiB retention and pathologic CSF levels as well as decreased glucose metabolism when compared with HCs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The lack of fibrillar &#x3b2;-amyloid (A&#x3b2;) as visualized by PiB PET in APParc mutation carriers suggests, given the reduced glucose metabolism and levels of A&#x3b2;(1-42) in CSF, that other forms of A&#x3b2; such as oligomers and protofibrils are important for the pathologic processes leading to clinical Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thordardottir</LastName><ForeName>Steinunn</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bogdanovic</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>L&#xe5;ngstr&#xf6;m</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Almkvist</LastName><ForeName>Ove</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Jul 17;79(3):206-7. doi: 10.1212/WNL.0b013e31825fe11f.</RefSource><PMID Version="1">22700807</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22700814</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31825fdf18</ArticleId><ArticleId IdType="pii">WNL.0b013e31825fdf18</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22745165</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>28</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Conserved features of intermediates in amyloid assembly determine their benign or toxic states.</ArticleTitle><Pagination><StartPage>11172</StartPage><EndPage>11177</EndPage><MedlinePgn>11172-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1209527109</ELocationID><Abstract><AbstractText>Some amyloid-forming polypeptides are associated with devastating human diseases and others provide important biological functions. For both, oligomeric intermediates appear during amyloid assembly. Currently we have few tools for characterizing these conformationally labile intermediates and discerning what governs their benign versus toxic states. Here, we examine intermediates in the assembly of a normal, functional amyloid, the prion-determining region of yeast Sup35 (NM). During assembly, NM formed a variety of oligomers with different sizes and conformation-specific antibody reactivities. Earlier oligomers were less compact and reacted with the conformational antibody A11. More mature oligomers were more compact and reacted with conformational antibody OC. We found we could arrest NM in either of these two distinct oligomeric states with small molecules or crosslinking. The A11-reactive oligomers were more hydrophobic (as measured by Nile Red binding) and were highly toxic to neuronal cells, while OC-reactive oligomers were less hydrophobic and were not toxic. The A11 and OC antibodies were originally raised against oligomers of A&#x3b2;, an amyloidogenic peptide implicated in Alzheimer's disease (AD) that is completely unrelated to NM in sequence. Thus, this natural yeast prion samples two conformational states similar to those sampled by A&#x3b2;, and when assembly stalls at one of these two states, but not the other, it becomes extremely toxic. Our results have implications for selective pressures operating on the evolution of amyloid folds across a billion years of evolution. Understanding the features that govern such conformational transitions will shed light on human disease and evolution alike.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Rajaraman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Mukhopadhyay</LastName><ForeName>Samrat</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Chris D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Lemke</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Deniz</LastName><ForeName>Ashok A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS067782-02</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS067782</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM066833</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM025874</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM066833</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM025874</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM025874</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22745165</ArticleId><ArticleId IdType="pmc">PMC3396487</ArticleId><ArticleId IdType="doi">10.1073/pnas.1209527109</ArticleId><ArticleId IdType="pii">1209527109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem. 2008;283:29639&#x2013;29643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573087</ArticleId><ArticleId IdType="pubmed">18723507</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274:25945&#x2013;25952.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464339</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lieber CM, Lansbury PT., Jr Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer&#x2019;s disease amyloid-beta protein. Chem Biol. 1997;4:951&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427660</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio TR, et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 2000;289:1317&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958771</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science. 2004;304:1793&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">15155912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemporad F, Chiti F. Protein misfolded oligomers: Experimental approaches, mechanism of formation, and structure-toxicity relationships. Chem Biol. 2012;19:315&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">22444587</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Resenberger UK, et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. Embo J. 2011;30:2057&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098494</ArticleId><ArticleId IdType="pubmed">21441896</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Campioni S, et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010;6:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20081829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieschke J, et al. Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils. Nat Chem Biol. 2011;8:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">22101602</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J, Lindquist S. Prions as adaptive conduits of memory and inheritance. Nat Rev Genet. 2005;6:435&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15931169</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann R, et al. Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature. 2012;482:363&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319070</ArticleId><ArticleId IdType="pubmed">22337056</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki G, Shimazu N, Tanaka M. A yeast prion, Mod5, promotes acquired drug resistance and cell survival under environmental stress. Science. 2012;336:355&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">22517861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan R, Lindquist SL. Structural insights into a yeast prion illuminate nucleation and strain diversity. Nature. 2005;435:765&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405905</ArticleId><ArticleId IdType="pubmed">15944694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Nayak PK, Udgaonkar JB, Krishnamoorthy G. Characterization of the formation of amyloid protofibrils from barstar by mapping residue-specific fluorescence dynamics. J Mol Biol. 2006;358:935&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Deniz AA. Fluorescence from diffusing single molecules illuminates biomolecular structure and dynamics. J Fluoresc. 2007;17:775&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">17641956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Krishnan R, Lemke EA, Lindquist S, Deniz AA. A natively unfolded yeast prion monomer adopts an ensemble of collapsed and rapidly fluctuating structures. Proc Natl Acad Sci USA. 2007;104:2649&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1815236</ArticleId><ArticleId IdType="pubmed">17299036</ArticleId></ArticleIdList></Reference><Reference><Citation>Marme N, Knemeyer JP, Sauer M, Wolfrum J. Inter- and intramolecular fluorescence quenching of organic dyes by tryptophan. Bioconjug Chem. 2003;14:1133&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">14624626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng BY, et al. Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol. 2008;4:197&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730835</ArticleId><ArticleId IdType="pubmed">18223646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnhoefer DE, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15:558&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">18511942</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi YG, Ingrosso L, Ladogana A, Masullo C, Pocchiari M. Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature. 1992;356:598&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">1348570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sackett DL, Wolff J. Nile red as a polarity-sensitive fluorescent probe of hydrophobic protein surfaces. Anal Biochem. 1987;167:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">3442318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci. 1999;24:329&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">10470028</ArticleId></ArticleIdList></Reference><Reference><Citation>Laganowsky A, et al. Atomic view of a toxic amyloid small oligomer. Science. 2012;335:1228&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959867</ArticleId><ArticleId IdType="pubmed">22403391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi B, et al. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol. 2010;5:735&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">20550130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Smith DR, Jones JW, Chapman MR. In vitro polymerization of a functional Escherichia coli amyloid protein. J Biol Chem. 2007;282:3713&#x2013;3719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838475</ArticleId><ArticleId IdType="pubmed">17164238</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler DM, et al. Functional amyloid formation within mammalian tissue. PLoS Biol. 2006;4:e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288039</ArticleId><ArticleId IdType="pubmed">16300414</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Halfmann R, King O, Kapila A, Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell. 2009;137:146&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683788</ArticleId><ArticleId IdType="pubmed">19345193</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann R, et al. Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol Cell. 2011;43:72&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132398</ArticleId><ArticleId IdType="pubmed">21726811</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, et al. Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer&#x2019;s disease risk factors in yeast. Science. 2011;334:1241&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21613623</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>84</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.</ArticleTitle><Pagination><StartPage>84ra44</StartPage><MedlinePgn>84ra44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3002230</ELocationID><Abstract><AbstractText>Monoclonal antibodies have therapeutic potential for treating diseases of the central nervous system, but their accumulation in the brain is limited by the blood-brain barrier (BBB). Here, we show that reducing the affinity of an antibody for the transferrin receptor (TfR) enhances receptor-mediated transcytosis of the anti-TfR antibody across the BBB into the mouse brain where it reaches therapeutically relevant concentrations. Anti-TfR antibodies that bind with high affinity to TfR remain associated with the BBB, whereas lower-affinity anti-TfR antibody variants are released from the BBB into the brain and show a broad distribution 24 hours after dosing. We designed a bispecific antibody that binds with low affinity to TfR and with high affinity to the enzyme &#x3b2;-secretase (BACE1), which processes amyloid precursor protein into amyloid-&#x3b2; (A&#x3b2;) peptides including those associated with Alzheimer's disease. Compared to monospecific anti-BACE1 antibody, the bispecific antibody accumulated in the mouse brain and led to a greater reduction in brain A&#x3b2; after a single systemic dose. TfR-facilitated transcytosis of this bispecific antibody across the BBB may enhance its potency as an anti-BACE1 therapy for treating Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Y Joy</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Neurodegeneration Labs, Department of Neuroscience, Genentech Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kenrick</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hoyte</LastName><ForeName>Kwame</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Wilman</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Atwal</LastName><ForeName>Jasvinder</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Prabhu</LastName><ForeName>Saileta</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018033">Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2011 Jun 21;7(7):359. doi: 10.1038/nrneurol.2011.95.</RefSource><PMID Version="1">21691336</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018033" MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="N">Transcytosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21613623</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3002230</ArticleId><ArticleId IdType="pii">3/84/84ra44</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17548355</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>282</Volume><Issue>33</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.</ArticleTitle><Pagination><StartPage>23818</StartPage><EndPage>23828</EndPage><MedlinePgn>23818-28</MedlinePgn></Pagination><Abstract><AbstractText>Many proteins suspected of causing neurodegenerative diseases exist in diverse assembly states. For most, it is unclear whether shifts from one state to another would be helpful or harmful. We used mutagenesis to change the assembly state of Alzheimer disease (AD)-associated amyloid-beta (Abeta) peptides. In vitro, the "Arctic" mutation (AbetaE22G) accelerated Abeta fibrillization but decreased the abundance of nonfibrillar Abeta assemblies, compared with wild-type Abeta. In human amyloid precursor protein (hAPP) transgenic mice carrying mutations adjacent to Abeta that increase Abeta production, addition of the Arctic mutation markedly enhanced the formation of neuritic amyloid plaques but reduced the relative abundance of a specific nonfibrillar Abeta assembly (Abeta*56). Mice overexpressing Arctic mutant or wild-type Abeta had similar behavioral and neuronal deficits when they were matched for Abeta*56 levels but had vastly different plaque loads. Thus, Abeta*56 is a likelier determinant of functional deficits in hAPP mice than fibrillar Abeta deposits. Therapeutic interventions that reduce Abeta fibrils at the cost of augmenting nonfibrillar Abeta assemblies could be harmful.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Irene H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Legleiter</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Hilary</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bien-Ly</LastName><ForeName>Nga</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Puoliv&#xe4;li</LastName><ForeName>Jukka</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lesn&#xe9;</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Muchowski</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR 18928-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId><ArticleId IdType="doi">10.1074/jbc.M701078200</ArticleId><ArticleId IdType="pii">S0021-9258(20)54368-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12084879</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>12</Issue><PubDate><Year>2002</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Phases of A beta-deposition in the human brain and its relevance for the development of AD.</ArticleTitle><Pagination><StartPage>1791</StartPage><EndPage>1800</EndPage><MedlinePgn>1791-800</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The deposition of the amyloid beta protein (Abeta) is a histopathologic hallmark of AD. The regions of the medial temporal lobe (MTL) are hierarchically involved in Abeta-deposition.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To clarify whether there is a hierarchical involvement of the regions of the entire brain as well and whether there are differences in the expansion of Abeta-pathology between clinically proven AD cases and nondemented cases with AD-related pathology, the authors investigated 47 brains from demented and nondemented patients with AD-related pathology covering all phases of beta-amyloidosis in the MTL (AbetaMTL phases) and four control brains without any AD-related pathology.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Abeta deposits were detected by the use of the Campbell-Switzer silver technique and by immunohistochemistry in sections covering all brain regions and brainstem nuclei. It was analyzed how often distinct regions exhibited Abeta deposits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the first of five phases in the evolution of beta-amyloidosis Abeta deposits are found exclusively in the neocortex. The second phase is characterized by the additional involvement of allocortical brain regions. In phase 3, diencephalic nuclei, the striatum, and the cholinergic nuclei of the basal forebrain exhibit Abeta deposits as well. Several brainstem nuclei become additionally involved in phase 4. Phase 5, finally, is characterized by cerebellar Abeta-deposition. The 17 clinically proven AD cases exhibit Abeta-phases 3, 4, or 5. The nine nondemented cases with AD-related Abeta pathology show Abeta-phases 1, 2, or 3.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Abeta-deposition in the entire brain follows a distinct sequence in which the regions are hierarchically involved. Abeta-deposition, thereby, expands anterogradely into regions that receive neuronal projections from regions already exhibiting Abeta. There are also indications that clinically proven AD cases with full-blown beta-amyloidosis may be preceded in early stages by nondemented cases exhibiting AD-related Abeta pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Anatomy, J. W. Goethe University, Frankfurt am Main, Germany. Dietmar.Thal@uni-bonn.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;b</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Orantes</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>24</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId><ArticleId IdType="doi">10.1212/wnl.58.12.1791</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22265587</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>13</EndPage><MedlinePgn>1-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2011.10.007</ELocationID><Abstract><AbstractText>A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre-clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP-43 inclusions, and recommend standard approaches for the workup of cases and their clinico-pathologic correlation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 The Alzheimer's Association. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>Creighton H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Duyckaerts</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mirra</LastName><ForeName>Suzanne S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar Rudolf</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Thies</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG28383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG24904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18840</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG012435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS62684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015975" MajorTopicYN="N">Consensus Development Conferences, NIH as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054561" MajorTopicYN="N">National Institute on Aging (U.S.)</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22265587</ArticleId><ArticleId IdType="mid">NIHMS334821</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pii">S1552-5260(11)02980-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer&#x2019;s disease. Neurology. 1988;38:1682&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett. 2010;473:168&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851172</ArticleId><ArticleId IdType="pubmed">20153809</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Kuo YM, Spiegel K, Emmerling MR, Sue LI, Kokjohn K, et al. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:308&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10759186</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, et al. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer&#x2019;s disease. Acta Neuropathol. 2011;122:49&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3362487</ArticleId><ArticleId IdType="pubmed">21533854</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Honer WG, Hughes LH. Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer&#x2019;s disease? Acta Neuropathol. 1997;93:146&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039461</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal HA, Dickson DW, Sliwinski MJ, Lipton RB, Grober E, Marks-Nelson H, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol. 1993;34:566&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">8215244</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13:179&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex. 1994;4:138&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038565</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. &#x201c;Preclinical&#x201d; AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000;55:370&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932270</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer&#x2019;s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38:1688&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">3054625</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta Neuropathol. 2011;121:171&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Yilmazer-Hanke DM, Braak H, Braak E, Schultz C, Hanke J. Assessment of the pathological stages of Alzheimer&#x2019;s disease in thin paraffin sections: a comparative study. Dement Geriatr Cogn Disord. 1998;9:140&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9622001</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer&#x2019;s disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008;18:484&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659377</ArticleId><ArticleId IdType="pubmed">18371174</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997;56:321&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9100663</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer&#x2019;s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:452&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546792</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Terry RD, Mallory M, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer&#x2019;s disease. Am J Pathol. 1990;137:1293&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877714</ArticleId><ArticleId IdType="pubmed">2124413</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Deerinck T, DeTeresa R, Lamont S, Miller A, et al. Reevaluation of the structural organization of neuritic plaques in Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol. 1993;52:619&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229081</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) Part II Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S, Bodi I, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117:309&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910889</ArticleId><ArticleId IdType="pubmed">19184666</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000;59:733&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952063</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Larson EB. Late-life dementias: does this unyielding global challenge require a broader view? Jama. 2009;302:2593&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827770</ArticleId><ArticleId IdType="pubmed">20009062</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 2010;20:66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864342</ArticleId><ArticleId IdType="pubmed">19021630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL. Lewy bodies in Alzheimer&#x2019;s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10:378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098522</ArticleId><ArticleId IdType="pubmed">10885656</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65:685&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706655</ArticleId><ArticleId IdType="pubmed">16825955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353469</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Fishel MA, Peskind ER, Montine TJ, Nochlin D, Steinbart E, et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol. 2006;63:370&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892620</ArticleId><ArticleId IdType="pubmed">16533963</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging. 2005;26:1183&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917102</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson&#x2019;s disease. Acta Neuropathol. 2008;115:409&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18231798</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, Emre M, O&#x2019;Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol Aging. 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, White CL, 3rd, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 2009;117:169&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631085</ArticleId><ArticleId IdType="pubmed">18982334</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12030260</ArticleId></ArticleIdList></Reference><Reference><Citation>Selnes OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol. 2006;2:538&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990827</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) Part X Neuropathology confirmation of the clinical diagnosis of Alzheimer&#x2019;s disease. Neurology. 1995;45:461&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898697</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, et al. Cognitive impact of subcortical vascular and Alzheimer&#x2019;s disease pathology. Ann Neurol. 2006;60:677&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851933</ArticleId><ArticleId IdType="pubmed">17192928</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke. 2010;41:S144&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967303</ArticleId><ArticleId IdType="pubmed">20876491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis of age-related cognitive decline. Neurology. 2010;75:1070&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942064</ArticleId><ArticleId IdType="pubmed">20844243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Haneuse S, Woltjer R, Li G, Crane PK, et al. Neuropathology in the adult changes in thought study: a review. J Alzheimers Dis. 2009;18:703&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008877</ArticleId><ArticleId IdType="pubmed">19661627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">3551211</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol. 2000;59:931&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089571</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta Neuropathol. 2010;119:277&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831184</ArticleId><ArticleId IdType="pubmed">20155424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV. Cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? Ann Neurol. 2001;49:691&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409417</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV. Cerebral amyloid angiopathy and Alzheimer&#x2019;s disease: two entities or one? J Neurol Sci. 1992;112:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">1469419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol. 2009;66:315&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2766529</ArticleId><ArticleId IdType="pubmed">19139294</ArticleId></ArticleIdList></Reference><Reference><Citation>Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, et al. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol. 2010;20:459&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127860</ArticleId><ArticleId IdType="pubmed">19725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Dickson DW. Neuropathology of hippocampal sclerosis. Handb Clin Neurol. 2008;89:569&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631779</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 2011;134:1506&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097889</ArticleId><ArticleId IdType="pubmed">21596774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanpaa KJ, Blass DM, Pletnikova O, Crain BJ, Bigio EH, Hedreen JC, et al. Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology. 2004;63:538&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304590</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:435&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y, Mori F, Hori E, Kaimori M, Wakabayashi K. Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol. 2009;117:713&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19360425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ, Neumann M. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 2008;115:305&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18087705</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:125&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AC, Dugger BN, Dickson DW, Wang DS. TDP-43 in aging and Alzheimer&#x2019;s disease - a review. Int J Clin Exp Pathol. 2011;4:147&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037200</ArticleId><ArticleId IdType="pubmed">21326809</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 2009;117:15&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710877</ArticleId><ArticleId IdType="pubmed">19015862</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia) Brain Pathol. 1998;8:367&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098213</ArticleId><ArticleId IdType="pubmed">9546293</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Zhukareva V, Newell KL, Lee VM, Trojanowski JQ. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer&#x2019;s disease. Acta Neuropathol. 2001;101:518&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka K. Diffuse neurofibrillary tangles with calcification: a new presenile dementia. J Neurol Neurosurg Psychiatry. 1994;57:594&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072922</ArticleId><ArticleId IdType="pubmed">8201331</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T, Nakamura A, Yamazaki M, Mori O, Ikeda K, Tsuchiya K. Different conformation of neuronal tau deposits distinguished by double immunofluorescence with AT8 and thiazin red combined with Gallyas method. Acta Neuropathol. 2001;102:462&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11699559</ArticleId></ArticleIdList></Reference><Reference><Citation>Dlouhy SR, Hsiao K, Farlow MR, Foroud T, Conneally PM, Johnson P, et al. Linkage of the Indiana kindred of Gerstmann-Straussler-Scheinker disease to the prion protein gene. Nat Genet. 1992;1:64&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1363809</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43:436&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011;12:e426&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">21348917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho RC, Cheung MW, Fu E, Win HH, Zaw MH, Ng A, et al. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry. 2011;19:607&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">21705865</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology. 2011;22:646&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640480</ArticleId><ArticleId IdType="pubmed">21705906</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008;18:220&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689097</ArticleId><ArticleId IdType="pubmed">18241240</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117:613&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757320</ArticleId><ArticleId IdType="pubmed">19399512</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP., Jr Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763890</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer&#x2019;s disease. Acta Neuropathol. 2008;115:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369648</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008;116:277&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708176</ArticleId><ArticleId IdType="pubmed">18626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2008;67:125&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">18219257</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896308</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol. 2004;63:742&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290899</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010;25:642&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935627</ArticleId><ArticleId IdType="pubmed">20175211</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson&#x2019;s disease. Acta Neuropathol. 2008;115:437&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18264713</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008;115:445&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724592</ArticleId><ArticleId IdType="pubmed">17985144</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Schmitt FA, Abner E, Nelson PT, Cooper GE, Smith CD, et al. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging. 2010;31:1805&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891418</ArticleId><ArticleId IdType="pubmed">19026468</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol. 2009;68:816&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704264</ArticleId><ArticleId IdType="pubmed">19535990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Kryscio RJ, Jicha GA, Abner EL, Schmitt FA, Xu LO, et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology. 2009;73:1127&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764396</ArticleId><ArticleId IdType="pubmed">19805729</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer&#x2019;s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2007;113:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021755</ArticleId></ArticleIdList></Reference><Reference><Citation>White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18:713&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661625</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62:406&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17879383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42:2672&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Santacruz K, et al. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol. 2009;68:774&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725359</ArticleId><ArticleId IdType="pubmed">19535994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22359596</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Metabolite profiling of Alzheimer's disease cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>e31501</StartPage><MedlinePgn>e31501</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e31501</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0031501</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of cognitive functions. Today the diagnosis of AD relies on clinical evaluations and is only late in the disease. Biomarkers for early detection of the underlying neuropathological changes are still lacking and the biochemical pathways leading to the disease are still not completely understood. The aim of this study was to identify the metabolic changes resulting from the disease phenotype by a thorough and systematic metabolite profiling approach. For this purpose CSF samples from 79 AD patients and 51 healthy controls were analyzed by gas and liquid chromatography-tandem mass spectrometry (GC-MS and LC-MS/MS) in conjunction with univariate and multivariate statistical analyses. In total 343 different analytes have been identified. Significant changes in the metabolite profile of AD patients compared to healthy controls have been identified. Increased cortisol levels seemed to be related to the progression of AD and have been detected in more severe forms of AD. Increased cysteine associated with decreased uridine was the best paired combination to identify light AD (MMSE&gt;22) with specificity and sensitivity above 75%. In this group of patients, sensitivity and specificity above 80% were obtained for several combinations of three to five metabolites, including cortisol and various amino acids, in addition to cysteine and uridine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Czech</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche, Pharmaceuticals Division, Basel, Switzerland. christian.czech@roche.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berndt</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Wiemer</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Most</LastName><ForeName>Veronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kastler</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Senn</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical><Chemical><RegistryNumber>WHI7HQ7H85</RegistryNumber><NameOfSubstance UI="D014529">Uridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008401" MajorTopicYN="N">Gas Chromatography-Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="Y">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014529" MajorTopicYN="N">Uridine</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have read the journal's policy and have the following conflicts: CC, HS, and PB are employees of F. Hoffmann-La Roche. KB, OS, JW and JK were employed by metanomics during the time of the study. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22359596</ArticleId><ArticleId IdType="pmc">PMC3281064</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0031501</ArticleId><ArticleId IdType="pii">PONE-D-11-16419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings JL, Cole G. Alzheimer disease. Jama. 2002;287:2335&#x2013;2338.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988038</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto M, Lewczuk P, Wiltfang J. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods. 2008;44:289&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">18374272</ArticleId></ArticleIdList></Reference><Reference><Citation>Czech C, Adessi C. Disease Modifying Therapeutic Strategies in Alzheimer's Disease Targeting the Amyloid Cascade. Current Neuropharmacology. 2004;2:295&#x2013;307.</Citation></Reference><Reference><Citation>Schlotterbeck G, Ross A, Dieterle F, Senn H. Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics. 2006;7:1055&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">17054416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweatman BC, Farrant RD, Holmes E, Ghauri FY, Nicholson JK, et al. 600 MHz 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances. J Pharm Biomed Anal. 1993;11:651&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">8257730</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ravenzwaay B, Cunha GC, Leibold E, Looser R, Mellert W, et al. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett. 2007;172:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">17614222</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessner U, Wagner C, Kopka J, Trethewey RN, Willmitzer L. Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant J. 2000;23:131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">10929108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada H, Yamahara A, Yasuda S, Abe M, Oguri K, et al. Dansyl chloride derivatization of methamphetamine: a method with advantages for screening and analysis of methamphetamine in urine. J Anal Toxicol. 2002;26:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11888012</ArticleId></ArticleIdList></Reference><Reference><Citation>R-Development-Core-Team. R: A language and environment for statistical computing. 2008. R Foundation for Statistical Computing, Vienna, Austria.</Citation></Reference><Reference><Citation>Park M, Hastie T. Penalized logistic regression for detecting gene interactions. Biostatistics. 2008;9:30&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">8472349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus RTDR, Beer B, Lippa AS. The cholinergic hypothesis of geriatic memory dysfunction. Science. 1982;217:408&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">7046051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H, Abe T, Hashiguchi K, Saheki M, Takahashi S. Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett FIELD Full Journal Title:Neuroscience Letters. 1994;177:139&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology FIELD Full Journal Title:Neurology. 1982;32:164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">7198741</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer's disease: implications for diagnostics and therapy. J Neurosci Res FIELD Full Journal Title:Journal of Neuroscience Research. 1990;27:576&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">1981917</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrod R, Peskind ER, DiGiacomo L, Brodkin KI, Veith RC, et al. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry FIELD Full Journal Title:The American journal of psychiatry. 1997;154:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8988954</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging FIELD Full Journal Title:Neurobiology of Aging. 2006;27:38&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298239</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinikainen KJ, Paljarvi L, Halonen T, Malminen O, Kosma VM, et al. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging FIELD Full Journal Title:Neurobiology of aging. 1988;9:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">3398991</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF, Growdon JH. CSF neurotransmitter markers in Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry FIELD Full Journal Title:Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry. 1986;10:259&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">2879317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H, Ueno M, Abe T, Takahashi S, Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J Neural Transm: Parkinson's Dis Dementia Sect FIELD Full Journal Title:Journal of Neural Transmission: Parkinson's Disease and Dementia Section. 1992;4:69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">1540305</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, et al. Cortisol and Alzheimer's disease, I: Basal studies. Am J Psychiatry. 1986;143:300&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">3953862</ArticleId></ArticleIdList></Reference><Reference><Citation>Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1&#x2013;42 ratios in CSF in patients with mild Alzheimer's disease dementia. Eur Arch Psychiatry Clin Neurosci. 2009;259:80&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">18806919</ArticleId></ArticleIdList></Reference><Reference><Citation>Popp J, Schaper K, Kolsch H, Cvetanovska G, Rommel F, et al. CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2009;30:498&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner AJ, Elston RC, Chen CH, Friedland RP. Response of the hypothalamic-pituitary-adrenal axis to lumbar puncture induced stress. J Alzheimers Dis. 2000;2:193&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurtman RJ, Cansev M, Sakamoto T, Ulus I. Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev. 2010;68(Suppl 2):S88&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062998</ArticleId><ArticleId IdType="pubmed">21091953</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray IV, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) 2011;236:772&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">21680755</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, et al. Alzheimer's disease and total plasma aminothiols. Biol Psychiatry. 2003;53:254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559659</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel T, Dali-Youcef N, Kaltenbach G, Andres E. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract. 2009;63:1061&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">19570123</ArticleId></ArticleIdList></Reference><Reference><Citation>Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, et al. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis. 2009;18:819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661622</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935890</ArticleId><ArticleId IdType="pubmed">20838622</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YS, Choe LH, Lee KH. Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Rev Proteomics. 2010;7:919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">21142892</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22820466</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Alzheimer amyloid-&#x3b2; oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.</ArticleTitle><Pagination><StartPage>1227</StartPage><EndPage>1235</EndPage><MedlinePgn>1227-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3178</ELocationID><Abstract><AbstractText>Amyloid-beta (A&#x3b2;) oligomers are thought to trigger Alzheimer's disease pathophysiology. Cellular prion protein (PrP(C)) selectively binds oligomeric A&#x3b2; and can mediate Alzheimer's disease-related phenotypes. We examined the specificity, distribution and signaling of A&#x3b2;-PrP(C) complexes, seeking to understand how they might alter the function of NMDA receptors (NMDARs) in neurons. PrP(C) is enriched in postsynaptic densities, and A&#x3b2;-PrP(C) interaction leads to Fyn kinase activation. Soluble A&#x3b2; assemblies derived from the brains of individuals with Alzheimer's disease interacted with PrP(C) to activate Fyn. A&#x3b2; engagement of PrP(C)-Fyn signaling yielded phosphorylation of the NR2B subunit of NMDARs, which was coupled to an initial increase and then a loss of surface NMDARs. A&#x3b2;-induced dendritic spine loss and lactate dehydrogenase release required both PrP(C) and Fyn, and human familial Alzheimer's disease transgene-induced convulsive seizures did not occur in mice lacking PrP(C). These results delineate an A&#x3b2; oligomer signal transduction pathway that requires PrP(C) and Fyn to alter synaptic function, with deleterious consequences in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Um</LastName><ForeName>Ji Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Cellular Neuroscience, Neurodegeneration and Repair Program, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Haakon B</ForeName><Initials>HB</Initials></Author><Author ValidYN="Y"><LastName>Heiss</LastName><ForeName>Jacqueline K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Kostylev</LastName><ForeName>Mikhail A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Stagi</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vortmeyer</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gunther</LastName><ForeName>Erik C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG034924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073502</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020245</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047433</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS033020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37NS033020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS073502</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074319</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS47433</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS074319</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DA018343</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30DA018343</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018621">PrPC Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C494957">FYN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D051076">Proto-Oncogene Proteins c-fyn</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2012 Nov;27(13):1612. doi: 10.1002/mds.25234.</RefSource><PMID Version="1">23326857</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018621" MajorTopicYN="N">PrPC Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051076" MajorTopicYN="N">Proto-Oncogene Proteins c-fyn</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22820466</ArticleId><ArticleId IdType="mid">NIHMS391094</ArticleId><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="doi">10.1038/nn.3178</ArticleId><ArticleId IdType="pii">nn.3178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou WQ, et al. Amyloid-{beta}42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain. J Biol Chem. 2011;286:15095&#x2013;15105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083157</ArticleId><ArticleId IdType="pubmed">21393248</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010;107:2295&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem. 2010;285:26377&#x2013;26383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924066</ArticleId><ArticleId IdType="pubmed">20576610</ArticleId></ArticleIdList></Reference><Reference><Citation>Calella AM, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med. 2010;2:306&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962809</ArticleId><ArticleId IdType="pubmed">20665634</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011;2:336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, et al. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci. 2011;31:10427&#x2013;10431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314063</ArticleId><ArticleId IdType="pubmed">21775587</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature. 2010;466:E3&#x2013;E4. discussion E4&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057871</ArticleId><ArticleId IdType="pubmed">20703260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel DA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30:6367&#x2013;6374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, et al. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci. 2010;11:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964735</ArticleId><ArticleId IdType="pubmed">20946660</ArticleId></ArticleIdList></Reference><Reference><Citation>Resenberger UK, et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. Embo J. 2011;30:2057&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098494</ArticleId><ArticleId IdType="pubmed">21441896</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry AE, et al. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci. 2011;31:7259&#x2013;7263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622598</ArticleId><ArticleId IdType="pubmed">21593310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate C, Williams A. Amyloid-beta-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem. 2011;286:37955&#x2013;37963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207431</ArticleId><ArticleId IdType="pubmed">21900234</ArticleId></ArticleIdList></Reference><Reference><Citation>You H, et al. Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A. 2012;109:1737&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277185</ArticleId><ArticleId IdType="pubmed">22307640</ArticleId></ArticleIdList></Reference><Reference><Citation>Alier K, Ma L, Yang J, Westaway D, Jhamandas JH. Abeta inhibition of ionic conductance in mouse basal forebrain neurons is dependent upon the cellular prion protein PrPC. J Neurosci. 2011;31:16292&#x2013;16297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633251</ArticleId><ArticleId IdType="pubmed">22072680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo W, et al. Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. Hum Mol Genet. 2012;21:1138&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277312</ArticleId><ArticleId IdType="pubmed">22100763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantera B, et al. PrPc activation induces neurite outgrowth and differentiation in PC12 cells: role for caveolin-1 in the signal transduction pathway. Journal of neurochemistry. 2009;110:194&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">19457127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouillet-Richard S, et al. Cellular prion protein signaling in serotonergic neuronal cells. Ann N Y Acad Sci. 2007;1096:106&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17405922</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson R, Usardi A, Hanger DP, Anderton BH. Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J. 2008;22:1552&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pubmed">18096814</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaga-Trillo E, et al. Regulation of embryonic cell adhesion by the prion protein. PLoS Biol. 2009;7:e55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653553</ArticleId><ArticleId IdType="pubmed">19278297</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizat N, et al. Neuron dysfunction is induced by prion protein with an insertional mutation via a Fyn kinase and reversed by sirtuin activation in Caenorhabditis elegans. J Neurosci. 2010;30:5394&#x2013;5403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632766</ArticleId><ArticleId IdType="pubmed">20392961</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Okumura-Noji K. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem Biophys Res Commun. 1995;216:582&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">7488151</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SG, et al. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992;258:1903&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa T, et al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 2001;276:693&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">11024032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner M, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010;66:739&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111138</ArticleId><ArticleId IdType="pubmed">20547131</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MO, et al. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. Journal of neurochemistry. 2006;97(Suppl 1):16&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16635246</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuermer CA, et al. PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J. 2004;18:1731&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15345693</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. 2004;5:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A. 2010;107:19014&#x2013;19019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973892</ArticleId><ArticleId IdType="pubmed">20956308</ArticleId></ArticleIdList></Reference><Reference><Citation>Prybylowski K, et al. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron. 2005;47:845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350965</ArticleId><ArticleId IdType="pubmed">16157279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Gu Z, Liu W, Yan Z. Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol Pharmacol. 2007;72:40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17400762</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging. 1990;11:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">2325814</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, et al. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133:1328&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinerman JR, et al. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol. 2008;65:906&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586606</ArticleId><ArticleId IdType="pubmed">18625856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, et al. Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry. J Biol Chem. 2004;279:21003&#x2013;21011.</Citation><ArticleIdList><ArticleId IdType="pubmed">15020595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura Y, et al. Molecular constituents of the postsynaptic density fraction revealed by proteomic analysis using multidimensional liquid chromatography-tandem mass spectrometry. Journal of neurochemistry. 2004;88:759&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720225</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Soluble A{beta} Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. J Neurosci. 2011;31:6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Ishibashi H, Obata K, Kandel ER. Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice. Learn Mem. 1998;5:429&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311255</ArticleId><ArticleId IdType="pubmed">10489260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PL, Lee HM, Rich S, Soriano P. pp59fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell. 1992;70:741&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">1387588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn R, von Schroetter C, Wuthrich K. Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding. FEBS letters. 1997;417:400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409760</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22815558</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II.</ArticleTitle><Pagination><StartPage>633</StartPage><EndPage>641</EndPage><MedlinePgn>633-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318264e380</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Previous studies have shown that high serum ceramides are associated with memory impairment and hippocampal volume loss, but have not examined dementia as an outcome. The aim of this study was to examine whether serum ceramides and sphingomyelins (SM) were associated with an increased risk of all-cause dementia and Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants included 99 women without dementia aged 70-79, with baseline serum SM and ceramides, enrolled in a longitudinal population-based study and followed for up to 6 visits over 9 years. Baseline lipids, in tertiles, were examined in relation to all-cause dementia and AD using discrete time Cox proportional survival analysis. Lipids were analyzed using electrospray ionization tandem mass spectrometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-seven (27.3%) of the 99 women developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable AD. Higher baseline serum ceramides, but not SM, were associated with an increased risk of AD; these relationships were stronger than with all-cause dementia. Compared to the lowest tertile, the middle and highest tertiles of ceramide d18:1-C16:0 were associated with a 10-fold (95% confidence interval [CI] 1.2-85.1) and 7.6-fold increased risk of AD (95% CI 0.9-62.1), respectively. The highest tertiles of ceramide d18:1-C24:0 (hazard ratio [HR] = 5.1, 95% CI 1.1-23.6) and lactosylceramide (HR = 9.8, 95% CI 1.2-80.1) were also associated with risk of AD. Total and high-density lipoprotein cholesterol and triglycerides were not associated with dementia or AD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results from this preliminary study suggest that particular species of serum ceramides are associated with incident AD and warrant continued examination in larger studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, College of Medicine, Mayo Clinic, Rochester, MN, USA. mielke.michelle@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandaru</LastName><ForeName>Veera Vankata Ratnam</ForeName><Initials>VV</Initials></Author><Author ValidYN="Y"><LastName>Haughey</LastName><ForeName>Norman J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fried</LastName><ForeName>Linda P</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Yasar</LastName><ForeName>Sevil</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Varma</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Rabins</LastName><ForeName>Peter V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Bandeen-Roche</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG19825-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG032427</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG037526-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 P30 AG021334-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG032427-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146-27</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS060271</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG19905</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG037526</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002518">Ceramides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Aug 14;79(7):639. doi: 10.1212/WNL.0b013e318264e3e2.</RefSource><PMID Version="1">22815553</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016387" MajorTopicYN="N">Women's Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22815558</ArticleId><ArticleId IdType="pmc">PMC3414665</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318264e380</ArticleId><ArticleId IdType="pii">WNL.0b013e318264e380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Han X, Rozen S, Boyle SH, et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011; 6: e21643 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136924</ArticleId><ArticleId IdType="pubmed">21779331</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 2010; 31: 398&#x2013; 408 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829762</ArticleId><ArticleId IdType="pubmed">18547682</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 2007; 32: 845&#x2013; 856 .</Citation><ArticleIdList><ArticleId IdType="pubmed">17342407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med 2010; 12: 331&#x2013; 340 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129545</ArticleId><ArticleId IdType="pubmed">20571935</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 2010; 1801: 878&#x2013; 886 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907186</ArticleId><ArticleId IdType="pubmed">20452460</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi EY, Ege C, Winans A, et al. Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide. Proteins 2008; 72: 1&#x2013; 24 .</Citation><ArticleIdList><ArticleId IdType="pubmed">18186465</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi EY, Frey SL, Lee KY. Ganglioside G(M1)-mediated amyloid-beta fibrillogenesis and membrane disruption. Biochemistry 2007; 46: 1913&#x2013; 1924 .</Citation><ArticleIdList><ArticleId IdType="pubmed">17256880</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SI, Yi JS, Ko YG. Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem 2006; 99: 878&#x2013; 889 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16721824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002; 41: 7385&#x2013; 7390 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12044171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Yamaguchi T, Fukunaga S, Hoshino M, Matsuzaki K. Mechanism of amyloid beta-protein aggregation mediated by GM1 ganglioside clusters. Biochemistry 2011; 50: 6433&#x2013; 6440 .</Citation><ArticleIdList><ArticleId IdType="pubmed">21682276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex. J Biol Chem 2000; 275: 35617&#x2013; 35623 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10962008</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh HL, Seok JY, Kwon CH, Kang SK, Kim YK. Role of MAPK in ceramide-induced cell death in primary cultured astrocytes from mouse embryonic brain. Neurotoxicology 2006; 27: 31&#x2013; 38 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16143399</ArticleId></ArticleIdList></Reference><Reference><Citation>Detre C, Kiss E, Varga Z, et al. Death or survival: membrane ceramide controls the fate and activation of antigen-specific T-cells depending on signal strength and duration. Cell Signal 2006; 18: 294&#x2013; 306 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16099142</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica BA, Movsesyan VA, Lea PM, 4th, Faden AI. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003; 22: 365&#x2013; 382 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12691738</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen YH, Godlewski J, Zhu J, et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 2003; 278: 26715&#x2013; 26721 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12738796</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Kelly J, Storie K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 2070&#x2013; 2075 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357053</ArticleId><ArticleId IdType="pubmed">14970312</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoi H, Tomimoto H, Ohtani R, et al. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005; 130: 657&#x2013; 666 .</Citation><ArticleIdList><ArticleId IdType="pubmed">15590150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Haughey NJ, Ratnam Bandaru VV, et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 2010; 6: 378&#x2013; 385 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933928</ArticleId><ArticleId IdType="pubmed">20813340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010; 31: 17&#x2013; 24 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783210</ArticleId><ArticleId IdType="pubmed">18455839</ArticleId></ArticleIdList></Reference><Reference><Citation>Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63: 494&#x2013; 506 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375143</ArticleId><ArticleId IdType="pubmed">18300306</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson MC, Fried LP, Xue QL, Bandeen-Roche K, Zeger SL, Brandt J. Association between executive attention and physical functional performance in community-dwelling older women. J Gerontol B Psychol Sci Soc Sci 1999; 54: S262&#x2013; 270 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10542828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Bandeen-Roche K, Chaves PH, Johnson BA. Preclinical mobility disability predicts incident mobility disability in older women. J Gerontol A Biol Sci Med Sci 2000; 55: M43&#x2013; 52 .</Citation><ArticleIdList><ArticleId IdType="pubmed">10719772</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed Washington, DC: American Psychiatric Association; 2000. ..</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939&#x2013; 944 .</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandaru VV, Troncoso J, Wheeler D, et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 2009; 30: 591&#x2013; 599 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758772</ArticleId><ArticleId IdType="pubmed">17888544</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc B 1972; 34: 187&#x2013; 202 .</Citation></Reference><Reference><Citation>Han X, Holtzman DM, McKeel DW, Jr, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002; 82: 809&#x2013; 818 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12358786</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MO, Grimm HS, Patzold AJ, et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 2005; 7: 1118&#x2013; 1123 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana A, Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase: Implications for Alzheimer's disease. J Biol Chem 2004; 279: 51451&#x2013; 51459 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1987357</ArticleId><ArticleId IdType="pubmed">15452132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JT, Xu J, Lee JM, et al. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004; 164: 123&#x2013; 131 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171973</ArticleId><ArticleId IdType="pubmed">14709545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cutler RG, Jo DG. Alzheimer peptides perturb lipid-regulating enzymes. Nat Cell Biol 2005; 7: 1045&#x2013; 1047 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16385731</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100: 11735&#x2013; 11740 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208827</ArticleId><ArticleId IdType="pubmed">14504402</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalvodova L, Kahya N, Schwille P, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cho-lesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005; 280: 36815&#x2013; 36823 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Lin W, et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 2004; 279: 44945&#x2013; 44954 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem 2003; 278: 19777&#x2013; 19783 .</Citation><ArticleIdList><ArticleId IdType="pubmed">12649271</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandaru VV, Mielke MM, Chu M, et al. CSF sphingolipids are biomarkers for neurocognitive status in HIV-infected patients. In: 10th International Symposium on Neurovirology, Milan, Italy, October 12&#x2013;16, 2010. ..</Citation></Reference><Reference><Citation>Ichi I, Nakahara K, Miyashita Y, et al. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 2006; 41: 859&#x2013; 863 .</Citation><ArticleIdList><ArticleId IdType="pubmed">17152923</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson JC, Jiang XC, Tabas I, Tall A, Shea S. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006; 163: 903&#x2013; 912 .</Citation><ArticleIdList><ArticleId IdType="pubmed">16611667</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers SA. Sphingolipids and insulin resistance: the five Ws. Curr Opin Lipidol 2010; 21: 128&#x2013; 135 .</Citation><ArticleIdList><ArticleId IdType="pubmed">20216312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22817896</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis.</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>350</EndPage><MedlinePgn>339-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2012.06.019</ELocationID><Abstract><AbstractText>RIP1 and RIP3 kinases are central players in TNF-induced programmed necrosis. Here, we report that&#xa0;the RIP homotypic interaction motifs (RHIMs) of RIP1 and RIP3 mediate the assembly of heterodimeric filamentous structures. The fibrils exhibit classical characteristics of &#x3b2;-amyloids, as shown by Thioflavin T (ThT) and Congo red (CR) binding, circular dichroism, infrared spectroscopy, X-ray diffraction, and solid-state NMR. Structured amyloid cores are mapped in RIP1 and RIP3 that are flanked&#xa0;by regions of mobility. The endogenous RIP1/RIP3 complex isolated from necrotic cells binds ThT, is ultrastable, and has a fibrillar core structure, whereas necrosis is partially inhibited by ThT, CR, and another amyloid dye, HBX. Mutations in the RHIMs of RIP1 and RIP3 that are defective in the interaction compromise cluster formation, kinase activation, and programmed necrosis in&#xa0;vivo. The current study provides insight into the structural changes that occur when RIP kinases are triggered to execute different signaling outcomes and expands the realm of amyloids to complex formation and signaling.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jixi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Weill Cornell Medical College, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Siemer</LastName><ForeName>Ansgar B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Napetschnig</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Moriwaki</LastName><ForeName>Kenta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Yu-Shan</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Damko</LastName><ForeName>Ermelinda</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Moquin</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Walz</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Francis Ka-Ming</ForeName><Initials>FK</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI083497</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI07349</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK032520</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK32520</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI083497</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI088502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007349</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI045937</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI088502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI045937</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C119705">RIPK3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2012 Sep;13(9):540. doi: 10.1038/nrm3415.</RefSource><PMID Version="1">22850818</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2023 Feb;24(2):85. doi: 10.1038/s41580-022-00553-z.</RefSource><PMID Version="1">36266548</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053422" MajorTopicYN="N">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22817896</ArticleId><ArticleId IdType="mid">NIHMS390143</ArticleId><ArticleId IdType="pmc">PMC3664196</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2012.06.019</ArticleId><ArticleId IdType="pii">S0092-8674(12)00772-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alavez S, Vantipalli MC, Zucker DJ, Klang IM, Lithgow GJ. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature. 2011;472:226&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610427</ArticleId><ArticleId IdType="pubmed">21451522</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, G&#xf3;mez de Barreda E, Engel T, Lucas JJ, Hern&#xe1;ndez F. Tau phosphorylation in hippocampus results in toxic gain-of-function. Biochem. Soc. Trans. 2010;38:977&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">20658988</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbirnie M, Grothe R, Eisenberg DS. An amyloid-forming peptide from the yeast prion Sup35 reveals a dehydrated beta-sheet structure for amyloid. Proc. Natl. Acad. Sci. USA. 2001;98:2375&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30146</ArticleId><ArticleId IdType="pubmed">11226247</ArticleId></ArticleIdList></Reference><Reference><Citation>Challa S, Woelfel M, Guildford M, Moquin D, Chan FK. Viral cell death inhibitor MC159 enhances innate immunity against vaccinia virus infection. J. Virol. 2010;84:10467&#x2013;10476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950582</ArticleId><ArticleId IdType="pubmed">20702623</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, Orenstein J, Moss B, Lenardo MJ. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J. Biol. Chem. 2003;278:51613&#x2013;51621.</Citation><ArticleIdList><ArticleId IdType="pubmed">14532286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727676</ArticleId><ArticleId IdType="pubmed">19524513</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS ONE. 2011;6:e23209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154273</ArticleId><ArticleId IdType="pubmed">21853090</ArticleId></ArticleIdList></Reference><Reference><Citation>Detken A, Hardy EH, Ernst M, Meier BH. Simple and efficient decoupling in magic-angle spinning solid-state NMR: the XiX scheme. Chem. Phys. Lett. 2002;356:298&#x2013;304.</Citation></Reference><Reference><Citation>Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N, Castanares M, Wu M. Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell. Signal. 2007;19:2056&#x2013;2067.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644308</ArticleId></ArticleIdList></Reference><Reference><Citation>Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, H&#xe4;cker G, Leverkus M. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell. 2011;43:449&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163271</ArticleId><ArticleId IdType="pubmed">21737330</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank J, Radermacher M, Penczek P, Zhu J, Li Y, Ladjadj M, Leith A. SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J. Struct. Biol. 1996;116:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 2007;67:11493&#x2013;11498.</Citation><ArticleIdList><ArticleId IdType="pubmed">18089776</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">19524512</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc. Natl. Acad. Sci. USA. 2011;108:20054&#x2013;20059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3250173</ArticleId><ArticleId IdType="pubmed">22123964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell. 2011;146:448&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179916</ArticleId><ArticleId IdType="pubmed">21782231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser WJ, Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J. Immunol. 2005;174:4942&#x2013;4952.</Citation><ArticleIdList><ArticleId IdType="pubmed">15814722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, Caspary T, Mocarski ES. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471:368&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060292</ArticleId><ArticleId IdType="pubmed">21368762</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 1989;37:1273&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">2666510</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., III Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507030</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Hite RK, Cheng Y, Walz T. Evaluation of imaging plates as recording medium for images of negatively stained single particles and electron diffraction patterns of two-dimensional crystals. J. Electron Microsc. (Tokyo) 2010;59:53&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156676</ArticleId><ArticleId IdType="pubmed">19643814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999;13:2514&#x2013;2526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317073</ArticleId><ArticleId IdType="pubmed">10521396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888693</ArticleId><ArticleId IdType="pubmed">20485341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtke SJ, Baldwin PR, Chiu W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 1999;128:82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack C, Sickmann A, Lembo D, Brune W. Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein. Proc. Natl. Acad. Sci. USA. 2008;105:3094&#x2013;3099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268590</ArticleId><ArticleId IdType="pubmed">18287053</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F, Abedini A, Plesner A, Verchere CB, Raleigh DP. The flavanol (&#x2212;)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry. 2010;49:8127&#x2013;8133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199968</ArticleId><ArticleId IdType="pubmed">20707388</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M, Tschopp J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 2004;5:503&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">15064760</ArticleId></ArticleIdList></Reference><Reference><Citation>Moquin D, Chan FK. The molecular regulation of programmed necrotic cell injury. Trends Biochem. Sci. 2010;35:434&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904865</ArticleId><ArticleId IdType="pubmed">20346680</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471:363&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077893</ArticleId><ArticleId IdType="pubmed">21368763</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson&#x2019;s disease pathogenesis and therapies. Prog. Brain Res. 2010;183:115&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">20696318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramshini H, Parrini C, Relini A, Zampagni M, Mannini B, Pesce A, Saboury AA, Nemat-Gorgani M, Chiti F. Large proteins have a great tendency to aggregate but a low propensity to form amyloid fibrils. PLoS ONE. 2011;6:e16075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020945</ArticleId><ArticleId IdType="pubmed">21249193</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebsamen M, Heinz LX, Meylan E, Michallet MC, Schroder K, Hofmann K, Vazquez J, Benedict CA, Tschopp J. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep. 2009;10:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726668</ArticleId><ArticleId IdType="pubmed">19590578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rost B, Yachdav G, Liu J. The PredictProtein server. Nucleic Acids Res. 2004;32:W321&#x2013;W326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441515</ArticleId><ArticleId IdType="pubmed">15215403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambashivan S, Liu Y, Sawaya MR, Gingery M, Eisenberg D. Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure. Nature. 2005;437:266&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16148936</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003;421:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 1995;81:513&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">7538908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM. RIP3, a novel apoptosis-inducing kinase. J. Biol. Chem. 1999;274:16871&#x2013;16875.</Citation><ArticleIdList><ArticleId IdType="pubmed">10358032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Yin J, Starovasnik MA, Fairbrother WJ, Dixit VM. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J. Biol. Chem. 2002;277:9505&#x2013;9511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11734559</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265413</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007;448:501&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17618271</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C&#x2013;1H dipolar-assisted rotational resonance in magic-angle spinning NMR. Chem. Phys. Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell. 2011;43:432&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">21737329</ArticleId></ArticleIdList></Reference><Reference><Citation>Uptain SM, Lindquist S. Prions as protein-based genetic elements. Annu. Rev. Microbiol. 2002;56:703&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142498</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton JW, Kaiser WJ, Mocarski ES. Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe. 2010;7:302&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4279434</ArticleId><ArticleId IdType="pubmed">20413098</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe. 2012;11:290&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531981</ArticleId><ArticleId IdType="pubmed">22423968</ArticleId></ArticleIdList></Reference><Reference><Citation>Verel R, Ernst M, Meier BH. Adiabatic dipolar recoupling in solid-state NMR: the DREAM scheme. J. Magn. Reson. 2001;150:81&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">11330986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol. Rev. 2011;244:9&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">22017428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">18485876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yang JK, Kabaleeswaran V, Rice AJ, Cruz AC, Park AY, Yin Q, Damko E, Jang SB, Raunser S, et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol. 2010;17:1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988912</ArticleId><ArticleId IdType="pubmed">20935634</ArticleId></ArticleIdList></Reference><Reference><Citation>Welz PS, Wullaert A, Vlantis K, Kondylis V, Fern&#xe1;ndez-Majada V, Ermolaeva M, Kirsch P, Sterner-Kock A, van Loo G, Pasparakis M. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature. 2011;477:330&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804564</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 2004;32(Web Server issue):W668&#x2013;W673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441509</ArticleId><ArticleId IdType="pubmed">15215473</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu PW, Huang BC, Shen M, Quast J, Chan E, Xu X, Nolan GP, Payan DG, Luo Y. Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB. Curr. Biol. 1999;9:539&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">10339433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandomeneghi G, Krebs MR, McCammon MG, F&#xe4;ndrich M. FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Sci. 2004;13:3314&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287307</ArticleId><ArticleId IdType="pubmed">15537750</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">19498109</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011;471:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072026</ArticleId><ArticleId IdType="pubmed">21368761</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu ZG. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl. Acad. Sci. U S A. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325682</ArticleId><ArticleId IdType="pubmed">22421439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22787053</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>28</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>An effector-reduced anti-&#x3b2;-amyloid (A&#x3b2;) antibody with unique a&#x3b2; binding properties promotes neuroprotection and glial engulfment of A&#x3b2;.</ArticleTitle><Pagination><StartPage>9677</StartPage><EndPage>9689</EndPage><MedlinePgn>9677-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4742-11.2012</ELocationID><Abstract><AbstractText>Passive immunization against &#x3b2;-amyloid (A&#x3b2;) has become an increasingly desirable strategy as a therapeutic treatment for Alzheimer's disease (AD). However, traditional passive immunization approaches carry the risk of Fc&#x3b3; receptor-mediated overactivation of microglial cells, which may contribute to an inappropriate proinflammatory response leading to vasogenic edema and cerebral microhemorrhage. Here, we describe the generation of a humanized anti-A&#x3b2; monoclonal antibody of an IgG4 isotype, known as MABT5102A (MABT). An IgG4 subclass was selected to reduce the risk of Fc&#x3b3; receptor-mediated overactivation of microglia. MABT bound with high affinity to multiple forms of A&#x3b2;, protected against A&#x3b2;1-42 oligomer-induced cytotoxicity, and increased uptake of neurotoxic A&#x3b2; oligomers by microglia. Furthermore, MABT-mediated amyloid plaque removal was demonstrated using in vivo live imaging in hAPP((V717I))/PS1 transgenic mice. When compared with a human IgG1 wild-type subclass, containing the same antigen-binding variable domains and with equal binding to A&#x3b2;, MABT showed reduced activation of stress-activated p38MAPK (p38 mitogen-activated protein kinase) in microglia and induced less release of the proinflammatory cytokine TNF&#x3b1;. We propose that a humanized IgG4 anti-A&#x3b2; antibody that takes advantage of a unique A&#x3b2; binding profile, while also possessing reduced effector function, may provide a safer therapeutic alternative for passive immunotherapy for AD. Data from a phase I clinical trial testing MABT is consistent with this hypothesis, showing no signs of vasogenic edema, even in ApoE4 carriers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adolfsson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>AC Immune SA, 1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihlgren</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Varisco</LastName><ForeName>Yvan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Buccarello</LastName><ForeName>Anna Lucia</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Antoniello</LastName><ForeName>Katia</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lohmann</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Piorkowska</LastName><ForeName>Kasia</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gafner</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Atwal</LastName><ForeName>Jasvinder K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gogineni</LastName><ForeName>Alvin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Weimer</LastName><ForeName>Robby M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Deborah L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Friesenhahn</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Carole</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pfeifer</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Muhs</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22787053</ArticleId><ArticleId IdType="pmc">PMC6622286</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4742-11.2012</ArticleId><ArticleId IdType="pii">32/28/9677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT. Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res. 2006;84:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16724341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman DA, McLaurin J, Chakrabartty A. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci. 2007;8:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1871596</ArticleId><ArticleId IdType="pubmed">17475015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson C, Estergard W, Oh J, Suhy J, Jack CR, Jr, Siemers E, Barakos J. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement. 2011;7:396&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784350</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflamm. 2006;3:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479322</ArticleId><ArticleId IdType="pubmed">16686956</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark MR. IgG effector mechanisms. Chem Immunol. 1997;65:88&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">9018874</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV. IgG-assisted age-dependent clearance of Alzheimer's amyloid-&#x3b2; peptide by the blood&#x2013;brain barrier neonatal Fc receptor. J Neurosci. 2005;25:11495&#x2013;11503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726020</ArticleId><ArticleId IdType="pubmed">16354907</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle SE, O'Connell RM, Miranda GA, Vaidya SA, Chow EK, Liu PT, Suzuki S, Suzuki N, Modlin RL, Yeh WC, Lane TF, Cheng G. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med. 2004;199:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887723</ArticleId><ArticleId IdType="pubmed">14699082</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Stimson ER, Ghilardi JR, Lu YA, Felix AM, Vinters HV, Mantyh PW, Lee JP, Maggio JE. Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry. 1996;35:13914&#x2013;13921.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909288</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Balass M, Solomon B. N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. J Neuroimmunol. 1998;88:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9688328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC, Lee D, Boehm JC, Fier-Thompson SM, Abt JW, Soreson ME, Smietana JM, Hall RF, Garigipati RS, Bender PE, Erhard KF, Krog AJ, Hofmann GA, Sheldrake PL, McDonnell PC, et al. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem. 1997;5:49&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043657</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman DT, L&#xf3;pez-Deber MP, Ndao DM, Silva AB, Nand D, Pihlgren M, Giriens V, Madani R, St-Pierre A, Karastaneva H, Nagel-Steger L, Willbold D, Riesner D, Nicolau C, Baldus M, Pfeifer A, Muhs A. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem. 2011;286:13966&#x2013;13976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077597</ArticleId><ArticleId IdType="pubmed">21343310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective &#x3b2;-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, Bonhoeffer T, Chow DK, Chuckowree J, De Paola V, Hofer SB, H&#xfc;bener M, Keck T, Knott G, Lee WC, Mostany R, Mrsic-Flogel TD, Nedivi E, Portera-Cailliau C, Svoboda K, Trachtenberg JT, Wilbrecht L. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc. 2009;4:1128&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem. 2011;286:8585&#x2013;8596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048741</ArticleId><ArticleId IdType="pubmed">21156804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. Rapid microglial response around amyloid pathology after systemic anti-A&#x3b2; antibody administration in PDAPP mice. J Neurosci. 2008;28:14156&#x2013;14164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743894</ArticleId><ArticleId IdType="pubmed">19109498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 2005;579:2564&#x2013;2568.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">7997261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Schrader JW, Kim SU. p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine. 2000;12:874&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">10880231</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Yang L, Lindholm K, Konishi Y, Yue X, Hampel H, Zhang D, Shen Y. Tumor necrosis factor death receptor signaling cascade is required for amyloid-&#x3b2; protein-induced neuron death. J Neurosci. 2004;24:1760&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730458</ArticleId><ArticleId IdType="pubmed">14973251</ArticleId></ArticleIdList></Reference><Reference><Citation>Meberg PJ, Miller MW. Culturing hippocampal and cortical neurons. Methods Cell Biol. 2003;71:111&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">12884689</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der Auwera I, van Leuven F, Sugawara M, Weingertner MC, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A. 2007;104:9810&#x2013;9815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887581</ArticleId><ArticleId IdType="pubmed">17517595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413920</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by &#x3b2;-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993;13:1676&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576726</ArticleId><ArticleId IdType="pubmed">8463843</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo JF, Gilles EJ, Ramakrishnan M, Howell KG, Wengenack TM, Curran GL, Kandimalla KK. HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons. PLoS One. 2010;5:e8813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809098</ArticleId><ArticleId IdType="pubmed">20098681</ArticleId></ArticleIdList></Reference><Reference><Citation>Poling A, Morgan-Paisley K, Panos JJ, Kim EM, O'Hare E, Cleary JP, Lesn&#xe9; S, Ashe KH, Porritt M, Baker LE. Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. Behav Brain Res. 2008;193:230&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786170</ArticleId><ArticleId IdType="pubmed">18585407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bapineuzumab 201 Clinical Trial Investigators. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591&#x2013;6604.</Citation><ArticleIdList><ArticleId IdType="pubmed">11096108</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon PL, Laydon JT, Lee JC. A modified assay for interleukin-1 (IL-1) J Immunol Methods. 1985;84:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">3934287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, Schenk D, Hyman BT. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis. 2009;33:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672591</ArticleId><ArticleId IdType="pubmed">19028582</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med. 1991;173:1025&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190803</ArticleId><ArticleId IdType="pubmed">2007852</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature. 2002;420:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490942</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol. 1986;64:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1542347</ArticleId><ArticleId IdType="pubmed">3488859</ArticleId></ArticleIdList></Reference><Reference><Citation>AN1792 (QS-21)-251 Study Team. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res. 2009;6:144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825665</ArticleId><ArticleId IdType="pubmed">19355849</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans. 2005;33:1087&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid &#x3b2;-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009;118:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">19234858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-&#x3b2; antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;5346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22784036</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>367</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</ArticleTitle><Pagination><StartPage>795</StartPage><EndPage>804</EndPage><MedlinePgn>795-804</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1202753</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The order and magnitude of pathologic processes in Alzheimer's disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clinical and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests. We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calculate the estimated years from expected symptom onset (age of the participant minus parent's age at symptom onset). We conducted cross-sectional analyses of baseline data in relation to estimated years from expected symptom onset in order to determine the relative order and magnitude of pathophysiological changes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Concentrations of amyloid-beta (A&#x3b2;)(42) in the CSF appeared to decline 25 years before expected symptom onset. A&#x3b2; deposition, as measured by positron-emission tomography with the use of Pittsburgh compound B, was detected 15 years before expected symptom onset. Increased concentrations of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset. Cerebral hypometabolism and impaired episodic memory were observed 10 years before expected symptom onset. Global cognitive impairment, as measured by the Mini-Mental State Examination and the Clinical Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an average of 3 years after expected symptom onset.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found that autosomal dominant Alzheimer's disease was associated with a series of pathophysiological changes over decades in CSF biochemical markers of Alzheimer's disease, brain amyloid deposition, and brain metabolism as well as progressive cognitive impairment. Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease. (Funded by the National Institute on Aging and others; DIAN ClinicalTrials.gov number, NCT00869817.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, Department of Neurology, 660 S. Euclid Ave., Box 8111, St. Louis, MO 63110, USA. batemanr@wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xianyun</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Blazey</LastName><ForeName>Tyler M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Santacruz</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moulder</LastName><ForeName>Krista</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00869817</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>N Engl J Med. 2012 Aug 23;367(8):780</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Aug 30;367(9):864-6. doi: 10.1056/NEJMe1207995.</RefSource><PMID Version="1">22931321</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Nov 22;367(21):2050; author reply 2051-2. doi: 10.1056/NEJMc1211767.</RefSource><PMID Version="1">23171104</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Nov 22;367(21):2050-1; author reply 2051-2. doi: 10.1056/NEJMc1211767.</RefSource><PMID Version="1">23171105</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2012 Nov 22;367(21):2051; author reply 2051-2. doi: 10.1056/NEJMc1211767.</RefSource><PMID Version="1">23171106</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22784036</ArticleId><ArticleId IdType="mid">NIHMS405217</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of Alzheimer&#x2019;s disease in the United States. Alzheimers Dement. 2011;7:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052294</ArticleId><ArticleId IdType="pubmed">21255744</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bapineuzumab in patients with mild to moderate Alzheimer&#x2019;s disease (ApoE4 non-carrier) ClinicalTrials.gov. 2007 ( http://clinicaltrials.gov/ct2/show/NCT00574132).</Citation></Reference><Reference><Citation>Effect of LY2062430 on the progression of Alzheimer&#x2019;s disease (EXPEDITION) ClinicalTrials.gov. 2009 ( http://clinicaltrials.gov/ct2/show/NCT00905372).</Citation></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. [Erratum, Science 2002;297:2209.]</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">12904524</ArticleId></ArticleIdList></Reference><Reference><Citation>Summary of opinion (initial authorisation): Vyndaqel. London: European Medicines Agency; 2011.  ( http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002294/smops/Positive/human_smop_000246.jsp&amp;mid=WC0b01ac058001d127&amp;murl=menus/medicines/medicines.jsp&amp;jsenabled=true).</Citation></Reference><Reference><Citation>Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res. 2005;38:911&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">16359163</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Chakraverty S, Mayo K, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families. PLoS One. 2012;7(2):e31039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Mart&#xed;nez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277:793&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Daw EW, Yu X, et al. APOE and other loci affect age-at-onset in Alzheimer&#x2019;s disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer&#x2019;s Disease Cooperative Study experience. Neurology. 1997;48:1508&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191756</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state:&#x201d; a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale&#x2013;Revised: manual. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer&#x2019;s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Disease &amp; Frontotemporal Dementia Mutation Database home page. 2011 ( http://www.molgen.ua.ac.be/ADMutations).</Citation></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer&#x2019;s disease. Neurology. 1997;49:786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in non-demented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: a serial MRI study. Lancet Neurol. 2006;5:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Growdon WB, McNamara MJ, et al. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer&#x2019;s disease brain: evidence for other phenotype-modifying factors. Brain. 1999;122:1709&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10468510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980;35:259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">7362699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22745490</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>26</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression.</ArticleTitle><Pagination><StartPage>8890</StartPage><EndPage>8899</EndPage><MedlinePgn>8890-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5698-11.2012</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common cause of dementia. Much is known concerning AD pathophysiology but our understanding of the disease at the systems level remains incomplete. Previous AD research has used resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) to assess the integrity of functional networks within the brain. Most studies have focused on the default-mode network (DMN), a primary locus of AD pathology. However, other brain regions are inevitably affected with disease progression. We studied rs-fcMRI in five functionally defined brain networks within a large cohort of human participants of either gender (n = 510) that ranged in AD severity from unaffected [clinical dementia rating (CDR) 0] to very mild (CDR 0.5) to mild (CDR 1). We observed loss of correlations within not only the DMN but other networks at CDR 0.5. Within the salience network (SAL), increases were seen between CDR 0 and CDR 0.5. However, at CDR 1, all networks, including SAL, exhibited reduced correlations. Specific networks were preferentially affected at certain CDR stages. In addition, cross-network relations were consistently lost with increasing AD severity. Our results demonstrate that AD is associated with widespread loss of both intranetwork and internetwork correlations. These results provide insight into AD pathophysiology and reinforce an integrative view of the brain's functional organization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brier</LastName><ForeName>Mathew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jewell B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Abraham Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongyang</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23MH081786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS06833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NR012907</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR012657</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32GM007200-37</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NR012657</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR012907</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH081786</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007200</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="Y">Rest</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22745490</ArticleId><ArticleId IdType="mid">NIHMS389589</ArticleId><ArticleId IdType="pmc">PMC3458508</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5698-11.2012</ArticleId><ArticleId IdType="pii">32/26/8890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agosta F, Pievani M, Geroldi C, Copetti M, Frisoni GB, Filippi M. Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging. 2011 doi: 10.1016/j.neurobiolaging.2011.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.06.007</ArticleId><ArticleId IdType="pubmed">21813210</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159:738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond, B, Biol Sci. 2005;360:1001&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1854918</ArticleId><ArticleId IdType="pubmed">16087444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;chel C, Josephs O, Rees G, Turner R, Frith CD, Friston KJ. The functional anatomy of attention to visual motion: a functional MRI study. Brain. 1998;121:1281&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">9679780</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44:195&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun VD, Adali T, Pearlson GD, Pekar JJ. A method for making group inferences from functional MRI data using independent component analysis. Hum Brain Mapp. 2001;14:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871952</ArticleId><ArticleId IdType="pubmed">11559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey BJ, Cohen JD, O'Craven K, Davidson RJ, Irwin W, Nelson CA, Noll DC, Hu X, Lowe MJ, Rosen BR, Truwitt CL, Turski PA. Reproducibility of fMRI results across four institutions using a spatial working memory task. Neuroimage. 1998;8:249&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">9758739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MW, Pathak S, Schneider W. Identifying the brain's most globally connected regions. Neuroimage. 2010;49:3132&#x2013;3148.</Citation><ArticleIdList><ArticleId IdType="pubmed">19909818</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A. 2006;103:13848&#x2013;13853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564249</ArticleId><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zubicaray GI, McMahon K, Wilson SJ, Muthiah S. Brain activity during the encoding, retention, and retrieval of stimulus representations. Learn Mem. 2001;8:243&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311385</ArticleId><ArticleId IdType="pubmed">11584070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, Fair DA, Miezin FM, Cohen AL, Wenger KK, Dosenbach RA, Fox MD, Snyder AZ, Vincent JL, Raichle ME, Schlaggar BL, Petersen SE. Distinct brain networks for adaptive and stable task control in humans. Proc Natl Acad Sci U S A. 2007;104:11073&#x2013;11078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904171</ArticleId><ArticleId IdType="pubmed">17576922</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635&#x2013;1646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102239</ArticleId><ArticleId IdType="pubmed">21490054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellermann JM, Siegal JD, Strupp JP, Ebner TJ, Ugurbil K. Activation of visuomotor systems during visually guided movements: a functional MRI study. J Magn Reson. 1998;131:272&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">9571103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011;34:430&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275347</ArticleId><ArticleId IdType="pubmed">21696834</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Corbetta M, Snyder AZ, Vincent JL, Raichle ME. Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. Proc Natl Acad Sci U S A. 2006;103:10046&#x2013;10051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480402</ArticleId><ArticleId IdType="pubmed">16788060</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Zhang D, Snyder AZ, Raichle ME. The global signal and observed anticorrelated resting state brain networks. J Neurophysiol. 2009;101:3270&#x2013;3283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694109</ArticleId><ArticleId IdType="pubmed">19339462</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson M, Driesen N, Roth JK, Gore JC, Constable RT. Functional connectivity between task-positive and task-negative brain areas and its relation to working memory performance. Magn Reson Imaging. 2010;28:1051&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936669</ArticleId><ArticleId IdType="pubmed">20409665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke K, Mondadori CR, Treyer V, Nitsch RM, Buck A, Hock C. Nonconscious formation and reactivation of semantic associations by way of the medial temporal lobe. Neuropsychologia. 2003;41:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667523</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyv&#xe4;rinen A. Fast and robust fixed-point algorithms for independent component analysis. IEEE Trans Neural Netw. 1999;10:626&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">18252563</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter LC, Wilder LS, Pipe JG, Heiserman JE, Prigatano GP. Neural correlates of self-reflection. Brain. 2002;125:1808&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135971</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, Gunter JL, Przybelski SA, Avula RT, Knopman DS, Boeve BF, Petersen RC, Jack CR., Jr Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011;77:1524&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198977</ArticleId><ArticleId IdType="pubmed">21975202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjaer TW, Nowak M, Lou HC. Reflective self-awareness and conscious states: PET evidence for a common midline parietofrontal core. Neuroimage. 2002;17:1080&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377180</ArticleId></ArticleIdList></Reference><Reference><Citation>Macey PM, Macey KE, Kumar R, Harper RM. A method for removal of global effects from fMRI time series. Neuroimage. 2004;22:360&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15110027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazoyer B, Zago L, Mellet E, Bricogne S, Etard O, Houd&#xe9; O, Crivello F, Joliot M, Petit L, Tzourio-Mazoyer N. Cortical networks for working memory and executive functions sustain the conscious resting state in man. Brain Res Bull. 2001;54:287&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287133</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K, Birn RM, Handwerker DA, Jones TB, Bandettini PA. The impact of global signal regression on resting state correlations: are anti-correlated networks introduced? Neuroimage. 2009;44:893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750906</ArticleId><ArticleId IdType="pubmed">18976716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojemann JG, Buckner RL, Corbetta M, Raichle ME. Imaging studies of memory and attention. Neurosurg Clin N Am. 1997;8:307&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">9188540</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Sheldon FC, Prince SE, Calhoun VD, Doraiswamy PM. Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology. 2011;76:511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053179</ArticleId><ArticleId IdType="pubmed">21228297</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012;59:2142&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254728</ArticleId><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, Rombouts SA, Maris E, Barkhof F, Scheltens P, Stam CJ. Loss of &#x2018;small-world&#x2019; networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One. 2010;5:e13788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967467</ArticleId><ArticleId IdType="pubmed">21072180</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27:2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sestieri C, Corbetta M, Romani GL, Shulman GL. Episodic memory retrieval, parietal cortex, and the default mode network: functional and topographic analyses. J Neurosci. 2011;31:4407&#x2013;4420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098040</ArticleId><ArticleId IdType="pubmed">21430142</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehzad Z, Kelly AM, Reiss PT, Gee DG, Gotimer K, Uddin LQ, Lee SH, Margulies DS, Roy AK, Biswal BB, Petkova E, Castellanos FX, Milham MP. The resting brain: unconstrained yet reliable. Cereb Cortex. 2009;19:2209&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896030</ArticleId><ArticleId IdType="pubmed">19221144</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Corbetta M, Buckner RL, Fiez JA, Miezin FM, Raichle ME, Petersen SE. Common blood flow changes across visual tasks. I. increases in subcortical structures and cerebellum but not in nonvisual cortex. J Cogn Neurosci. 1997;9:624&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965121</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Pope DL, Astafiev SV, McAvoy MP, Snyder AZ, Corbetta M. Right hemisphere dominance during spatial selective attention and target detection occurs outside the dorsal frontoparietal network. J Neurosci. 2010;30:3640&#x2013;3651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872555</ArticleId><ArticleId IdType="pubmed">20219998</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, Filippini N, Watkins KE, Toro R, Laird AR, Beckmann CF. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci U S A. 2009;106:13040&#x2013;13045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722273</ArticleId><ArticleId IdType="pubmed">19620724</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyser CD, Inder TE, Shimony JS, Hill JE, Degnan AJ, Snyder AZ, Neil JJ. Longitudinal analysis of neural network development in preterm infants. Cereb Cortex. 2010;20:2852&#x2013;2862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978240</ArticleId><ArticleId IdType="pubmed">20237243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, M&#xfc;hlau M, Calhoun VD, Eichele T, L&#xe4;er L, Drzezga A, F&#xf6;rstl H, Kurz A, Zimmer C, Wohlschl&#xe4;ger AM. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol. 2008;4:e1000100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435273</ArticleId><ArticleId IdType="pubmed">18584043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvester CM, Shulman GL, Jack AI, Corbetta M. Asymmetry of anticipatory activity in visual cortex predicts the locus of attention and perception. J Neurosci. 2007;27:14424&#x2013;14433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673462</ArticleId><ArticleId IdType="pubmed">18160650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvester CM, Shulman GL, Jack AI, Corbetta M. Anticipatory and stimulus-evoked blood oxygenation level-dependent modulations related to spatial attention reflect a common additive signal. J Neurosci. 2009;29:10671&#x2013;10682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417151</ArticleId><ArticleId IdType="pubmed">19710319</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dijk KR, Sabuncu MR, Buckner RL. The influence of head motion on intrinsic functional connectivity MRI. Neuroimage. 2012;59:431&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683830</ArticleId><ArticleId IdType="pubmed">21810475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Liang M, Wang L, Tian L, Zhang X, Li K, Jiang T. Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study. Hum Brain Mapp. 2007;28:967&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871392</ArticleId><ArticleId IdType="pubmed">17133390</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissenbacher A, Kasess C, Gerstl F, Lanzenberger R, Moser E, Windischberger C. Correlations and anticorrelations in resting-state functional connectivity MRI: a quantitative comparison of preprocessing strategies. Neuroimage. 2009;47:1408&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Raichle ME. Disease and the brain's dark energy. Nat Rev Neurol. 2010;6:15&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">20057496</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Snyder AZ, Shimony JS, Fox MD, Raichle ME. Noninvasive functional and structural connectivity mapping of the human thalamocortical system. Cereb Cortex. 2010;20:1187&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852505</ArticleId><ArticleId IdType="pubmed">19729393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, Kramer JH, Weiner M, Miller BL, Seeley WW. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain. 2010;133:1352&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Dougherty JH, Jr, Hubner KF, Bai B, Cannon RL, Hutson RK. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. 2008;4:265&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielinski BA, Gennatas ED, Zhou J, Seeley WW. Network-level structural covariance in the developing brain. Proc Natl Acad Sci U S A. 2010;107:18191&#x2013;18196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964249</ArticleId><ArticleId IdType="pubmed">20921389</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo XN, Di Martino A, Kelly C, Shehzad ZE, Gee DG, Klein DF, Castellanos FX, Biswal BB, Milham MP. The oscillating brain: complex and reliable. Neuroimage. 2010;49:1432&#x2013;1445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856476</ArticleId><ArticleId IdType="pubmed">19782143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo XN, Ehmke R, Mennes M, Imperati D, Castellanos FX, Sporns O, Milham MP. Network centrality in the human functional connectome. Cereb Cortex. 2011 doi: 10.1093/cercor/bhr269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhr269</ArticleId><ArticleId IdType="pubmed">21968567</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22753898</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8140</ISSN><JournalIssue CitedMedium="Internet"><Volume>198</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>35</EndPage><MedlinePgn>23-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.201201076</ELocationID><Abstract><AbstractText>Presenilin (PSEN) deficiency is accompanied by accumulation of endosomes and autophagosomes, likely caused by impaired endo-lysosomal fusion. Recently, Lee et al. (2010. Cell. doi: http://dx.doi.org/10.1016/j.cell.2010.05.008) attributed this phenomenon to PSEN1 enabling the transport of mature V0a1 subunits of the vacuolar ATPase (V-ATPase) to lysosomes. In their view, PSEN1 mediates the N-glycosylation of V0a1 in the endoplasmic reticulum (ER); consequently, PSEN deficiency prevents V0a1 glycosylation, compromising the delivery of unglycosylated V0a1 to lysosomes, ultimately impairing V-ATPase function and lysosomal acidification. We show here that N-glycosylation is not a prerequisite for proper targeting and function of this V-ATPase subunit both in vitro and in vivo in Drosophila melanogaster. We conclude that endo-lysosomal dysfunction in PSEN(-/-) cells is not a consequence of failed N-glycosylation of V0a1, or compromised lysosomal acidification. Instead, lysosomal calcium storage/release is significantly altered in PSEN(-/-) cells and neurons, thus providing an alternative hypothesis that accounts for the impaired lysosomal fusion capacity and accumulation of endomembranes that accompanies PSEN deficiency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coen</LastName><ForeName>Katrijn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flannagan</LastName><ForeName>Ronald S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Baron</LastName><ForeName>Szilvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Carraro-Lacroix</LastName><ForeName>Luciene R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vermeire</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Baert</LastName><ForeName>Veerle</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Sugita</LastName><ForeName>Shuzo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wuytack</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hiesinger</LastName><ForeName>Peter Robin</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Grinstein</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY018884</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>R01EY018884</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM088803</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM088803</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C550849">Vha100-1 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Cell Biol. 2012 Jul 9;198(1):7-10. doi: 10.1083/jcb.201206003.</RefSource><PMID Version="1">22778275</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025262" MajorTopicYN="N">Vacuolar Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22753898</ArticleId><ArticleId IdType="pmc">PMC3392942</ArticleId><ArticleId IdType="doi">10.1083/jcb.201201076</ArticleId><ArticleId IdType="pii">jcb.201201076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert W., De Strooper B. 2010. Alzheimer&#x2019;s disease neurons fail the acid test. Cell. 141:1112&#x2013;1114 10.1016/j.cell.2010.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.009</ArticleId><ArticleId IdType="pubmed">20602994</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W.G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., George-Hyslop P.S., Cordell B., Fraser P., De Strooper B. 1999. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J. Cell Biol. 147:277&#x2013;294 10.1083/jcb.147.2.277</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.147.2.277</ArticleId><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W.G., Esselens C., Baert V., Boeve C., Snellings G., Cupers P., Craessaerts K., De Strooper B. 2001. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron. 32:579&#x2013;589 10.1016/S0896-6273(01)00512-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00512-8</ArticleId><ArticleId IdType="pubmed">11719200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I. 2009. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15:89&#x2013;100 10.1016/j.molmed.2009.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.01.001</ArticleId><ArticleId IdType="pmc">PMC3226745</ArticleId><ArticleId IdType="pubmed">19230774</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky G., Ganz M.B., Sterzel R.B., Boron W.F. 1988. pH regulation in single glomerular mesangial cells. II. Na+-dependent and -independent Cl(-)-HCO3- exchangers. Am. J. Physiol. 255:C857&#x2013;C869</Citation><ArticleIdList><ArticleId IdType="pubmed">3202154</ArticleId></ArticleIdList></Reference><Reference><Citation>Carraro-Lacroix L.R., Jaumouill&#xe9; V., Fairn G.D., Grinstein S. 2011. A weak base-generating system suitable for selective manipulation of lysosomal pH. Traffic. 12:1490&#x2013;1500 10.1111/j.1600-0854.2011.01266.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2011.01266.x</ArticleId><ArticleId IdType="pubmed">21819499</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Annaert W. 2010. Novel research horizons for presenilins and &#x3b3;-secretases in cell biology and disease. Annu. Rev. Cell Dev. Biol. 26:235&#x2013;260 10.1146/annurev-cellbio-100109-104117</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100109-104117</ArticleId><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C., Oorschot V., Baert V., Raemaekers T., Spittaels K., Serneels L., Zheng H., Saftig P., De Strooper B., Klumperman J., Annaert W. 2004. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J. Cell Biol. 166:1041&#x2013;1054 10.1083/jcb.200406060</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200406060</ArticleId><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabian-Fine R., Verstreken P., Hiesinger P.R., Horne J.A., Kostyleva R., Zhou Y., Bellen H.J., Meinertzhagen I.A. 2003. Endophilin promotes a late step in endocytosis at glial invaginations in Drosophila photoreceptor terminals. J. Neurosci. 23:10732&#x2013;10744</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740933</ArticleId><ArticleId IdType="pubmed">14627659</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgac M. 2007. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell Biol. 8:917&#x2013;929 10.1038/nrm2272</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2272</ArticleId><ArticleId IdType="pubmed">17912264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond C., Helenius A. 1994. Quality control in the secretory pathway: retention of a misfolded viral membrane glycoprotein involves cycling between the ER, intermediate compartment, and Golgi apparatus. J. Cell Biol. 126:41&#x2013;52 10.1083/jcb.126.1.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.126.1.41</ArticleId><ArticleId IdType="pmc">PMC2120101</ArticleId><ArticleId IdType="pubmed">8027184</ArticleId></ArticleIdList></Reference><Reference><Citation>Helenius A., Aebi M. 2001. Intracellular functions of N-linked glycans. Science. 291:2364&#x2013;2369 10.1126/science.291.5512.2364</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.291.5512.2364</ArticleId><ArticleId IdType="pubmed">11269317</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A., Van Gassen G., Bentahir M., Nyabi O., Craessaerts K., Mueller U., Annaert W., De Strooper B. 2003. gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J. Cell Sci. 116:1127&#x2013;1136 10.1242/jcs.00292</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00292</ArticleId><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiesinger P.R., Fayyazuddin A., Mehta S.Q., Rosenmund T., Schulze K.L., Zhai R.G., Verstreken P., Cao Y., Zhou Y., Kunz J., Bellen H.J. 2005. The v-ATPase V0 subunit a1 is required for a late step in synaptic vesicle exocytosis in Drosophila. Cell. 121:607&#x2013;620 10.1016/j.cell.2005.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.03.012</ArticleId><ArticleId IdType="pmc">PMC3351201</ArticleId><ArticleId IdType="pubmed">15907473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado-Lorenzo A., Skinner M., El Annan J., Futai M., Sun-Wada G.H., Bourgoin S., Casanova J., Wildeman A., Bechoua S., Ausiello D.A., et al. 2006. V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. Nat. Cell Biol. 8:124&#x2013;136 10.1038/ncb1348</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1348</ArticleId><ArticleId IdType="pubmed">16415858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahimi A., Vande Velde G., Reumers V., Toelen J., Thiry I., Vandeputte C., Vets S., Deroose C., Bormans G., Baekelandt V., et al. 2009. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum. Gene Ther. 20:845&#x2013;860 10.1089/hum.2008.188</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2008.188</ArticleId><ArticleId IdType="pubmed">19419274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.Y., Ingano L.A., Carey B.W., Pettingell W.H., Kovacs D.M. 2005a. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J. Biol. Chem. 280:23251&#x2013;23261 10.1074/jbc.M412938200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M412938200</ArticleId><ArticleId IdType="pubmed">15833746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Hamamoto S., Ravazzola M., Orci L., Schekman R. 2005b. Uncoupled packaging of amyloid precursor protein and presenilin 1 into coat protein complex II vesicles. J. Biol. Chem. 280:7758&#x2013;7768 10.1074/jbc.M411091200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M411091200</ArticleId><ArticleId IdType="pubmed">15623526</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Kleizen B., Choy R., Thinakaran G., Sisodia S.S., Schekman R.W. 2007. Biogenesis of gamma-secretase early in the secretory pathway. J. Cell Biol. 179:951&#x2013;963 10.1083/jcb.200709012</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200709012</ArticleId><ArticleId IdType="pmc">PMC2099203</ArticleId><ArticleId IdType="pubmed">18056412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.H., Yu W.H., Kumar A., Lee S., Mohan P.S., Peterhoff C.M., Wolfe D.M., Martinez-Vicente M., Massey A.C., Sovak G., et al. 2010. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 141:1146&#x2013;1158 10.1016/j.cell.2010.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.05.008</ArticleId><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Evans E., Morgan A.J., He X., Smith D.A., Elliot-Smith E., Sillence D.J., Churchill G.C., Schuchman E.H., Galione A., Platt F.M. 2008. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14:1247&#x2013;1255 10.1038/nm.1876</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1876</ArticleId><ArticleId IdType="pubmed">18953351</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzio J.P., Bright N.A., Pryor P.R. 2007. The role of calcium and other ions in sorting and delivery in the late endocytic pathway. Biochem. Soc. Trans. 35:1088&#x2013;1091 10.1042/BST0351088</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0351088</ArticleId><ArticleId IdType="pubmed">17956286</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely K.M., Green K.N., LaFerla F.M. 2011. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a &#x3b3;-secretase-independent manner. J. Neurosci. 31:2781&#x2013;2791 10.1523/JNEUROSCI.5156-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5156-10.2010</ArticleId><ArticleId IdType="pmc">PMC3064964</ArticleId><ArticleId IdType="pubmed">21414900</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi T., Forgac M. 2000. Molecular cloning and expression of three isoforms of the 100-kDa a subunit of the mouse vacuolar proton-translocating ATPase. J. Biol. Chem. 275:6824&#x2013;6830 10.1074/jbc.275.10.6824</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.10.6824</ArticleId><ArticleId IdType="pubmed">10702241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyabi O., Bentahir M., Horr&#xe9; K., Herreman A., Gottardi-Littell N., Van Broeckhoven C., Merchiers P., Spittaels K., Annaert W., De Strooper B. 2003. Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J. Biol. Chem. 278:43430&#x2013;43436 10.1074/jbc.M306957200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M306957200</ArticleId><ArticleId IdType="pubmed">12885769</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P., Klumperman J. 2009. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 10:623&#x2013;635 10.1038/nrm2745</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2745</ArticleId><ArticleId IdType="pubmed">19672277</ArticleId></ArticleIdList></Reference><Reference><Citation>Saw N.M., Kang S.Y., Parsaud L., Han G.A., Jiang T., Grzegorczyk K., Surkont M., Sun-Wada G.H., Wada Y., Li L., Sugita S. 2011. Vacuolar H(+)-ATPase subunits Voa1 and Voa2 cooperatively regulate secretory vesicle acidification, transmitter uptake, and storage. Mol. Biol. Cell. 22:3394&#x2013;3409 10.1091/mbc.E11-02-0155</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E11-02-0155</ArticleId><ArticleId IdType="pmc">PMC3172264</ArticleId><ArticleId IdType="pubmed">21795392</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D., Tolia A., Dillen K., Baert V., De Strooper B., Vrijens S., Annaert W. 2006. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J. Biol. Chem. 281:26569&#x2013;26577 10.1074/jbc.M600592200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600592200</ArticleId><ArticleId IdType="pubmed">16846981</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D., Raemaekers T., Dillen K., Declerck I., Baert V., Serneels L., F&#xfc;llekrug J., Annaert W. 2007. Rer1p competes with APH-1 for binding to nicastrin and regulates gamma-secretase complex assembly in the early secretory pathway. J. Cell Biol. 176:629&#x2013;640 10.1083/jcb.200609180</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200609180</ArticleId><ArticleId IdType="pmc">PMC2064021</ArticleId><ArticleId IdType="pubmed">17325205</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg B.E., Huynh K.K., Brodovitch A., Jabs S., Stauber T., Jentsch T.J., Grinstein S. 2010. A cation counterflux supports lysosomal acidification. J. Cell Biol. 189:1171&#x2013;1186 10.1083/jcb.200911083</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200911083</ArticleId><ArticleId IdType="pmc">PMC2894458</ArticleId><ArticleId IdType="pubmed">20566682</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimiri Govinda Raj D.B., Ghesqui&#xe8;re B., Tharkeshwar A.K., Coen K., Derua R., Vanderschaeghe D., Rysman E., Bagadi M., Baatsen P., De Strooper B., et al. 2011. A novel strategy for the comprehensive analysis of the biomolecular composition of isolated plasma membranes. Mol. Syst. Biol. 7:541 10.1038/msb.2011.74</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2011.74</ArticleId><ArticleId IdType="pmc">PMC3261717</ArticleId><ArticleId IdType="pubmed">22027552</ArticleId></ArticleIdList></Reference><Reference><Citation>Toei M., Saum R., Forgac M. 2010. Regulation and isoform function of the V-ATPases. Biochemistry. 49:4715&#x2013;4723 10.1021/bi100397s</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi100397s</ArticleId><ArticleId IdType="pmc">PMC2907102</ArticleId><ArticleId IdType="pubmed">20450191</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyomura T., Murata Y., Yamamoto A., Oka T., Sun-Wada G.H., Wada Y., Futai M. 2003. From lysosomes to the plasma membrane: localization of vacuolar-type H+ -ATPase with the a3 isoform during osteoclast differentiation. J. Biol. Chem. 278:22023&#x2013;22030 10.1074/jbc.M302436200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302436200</ArticleId><ArticleId IdType="pubmed">12672822</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub W.H., Machen T.E. 1989. pH regulation in hepatoma cells: roles for Na-H exchange, Cl-HCO3 exchange, and Na-HCO3 cotransport. Am. J. Physiol. 257:G317&#x2013;G327</Citation><ArticleIdList><ArticleId IdType="pubmed">2551179</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson W.R., Wang D., Haberman A.S., Hiesinger P.R. 2010. A dual function of V0-ATPase a1 provides an endolysosomal degradation mechanism in Drosophila melanogaster photoreceptors. J. Cell Biol. 189:885&#x2013;899 10.1083/jcb.201003062</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201003062</ArticleId><ArticleId IdType="pmc">PMC2878941</ArticleId><ArticleId IdType="pubmed">20513768</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson C.A., Murphy D.D., Giasson B.I., Zhang B., Trojanowski J.Q., Lee V.M. 2004. Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J. Cell Biol. 165:335&#x2013;346 10.1083/jcb.200403061</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200403061</ArticleId><ArticleId IdType="pmc">PMC2172178</ArticleId><ArticleId IdType="pubmed">15123735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22723704</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>25</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A role for presenilins in autophagy revisited: normal acidification of lysosomes in cells lacking PSEN1 and PSEN2.</ArticleTitle><Pagination><StartPage>8633</StartPage><EndPage>8648</EndPage><MedlinePgn>8633-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0556-12.2012</ELocationID><Abstract><AbstractText>Presenilins 1 and 2 (PS1 and PS2) are the catalytic subunits of the &#x3b3;-secretase complex, and genes encoding mutant PS1 and PS2 variants cause familial forms of Alzheimer's disease. Lee et al. (2010) recently reported that loss of PS1 activity lead to impairments in autophagosomal function as a consequence of lysosomal alkalinization, caused by failed maturation of the proton translocating V0a1 subunit of the vacuolar (H+)-ATPase and targeting to the lysosome. We have reexamined these issues in mammalian cells and in brains of mice lacking PS (PScdko) and have been unable to find evidence that the turnover of autophagic substrates, vesicle pH, V0a1 maturation, or lysosome function is altered compared with wild-type counterparts. Collectively, our studies fail to document a role for presenilins in regulating cellular autophagosomal function. On the other hand, our transcriptome studies of PScdko mouse brains reveal, for the first time, a role for PS in regulating lysosomal biogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xulun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Chicago, Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbett</LastName><ForeName>Krassimira</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Veeraraghavalu</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wilburn</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gilmore</LastName><ForeName>Reid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mirnics</LastName><ForeName>Karoly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG014248</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051778">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484068">Tcfeb protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.5</RegistryNumber><NameOfSubstance UI="D002402">Cathepsin D</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051778" MajorTopicYN="N">Basic Helix-Loop-Helix Leucine Zipper Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001755" MajorTopicYN="N">Blastocyst</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002402" MajorTopicYN="N">Cathepsin D</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025262" MajorTopicYN="N">Vacuolar Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22723704</ArticleId><ArticleId IdType="mid">NIHMS388036</ArticleId><ArticleId IdType="pmc">PMC3467018</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0556-12.2012</ArticleId><ArticleId IdType="pii">32/25/8633</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahn K, Shelton CC, Tian Y, Zhang X, Gilchrist ML, Sisodia SS, Li YM. Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci U S A. 2010;107:21435&#x2013;21440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003001</ArticleId><ArticleId IdType="pubmed">21115843</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Nakajima A, Choi SH, Xiong X, Sisodia SS, Tang YP. Adult neurogenesis is functionally associated with AD-like neurodegeneration. Neurobiol Dis. 2008;29:316&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2254142</ArticleId><ArticleId IdType="pubmed">17980611</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron. 2008;59:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Forni PE, Scuoppo C, Imayoshi I, Taulli R, Dastr &#xf9; W, Sala V, Betz UA, Muzzi P, Martinuzzi D, Vercelli AE, Kageyama R, Ponzetto C. High levels of Cre expression in neuronal progenitors cause defects in brain development leading to microencephaly and hydrocephaly. J Neurosci. 2006;26:9593&#x2013;9602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674592</ArticleId><ArticleId IdType="pubmed">16971543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S, Delorme N, Liu Z, Liu T, Velasco-Gonzalez C, Garai J, Pullikuth A, Koochekpour S. Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol Cancer. 2010;9:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825248</ArticleId><ArticleId IdType="pubmed">20132547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimura Y, Kominami E, Tanaka K, Komatsu M. Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy. 2008;4:1063&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">18776737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720&#x2013;5728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305793</ArticleId><ArticleId IdType="pubmed">11060023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Sisodia SS. Evidence that the &#x201c;NF&#x201d; motif in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2. J Biol Chem. 2005;280:41953&#x2013;41966.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234243</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Elazar Z, Seglen PO, Rubinsztein DC. Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy. 2008;4:849&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">18758232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, Levey AI. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci. 1997;17:1971&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793763</ArticleId><ArticleId IdType="pubmed">9045726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, Gandy SE, Seeger M, Koo E, Price DL, Sisodia SS. Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J Neurosci. 1996;16:7513&#x2013;7525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579112</ArticleId><ArticleId IdType="pubmed">8922407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med. 1997;3:756&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng XH, Nishi T, Forgac M. Transmembrane topography of the 100-kDa a subunit (Vph1p) of the yeast vacuolar proton-translocating ATPase. J Biol Chem. 1999;274:14655&#x2013;14661.</Citation><ArticleIdList><ArticleId IdType="pubmed">10329659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Norstrom EM, Garbett K, Choi SH, Zhang X, Ebert P, Sisodia SS. Molecular signatures of neurodegeneration in the cortex of PS1/PS2 double knockout mice. Mol Neurodegener. 2008;3:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569036</ArticleId><ArticleId IdType="pubmed">18834536</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">17611390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140:313&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852113</ArticleId><ArticleId IdType="pubmed">20144757</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868096</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely KM, Green KN, LaFerla FM. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a gamma-secretase-independent manner. J Neurosci. 2011;31:2781&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064964</ArticleId><ArticleId IdType="pubmed">21414900</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi T, Forgac M. Molecular cloning and expression of three isoforms of the 100-kDa a subunit of the mouse vacuolar proton-translocating ATPase. J Biol Chem. 2000;275:6824&#x2013;6830.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702241</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Citron M, Amarante P, Sherrington R, Xia W, Zhang J, Diehl T, Levesque G, Fraser P, Haass C, Koo EH, Seubert P, St George-Hyslop P, Teplow DB, Selkoe DJ. Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol Dis. 1997;3:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173929</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokop S, Shirotani K, Edbauer D, Haass C, Steiner H. Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex. J Biol Chem. 2004;279:23255&#x2013;23261.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratovitski T, Slunt HH, Thinakaran G, Price DL, Sisodia SS, Borchelt DR. Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J Biol Chem. 1997;272:24536&#x2013;24541.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Cuervo AM, Ravikumar B, Sarkar S, Korolchuk V, Kaushik S, Klionsky DJ. In search of an &#x201c;autophagomometer.&#x201d;. Autophagy. 2009;5:585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">19411822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Canada C, Kelleher DJ, Gilmore R. Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. Cell. 2009;136:272&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859625</ArticleId><ArticleId IdType="pubmed">19167329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S, Parenti G, Cattaneo E, Ballabio A. A gene network regulating lysosomal biogenesis and function. Science. 2009;325:473&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, III, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Semprini S, Troup TJ, Kotelevtseva N, King K, Davis JR, Mullins LJ, Chapman KE, Dunbar DR, Mullins JJ. Cryptic loxP sites in mammalian genomes: genome-wide distribution and relevance for the efficiency of BAC/PAC recombineering techniques. Nucleic Acids Res. 2007;35:1402&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865043</ArticleId><ArticleId IdType="pubmed">17284462</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, Sardiello M, Rubinsztein DC, Ballabio A. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332:1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638014</ArticleId><ArticleId IdType="pubmed">21617040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705980</ArticleId><ArticleId IdType="pubmed">15528435</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Kirisako T, Kamada Y, Mizushima N, Noda T, Ohsumi Y. The pre-autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formation. EMBO J. 2001;20:5971&#x2013;5981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125692</ArticleId><ArticleId IdType="pubmed">11689437</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 2005;1:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874052</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, Borchelt DR, Sisodia SS. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem. 1997;272:28415&#x2013;28422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyagarajan B, Guimar&#xe3;es MJ, Groth AC, Calos MP. Mammalian genomes contain active recombinase recognition sites. Gene. 2000;244:47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10689186</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen WL, Klionsky DJ. Atg27 is a second transmembrane cycling protein. Autophagy. 2007;3:254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi N, Maurer A, Nieke S, Kalbacher H. Cathepsin D: a cellular roadmap. Biochem Biophys Res Commun. 2008;376:5&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18762174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol. 2000;2:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22699914</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>24</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice.</ArticleTitle><Pagination><StartPage>8341</StartPage><EndPage>8353</EndPage><MedlinePgn>8341-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0936-12.2012</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD)-linked presenilin (PS) mutations result in pronounced endoplasmic reticulum calcium disruptions that occur before detectable histopathology and cognitive deficits. More subtly, these early AD-linked calcium alterations also reset neurophysiological homeostasis, such that calcium-dependent presynaptic and postsynaptic signaling appear functionally normal yet are actually operating under aberrant calcium signaling systems. In these 3xTg-AD mouse brains, upregulated ryanodine receptor (RyR) activity is associated with a shift toward synaptic depression, likely through a reduction in presynaptic vesicle stores and increased postsynaptic outward currents through small-conductance calcium-activated potassium SK2 channels. The deviant RyR-calcium involvement in the 3xTg-AD mice also compensates for an intrinsic predisposition for hippocampal long-term depression (LTD) and reduced long-term potentiation (LTP). In this study, we detail the impact of disrupted RyR-mediated calcium stores on synaptic transmission properties, LTD, and calcium-activated membrane channels of hippocampal CA1 pyramidal neurons in presymptomatic 3xTg-AD mice. Using electrophysiological recordings in young 3xTg-AD and nontransgenic (NonTg) hippocampal slices, we show that increased RyR-evoked calcium release in 3xTg-AD mice "normalizes" an altered synaptic transmission system operating under a shifted homeostatic state that is not present in NonTg mice. In the process, we uncover compensatory signaling mechanisms recruited early in the disease process that counterbalance the disrupted RyR-calcium dynamics, namely increases in presynaptic spontaneous vesicle release, altered probability of vesicle release, and upregulated postsynaptic SK channel activity. Because AD is increasingly recognized as a "synaptic disease," calcium-mediated signaling alterations may serve as a proximal trigger for the synaptic degradation driving the cognitive loss in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chakroborty</LastName><ForeName>Shreaya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Rosalind Franklin University/The Chicago Medical School, North Chicago, Illinois 60064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joyce</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Corinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Molg&#xf3;</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stutzmann</LastName><ForeName>Grace E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG030205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG055497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053496">Inositol 1,4,5-Trisphosphate Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051640">Small-Conductance Calcium-Activated Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053496" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate Receptors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="N">Long-Term Synaptic Depression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051640" MajorTopicYN="N">Small-Conductance Calcium-Activated Potassium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22699914</ArticleId><ArticleId IdType="mid">NIHMS385655</ArticleId><ArticleId IdType="pmc">PMC3417348</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0936-12.2012</ArticleId><ArticleId IdType="pii">32/24/8341</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alford S, Frenguelli BG, Schofield JG, Collingridge GL. Characterization of Ca2+ signals induced in hippocampal CA1 neurons by the synaptic activation of NMDA receptors. J Physiol. 1993;469:693&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1143895</ArticleId><ArticleId IdType="pubmed">8271224</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen D, Bond CT, Luj&#xe1;n R, Ballesteros-Merino C, Lin MT, Wang K, Klett N, Watanabe M, Shigemoto R, Stackman RW, Jr, Maylie J, Adelman JP. The SK2-long isoform directs synaptic localization and function of SK2-containing channels. Nat Neurosci. 2011;14:744&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417338</ArticleId><ArticleId IdType="pubmed">21602822</ArticleId></ArticleIdList></Reference><Reference><Citation>Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, Mariani J, Rovira C. Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. J Neurosci. 2009;29:10144&#x2013;10152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664983</ArticleId><ArticleId IdType="pubmed">19675248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardo S, Robertson B, Stephens GJ. Presynaptic internal Ca2+ stores contribute to inhibitory neurotransmitter release onto mouse cerebellar Purkinje cells. Br J Pharmacol. 2002;137:529&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1573523</ArticleId><ArticleId IdType="pubmed">12359635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bear MF. Mechanism for a sliding synaptic modification threshold. Neuron. 1995;15:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7619513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: LTP in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond CT, Maylie J, Adelman JP. Small-conductance calcium-activated potassium channels. Ann N Y Acad Sci. 1999;868:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">10414306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard R, Pattarini R, Geiger JD. Presence and functional significance of presynaptic ryanodine receptors. Prog Neurobiol. 2003;69:391&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">12880633</ArticleId></ArticleIdList></Reference><Reference><Citation>Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasov&#xe1; E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell. 1994;77:513&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">7514503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno AM, Huang JY, Bennett DA, Marr RA, Hastings ML, Stutzmann GE. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2011;33:1001.e1&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160507</ArticleId><ArticleId IdType="pubmed">21531043</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter AG, Regehr WG. Quantal events shape cerebellar interneuron firing. Nat Neurosci. 2002;5:1309&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavelier P, Attwell D. Tonic release of glutamate by a DIDS-sensitive mechanism in rat hippocampal slices. J Physiol. 2005;564:397&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464434</ArticleId><ArticleId IdType="pubmed">15695241</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Goussakov I, Miller MB, Stutzmann GE. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci. 2009;29:9458&#x2013;9470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666542</ArticleId><ArticleId IdType="pubmed">19641109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Shineman D, M&#xfc;ller M, C&#xe1;rdenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58:871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="pubmed">18579078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong SA, Benilova I, Shaban H, De Strooper B, Devijver H, Moechars D, Eberle W, Bartic C, Van Leuven F, Callewaert G. Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study. Neurobiol Dis. 2011;44:284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">21807097</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayan P, Willshaw DJ. Optimizing synaptic learning rules in linear associative memories. Biol Cybern. 1991;65:253&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">1932282</ArticleId></ArticleIdList></Reference><Reference><Citation>De&#xe1;k F, Shin OH, Kavalali ET, S&#xfc;dhof TC. Structural determinants of synaptobrevin 2 function in synaptic vesicle fusion. J Neurosci. 2006;26:6668&#x2013;6676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673840</ArticleId><ArticleId IdType="pubmed">16793874</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Ris L, Croes S, Borghgraef P, Devijver H, Voets T, Nilius B, Godaux E, Van Leuven F. Modulation of synaptic plasticity and Tau phosphorylation by wild-type and mutant presenilin1. Neurobiol Aging. 2008;29:639&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222948</ArticleId></ArticleIdList></Reference><Reference><Citation>Emptage N, Bliss TV, Fine A. Single synaptic events evoke NMDA receptor-mediated release of calcium from internal stores in hippocampal dendritic spines. Neuron. 1999;22:115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027294</ArticleId></ArticleIdList></Reference><Reference><Citation>Emptage NJ, Reid CA, Fine A. Calcium stores in hippocampal synaptic boutons mediate short-term plasticity, store-operated Ca2+ entry, and spontaneous transmitter release. Neuron. 2001;29:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182091</ArticleId></ArticleIdList></Reference><Reference><Citation>Enoki R, Hu YL, Hamilton D, Fine A. Expression of long-term plasticity at individual synapses in hippocampus is graded, bidirectional, and mainly presynaptic: optical quantal analysis. Neuron. 2009;62:242&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">19409269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioravante D, Regehr WG. Short-term forms of presynaptic plasticity. Curr Opin Neurobiol. 2011;21:269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3599780</ArticleId><ArticleId IdType="pubmed">21353526</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzjohn SM, Collingridge GL. Calcium stores and synaptic plasticity. Cell Calcium. 2002;32:405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543099</ArticleId></ArticleIdList></Reference><Reference><Citation>Foskett JK. Inositol trisphosphate receptor Ca2+ release channels in neurological diseases. Pflugers Arch. 2010;460:481&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893360</ArticleId><ArticleId IdType="pubmed">20383523</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Kourrich S, Soumireu-Mourat B, Mourre C. Apamin improves reference memory but not procedural memory in rats by blocking small conductance Ca2+-activated K+ channels in an olfactory discrimination task. Behav Brain Res. 2001;121:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11275286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii S, Matsumoto M, Igarashi K, Kato H, Mikoshiba K. Synaptic plasticity in hippocampal CA1 neurons of mice lacking type 1 inositol-1,4,5-triphosphate receptors. Learn Mem. 2000;7:312&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311349</ArticleId><ArticleId IdType="pubmed">11040263</ArticleId></ArticleIdList></Reference><Reference><Citation>Goussakov I, Miller MB, Stutzmann GE. NMDA-mediated Ca2+ influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. J Neurosci. 2010;30:12128&#x2013;12137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944253</ArticleId><ArticleId IdType="pubmed">20826675</ArticleId></ArticleIdList></Reference><Reference><Citation>Goussakov I, Chakroborty S, Stutzmann GE. Generation of dendritic Ca2+ oscillations as a consequence of altered ryanodine receptor function in AD neurons. Channels (Austin) 2011;5:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21139422</ArticleId></ArticleIdList></Reference><Reference><Citation>Groffen AJ, Martens S, D&#xed;ez Arazola R, Cornelisse LN, Lozovaya N, de Jong AP, Goriounova NA, Habets RL, Takai Y, Borst JG, Brose N, McMahon HT, Verhage M. Doc2b is a high affinity Ca2+ sensor for spontaneous neurotransmitter release. Science. 2010;327:1614&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846320</ArticleId><ArticleId IdType="pubmed">20150444</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol. 2004;165:1809&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618663</ArticleId><ArticleId IdType="pubmed">15509549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond RS, Bond CT, Strassmaier T, Ngo-Anh TJ, Adelman JP, Maylie J, Stackman RW. Small-conductance Ca2+-activated K+ channel type 2 (SK2) modulates hippocampal learning, memory, and synaptic plasticity. J Neurosci. 2006;26:1844&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793641</ArticleId><ArticleId IdType="pubmed">16467533</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey J, Collingridge GL. Signal transduction pathways involved in the acute potentiation of NMDA responses by 1S, 3R-ACPD in rat hippocampal slices. Br J Pharmacol. 1993;109:1085&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175740</ArticleId><ArticleId IdType="pubmed">8401919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschberg B, Maylie J, Adelman JP, Marrion NV. Gating properties of single SK channels in hippocampal CA1 pyramidal neurons. Biophys J. 1999;77:1905&#x2013;1913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1300472</ArticleId><ArticleId IdType="pubmed">10512811</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber KM, Roder JC, Bear MF. Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J Neurophysiol. 2001;86:321&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11431513</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaimovich E, Mattei C, Liberona JL, Cardenas C, Estrada M, Barbier J, Debitus C, Laurent D, Molg&#xf3; J. Xestospongin B, a competitive inhibitor of IP3-mediated Ca2+ signaling in cultured rat myotubes, isolated myonuclei, and neuroblastoma (NG108&#x2013;15) cells. FEBS Lett. 2005;579:2051&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">15811317</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, George-Hyslop PS, Tohyama M. Disturbed activation of endoplasmic reticulum stress transducers by Familial Alzheimer's disease-linked presenilin-1 mutations. J Biol Chem. 2001;276:43446&#x2013;43454.</Citation><ArticleIdList><ArticleId IdType="pubmed">11551913</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz B. The release of neural transmitter substances. Vol 10. Liverpool, UK: Liverpool UP; 1969.</Citation></Reference><Reference><Citation>Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O'Neill C. Alterations in ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience. 1999;92:499&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp A, Manahan-Vaughan D. Hippocampal long term depression and long term potentiation encode different aspects of novelty acquisition. Proc Natl Acad Sci U S A. 2004;101:8192&#x2013;8197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419579</ArticleId><ArticleId IdType="pubmed">15150407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuromi H, Kidokoro Y. Selective replenishment of two vesicle pools depends on the source of Ca2+ at the Drosophila synapse. Neuron. 2002;35:333&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160750</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Llano I, Gonz&#xe1;lez J, Caputo C, Lai FA, Blayney LM, Tan YP, Marty A. Presynaptic calcium stores underlie large-amplitude miniature IPSCs and spontaneous calcium transients. Nat Neurosci. 2000;3:1256&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100146</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin SJ, Grimwood PD, Morris RG. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci. 2000;23:649&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. ER calcium and Alzheimer's disease: in a state of flux. Sci Signal. 2010;3:pe10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091478</ArticleId><ArticleId IdType="pubmed">20332425</ArticleId></ArticleIdList></Reference><Reference><Citation>Maximov A, Shin OH, Liu X, S&#xfc;dhof TC. Synaptotagmin-12, a synaptic vesicle phosphoprotein that modulates spontaneous neurotransmitter release. J Cell Biol. 2007;176:113&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063632</ArticleId><ArticleId IdType="pubmed">17190793</ArticleId></ArticleIdList></Reference><Reference><Citation>McCutcheon JE, Loweth JA, Ford KA, Marinelli M, Wolf ME, Tseng KY. Group I mGluR activation reverses cocaine-induced accumulation of calcium-permeable AMPA receptors in nucleus accumbens synapses via a protein kinase C-dependent mechanism. J Neurosci. 2011;31:14536&#x2013;14541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220940</ArticleId><ArticleId IdType="pubmed">21994370</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney RA, Capogna M, D&#xfc;rr R, G&#xe4;hwiler BH, Thompson SM. Miniature synaptic events maintain dendritic spines via AMPA receptor activation. Nat Neurosci. 1999;2:44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Malenka RC. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron. 1992;9:967&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">1419003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, C&#xe1;rdenas C, Mei L, Cheung KH, Foskett JK. Constitutive cAMP response element binding protein (CREB) activation by Alzheimer's disease presenilin-driven inositol trisphosphate receptor (InsP3R) Ca2+ signaling. Proc Natl Acad Sci U S A. 2011;108:13293&#x2013;13298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156223</ArticleId><ArticleId IdType="pubmed">21784978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbantoglu J, Tirado-Santiago G, Lahsa&#xef;ni A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 1997;387:500&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama M, Hong K, Mikoshiba K, Poo MM, Kato K. Calcium stores regulate the polarity and input specificity of synaptic modification. Nature. 2000;408:584&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosyreva E, Kavalali ET. Activity-dependent augmentation of spontaneous neurotransmission during endoplasmic reticulum stress. J Neurosci. 2010;30:7358&#x2013;7368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892630</ArticleId><ArticleId IdType="pubmed">20505103</ArticleId></ArticleIdList></Reference><Reference><Citation>Obenaus A, Mody I, Baimbridge KG. Dantrolene-Na (Dantrium) blocks induction of long-term potentiation in hippocampal slices. Neurosci Lett. 1989;98:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">2710411</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliet SH, Malenka RC, Nicoll RA. Bidirectional control of quantal size by synaptic activity in the hippocampus. Science. 1996;271:1294&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">8638114</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliet SH, Malenka RC, Nicoll RA. Two distinct forms of long-term depression coexist in CA1 hippocampal pyramidal cells. Neuron. 1997;18:969&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">9208864</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozawa T. Effects of FK506 on Ca2+ release channels. Perspect Medicin Chem. 2008;2:51&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746578</ArticleId><ArticleId IdType="pubmed">19787097</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer MJ, Irving AJ, Seabrook GR, Jane DE, Collingridge GL. The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology. 1997;36:1517&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pubmed">9517422</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent A, Linden DJ, Sisodia SS, Borchelt DR. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol Dis. 1999;6:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078973</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda JC, Galarraga E, Foehring RC. Different Ca2+ source for slow AHP in completely adapting and repetitive firing pyramidal neurons. Neuroreport. 1999;10:1951&#x2013;1956.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501539</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt KG, Zimmerman EC, Cook DG, Sullivan JM. Presenilin 1 regulates homeostatic synaptic scaling through Akt signaling. Nat Neurosci. 2011;14:1112&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164917</ArticleId><ArticleId IdType="pubmed">21841774</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz-Baez R, Ferrera P, Rosendo-Guti&#xe9;rrez R, Mor&#xe1;n J, Berm&#xfa;dez-Rattoni F, Arias C. Caspase-12 activation is involved in amyloid-&#x3b2; protein-induced synaptic toxicity. J Alzheimers Dis. 2011;26:467&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">21694457</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond CR, Redman SJ. Spatial segregation of neuronal calcium signals encodes different forms of LTP in rat hippocampus. J Physiol. 2006;570:97&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464297</ArticleId><ArticleId IdType="pubmed">16284072</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes M, Stanton PK. Induction of hippocampal long-term depression requires release of Ca2+ from separate presynaptic and postsynaptic intracellular stores. J Neurosci. 1996;16:5951&#x2013;5960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579182</ArticleId><ArticleId IdType="pubmed">8815877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross WN, Nakamura T, Watanabe S, Larkum M, Lasser-Ross N. Synaptically activated Ca2+ release from internal stores in CNS neurons. Cell Mol Neurobiol. 2005;25:283&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11529495</ArticleId><ArticleId IdType="pubmed">16047542</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybalchenko V, Hwang SY, Rybalchenko N, Koulen P. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol. 2008;40:84&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P. Ca2+-activated K+ currents in neurons: types, physiological roles and modulation. Trends Neurosci. 1996;19:150&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">8658599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P, Bekkers JM. Apical dendritic location of slow afterhyperpolarization current in hippocampal pyramidal neurons: implications for the integration of long-term potentiation. J Neurosci. 1996;16:4537&#x2013;4542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579026</ArticleId><ArticleId IdType="pubmed">8764642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P, Davies P. Calcium-activated potassium currents in mammalian neurons. Clin Exp Pharmacol Physiol. 2000;27:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">10972528</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J Neuroinflammation. 2009;6:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806266</ArticleId><ArticleId IdType="pubmed">20035627</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapansky J, Olson K, Van Der Ploeg R, Glazner G. NF-kappa B activated by ER calcium release inhibits Abeta-mediated expression of CHOP protein: enhancement by AD-linked mutant presenilin 1. Exp Neurol. 2007;208:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927985</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging. 2003;24:1029&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneggenburger R, Sakaba T, Neher E. Vesicle pools and short-term synaptic depression: lessons from a large synapse. Trends Neurosci. 2002;25:206&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11998689</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Haylett DG. Ca2+ channels involved in the generation of the slow afterhyperpolarization in cultured rat hippocampal pyramidal neurons. J Neurophysiol. 2000;83:2554&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805657</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem. 2005;94:1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16156741</ArticleId></ArticleIdList></Reference><Reference><Citation>Stackman RW, Hammond RS, Linardatos E, Gerlach A, Maylie J, Adelman JP, Tzounopoulos T. Small conductance Ca2+-activated K+ channels modulate synaptic plasticity and memory encoding. J Neurosci. 2002;22:10163&#x2013;10171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758766</ArticleId><ArticleId IdType="pubmed">12451117</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton PK, Winterer J, Bailey CP, Kyrozis A, Raginov I, Laube G, Veh RW, Nguyen CQ, M&#xfc;ller W. Long-term depression of presynaptic release from the readily releasable vesicle pool induced by NMDA receptor-dependent retrograde nitric oxide. J Neurosci. 2003;23:5936&#x2013;5944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741233</ArticleId><ArticleId IdType="pubmed">12843298</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker M, Krause M, Pedarzani P. An apamin-sensitive Ca2+-activated K+ current in hippocampal pyramidal neurons. Proc Natl Acad Sci U S A. 1999;96:4662&#x2013;4667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16389</ArticleId><ArticleId IdType="pubmed">10200319</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE. The pathogenesis of Alzheimer's disease is it a lifelong &#x201c;calciumopathy&#x201d;? Neuroscientist. 2007;13:546&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">17901262</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Mattson MP. Endoplasmic reticulum Ca2+ handling in excitable cells in health and disease. Pharmacol Rev. 2011;63:700&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3141879</ArticleId><ArticleId IdType="pubmed">21737534</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, LaFerla FM, Parker I. Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci. 2003;23:758&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741910</ArticleId><ArticleId IdType="pubmed">12574404</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, LaFerla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006;26:5180&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, Laferla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci. 2007;1097:265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413028</ArticleId></ArticleIdList></Reference><Reference><Citation>Supnet C, Noonan C, Richard K, Bradley J, Mayne M. Up-regulation of the type 3 ryanodine receptor in neuroprotective in the TgCRND8 mouse model of Alzheimer's disease. J Neurochem. 2010;112:356&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">19903243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton MA, Wall NR, Aakalu GN, Schuman EM. Regulation of dendritic protein synthesis by miniature synaptic events. Science. 2004;304:1979&#x2013;1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">15218151</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami K, Terai K, Matsuo A, Walker DG, McGeer PL. Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer's disease brains. Brain Res. 1997;748:122&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">9067452</ArticleId></ArticleIdList></Reference><Reference><Citation>Taufiq AM, Fujii S, Yamazaki Y, Sasaki H, Kaneko K, Li J, Kato H, Mikoshiba K. Involvement of IP3 receptors in LTP and LTD induction in guinea pig hippocampal CA1 neurons. Learn Mem. 2005;12:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356177</ArticleId><ArticleId IdType="pubmed">16287718</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Vrede Y, Fossier P, Baux G, Joels M, Chameau P. Control of IsAHP in mouse hippocampus CA1 pyramidal neurons by RyR3-mediated calcium-induced calcium release. Pflugers Arch. 2007;455:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562071</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhage M, Maia AS, Plomp JJ, Brussaard AB, Heeroma JH, Vermeer H, Toonen RF, Hammer RE, van den Berg TK, Missler M, Geuze HJ, S&#xfc;dhof TC. Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science. 2000;287:864&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">10657302</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A. The endoplasmic reticulum and neuronal calcium signaling. Cell Calcium. 2002;32:393&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543098</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker M, Chan D, Thom M. Hippocampus and human disease. In: Andersen P, Morris R, Amaral D, Bliss T, O'Keefe J, editors. The hippocampus book. Oxford: Oxford UP; 2007. pp. 769&#x2013;812.</Citation></Reference><Reference><Citation>Wasser CR, Kavalali ET. Leaky synapses: regulation of spontaneous neurotransmission in central synapses. Neuroscience. 2009;158:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662333</ArticleId><ArticleId IdType="pubmed">18434032</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Hong M, Lasser-Ross N, Ross WN. Modulation of calcium wave propagation in the dendrites and to the soma of rat hippocampal pyramidal neurons. J Physiol. 2006;575:455&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1819440</ArticleId><ArticleId IdType="pubmed">16809362</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao RP, Valdivia HH, Bogdanov K, Valdivia C, Lakatta EG, Cheng H. The immunophilin FK506-binding protein modulates Ca2+ release channel closure in rat heart. J Physiol. 1997;500:343&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1159388</ArticleId><ArticleId IdType="pubmed">9147322</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Pang ZP, Shin OH, S&#xfc;dhof TC. Synaptotagmin-1 functions as a Ca2+ sensor for spontaneous release. Nat Neurosci. 2009;12:759&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739891</ArticleId><ArticleId IdType="pubmed">19412166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, S&#xfc;dhof TC, Shen J. Presenilins are essential for regulating neurotransmitter release. Nature. 2009;460:632&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744588</ArticleId><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu Rev Physiol. 2002;64:355&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22751036</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities.</ArticleTitle><Pagination><StartPage>1111</StartPage><EndPage>1113</EndPage><MedlinePgn>1111-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3151</ELocationID><Abstract><AbstractText>Cognitive abilities decline in normal aging, yet the underlying molecular mechanisms are poorly understood. We found that aging was associated with a decrease in the expression of the DNA methyltransferase Dnmt3a2 in the hippocampus and that rescuing Dnmt3a2 levels restored cognitive functions. Moreover, we found that Dnmt3a2 is an activity-regulated immediate early gene that is partly dependent on nuclear calcium signaling and that hippocampal Dnmt3a2 levels determine cognitive abilities in both young adult and aged mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Ana M M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Interdisciplinary Centre for Neurosciences, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemstedt</LastName><ForeName>Thekla J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Bading</LastName><ForeName>Hilmar</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.1.1.37</RegistryNumber><NameOfSubstance UI="D004248">DNA (Cytosine-5-)-Methyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.37</RegistryNumber><NameOfSubstance UI="D000090205">DNA Methyltransferase 3A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Epigenomics. 2012 Dec;4(6):601-3. doi: 10.2217/epi.12.57.</RefSource><PMID Version="1">23244306</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004248" MajorTopicYN="N">DNA (Cytosine-5-)-Methyltransferases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090205" MajorTopicYN="N">DNA Methyltransferase 3A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="N">Memory, Long-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22751036</ArticleId><ArticleId IdType="doi">10.1038/nn.3151</ArticleId><ArticleId IdType="pii">nn.3151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 2002 Oct 11;277(41):38746-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12138111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologia. 1973;19(3):138-52</Citation><ArticleIdList><ArticleId IdType="pubmed">4763637</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biochem Sci. 2006 Feb;31(2):89-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16403636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1987 Jul 25;262(21):9948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">3611071</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2001 Jun 1;498(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11389887</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Mar 15;53(6):857-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17359920</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2003 Jan-Feb;38(1-2):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12543262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2008 Jun;9(6):465-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18463664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hum Genet. 2004 May;68(Pt 3):196-204</Citation><ArticleIdList><ArticleId IdType="pubmed">15180700</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(5):e19958</Citation><ArticleIdList><ArticleId IdType="pubmed">21625500</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 May 30;320(5880):1224-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18511691</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2011 Aug 28;14(10):1345-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21874013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Jan 16;385(6613):260-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9000075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2011 Apr;31(7):1577-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21262766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2005 Feb;28(2):347-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15691715</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1991 Aug 23;253(5022):912-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1715095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2010 Apr;13(4):423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20228804</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2009 Aug;5(8):e1000604</Citation><ArticleIdList><ArticleId IdType="pubmed">19680447</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anat. 1953 Oct;87(4):387-406</Citation><ArticleIdList><ArticleId IdType="pubmed">13117757</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22723713</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>25</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Gene network effects on brain microstructure and intellectual performance identified in 472 twins.</ArticleTitle><Pagination><StartPage>8732</StartPage><EndPage>8745</EndPage><MedlinePgn>8732-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5993-11.2012</ELocationID><Abstract><AbstractText>A major challenge in neuroscience is finding which genes affect brain integrity, connectivity, and intellectual function. Discovering influential genes holds vast promise for neuroscience, but typical genome-wide searches assess approximately one million genetic variants one-by-one, leading to intractable false positive rates, even with vast samples of subjects. Even more intractable is the question of which genes interact and how they work together to affect brain connectivity. Here, we report a novel approach that discovers which genes contribute to brain wiring and fiber integrity at all pairs of points in a brain scan. We studied genetic correlations between thousands of points in human brain images from 472 twins and their nontwin siblings (mean age: 23.7 &#xb1; 2.1 SD years; 193 male/279 female). We combined clustering with genome-wide scanning to find brain systems with common genetic determination. We then filtered the image in a new way to boost power to find causal genes. Using network analysis, we found a network of genes that affect brain wiring in healthy young adults. Our new strategy makes it computationally more tractable to discover genes that affect brain integrity. The gene network showed small-world and scale-free topologies, suggesting efficiency in genetic interactions and resilience to network disruption. Genetic variants at hubs of the network influence intellectual performance by modulating associations between performance intelligence quotient and the integrity of major white matter tracts, such as the callosal genu and splenium, cingulum, optic radiations, and the superior longitudinal fasciculus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Ming-Chang</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, National Yang-Ming University, Taipei, 112, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barysheva</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Katie L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>de Zubicaray</LastName><ForeName>Greig I</ForeName><Initials>GI</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kori</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Grant W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Nicholas G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Margaret J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Shapshak</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 EB001561</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB01651</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008432</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014429" MajorTopicYN="N">Twins, Dizygotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22723713</ArticleId><ArticleId IdType="mid">NIHMS388054</ArticleId><ArticleId IdType="pmc">PMC3420968</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5993-11.2012</ArticleId><ArticleId IdType="pii">32/25/8732</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. Am J Hum Genet. 2000;66:279&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288332</ArticleId><ArticleId IdType="pubmed">10631157</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000;406:378&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10935628</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander DC, Pierpaoli C, Basser PJ, Gee JC. Spatial transformations of diffusion tensor magnetic resonance. IEEE Trans Med Imaging. 2001;20:1131&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700739</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsigny V, Fillard P, Pennec X, Ayache N. Fast and simple calculus on tensors in the log-Euclidean framework. Med Image Comput Assist Interv. 2005;8:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">16685836</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabasi AL, Albert R. Emergence of scaling in random networks. Science. 1999;286:509&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521342</ArticleId></ArticleIdList></Reference><Reference><Citation>Barab&#xe1;si AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet. 2004;5:101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735121</ArticleId></ArticleIdList></Reference><Reference><Citation>Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">8661285</ArticleId></ArticleIdList></Reference><Reference><Citation>Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J. 1994;66:259&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275686</ArticleId><ArticleId IdType="pubmed">8130344</ArticleId></ArticleIdList></Reference><Reference><Citation>Batagelj V, Mrvar A. Pajek&#x2014;program for large network analysis. Connections. 1998;21:47&#x2013;57.</Citation></Reference><Reference><Citation>Becker T, Herold C, Meesters C, Mattheisen M, Baur MP. Significance levels in genome-wide interaction analysis (GWIA) Ann Hum Genet. 2011;75:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">20950400</ArticleId></ArticleIdList></Reference><Reference><Citation>Begr&#xe9; S, Frommer A, von K&#xe4;nel R, Kiefer C, Federspiel A. Relation of white matter anisotropy to visual memory in 17 healthy subjects. Brain Res. 2007;1168:60&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707351</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Braskie MN, Jahanshad N, Stein JL, Barysheva M, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Ringman JM, Toga AW, Thompson PM. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci. 2011;31:6764&#x2013;6770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176803</ArticleId><ArticleId IdType="pubmed">21543606</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">19190637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10827444</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson MR, Zhang B, Fang Z, Mischel PS, Horvath S, Nelson SF. Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. BMC Genomics. 2006;7:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413526</ArticleId><ArticleId IdType="pubmed">16515682</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Gutierrez ED, Thompson W, Panizzon MS, Jernigan TL, Eyler LT, Fennema-Notestine C, Jak AJ, Neale MC, Franz CE, Lyons MJ, Grant MD, Fischl B, Seidman LJ, Tsuang MT, Kremen WS, Dale AM. Hierarchical genetic organization of human cortical surface area. Science. 2012;335:1634&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690329</ArticleId><ArticleId IdType="pubmed">22461613</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Dutton RA, Hayashi KM, Lopez OL, Aizenstein HJ, Toga AW, Becker JT, Thompson PM. 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage. 2007;34:44&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197835</ArticleId><ArticleId IdType="pubmed">17035049</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Avedissian C, Barysheva M, Toga AW, McMahon KL, de Zubicaray GI, Wright MJ, Thompson PM. Extending genetic linkage analysis to diffusion tensor images to map single gene effects on brain fiber architecture. Med Image Comput Comput Assist Interv. 2009a;12:506&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">20426150</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Barysheva M, Shattuck DW, Lee AD, Madsen SK, Avedissian C, Klunder AD, Toga AW, McMahon KL, de Zubicaray GI, Wright MJ, Srivastava A, Balov N, Thompson PM. Genetics of brain fiber architecture and intellectual performance. J Neurosci. 2009b;29:2212&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773128</ArticleId><ArticleId IdType="pubmed">19228974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Barysheva M, Toga AW, Medland SE, Hansell NK, James MR, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Thompson PM. BDNF gene effects on brain circuitry replicated in 455 twins. Neuroimage. 2011;55:448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192852</ArticleId><ArticleId IdType="pubmed">21195196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumbley JR, Friston KJ. False discovery rate revisited: FDR and topological inference using Gaussian random fields. Neuroimage. 2009;44:62&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18603449</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen R, Havlin S. Scale-free networks are ultrasmall. Phys Rev Lett. 2003;90 058701.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633404</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies G, Tenesa A, Payton A, Yang J, Harris SE, Liewald D, Ke X, Le Hellard S, Christoforou A, Luciano M, McGhee K, Lopez L, Gow AJ, Corley J, Redmond P, Fox HC, Haggarty P, Whalley LJ, McNeill G, Goddard ME, et al. Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol Psychiatry. 2011;16:996&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182557</ArticleId><ArticleId IdType="pubmed">21826061</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVito LM, Konigsberg R, Lykken C, Sauvage M, Young WS, 3rd, Eichenbaum H. Vasopressin 1b receptor knock-out impairs memory for temporal order. J Neurosci. 2009;29:2676&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671073</ArticleId><ArticleId IdType="pubmed">19261862</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zubicaray G, Chiang MC, McMahon KL, Shattuck DW, Toga AW, Martin NG, Wright MJ, Thompson PM. Meeting the challenges of neuroimaging genetics. Brain Imaging Behav. 2008;2:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794202</ArticleId><ArticleId IdType="pubmed">20016769</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan D, Prodduturi N, Zhang B. WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. BMC Bioinformatics. 2010;11(Suppl 4):10.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Egu&#xed;luz VM, Chialvo DR, Cecchi GA, Baliki M, Apkarian AV. Scale-free brain functional networks. Phys Rev Lett. 2005;94 018102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15698136</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863&#x2013;14868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24541</ArticleId><ArticleId IdType="pubmed">9843981</ArticleId></ArticleIdList></Reference><Reference><Citation>Esaki T, Suzuki H, Cook M, Shimoji K, Cheng SY, Sokoloff L, Nunez J. Functional activation of cerebral metabolism in mice with mutated thyroid hormone nuclear receptors. Endocrinology. 2003;144:4117&#x2013;4122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12933686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Wood NW. Genome-wide association studies: the key to unlocking neurodegeneration? Nat Neurosci. 2010;13:789&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">20581814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazalpour A, Doss S, Zhang B, Wang S, Plaisier C, Castellanos R, Brozell A, Schadt EE, Drake TA, Lusis AJ, Horvath S. Integrating genetic and network analysis to characterize genes related to mouse weight. PLoS Genet. 2006;2:e130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550283</ArticleId><ArticleId IdType="pubmed">16934000</ArticleId></ArticleIdList></Reference><Reference><Citation>He XY, Schulz H, Yang SY. A human brain l-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer's disease. J Biol Chem. 1998;273:10741&#x2013;10746.</Citation><ArticleIdList><ArticleId IdType="pubmed">9553139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Kohannim O, Jahanshad N, Saykin AJ, Shen L, Kim S, Pankratz N, Foroud T, Huentelman MJ, Potkin SG, Jack CR, Jr, Weiner MW, Toga AW, Thompson PM. Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage. 2011;56:1875&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366726</ArticleId><ArticleId IdType="pubmed">21497199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill WG, Robertson A. Linkage disequilibrium in finite populations. Theor Appl Genet. 1968;38:226&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">24442307</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes CJ, Hoge R, Collins L, Woods R, Toga AW, Evans AC. Enhancement of MR images using registration for signal averaging. J Comput Assist Tomogr. 1998;22:324&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulshoff Pol HE, Schnack HG, Posthuma D, Mandl RC, Baar&#xe9; WF, van Oel C, van Haren NE, Collins DL, Evans AC, Amunts K, B&#xfc;rgel U, Zilles K, de Geus E, Boomsma DI, Kahn RS. Genetic contributions to human brain morphology and intelligence. J Neurosci. 2006;26:10235&#x2013;10242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674628</ArticleId><ArticleId IdType="pubmed">17021179</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries MD, Gurney K. Network &#x2018;small-world-ness&#x2019;: a quantitative method for determining canonical network equivalence. PLoS One. 2008;3:e0002051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323569</ArticleId><ArticleId IdType="pubmed">18446219</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DN. MAB, multidimensional aptitude battery: manual. Port Hurton, MI: Research Psychologists; 1984.</Citation></Reference><Reference><Citation>Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada T, Kawai S. An algorithm for drawing general undirected graphs. Inform Process Lett. 1989;31:7&#x2013;15.</Citation></Reference><Reference><Citation>Kravitz DJ, Saleem KS, Baker CI, Mishkin M. A new neural framework for visuospatial processing. Nat Rev Neurosci. 2011;12:217&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388718</ArticleId><ArticleId IdType="pubmed">21415848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok SC, Buckley MJ. Fornix transection selectively impairs fast learning of conditional visuospatial discriminations. Hippocampus. 2010;20:413&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">19475652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11:241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">7581446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenroot RK, Schmitt JE, Ordaz SJ, Wallace GL, Neale MC, Lerch JP, Kendler KS, Evans AC, Giedd JN. Differences in genetic and environmental influences on the human cerebral cortex associated with development during childhood and adolescence. Hum Brain Mapp. 2009;30:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870600</ArticleId><ArticleId IdType="pubmed">18041741</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, Caselli RJ, Kukull WA, McKeel D, Morris JC, Hulette C, Schmechel D, Alexander GE, Reiman EM, Rogers J, Stephan DA. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics. 2007;28:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2259385</ArticleId><ArticleId IdType="pubmed">17077275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GG, Fong E, Zeng X. GNCPro: navigate human genes and relationships through net-walking. Adv Exp Med Biol. 2010;680:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">20865508</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciano M, Wright MJ, Geffen GM, Geffen LB, Smith GA, Evans DM, Martin NG. A genetic two-factor model of the covariation among a subset of Multidimensional Aptitude Battery and Wechsler Adult Intelligence Scale&#x2013;Revised subtests. Intelligence. 2003;31:589&#x2013;605.</Citation></Reference><Reference><Citation>Malo MS, Srivastava K, Andresen JM, Chen XN, Korenberg JR, Ingram VM. Targeted gene walking by low stringency polymerase chain reaction: assignment of a putative human brain sodium channel gene (SCN3A) to chromosome 2q24-31. Proc Natl Acad Sci USA. 1994;91:2975&#x2013;2979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43497</ArticleId><ArticleId IdType="pubmed">8159690</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831613</ArticleId><ArticleId IdType="pubmed">19812666</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet. 2005;37:413&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">15793588</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science. 2002;296:910&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988575</ArticleId></ArticleIdList></Reference><Reference><Citation>Medland SE, Nyholt DR, Painter JN, McEvoy BP, McRae AF, Zhu G, Gordon SD, Ferreira MA, Wright MJ, Henders AK, Campbell MJ, Duffy DL, Hansell NK, Macgregor S, Slutske WS, Heath AC, Montgomery GW, Martin NG. Common variants in the trichohyalin gene are associated with straight hair in Europeans. Am J Hum Genet. 2009;85:750&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775823</ArticleId><ArticleId IdType="pubmed">19896111</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale MC, Cardon LR. the NATO Scientific Affairs Division. Methodology for genetic studies of twins and families. Dordrecht; Boston: Kluwer Academic Publishers; 1992.</Citation></Reference><Reference><Citation>Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci. 2004;24:10099&#x2013;10102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730170</ArticleId><ArticleId IdType="pubmed">15537879</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner MI, Rothbart MK. Influencing brain networks: implications for education. Trends Cogn Sci. 2005;9:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737817</ArticleId></ArticleIdList></Reference><Reference><Citation>Posthuma D, de Geus EJ, Neale MC, Hulshoff Pol HE, Baar&#xe9; WEC, Kahn RS, Boomsma D. Multivariate genetic analysis of brain structure in an extended twin design. Behav Genet. 2000;30:311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11206086</ArticleId></ArticleIdList></Reference><Reference><Citation>Prata DP, Mechelli A, Fu CH, Picchioni M, Toulopoulou T, Bramon E, Walshe M, Murray RM, Collier DA, McGuire P. Epistasis between the DAT 3&#x2032; UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc Natl Acad Sci USA. 2009;106:13600&#x2013;13605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726372</ArticleId><ArticleId IdType="pubmed">19666577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barab&#xe1;si AL. Hierarchical organization of modularity in metabolic networks. Science. 2002;297:1551&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202830</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed JE, Dunn JR, du Plessis DG, Shaw EJ, Reeves P, Gee AL, Warnke PC, Sellar GC, Moss DJ, Walker C. Expression of cellular adhesion molecule &#x2018;OPCML&#x2019; is down-regulated in gliomas and other brain tumours. Neuropathol Appl Neurobiol. 2007;33:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239010</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichmann H, Maltese WA, DeVivo DC. Enzymes of fatty acid beta-oxidation in developing brain. J Neurochem. 1988;51:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899130</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427&#x2013;4433.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154050</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. Neuroimage. 2010;52:1059&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">19819337</ArticleId></ArticleIdList></Reference><Reference><Citation>Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev. 2009;19:212&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914559</ArticleId><ArticleId IdType="pubmed">19481926</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Jr, Weiner MW. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, Behrens TE. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31:1487&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Hua X, Lee S, Ho AJ, Leow AD, Toga AW, Saykin AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Dechairo BM, Potkin SG, Weiner MW, Thompson P. Voxelwise genome-wide association study (vGWAS) Neuroimage. 2010;53:1160&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900429</ArticleId><ArticleId IdType="pubmed">20171287</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkamani A, Dean B, Schork NJ, Thomas EA. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res. 2010;20:403&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847743</ArticleId><ArticleId IdType="pubmed">20197298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuch DS, Salat DH, Wisco JJ, Zaleta AK, Hevelone ND, Rosas HD. Choice reaction time performance correlates with diffusion anisotropy in white matter pathways supporting visuospatial attention. Proc Natl Acad Sci USA. 2005;102:12212&#x2013;12217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189298</ArticleId><ArticleId IdType="pubmed">16103359</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestergaard M, Madsen KS, Baare WF, Skimminge A, Ejersbo LR, Rams&#xf8;y TZ, Gerlach C, Akeson P, Paulson OB, Jernigan TL. White matter microstructure in superior longitudinal fasciculus associated with spatial working memory performance in children. J Cogn Neurosci. 2011;23:2135&#x2013;2146.</Citation><ArticleIdList><ArticleId IdType="pubmed">20964591</ArticleId></ArticleIdList></Reference><Reference><Citation>Visscher PM. Sizing up human height variation. Nat Genet. 2008;40:489&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">18443579</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts DJ, Strogatz SH. Collective dynamics of &#x2018;small-world&#x2019; networks. Nature. 1998;393:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright MJ, Martin NG. Brisbane adolescent twin study: outline of study methods and research projects. Aust J Psychol. 2004;56:65&#x2013;78.</Citation></Reference><Reference><Citation>Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005;33:W741&#x2013;W748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160236</ArticleId><ArticleId IdType="pubmed">15980575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22814377</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>31</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Molecular basis of &#x3b2;-amyloid oligomer recognition with a conformational antibody fragment.</ArticleTitle><Pagination><StartPage>12503</StartPage><EndPage>12508</EndPage><MedlinePgn>12503-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1206433109</ELocationID><Abstract><AbstractText>Oligomers are intermediates of the &#x3b2;-amyloid (A&#x3b2;) peptide fibrillogenic pathway and are putative pathogenic culprits in Alzheimer's disease (AD). Here we report the biotechnological generation and biochemical characterization of an oligomer-specific antibody fragment, KW1. KW1 not only discriminates between oligomers and other A&#x3b2; conformations, such as fibrils or disaggregated peptide; it also differentiates between different types of A&#x3b2; oligomers, such as those formed by A&#x3b2; (1-40) and A&#x3b2; (1-42) peptide. This high selectivity of binding contrasts sharply with many other conformational antibodies that interact with a large number of structurally analogous but sequentially different antigens. X-ray crystallography, NMR spectroscopy, and peptide array measurements imply that KW1 recognizes oligomers through a hydrophobic and significantly aromatic surface motif that includes A&#x3b2; residues 18-20. KW1-positive oligomers occur in human AD brain samples and induce synaptic dysfunctions in living brain tissues. Bivalent KW1 potently neutralizes this effect and interferes with A&#x3b2; assembly. By altering a specific step of the fibrillogenic cascade, it prevents the formation of mature A&#x3b2; fibrils and induces the accumulation of nonfibrillar aggregates. Our data illuminate significant mechanistic differences in oligomeric and fibril recognition and suggest the considerable potential of KW1 in future studies to detect or inhibit specific types of A&#x3b2; conformers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morgado</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, 06120 Halle, Saale, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieligmann</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bereza</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>R&#xf6;nicke</LastName><ForeName>Raik</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Meinhardt</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Annamalai</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wacker</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hortschansky</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Male&#x161;evi&#x107;</LastName><ForeName>Miroslav</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Parthier</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mawrin</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schiene-Fischer</LastName><ForeName>Cordelia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Reymann</LastName><ForeName>Klaus G</ForeName><Initials>KG</Initials></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Milton T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Balbach</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>G&#xf6;rlach</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>F&#xe4;ndrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>3TPK</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22814377</ArticleId><ArticleId IdType="pmc">PMC3412029</ArticleId><ArticleId IdType="doi">10.1073/pnas.1206433109</ArticleId><ArticleId IdType="pii">1206433109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finder VH, Glockshuber R. Amyloid-&#x3b2; aggregation. Neurodegener Dis. 2007;4:13&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429215</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer&#x2019;s amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Haupt C, et al. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. J Mol Biol. 2011;408:529&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376731</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, et al. Globular amyloid &#x3b2;-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer&#x2019;s disease. J Neurochem. 2005;95:834&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">16135089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem. 2009;284:4230&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640961</ArticleId><ArticleId IdType="pubmed">19098006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer&#x2019;s disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Habicht G, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci USA. 2007;104:19232&#x2013;19237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148273</ArticleId><ArticleId IdType="pubmed">18042730</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandberg A, et al. Stabilization of neurotoxic Alzheimer amyloid-&#x3b2; oligomers by protein engineering. Proc Natl Acad Sci USA. 2010;107:15595&#x2013;15600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932621</ArticleId><ArticleId IdType="pubmed">20713699</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xe4;ndrich M. Oligomeric intermediates in amyloid formation: Structure determination and mechanisms of toxicity. J Mol Biol. 2012 doi: 10.1016/j.jmb.2012.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2012.01.006</ArticleId><ArticleId IdType="pubmed">22248587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, et al. Structural conversion of neurotoxic amyloid-&#x3b2;(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17:561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922021</ArticleId><ArticleId IdType="pubmed">20383142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S, et al. Evidence of fibril-like &#x3b2;-sheet structures in a neurotoxic amyloid intermediate of Alzheimer&#x2019;s &#x3b2;-amyloid. Nat Struct Mol Biol. 2007;14:1157&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059284</ArticleId></ArticleIdList></Reference><Reference><Citation>Haupt C, et al. Structural basis of &#x3b2;-amyloid-dependent synaptic dysfunctions. Angew Chem Int Ed Engl. 2012;51:1576&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pubmed">22234970</ArticleId></ArticleIdList></Reference><Reference><Citation>Laganowsky A, et al. Atomic view of a toxic amyloid small oligomer. Science. 2012;335:1228&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959867</ArticleId><ArticleId IdType="pubmed">22403391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Culyba EK, Powers ET, Kelly JW. Amyloid-&#x3b2; forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol. 2011;7:602&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158298</ArticleId><ArticleId IdType="pubmed">21804535</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, et al. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem. 2011;286:8585&#x2013;8596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048741</ArticleId><ArticleId IdType="pubmed">21156804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid &#x3b2;-protein oligomers. Proc Natl Acad Sci USA. 2009;106:14745&#x2013;14750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736424</ArticleId><ArticleId IdType="pubmed">19706468</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, et al. Amyloid &#x3b2;-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411&#x2013;14419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Schachter JB. Demonstration of a common artifact in immunosorbent assays of brain extracts: Development of a solid-phase extraction protocol to enable measurement of amyloid-&#x3b2; from wild-type rodent brain. J Neurosci Methods. 2006;157:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678274</ArticleId></ArticleIdList></Reference><Reference><Citation>Cizas P, et al. Size-dependent neurotoxicity of &#x3b2;-amyloid oligomers. Arch Biochem Biophys. 2010;496:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853175</ArticleId><ArticleId IdType="pubmed">20153288</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumoulin M, Dobson CM. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie. 2004;86:589&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15556268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA. 2002;99:1485&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122217</ArticleId><ArticleId IdType="pubmed">11818542</ArticleId></ArticleIdList></Reference><Reference><Citation>Haupt C, et al. Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J Mol Biol. 2011;405:341&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">21059358</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer&#x2019;s disease. Philos Trans R Soc Lond B Biol Sci. 2003;358:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693153</ArticleId><ArticleId IdType="pubmed">12740129</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazawa T, Blout ER. The infrared spectra of polypeptides in various conformations: Amide I and II bands. J Am Chem Soc. 1961;83:712&#x2013;719.</Citation></Reference><Reference><Citation>Morgado I, F&#xe4;ndrich M. Assembly of Alzheimer's A&#x3b2; peptide into nanostructured amyloid fibrils. Curr Opin Colloid Interface Sci. 2011;16:508&#x2013;514.</Citation></Reference><Reference><Citation>Greenwald J, Riek R. Biology of amyloid: Structure, function, and regulation. Structure. 2010;18:1244&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20947013</ArticleId></ArticleIdList></Reference><Reference><Citation>Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM. Structure-based design of conformation- and sequence-specific antibodies against amyloid &#x3b2;. Proc Natl Acad Sci USA. 2012;109:84&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252897</ArticleId><ArticleId IdType="pubmed">22171009</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-R, Glabe CG. Distinct early folding and aggregation properties of Alzheimer amyloid-&#x3b2; peptides A&#x3b2;40 and A&#x3b2;42. J Biol Chem. 2006;281:24414&#x2013;24422.</Citation><ArticleIdList><ArticleId IdType="pubmed">16809342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong W, et al. Structure determination of micelle-like intermediates in amyloid &#x3b2; -protein fibril assembly by using small angle neutron scattering. Proc Natl Acad Sci USA. 2002;99:150&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117530</ArticleId><ArticleId IdType="pubmed">11756677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat&#xe9; R, Estelrich J. Evidence of the existence of micelles in the fibrillogenesis of &#x3b2;-amyloid peptide. J Phys Chem B. 2005;109:11027&#x2013;11032.</Citation><ArticleIdList><ArticleId IdType="pubmed">16852343</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci USA. 2009;106:19813&#x2013;19818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764733</ArticleId><ArticleId IdType="pubmed">19843697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, F&#xe4;ndrich M, Grigorieff N. Paired &#x3b2;-sheet structure of an Abeta(1-40) amyloid fibril revealed by electron microscopy. Proc Natl Acad Sci USA. 2008;105:7462&#x2013;7466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396686</ArticleId><ArticleId IdType="pubmed">18483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Luo Y, Mattson MP, Tycko R. Antiparallel &#x3b2;-sheet architecture in Iowa-mutant &#x3b2;-amyloid fibrils. Proc Natl Acad Sci USA. 2012;109:4443&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311365</ArticleId><ArticleId IdType="pubmed">22403062</ArticleId></ArticleIdList></Reference><Reference><Citation>Colletier JP, et al. Molecular basis for amyloid-&#x3b2; polymorphism. Proc Natl Acad Sci USA. 2011;108:16938&#x2013;16943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193189</ArticleId><ArticleId IdType="pubmed">21949245</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheidt HA, Morgado I, Rothemund S, Huster D, F&#xe4;ndrich M. Solid-state NMR spectroscopic investigation of A&#x3b2; protofibrils: Implication of a &#x3b2;-sheet remodeling upon maturation into terminal amyloid fibrils. Angew Chem Int Ed Engl. 2011;50:2837&#x2013;2840.</Citation><ArticleIdList><ArticleId IdType="pubmed">21387500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerelius C, et al. &#x3b1;-Helix targeting reduces amyloid-&#x3b2; peptide toxicity. Proc Natl Acad Sci USA. 2009;106:9191&#x2013;9196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695042</ArticleId><ArticleId IdType="pubmed">19458258</ArticleId></ArticleIdList></Reference><Reference><Citation>Luheshi LM, et al. Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. 2010;8:e1000334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838747</ArticleId><ArticleId IdType="pubmed">20305716</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopeit T, et al. Mutagenic analysis of the nucleation propensity of oxidized Alzheimer&#x2019;s &#x3b2;-amyloid peptide. Protein Sci. 2005;14:2125&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2279324</ArticleId><ArticleId IdType="pubmed">15987892</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvey M, et al. Phosphate and HEPES buffers potently affect the fibrillation and oligomerization mechanism of Alzheimer&#x2019;s A&#x3b2; peptide. Biochem Biophys Res Commun. 2011;409:385&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">21575606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17556541</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>25</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression.</ArticleTitle><Pagination><StartPage>10613</StartPage><EndPage>10618</EndPage><MedlinePgn>10613-8</MedlinePgn></Pagination><Abstract><AbstractText>Presenilins (PS, PS1/PS2) are necessary for the proteolytic activity of gamma-secretase, which cleaves multiple type I transmembrane proteins including Alzheimer's beta-amyloid precursor protein (APP), Notch, ErbB4, etc. Cleavage by PS/gamma-secretase releases the intracellular domain (ICD) of its substrates. Notch ICD translocates into the nucleus to regulate expression of genes important for development. However, the patho/physiological role of other ICDs, especially APP ICD (AICD), in regulating gene expression remains controversial because evidence supporting this functionality stems mainly from studies performed under supraphysiological conditions. EGF receptor (EGFR) is up-regulated in a wide variety of tumors and hence is a target for cancer therapeutics. Abnormal expression/activation of EGFR contributes to keratinocytic carcinomas, and mice with reduced PS dosages have been shown to develop skin tumors. Here we demonstrate that the levels of PS and EGFR in the skin tumors of PS1(+/-)/ PS2(-/-) mice and the brains of PS1/2 conditional double knockout mice are inversely correlated. Deficiency in PS/gamma-secretase activity or APP expression results in a significant increase of EGFR in fibroblasts. Importantly, we show that AICD mediates transcriptional regulation of EGFR. Furthermore, we provide in vivo evidence demonstrating direct binding of endogenous AICD to the EGFR promoter. Our results indicate an important role of PS/gamma-secretase-generated APP metabolite AICD in gene transcription and in EGFR-mediated tumorigenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-wu</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Aging, Burnham Institute for Medical Research, La Jolla, CA 92037, USA. yunzhang@xmu.edu.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruishan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Han</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Francesca-Fang</ForeName><Initials>FF</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS054880</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG024895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17556541</ArticleId><ArticleId IdType="pmc">PMC1888796</ArticleId><ArticleId IdType="doi">10.1073/pnas.0703903104</ArticleId><ArticleId IdType="pii">0703903104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vetrivel KS, Zhang YW, Xu H, Thinakaran G. Mol Neurodegener. 2006;1:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513131</ArticleId><ArticleId IdType="pubmed">16930451</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T. Curr Opin Neurobiol. 2004;14:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194119</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield JP, Gross RS, Gouras GK, Xu H. Front Biosci. 2000;5:D72&#x2013;D83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Schroeter EH, Weintraub H, Nye JS. Proc Natl Acad Sci USA. 1996;93:1683&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40002</ArticleId><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Kisslinger JA, Kopan R. Nature. 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Cell. 2002;110:55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, Kim EM, Lee JP, Park CH, Kim S, Seo JH, Chang KA, Yu E, Jeong SJ, Chong YH, et al. FASEB J. 2003;17:1951&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, Muller U, et al. Neuron. 2005;46:541&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944124</ArticleId></ArticleIdList></Reference><Reference><Citation>von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U. J Cell Sci. 2004;117:4435&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, Filippov MA, Muller U, De Strooper B. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Genes Dev. 1999;13:2801&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317124</ArticleId><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Ma G, Cai H, Price DL, Wong PC. J Neurosci. 2003;23:3272&#x2013;3277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742329</ArticleId><ArticleId IdType="pubmed">12716934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price DL, Wong PC. J Neurosci. 2005;25:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, Kopan R. Nature. 2000;405:966&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879540</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Genes Dev. 1994;8:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">7926761</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, III, Kandel ER, Duff K, et al. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H. Neuron. 1998;20:611&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539133</ArticleId></ArticleIdList></Reference><Reference><Citation>Qyang Y, Chambers SM, Wang P, Xia X, Chen X, Goodell MA, Zheng H. Biochemistry. 2004;43:5352&#x2013;5359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122901</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X, Zheng H. Proc Natl Acad Sci USA. 2001;98:10863&#x2013;10868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58565</ArticleId><ArticleId IdType="pubmed">11517342</ArticleId></ArticleIdList></Reference><Reference><Citation>Astsaturov I, Cohen RB, Harari P. Expert Rev Anticancer Ther. 2006;6:1179&#x2013;1193.</Citation><ArticleIdList><ArticleId IdType="pubmed">17020453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipples R. Semin Oncol Nurs. 2006;22:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jost M, Kari C, Rodeck U. Eur J Dermatol. 2000;10:505&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">11056418</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Luo WJ, Wang H, Lin P, Vetrivel KS, Liao F, Li F, Wong PC, Farquhar MG, Thinakaran G, et al. J Biol Chem. 2005;280:17020&#x2013;17026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201533</ArticleId><ArticleId IdType="pubmed">15711015</ArticleId></ArticleIdList></Reference><Reference><Citation>Citri A, Yarden Y. Nat Rev Mol Cell Biol. 2006;7:505&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829981</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Koo EH. Mol Neurodegener. 2006;1:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ. J Biol Chem. 2001;276:40288&#x2013;40292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Goate A. Genes Dev. 2000;14:2799&#x2013;2806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090127</ArticleId></ArticleIdList></Reference><Reference><Citation>Telese F, Bruni P, Donizetti A, Gianni D, D'Ambrosio C, Scaloni A, Zambrano N, Rosenfeld MG, Russo T. EMBO Rep. 2005;6:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299219</ArticleId><ArticleId IdType="pubmed">15592452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan KA, Pimplikar SW. J Cell Biol. 2005;171:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171208</ArticleId><ArticleId IdType="pubmed">16230462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Bolotin D, ChuDH , Polak L, Williams T, Fuchs E. J Cell Biol. 2006;172:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063650</ArticleId><ArticleId IdType="pubmed">16449191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, et al. J Neurosci. 2005;25:1219&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo AC, Haass C, Wagner SL, Teplow DB, Sisodia SS. J Biol Chem. 1994;269:30966&#x2013;30973.</Citation><ArticleIdList><ArticleId IdType="pubmed">7983032</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G. J Biol Chem. 2004;279:44945&#x2013;44954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, et al. Neuron. 1996;17:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S. Proc Natl Acad Sci USA. 1997;94:3748&#x2013;3752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12297048</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>110</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Sep</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis.</ArticleTitle><Pagination><StartPage>751</StartPage><EndPage>762</EndPage><MedlinePgn>751-62</MedlinePgn></Pagination><Abstract><AbstractText>The Alzheimer's disease-linked gene presenilin 1 (PS1) is required for intramembrane proteolysis of APP and Notch. In addition, recent observations strongly implicate PS1 as a negative regulator of the Wnt/beta-catenin signaling pathway, although the mechanism underlying this activity is unknown. Here, we show that presenilin functions as a scaffold that rapidly couples beta-catenin phosphorylation through two sequential kinase activities independent of the Wnt-regulated Axin/CK1alpha complex. Thus, presenilin deficiency results in increased beta-catenin stability in vitro and in vivo by disconnecting the stepwise phosphorylation of beta-catenin, both in the presence and absence of Wnt stimulation. These findings highlight an aspect of beta-catenin regulation outside of the canonical Wnt-regulated pathway and a function of presenilin separate from intramembrane proteolysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Salvador</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Xuefeng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Eberhart</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5T32 AG00216-10</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS28121</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060466">Axin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495270">CTNNB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495267">CTNNB1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060466" MajorTopicYN="N">Axin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006965" MajorTopicYN="N">Hyperplasia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008527" MajorTopicYN="N">Medulloblastoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="Y">Repressor Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051153" MajorTopicYN="N">Wnt Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029961" MajorTopicYN="Y">Zebrafish Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12297048</ArticleId><ArticleId IdType="doi">10.1016/s0092-8674(02)00970-4</ArticleId><ArticleId IdType="pii">S0092867402009704</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23412472</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>Physiological release of endogenous tau is stimulated by neuronal activity.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>394</EndPage><MedlinePgn>389-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/embor.2013.15</ELocationID><Abstract><AbstractText>Propagation of tau pathology is linked with progressive neurodegeneration, but the mechanism underlying trans-synaptic spread of tau is unknown. We show that stimulation of neuronal activity, or AMPA receptor activation, induces tau release from healthy, mature cortical neurons. Notably, phosphorylation of extracellular tau appears reduced in comparison with intracellular tau. We also find that AMPA-induced release of tau is calcium-dependent. Blocking pre-synaptic vesicle release by tetanus toxin and inhibiting neuronal activity with tetrodotoxin both significantly impair AMPA-mediated tau release. Tau secretion is therefore a regulatable process, dysregulation of which could lead to the spread of tau pathology in disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pooler</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience (PO37), King's College London, Institute of Psychiatry, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Emma C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Dawn H W</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Hanger</LastName><ForeName>Diane P</ForeName><Initials>DP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>118876-58-7</RegistryNumber><NameOfSubstance UI="C062865">2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23412472</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pii">embor201315</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70: 960&#x2013;969</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11: 909&#x2013;913</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845&#x2013;12852</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A et al. (2012) Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73: 685&#x2013;697</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7: e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim W, Li Z, Hall GF (2012) Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Int J Alzheimers Dis 2012: 172837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270555</ArticleId><ArticleId IdType="pubmed">22315694</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J (2012) Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 586: 47&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">22138183</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S et al. (2012) Exosome-associated Tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287: 3842&#x2013;3849</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Dage JL, Citron M (2012) Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis 48: 356&#x2013;366</Citation><ArticleIdList><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Goate AM (2012) Calcium phosphatase calcineurin influences tau metabolism. Neurobiol Aging 34: 374&#x2013;386</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879081</ArticleId><ArticleId IdType="pubmed">22676853</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlatterer SD, Tremblay MA, Acker CM, Davies P (2011) Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis 25: 119&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349237</ArticleId><ArticleId IdType="pubmed">21368377</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Trelles R, Solana-Lopez A, Fernandez-Gonzalez JR, Novelli A, Fernandez-Sanchez MT (1999) Terfenadine induces toxicity in cultured cerebellar neurons: a role for glutamate receptors. Amino Acids 16: 59&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">10078334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Wurtman RJ, Lee RK (2000) Amyloid precursor protein and membrane phospholipids in primary cortical neurons increase with development, or after exposure to nerve growth factor or Abeta(1-40). Brain Res 865: 157&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">10821917</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Hernandez M, G&#xf3;mez-Ramos A, Rubio A, G&#xf3;mez-Villafuertes R, Naranjo JR, Miras-Portugal MT, Avila J (2010) Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem 285: 32539&#x2013;32548</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952256</ArticleId><ArticleId IdType="pubmed">20634292</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP (2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 33: 431 e427&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pubmed">21388709</ArticleId></ArticleIdList></Reference><Reference><Citation>Plouffe V et al. (2012) Hyperphosphorylation and cleavage at d421 enhance tau secretion. PLoS One 7: e36873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352936</ArticleId><ArticleId IdType="pubmed">22615831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112&#x2013;119</Citation><ArticleIdList><ArticleId IdType="pubmed">19246243</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DR et al. (1995) The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem J 309: 941&#x2013;949</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1135722</ArticleId><ArticleId IdType="pubmed">7639714</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz Y, Luccarelli J, Kim M, Wang M, Sulzer D (2009) Glutamate controls growth rate and branching of dopaminergic axons. J Neurosci 29: 11973&#x2013;11981</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818361</ArticleId><ArticleId IdType="pubmed">19776283</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan J, Galindo MF, Gonzalez-Garcia C, Cena V (2003) Role and regulation of p53 in depolarization-induced neuronal death. Neuroscience 122: 707&#x2013;715</Citation><ArticleIdList><ArticleId IdType="pubmed">14622914</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832&#x2013;835</Citation><ArticleIdList><ArticleId IdType="pubmed">1331807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, Bodon G, Blot B, Haase G, Goldberg Y, Sadoul R (2011) Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci 46: 409&#x2013;418</Citation><ArticleIdList><ArticleId IdType="pubmed">21111824</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM (2012) Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem 287: 20522&#x2013;20533</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370237</ArticleId><ArticleId IdType="pubmed">22496370</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30: 6838&#x2013;6851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="pubmed">20484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K (2011) Alzheimer&#x2019;s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121: 589&#x2013;595</Citation><ArticleIdList><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O (2008) Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science 321: 1686&#x2013;1689</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J (2006) Extracellular tau is toxic to neuronal cells. FEBS Lett 580: 4842&#x2013;4850</Citation><ArticleIdList><ArticleId IdType="pubmed">16914144</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CH et al. (2008) Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 283: 18177&#x2013;18186</Citation><ArticleIdList><ArticleId IdType="pubmed">18467332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J (2008) Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 37: 673&#x2013;681</Citation><ArticleIdList><ArticleId IdType="pubmed">18272392</ArticleId></ArticleIdList></Reference><Reference><Citation>Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W (2011) Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2: e167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168992</ArticleId><ArticleId IdType="pubmed">21633390</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Couck AM, Robertson J, Loviny TL, Anderton BH (1993) Neurofilament monoclonal antibodies RT97 and 8D8 recognize different modified epitopes in paired helical filament-tau in Alzheimer&#x2019;s disease. J Neurochem 60: 1372&#x2013;1382</Citation><ArticleIdList><ArticleId IdType="pubmed">7681101</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM (2011) Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 42: 360&#x2013;367</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107939</ArticleId><ArticleId IdType="pubmed">21303699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">9600986</PMID><DateCompleted><Year>1998</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>95</Volume><Issue>11</Issue><PubDate><Year>1998</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.</ArticleTitle><Pagination><StartPage>6448</StartPage><EndPage>6453</EndPage><MedlinePgn>6448-53</MedlinePgn></Pagination><Abstract><AbstractText>Abeta1-42 is a self-associating peptide whose neurotoxic derivatives are thought to play a role in Alzheimer's pathogenesis. Neurotoxicity of amyloid beta protein (Abeta) has been attributed to its fibrillar forms, but experiments presented here characterize neurotoxins that assemble when fibril formation is inhibited. These neurotoxins comprise small diffusible Abeta oligomers (referred to as ADDLs, for Abeta-derived diffusible ligands), which were found to kill mature neurons in organotypic central nervous system cultures at nanomolar concentrations. At cell surfaces, ADDLs bound to trypsin-sensitive sites and surface-derived tryptic peptides blocked binding and afforded neuroprotection. Germ-line knockout of Fyn, a protein tyrosine kinase linked to apoptosis and elevated in Alzheimer's disease, also was neuroprotective. Remarkably, neurological dysfunction evoked by ADDLs occurred well in advance of cellular degeneration. Without lag, and despite retention of evoked action potentials, ADDLs inhibited hippocampal long-term potentiation, indicating an immediate impact on signal transduction. We hypothesize that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer's disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Abeta-derived diffusible ligands acting upon particular neural signal transduction pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>M P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barlow</LastName><ForeName>A K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Chromy</LastName><ForeName>B A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Freed</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Liosatos</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>T E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Rozovsky</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Trommer</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Wals</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Krafft</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>W L</ForeName><Initials>WL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>30</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>30</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1998</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9600986</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price D L. Annu Rev Neurosci. 1986;9:489&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">3518588</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia S S, Price D J. FASEB J. 1995;9:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7896005</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner B A, Duffy L K, Kirschner D A. Science. 1990;250:279&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike C J, Walencewicz A J, Glabe C G, Cotman C W. Brain Res. 1991;563:311&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">1786545</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike C J, Burdick D, Walencewicz A J, Glabe C G, Cotman C W. J Neurosci. 1993;13:1676&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576726</ArticleId><ArticleId IdType="pubmed">8463843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett J T, Berger E P, Lansbury P T., Jr Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder S W, Ladror U S, Wade W S, Wang G T, Barrett L W, Matayoshi E D, Krafft G A, Holzman T F. Biophys J. 1994;67:1216&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1225478</ArticleId><ArticleId IdType="pubmed">7811936</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D J. Ann Rev Cell Biol. 1994;10:373&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888181</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung T T, Cai X D, Odaka A, Otvos L, Jr, Eckman C, Golde T E, Younkin S G. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel D E, Saunders A M, Strittmatter W J, Crain B J, Hulette C M, Joo S H, Pericak-Vance M A, Goldgaber D, Roses A D. Proc Natl Acad Sci USA. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran P M, Higgins L S, Cordell B, Moser P C. Proc Natl Acad Sci USA. 1995;92:5341&#x2013;5345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41690</ArticleId><ArticleId IdType="pubmed">7777509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K K, Borchelt D R, Olson K, Johannsdottir R, Kitt C, et al. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx J. Science. 1992;257:1336&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">1529329</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D W, Yen S H. Neurobiol Aging. 1989;10:402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">2682317</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R D, Masliah E, Salmon D P, Butters N, DeTeresa R, Hill R, Katzman R. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, et al. Nature (London) 1992;359:325&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Pasinetti G M, Osterberg H H, Anderson C, Johnson S A, Finch C E. Biochem Biophys Res Commun. 1994;204:1131&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">7980587</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Wals P, Osterburg H H, Johnson S A, Pasinetti G M, et al. Exp Neurol. 1995;136:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">7589331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yankner B A. Proc Natl Acad Sci USA. 1994;91:12243&#x2013;12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett D R, Jennings K H, Lee D C, Clark M S, Brown F, Wetzel R, Wood S J, Camilleri P, Roberts G W. Neurodegeneration. 1995;4:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600183</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham C R, Shirahama T, Potter H. Neurobiol Aging. 1990;11:123&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190106</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveugle B, Scanameo A, Ding W, Fillit H. NeuroReport. 1994;5:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522615</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P L, Kawamata T, Walker D G. Brain Res. 1992;579:337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">1378350</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W J, Saunders A M, Schmechel D, Pericak-Vance M, Enghild J, Roses A D. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W J, Weisgraber K H, Huang D Y, Dong L M, Salvesen G S, Schmechel D, Saunders A M, Goldgaber D, Roses A D. Proc Natl Acad Sci USA. 1993;90:8098&#x2013;8102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Boggs L N, Fuson K S, Baez M, Churgay L, McClure D, Becker G, May P C. J Neurochem. 1997;67:1324&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752142</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirazi S K, Wood J G. NeuroReport. 1993;4:435&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">8388744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert M P, Stevens G, Sabo S, Barber K, Wang G, Wade W, Krafft G, Holzman T F, Klein W L. J Neurosci Res. 1994;39:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">7533843</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine W B, Jr, Snyder S W, Ladror U S, Wade W S, Miller M F, Perun T J, Krafft G A. J Protein Chem. 1996;15:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8924204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Lambert M P, Bunch C, Barber K, Wade W S, Krafft G A, Klein W L. J Biol Chem. 1994;269:25247&#x2013;25250.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevchenko A, Wilm M, Vorm O, Mann M. Anal Chem. 1996;68:850&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">8779443</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs P-A, Muller D. J Neurosci Methods. 1991;37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, Patrick J, Steinbach J H, Culp W, Brandt B L. Nature (London) 1974;249:224&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">4151463</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommer B L, Kennelly J J, Colley P A, Overstreet L S, Slater N T, Pasternak J F. Exp Neurol. 1995;131:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895815</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens G R, Zhang C, Berg M M, Lambert M P, Barber K, Cantallops I, Routtenberg A, Klein W L. J Neurosci Res. 1996;46:445&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">8950704</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S D, Chen X, Fu J, Chen M, Zhu H, et al. Nature (London) 1996;382:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas C A, Cao L, Silverstein S, Loike J D. Nature (London) 1996;382:716&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751442</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke E A, Brugge J S. Science. 1995;268:233&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">7716514</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Qui H E, Krafft G A, Klein W L. Neurosci Lett. 1996;211:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817572</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant S G, O&#x2019;Dell T J, Karl K A, Stein P L, Soriano P, Kandel E R. Science. 1992;258:1903&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce A J, Sakhi S, Schreiber S S, Baudry M. Exp Neurol. 1995;132:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">7540554</ArticleId></ArticleIdList></Reference><Reference><Citation>Vornov J J, Coyle J T. J Neurochem. 1991;56:996&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, Matsubara E, Koudinov A, Choi-Miura N H, Tomita M, Wisniewski T, Frangione B. Biochem J. 1993;293:27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1134315</ArticleId><ArticleId IdType="pubmed">8328966</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangione, B., Wisniewski, T. &amp; Ghiso, J. (1994) Neurobiol. Aging 15 Suppl 2, S97&#x2013;S99.</Citation><ArticleIdList><ArticleId IdType="pubmed">7700474</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Biochem J. 1996;316:671&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217400</ArticleId><ArticleId IdType="pubmed">8687416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B V, Martel C L, Matsubara E, McComb J G, Zheng G, McCluskey RT, Frangione B, Ghiso J. Proc Natl Acad Sci USA. 1996;93:4229&#x2013;4234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39517</ArticleId><ArticleId IdType="pubmed">8633046</ArticleId></ArticleIdList></Reference><Reference><Citation>May P C, Lampert-Etchells M, Johnson S A, Poirier J, Masters J N, Finch C E. Neuron. 1990;5:831&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">1702645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y M, Emmerling M R, Vigo-Pelfrey C, Kasunic T C, Kirkpatrick J B, Murdoch G H, Ball M J, Roher A E. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Teller J K, Russo C, DeBusk L M, Angelini G, Zaccheo D, et al. Nat Med. 1996;2:93&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">8564851</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny M B, Ostaszewski B L, Squazzo S L, Koo E H, Rydell R E, Teplow D B, Selkoe D J. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Zhang J, Kholodenko D, Citron M, Podlisny M B, et al. J Biol Chem. 1997;272:7977&#x2013;7982.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065468</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine H. Neurobiol Aging. 1995;16:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532108</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger M, Herz J. Annu Rev Biochem. 1994;63:601&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">7979249</ArticleId></ArticleIdList></Reference><Reference><Citation>Erpel T, Courtneidge S A. Curr Opin Cell Biol. 1995;7:176&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">7612268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M P, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel R E. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M P, Tomaselli K J, Rydel R E. Brain Res. 1993;621:35&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221072</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald D R, Brunden K R, Landreth G E. J Neurosci. 1997;17:2284&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>Archuleta M M, Schieven G L, Ledbetter J A, Deanin G G, Burchiel S W. Proc Natl Acad Sci USA. 1993;90:6105&#x2013;6109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46876</ArticleId><ArticleId IdType="pubmed">8327490</ArticleId></ArticleIdList></Reference><Reference><Citation>Calautti E, Missero C, Stein P L, Ezzell R M, Dotto G P. Genes Dev. 1995;9:2279&#x2013;2291.</Citation><ArticleIdList><ArticleId IdType="pubmed">7557381</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Qiu H E, Krafft G A, Klein W L. FEBS Lett. 1996;386:185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">8647278</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg M M, Krafft G A, Klein W L. J Neurosci Res. 1997;50:979&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452012</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson D, Fournel M, Veilette A. J Biol Chem. 1994;269:10956&#x2013;10963.</Citation><ArticleIdList><ArticleId IdType="pubmed">8144681</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Busser J C. Development (Cambridge, UK) 1995;121:2385&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pubmed">7671804</ArticleId></ArticleIdList></Reference><Reference><Citation>Koijma H, Wang J, Mansuy I M, Grant S G N, Mayford M, Kandel E R. Proc Natl Acad Sci USA. 1997;94:4761&#x2013;4765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20798</ArticleId><ArticleId IdType="pubmed">9114065</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J, Geldmacher D S, Herrup K. J Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21296022</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>213</StartPage><EndPage>220</EndPage><MedlinePgn>213-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70323-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mild cognitive impairment (MCI) and pre-MCI have been proposed as stages preceding Alzheimer's disease (AD) dementia. We assessed descendants of individuals with a mutation in presenilin 1 (PSEN1) that causes familial AD, with the aim of identifying distinct stages of clinical progression to AD dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively studied a cohort of descendants of carriers of the PSEN1 E280A mutation. Pre-dementia cognitive impairment was defined by a score 2 SD away from normal values in objective cognitive tests, and was subdivided as follows: asymptomatic pre-MCI was defined by an absence of memory complaints and no effect on activities of daily living; symptomatic pre-MCI was defined by a score on the subjective memory complaints checklist higher than the mean and no effect on activities of daily living; and MCI was defined by a score on the subjective memory complaints checklist higher than the mean, with no effect on basic activities of daily living and little or no effect on complex daily activities. Dementia was defined according to the diagnostic and statistical manual of mental disorders, fourth edition. Reference mean scores were those of participants who did not carry the PSEN1 E280A mutation. We used the Turnbull survival analysis method to identify ages at onset of each stage of the disease. We measured the time from birth until onset of the three pre-dementia stages, dementia, and death, and assessed decline in cognitive domains for each stage.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Follow-up was from Jan 1, 1995, to Jan 27, 2010. 1784 patients were initially identified, 449 of whom were PSEN1 E280A carriers who had complete clinical follow-up. Median age at onset was 35 years (95% CI 30-36) for asymptomatic pre-MCI, 38 years (37-40) for symptomatic pre-MCI, 44 years (43-45) for MCI, and 49 years (49-50) for dementia. The median age at death was 59 years (95% CI 58-61). The median time of progression from asymptomatic to symptomatic pre-MCI was 4 years (95% CI 2-8), from symptomatic pre-MCI to MCI was 6 years (4-7), from MCI to dementia was 5 years (4-6), and from dementia to death was 10 years (9-12). The cognitive profile was predominantly amnestic and was associated with multiple domains. Affected domains showed variability in initial stages, with some transient recovery in symptomatic pre-MCI followed by continuous decline.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Clinical deterioration can be detected as measurable cognitive impairment around two decades before dementia onset in PSEN1 E280A carriers. Onset and progression of pre-dementia stages should be considered in the investigation and use of therapeutic interventions for familial AD.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Departamento Administrativo de Ciencia, Tecnolog&#xed;a e Innovaci&#xf3;n, COLCIENCIAS, Republic of Colombia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Acosta-Baena</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroscience Group of Antioquia, Faculty of Medicine, University of Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulveda-Falla</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lopera-G&#xf3;mez</LastName><ForeName>Carlos Mario</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Jaramillo-Elorza</LastName><ForeName>Mario C&#xe9;sar</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aguirre-Acevedo</LastName><ForeName>Daniel Camilo</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Saldarriaga</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2011 Mar;10(3):200-1. doi: 10.1016/S1474-4422(10)70328-8.</RefSource><PMID Version="1">21296021</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70323-9</ArticleId><ArticleId IdType="pii">S1474-4422(10)70323-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22505025</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease.</ArticleTitle><Pagination><StartPage>2261</StartPage><EndPage>2274</EndPage><MedlinePgn>2261-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2012.79</ELocationID><Abstract><AbstractText>The mechanisms by which mutations in the presenilins (PSEN) or the amyloid precursor protein (APP) genes cause familial Alzheimer disease (FAD) are controversial. FAD mutations increase the release of amyloid &#x3b2; (A&#x3b2;)42 relative to A&#x3b2;40 by an unknown, possibly gain-of-toxic-function, mechanism. However, many PSEN mutations paradoxically impair &#x3b3;-secretase and 'loss-of-function' mechanisms have also been postulated. Here, we use kinetic studies to demonstrate that FAD mutations affect A&#x3b2; generation via three different mechanisms, resulting in qualitative changes in the A&#x3b2; profiles, which are not limited to A&#x3b2;42. Loss of &#x25b;-cleavage function is not generally observed among FAD mutants. On the other hand, &#x3b3;-secretase inhibitors used in the clinic appear to block the initial &#x25b;-cleavage step, but unexpectedly affect more selectively Notch than APP processing, while modulators act as activators of the carboxypeptidase-like (&#x3b3;) activity. Overall, we provide a coherent explanation for the effect of different FAD mutations, demonstrating the importance of qualitative rather than quantitative changes in the A&#x3b2; products, and suggest fundamental improvements for current drug development efforts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Guti&#xe9;rrez</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bammens</LastName><ForeName>Leen</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Benilova</LastName><ForeName>Iryna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Vandersteen</LastName><ForeName>Annelies</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Benurwar</LastName><ForeName>Manasi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Borgers</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lismont</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lujia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Van Cleynenbreugel</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Esselmann</LastName><ForeName>Hermann</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Serneels</LastName><ForeName>Lutgarde</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Karran</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gijsen</LastName><ForeName>Harrie</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Broersen</LastName><ForeName>Kerensa</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C050361">CDH2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015820">Cadherins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497761">NOTCH1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C587689">ERBB4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066247">Receptor, ErbB-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>EMBO J. 2012 May 16;31(10):2237-9. doi: 10.1038/emboj.2012.111.</RefSource><PMID Version="1">22505028</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066247" MajorTopicYN="N">Receptor, ErbB-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051881" MajorTopicYN="N">Receptor, Notch1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Harrie Gijsen is an employee of Janssen Pharmaceutica. Bart de Strooper is a consultant for Janssen Pharmaceutica, Envivo Pharmaceutics and Remynd and is supported by research grants from Janssen Pharmaceutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22505025</ArticleId><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="doi">10.1038/emboj.2012.79</ArticleId><ArticleId IdType="pii">emboj201279</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B (2001) Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron 32: 579&#x2013;589</Citation><ArticleIdList><ArticleId IdType="pubmed">11719200</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop PS, Cordell B, Fraser P, De Strooper B (1999) Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol 147: 277&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732&#x2013;742</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, Hyman BT (2005) Familial Alzheimer&#x2019;s disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 25: 3009&#x2013;3017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725136</ArticleId><ArticleId IdType="pubmed">15772361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmans BA, De Strooper B (2010) Gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol 9: 2215&#x2013;226</Citation><ArticleIdList><ArticleId IdType="pubmed">20129170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer&#x2019;s disease. Trends Neurosci 31: 454&#x2013;463</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Baker M, Dickson DW, Parisi JE, Giannini C, Josephs KA, Hutton M, Pickering-Brown SM, Rademakers R, Tang-Wai D, Jack CR Jr., Kantarci K, Shiung MM, Golde T, Smith GE, Geda YE, Knopman DS, Petersen RC (2006) Frontotemporal dementia and parkinsonism associated with the IVS1+1G&#x2212;&gt;a mutation in progranulin: a clinicopathologic study. Brain 129: Pt 113103&#x2013;3114</Citation><ArticleIdList><ArticleId IdType="pubmed">17030535</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer&#x2019;s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005&#x2013;1013</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Tolia A, Maes E, Li T, Wong PC, de Strooper B (2008) Glu(332) in the Nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity. J Biol Chem 283: 20096&#x2013;20105</Citation><ArticleIdList><ArticleId IdType="pubmed">18502756</ArticleId></ArticleIdList></Reference><Reference><Citation>Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, Paul S, Schubenel R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann K, Koo EH, Weggen S (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem 283: 17049&#x2013;17054</Citation><ArticleIdList><ArticleId IdType="pubmed">18426795</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 141&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W (2010) Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol 26: 235&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 387&#x2013;390</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6: 99&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879045</ArticleId><ArticleId IdType="pubmed">20139999</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710&#x2013;713</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, Annaert W (2004) Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol 166: 1041&#x2013;1054</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004) Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22: 1302&#x2013;1306</Citation><ArticleIdList><ArticleId IdType="pubmed">15361882</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumori A, Fluhrer R, Steiner H, Haass C (2010) Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis. J Neurosci 30: 7853&#x2013;7862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632680</ArticleId><ArticleId IdType="pubmed">20534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, Ihara Y (2004) Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry 43: 13532&#x2013;13540</Citation><ArticleIdList><ArticleId IdType="pubmed">15491160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillman KW, Starrett JE, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, Williams R, Meredith JE, Burton CR, Barten DM, Toyn JH, Roberts SB, Lentz KA, Houston JG, Zaczek R, Albright CF, Decicco CP et al. (2011) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable &#xce;3-secretase inhibitor. ACS Med Chem Lett 1: 120&#x2013;124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007960</ArticleId><ArticleId IdType="pubmed">24900185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Serneels L, Dejaegere T, Horre K, Dabrowski M, Baert V, Annaert W, Hartmann D, De Strooper B (2004) Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis 17: 260&#x2013;272</Citation><ArticleIdList><ArticleId IdType="pubmed">15474363</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Xia W, Shen J, Kelleher RJ III (2010) A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. J Biol Chem 285: 22350&#x2013;22359</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903357</ArticleId><ArticleId IdType="pubmed">20460383</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B (2000) Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2: 461&#x2013;462</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT Jr. (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer&#x2019;s disease. Biochemistry 32: 4693&#x2013;4697</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT Jr (1993) Seeding &#x2018;one-dimensional crystallization&#x2019; of amyloid: a pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie? Cell 73: 1055&#x2013;1058</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, Ihara Y (2006) Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J Biol Chem 281: 14776&#x2013;14786</Citation><ArticleIdList><ArticleId IdType="pubmed">16595682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher RJ 3rd, Shen J (2010) Genetics. Gamma-secretase and human disease. Science 330: 1055&#x2013;1056</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556372</ArticleId><ArticleId IdType="pubmed">21097925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E (2007) Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27: 627&#x2013;633</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D&#x2019;Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B (2010) Neurotoxicity of Alzheimer&#x2019;s disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 29: 3408&#x2013;3420</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141: 1146&#x2013;1158</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A et al. (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer&#x2019;s disease. J Pharmacol Exp Ther 331: 598&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pubmed">19671883</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 99: 8025&#x2013;8030</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, Iwatsubo T, Takashima A (1999) Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer&#x2019;s disease. Neurosci Lett 265: 61&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pubmed">10327206</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, Uljon SN, Golde TE, Wang R (2002) FAD-linked mutations in presenilin 1 alter the length of Abeta peptides derived from betaAPP transmembrane domain mutants. Biochim Biophys Acta 1586: 199&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pubmed">11959461</ArticleId></ArticleIdList></Reference><Reference><Citation>Oehlrich D, Berthelot DJ, Gijsen HJ (2011) Gamma-secretase modulators as potential disease modifying anti-alzheimer&#x2019;s drugs. J Med Chem 54: 669&#x2013;698</Citation><ArticleIdList><ArticleId IdType="pubmed">21141968</ArticleId></ArticleIdList></Reference><Reference><Citation>Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C (2008) Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283: 677&#x2013;683</Citation><ArticleIdList><ArticleId IdType="pubmed">17962197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pink AE, Simpson MA, Brice GW, Smith CH, Desai N, Mortimer PS, Barker JN, Trembath RC (2011) PSENEN and NCSTN mutations in familial hidradenitis suppurativa (acne inversa). J Invest Dermatol 131: 1568&#x2013;1570</Citation><ArticleIdList><ArticleId IdType="pubmed">21412258</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H (2010) Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer&#x2019;s disease. Mol Neurodegener 5: 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818651</ArticleId><ArticleId IdType="pubmed">20145736</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25: 436&#x2013;445</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero-Monzon O, Martin MM, Fernandez MA, Cappello CA, Krzysiak AJ, Osenkowski P, Wolfe MS (2011) Dissociation between the processivity and total activity of gamma-secretase: implications for the mechanism of Alzheimer&#x2019;s disease-causing presenilin mutations. Biochemistry 50: 9023&#x2013;9035</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205908</ArticleId><ArticleId IdType="pubmed">21919498</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y, Saido TC (2011) Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci 14: 1023&#x2013;1032</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835&#x2013;841</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084035</ArticleId><ArticleId IdType="pubmed">11520861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama H, Koo EH, Haass C, Takio K, Morishima-Kawashima M, Ishiura S, Ihara Y (2003) Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J Biol Chem 278: 24294&#x2013;24301</Citation><ArticleIdList><ArticleId IdType="pubmed">12707272</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ III, Kandel ER, Duff K, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med 2: 864&#x2013;870</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ III (2007) The presenilin hypothesis of Alzheimer&#x2019;s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104: 403&#x2013;409</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo M, Sahara N, Murayama M, Ichinose H, Takashima A (2007) Decreased Abeta secretion by cells expressing familial Alzheimer&#x2019;s disease-linked mutant presenilin 1. Neurosci Res 57: 446&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pubmed">17210196</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Edbauer D, Prokop S, Haass C, Steiner H (2004) Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem 279: 41340&#x2013;41345</Citation><ArticleIdList><ArticleId IdType="pubmed">15286082</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA (1999) Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci USA 96: 6959&#x2013;6963</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29: 13042&#x2013;13052</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell 120: 545&#x2013;555</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia A, De Strooper B (2009) Structure and function of gamma-secretase. Semin Cell Dev Biol 20: 211&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pubmed">19007897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia A, Horre K, De Strooper B (2008) Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma-secretase. J Biol Chem 283: 19793&#x2013;19803</Citation><ArticleIdList><ArticleId IdType="pubmed">18482978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi T, De Strooper B (2008) Presenilins: members of the {gamma}-secretase quartets, but part-time soloists too. Physiology (Bethesda) 23: 194&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pubmed">18697993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T, Chen M, Sun M, Shen Y, Zhang X (2010) Gamma-secretase gene mutations in familial acne inversa. Science 330: 1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">20929727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Wang B, He W, Zheng H (2006) Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J Biol Chem 281: 15330&#x2013;15336</Citation><ArticleIdList><ArticleId IdType="pubmed">16574645</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, Image I II, Takagi S, Tominaga A, Image Image I, Tomita T, Iwatsubo T (2010) Functional analysis of the transmembrane domains of presenilin 1: participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of gamma-secretase. J Biol Chem 285: 19738&#x2013;19746</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888384</ArticleId><ArticleId IdType="pubmed">20418378</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, Eggert S, Reinhard FB, Vogel M, Paliga K, Baier G, Masters CL, Beyreuther K, Evin G (2002) A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41: 2825&#x2013;2835</Citation><ArticleIdList><ArticleId IdType="pubmed">11851430</ArticleId></ArticleIdList></Reference><Reference><Citation>Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110: 697&#x2013;706</Citation><ArticleIdList><ArticleId IdType="pubmed">19457079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CA, Murphy DD, Giasson BI, Zhang B, Trojanowski JQ, Lee VM (2004) Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J Cell Biol 165: 335&#x2013;346</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172178</ArticleId><ArticleId IdType="pubmed">15123735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Ruther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer&#x2019;s disease and in patients with chronic neuroinflammation. J Neurochem 81: 481&#x2013;496</Citation><ArticleIdList><ArticleId IdType="pubmed">12065657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS (2007) When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 136&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796780</ArticleId><ArticleId IdType="pubmed">17268504</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagishita S, Morishima-Kawashima M, Ishiura S, Ihara Y (2008) Abeta46 is processed to Abeta40 and Abeta43, but not to Abeta42, in the low density membrane domains. J Biol Chem 283: 733&#x2013;738</Citation><ArticleIdList><ArticleId IdType="pubmed">18024430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I (2010) Role of presenilins in neuronal calcium homeostasis. J Neurosci 30: 8566&#x2013;8580</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906098</ArticleId><ArticleId IdType="pubmed">20573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Brouwers N, Benilova I, Vandersteen A, Mercken M, Van Laere K, Van Damme P, Demedts D, Van Leuven F, Sleegers K, Broersen K, Van Broeckhoven C, Vandenberghe R, De Strooper B (2011) Amyloid precursor protein mutation E682K at the alternative beta-secretase cleavage beta&#x2019;-site increases Abeta generation. EMBO Mol Med 3: 291&#x2013;302</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377078</ArticleId><ArticleId IdType="pubmed">21500352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23484795</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>368</Volume><Issue>13</Issue><PubDate><Year>2013</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Regulatory innovation and drug development for early-stage Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1169</StartPage><EndPage>1171</EndPage><MedlinePgn>1169-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMp1302513</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kozauer</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Neurology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jul 18;369(3):288. doi: 10.1056/NEJMc1305880.</RefSource><PMID Version="1">23863069</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jul 18;369(3):288. doi: 10.1056/NEJMc1305880.</RefSource><PMID Version="1">23863070</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033161" MajorTopicYN="N">Government Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23484795</ArticleId><ArticleId IdType="doi">10.1056/NEJMp1302513</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16360788</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>366</Volume><Issue>9503</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Global prevalence of dementia: a Delphi consensus study.</ArticleTitle><Pagination><StartPage>2112</StartPage><EndPage>2117</EndPage><MedlinePgn>2112-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">100 years after the first description, Alzheimer's disease is one of the most disabling and burdensome health conditions worldwide. We used the Delphi consensus method to determine dementia prevalence for each world region.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">12 international experts were provided with a systematic review of published studies on dementia and were asked to provide prevalence estimates for every WHO world region, for men and women combined, in 5-year age bands from 60 to 84 years, and for those aged 85 years and older. UN population estimates and projections were used to estimate numbers of people with dementia in 2001, 2020, and 2040. We estimated incidence rates from prevalence, remission, and mortality.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Evidence from well-planned, representative epidemiological surveys is scarce in many regions. We estimate that 24.3 million people have dementia today, with 4.6 million new cases of dementia every year (one new case every 7 seconds). The number of people affected will double every 20 years to 81.1 million by 2040. Most people with dementia live in developing countries (60% in 2001, rising to 71% by 2040). Rates of increase are not uniform; numbers in developed countries are forecast to increase by 100% between 2001 and 2040, but by more than 300% in India, China, and their south Asian and western Pacific neighbours.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We believe that the detailed estimates in this paper constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Cleusa P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Section of Epidemiology, Institute of Psychiatry, King's College, London, UK. c.ferri@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ganguli</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hendrie</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yueqin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Jorm</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mathers</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Menezes</LastName><ForeName>Paulo R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Rimmer</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Scazufca</LastName><ForeName>Marcia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease International</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG009956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="Y">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16360788</ArticleId><ArticleId IdType="mid">NIHMS190462</ArticleId><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(05)67889-0</ArticleId><ArticleId IdType="pii">S0140-6736(05)67889-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . World Health Report 2003&#x2014;Shaping the future. WHO; Geneva: 2003.</Citation></Reference><Reference><Citation>Comas-Herrera A, Wittenberg R, Pickard L, Knapp M, MRC-CFAS . PSSRU Discussion Paper. 2005. Cognitive impairment in older people: its implications for future demand for services and costs; p. 1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">17603823</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider J, Murray J, Banerjee S, Mann A. EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I&#x2014;factors associated with carer burden. Int J Geriatr Psychiatry. 1999;14:651&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10489656</ArticleId></ArticleIdList></Reference><Reference><Citation>10/66 Dementia Research Group Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry. 2004;19:170&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758582</ArticleId></ArticleIdList></Reference><Reference><Citation>Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1495283</ArticleId><ArticleId IdType="pubmed">11722692</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince MJ. The need for research on dementia in developing countries. Trop Med Health. 1997;2:993&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">9357490</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A, Winblad B, Aguero-Torres H, vonStrauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2004;17:63&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794381</ArticleId></ArticleIdList></Reference><Reference><Citation>10/66 Dementia Research Group Methodological issues in population-based research into dementia in developing countries: a position paper from the 10/66 Dementia Research Group. Int J Geriatr Psychiatry. 2000;15:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10637401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST. Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology. 1998;51:1000&#x2013;08.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry. 1995;152:1485&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">7573588</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2550437</ArticleId><ArticleId IdType="pubmed">7640549</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1988;2:1&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9561895</ArticleId></ArticleIdList></Reference><Reference><Citation>Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156029</ArticleId><ArticleId IdType="pubmed">12773212</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagger C, Andersen K, Breteler MM, et al. Prognosis with dementia in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:S16&#x2013;S20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854356</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaji S, Promodu K, Abraham T, Roy KJ, Varghese A. An epidemiological study of dementia in a rural community in Kerala, India. Br J Psychiatry. 1996;186:745&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar S, Kumar S, Thara R. Prevalence of dementia in a rural setting: a report from India. Int J Geriatr Psychiatry. 1997;12:702&#x2013;07.</Citation><ArticleIdList><ArticleId IdType="pubmed">9251930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZX, Zahner GEP, Roman GC, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shangai, and Chengdu. Arch Neurol. 2005;62:447&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001;285:739&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001;57:985&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571321</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandav RS, Chandra V, Dodge HH, DeKosky ST, Ganguli M. Hemoglobin levels and Alzheimer disease: an epidemiologic study in India. Am J Geriatr Psychiatry. 2004;12:523&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353391</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee MA, Brayne C. The impact on prevalence of dementia in the oldest age groups of differential mortality patterns: a deterministic approach. Int J Epidemiol. 1998;27:87&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9563699</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee MA, Brayne C. Exploring the impact of prevalence and mortality on incidence of dementia in the oldest old: the sensitivity of a deterministic approach. Neuroepidemiology. 2001;20:221&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11684896</ArticleId></ArticleIdList></Reference><Reference><Citation>Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis. 1998;28:167&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10420064</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaji KS, Smitha K, Praveen Lal K, Prince M. Caregivers of patients with Alzheimer's disease : a qualitative study from the Indian 10/66 Dementia Research Network. Int J Geriatr Psychiatry. 2003;18:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12497550</ArticleId></ArticleIdList></Reference><Reference><Citation>10/66 Dementia Research Group Behavioral and psychological symptoms of dementia in developing countries. Int Psychogeriatr. 2004;16:441&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715360</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel V, Prince M. Ageing and mental health in a developing country: who cares? Qualitative studies from Goa, India. Psychol Med. 2001;31:29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11200957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalache A. Ageing is a third world problem too. Int J Geriatr Psychiatry. 1991;6:617&#x2013;18.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17610815</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits.</ArticleTitle><Pagination><StartPage>25</StartPage><EndPage>36</EndPage><MedlinePgn>25-36</MedlinePgn></Pagination><Abstract><AbstractText>Many biological functions depend critically upon fine details of tissue molecular architecture that have resisted exploration by existing imaging techniques. This is particularly true for nervous system tissues, where information processing function depends on intricate circuit and synaptic architectures. Here, we describe a new imaging method, called array tomography, which combines and extends superlative features of modern optical fluorescence and electron microscopy methods. Based on methods for constructing and repeatedly staining and imaging ordered arrays of ultrathin (50-200 nm), resin-embedded serial sections on glass microscope slides, array tomography allows for quantitative, high-resolution, large-field volumetric imaging of large numbers of antigens, fluorescent proteins, and ultrastructure in individual tissue specimens. Compared to confocal microscopy, array tomography offers the advantage of better spatial resolution, in particular along the z axis, as well as depth-independent immunofluorescent staining. The application of array tomography can reveal important but previously unseen features of brain molecular architecture.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Micheva</LastName><ForeName>Kristina D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA. kmicheva@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS054252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016704">Synapsins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2007 Sep 6;55(5):824</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="Y">Diagnostic Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="N">Neurology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038761" MajorTopicYN="N">Photobleaching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016704" MajorTopicYN="N">Synapsins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016610" MajorTopicYN="N">Tissue Embedding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17610815</ArticleId><ArticleId IdType="mid">NIHMS28480</ArticleId><ArticleId IdType="pmc">PMC2080672</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.06.014</ArticleId><ArticleId IdType="pii">S0896-6273(07)00441-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albrecht U, Seulberger H, Schwarz H, Risau W. Correlation of blood-brain barrier function and HT7 protein distribution in chick brain circumventricular organs. Brain Res. 1990;535:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">2292029</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumer MJ, Gahleitner P, Narzt T, Handl C, Ruthensteiner B. Ribbons of semithin sections: an advanced method with a new type of diamond knife. J. Neurosci. Methods. 2002;120:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">12351202</ArticleId></ArticleIdList></Reference><Reference><Citation>Brorson S-H, Roos N, Skjcrten F. Antibody penetration into LR-White sections. Micron. 1994;25:453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">7850351</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J. Neurocytol. 1996;25:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">9023727</ArticleId></ArticleIdList></Reference><Reference><Citation>De-Camilli P, Cameron R, Greengard P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. I. Its general distribution in synapses of the central and peripheral nervous system demonstrated by immunofluorescence in frozen and plastic sections. J. Cell Biol. 1983;96:1337&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112636</ArticleId><ArticleId IdType="pubmed">6404910</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialka I, Schwarz H, Reichmann E, Oft M, Busslinger M, Beug H. The estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctions. J. Cell Biol. 1996;132:1115&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120757</ArticleId><ArticleId IdType="pubmed">8601589</ArticleId></ArticleIdList></Reference><Reference><Citation>Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M. Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131:813&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749336</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, Gundersen HJ, van der Zee E, West MJ. Unbiased stereological estimation of the total number of synapses in a brain region. J. Neurocytol. 1996;25:805&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">9023726</ArticleId></ArticleIdList></Reference><Reference><Citation>Haraguchi CM, Yokota S. Immunofluorescence technique for 100-nm-thick semithin sections of Epon-embedded tissues. Histochem. Cell. Biol. 2002;117:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11819100</ArticleId></ArticleIdList></Reference><Reference><Citation>Herken R, Fussek M, Barth S, Gotz W. LR-White and LR-Gold resins for postembedding immunofluorescence staining of laminin in mouse kidney. Histochem. J. 1988;20:427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">3058649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolodziejczyk E, Baertschi AJ. Multiple immunolabeling in histology: a new method using thermo-inactivation of immunoglobulins. J. Histochem. Cytochem. 1986;34:1725&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">3023476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurth T, Schwarz H, Schneider S, Hausen P. Fine structural immunocytochemistry of catenins in amphibian and mammalian muscle. Cell Tissue Res. 1996;286:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8781207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Ong SL, Hu JY, Ng WJ, Feng Y, Tan X, Wong SW. Use of semiconductor quantum dots for photostable immunofluorescence labeling of Cryptosporidium parvum. Appl. Environ. Microbiol. 2004;70:5732&#x2013;5736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC522072</ArticleId><ArticleId IdType="pubmed">15466507</ArticleId></ArticleIdList></Reference><Reference><Citation>Luby-Phelps K, Ning G, Fogerty J, Besharse JC. Visualization of identified GFP-expressing cells by light and electron microscopy. J. Histochem. Cytochem. 2003;51:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12588954</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga W, Miyata S, Itoh M, Kiyohara T, Maekawa S. Expression of high levels of tubulin and microtubule-associated protein 2d in the neurohypophysial astrocytes of adult rat. Neuroscience. 2002;111:151&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955719</ArticleId></ArticleIdList></Reference><Reference><Citation>Matus AI, Walters BB, Mughal S. Immunohistochemical demonstration of tubulin associated with microtubules and synaptic junctions in mammalian brain. J. Neurocytol. 1975;4:733&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">1104776</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, Beaulieu C. Quantitative aspects of synaptogenesis in the rat barrel field cortex with special reference to GABA circuitry. J. Comp. Neurol. 1996;373:340&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">8889932</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, Vallee A, Beaulieu C, Herman IM, Leclerc N. beta-Actin is confined to structures having high capacity of remodelling in developing and adult rat cerebellum. Eur. J. Neurosci. 1998;10:3785&#x2013;3798.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori M, Ishikawa G, Takeshita T, Goto T, Robinson JM, Takizawa T. Ultrahigh-resolution immunofluorescence microscopy using ultrathin cryosections: subcellular distribution of caveolin-1alpha and CD31 in human placental endothelial cells. J. Electron Microsc. (Tokyo) 2006;55:107&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">16670105</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman GR, Hobot JA. Modern acrylics for post-embedding immunostaining techniques. J. Histochem. Cytochem. 1987;35:971&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pubmed">3302021</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman GR, Hobot JA. Resins for combined light and electron microscopy: a half century of development. Histochem. J. 1999;31:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507456</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman GR, Jasani B, Williams ED. A simple post-embedding system for the rapid demonstration of tissue antigens under the electron microscope. Histochem. J. 1983;15:543&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">6409845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojeda JL, Ros MA, Icardo JM. A technique for fluorescence microscopy in semithin sections. Stain Technol. 1989;64:243&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">2699110</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, Bhalgat MK, Millard PJ, Mao F, Leung WY, Haugland RP. Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. J. Histochem. Cytochem. 1999;47:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10449539</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawley JB. Handbook of biological confocal microscopy. Plenum Press; New York: 1995.</Citation></Reference><Reference><Citation>Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Bockelmann R, Malykh Y, Gollnick H, Friedenberger M, Bode M, Dress AW. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat. Biotechnol. 2006;24:1270&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;z A, Palm G. Density of neurons and synapses in the cerebral cortex of the mouse. J. Comp. Neurol. 1989;286:442&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">2778101</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Hennink EJ, Young IT, Tanke HJ. Photobleaching kinetics of fluorescein in quantitative fluorescence microscopy. Biophys. J. 1995;68:2588&#x2013;2600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1282169</ArticleId><ArticleId IdType="pubmed">7647262</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukhanova A, Venteo L, Devy J, Artemyev M, Oleinikov V, Pluot M, Nabiev I. Highly stable fluorescent nanocrystals as a novel class of labels for immunohistochemical analysis of paraffin-embedded tissue sections. Lab. Invest. 2002;82:1259&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218088</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafoya LCR, Mameli M, Miyashita T, Guzowski JF, Valenzuela CF, Wilson MC. Expression and Function of SNAP-25 as a Universal SNARE Component in GABAergic Neurons. J. Neurosci. 2006;26:7826&#x2013;7838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674219</ArticleId><ArticleId IdType="pubmed">16870728</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;venaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Transactions on Image Processing. 1998;7:27&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18267377</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramu G, Pillez A, Leonardelli J. An efficient method of antibody elution for the successive or simultaneous localization of two antigens by immunocytochemistry. J. Histochem. Cytochem. 1978;26:322&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">207771</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlby C, Erlandsson F, Bengtsson E, Zetterberg A. Sequential immunofluorescence staining and image analysis for detection of large numbers of antigens in individual cell nuclei. Cytometry. 2002;47:32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11774347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondervan R, Kulzer F, Kol&#x2019;chenko MA, Orrit M. Photobleaching of rhodamine 6G in Poly(vinyl alcohol) at the ensemble and single-molecule levels. J. Phys. Chem. 2004;108:1657&#x2013;1665.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1689489</PMID><DateCompleted><Year>1990</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>4</Issue><PubDate><Year>1990</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.</ArticleTitle><Pagination><StartPage>1561</StartPage><EndPage>1565</EndPage><MedlinePgn>1561-5</MedlinePgn></Pagination><Abstract><AbstractText>In the brains of aged humans and cases of Alzheimer disease, deposits of amyloid in senile plaques are located in proximity to nerve processes. The principal component of this extracellular amyloid is beta/A4, a peptide derived from a larger amyloid precursor protein (APP), which is actively expressed in brain and systemic organs. Mechanisms that result in the proteolysis of APP to form beta/A4, previously termed beta-amyloid protein, and the subsequent deposition of the peptide in brain are unknown. If beta/A4 in senile plaques is derived from neuronally synthesized APP and deposited at locations remote from sites of synthesis, then APP must be transported from neuronal cell bodies to distal nerve processes in proximity to deposits of amyloid. In this study, using several immunodetection methods, we demonstrate that APP is transported axonally in neurons of the rat peripheral nervous system. Moreover, our investigations show that APP is transported by means of the fast anterograde component. These findings are consistent with the hypothesis of a neuronal origin of beta/A4, in which amyloid is deposited in the brain parenchyma of aged individuals and cases of Alzheimer disease. In this setting, we suggest that APP is synthesized in neurons and delivered to dystrophic nerve endings, where subsequent alterations of local processing of APP result in deposits of brain amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>E H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2181.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Weidemann</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 03359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 07179</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1990</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1689489</ArticleId><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="doi">10.1073/pnas.87.4.1561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annu Rev Neurosci. 1986;9:489-512</Citation><ArticleIdList><ArticleId IdType="pubmed">3518588</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1969 Nov;115(3):465-72</Citation><ArticleIdList><ArticleId IdType="pubmed">4982085</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42</Citation><ArticleIdList><ArticleId IdType="pubmed">2503832</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 1989;58:287-307</Citation><ArticleIdList><ArticleId IdType="pubmed">2673012</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Aug 26;241(4869):1080-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2457949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1989 Apr 7;57(1):115-26</Citation><ArticleIdList><ArticleId IdType="pubmed">2649245</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Mar;86(6):2066-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2494659</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 1989;12:463-90</Citation><ArticleIdList><ArticleId IdType="pubmed">2648956</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1988 Apr;7(4):949-57</Citation><ArticleIdList><ArticleId IdType="pubmed">2900137</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1988 May;25(2):401-17</Citation><ArticleIdList><ArticleId IdType="pubmed">3399052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioessays. 1989 Feb-Mar;10(2-3):69-74</Citation><ArticleIdList><ArticleId IdType="pubmed">2655587</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 19-25;325(6106):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1987 Oct;84(19):6953-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3477820</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1987 Jul 3;237(4810):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3299701</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1986 Dec 15;141(2):782-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3541938</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1987 Dec 1;6(12):3627-32</Citation><ArticleIdList><ArticleId IdType="pubmed">3322812</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Mar;85(5):1691-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3278324</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1988 Nov;102(2):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2460367</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Feb 11;331(6156):528-30</Citation><ArticleIdList><ArticleId IdType="pubmed">2893290</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Feb 11;331(6156):525-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2893289</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Feb;85(4):1227-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3277188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1988 Feb 11;331(6156):530-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2893291</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1985 Nov;4(11):2757-63</Citation><ArticleIdList><ArticleId IdType="pubmed">4065091</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Feb;85(4):1297-301</Citation><ArticleIdList><ArticleId IdType="pubmed">3277189</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1984 Dec 21;226(4681):1443-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6505701</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1985 Jul;41(3):1017-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3924408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1985 Dec 30;361(1-2):267-75</Citation><ArticleIdList><ArticleId IdType="pubmed">4084799</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 May 16;120(3):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 1980 Oct;60(4):1167-283</Citation><ArticleIdList><ArticleId IdType="pubmed">6159657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1980 Nov;35(5):1053-66</Citation><ArticleIdList><ArticleId IdType="pubmed">6109004</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1988 Oct;1(8):669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">2908447</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8331390</PMID><DateCompleted><Year>1993</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0270-6474</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>1993</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system.</ArticleTitle><Pagination><StartPage>3136</StartPage><EndPage>3142</EndPage><MedlinePgn>3136-42</MedlinePgn></Pagination><Abstract><AbstractText>Amyloid deposits are a characteristic feature of the senile plaques identified in the brains of aged primates, individuals with Down's syndrome, and cases of Alzheimer's disease. The beta-amyloid protein (A beta), the principal component of amyloid, is a 4 kDa peptide derived from larger amyloid precursor protein(s) (APP). Four mRNAs, generated by alternative splicing of pre-mRNA derived from a single gene, encode A beta-containing membrane glycoproteins termed APP-695, -714, -751, and -770; the latter two isoforms contain a domain homologous to Kunitz protease inhibitors (KPI). The present study uses in vitro and in vivo strategies to examine the expression of APP in neurons of the dorsal root ganglia and the nature of APP transported in sciatic nerves of rats. Using quantitative in situ hybridization and semiquantitative PCR analysis, we document that mRNAs encoding APP-695 are expressed preferentially over transcripts that encode KPI-containing isoforms in rat sensory ganglia. Furthermore, we provide compelling evidence that APP-695 is the predominant isoform synthesized in sensory neurons of the rat PNS and that full-length APP-695 and, to a lesser extent, APP-751/770 are rapidly transported anterogradely in axons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>S S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>P N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>AG 05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 09287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 20471</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009475" MajorTopicYN="N">Neurons, Afferent</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8331390</ArticleId><ArticleId IdType="pmc">PMC6576678</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.13-07-03136.1993</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15745965</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>9</Issue><PubDate><Year>2005</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited.</ArticleTitle><Pagination><StartPage>2386</StartPage><EndPage>2395</EndPage><MedlinePgn>2386-95</MedlinePgn></Pagination><Abstract><AbstractText>The sequential enzymatic actions of beta-APP cleaving enzyme 1 (BACE1), presenilins (PS), and other proteins of the gamma-secretase complex liberate beta-amyloid (Abeta) peptides from larger integral membrane proteins, termed beta-amyloid precursor proteins (APPs). Relatively little is known about the normal function(s) of APP or the neuronal compartment(s) in which APP undergoes proteolytic processing. Recent studies have been interpreted as consistent with the idea that APP serves as a kinesin-1 cargo receptor and that PS and BACE1 are associated with the APP-resident membranous cargos that undergo rapid axonal transport. In this report, derived from a collaboration among several independent laboratories, we examined the potential associations of APP and kinesin-1 using glutathione S-transferase pull-down and coimmunoprecipitation assays. In addition, we assessed the trafficking of membrane proteins in the sciatic nerves of transgenic mice with heterozygous or homozygous deletions of APP. In contrast to previous reports, we were unable to find evidence for direct interactions between APP and kinesin-1. Furthermore, the transport of kinesin-1 and tyrosine kinase receptors, previously reported to require APP, was unchanged in axons of APP-deficient mice. Finally, we show that two components of the APP proteolytic machinery, i.e., PS1 and BACE1, are not cotransported with APP in the sciatic nerves of mice. These findings suggest that the hypothesis that APP serves as a kinesin-1 receptor and that the proteolytic processing machinery responsible for generating Abeta is transported in the same vesicular compartment in axons of peripheral nerves requires revision.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Orly</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Pharmacology, and Physiology, The University of Chicago, Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morfini</LastName><ForeName>Gerardo A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Farah</LastName><ForeName>Mohamed H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Szodorai</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>DeBoer</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Koliatsos</LastName><ForeName>Vassilis E</ForeName><Initials>VE</Initials></Author><Author ValidYN="Y"><LastName>Kins</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Scott T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS043408</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS45150</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS023868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045150</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS43408</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG011542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS23868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS23320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.5.1.18</RegistryNumber><NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005982" MajorTopicYN="N">Glutathione Transferase</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012584" MajorTopicYN="N">Sciatic Nerve</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020426" MajorTopicYN="N">Sciatic Neuropathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2005</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15745965</ArticleId><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3089-04.2005</ArticleId><ArticleId IdType="pii">25/9/2386</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate A&#x3b2;1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman AB, Kamal A, Ritchings BW, Philp AV, McGrail M, Gindhart JG, Goldstein LS (2000) Kinesin-dependent axonal transport is mediated by the Sunday Driver (SYD) protein. Cell 103: 583-594.</Citation><ArticleIdList><ArticleId IdType="pubmed">11106729</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Pfister KK, Bloom GS (1990) A monoclonal antibody against kinesin inhibits both anterograde and retrograde fast axonal transport in squid axoplasm. Proc Natl Acad Sci USA 87: 1061-1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53410</ArticleId><ArticleId IdType="pubmed">1689058</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18: 9629-9637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793291</ArticleId><ArticleId IdType="pubmed">9822724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat Neurosci 4: 233-234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2003) APH-1, PEN-2, and nicastrin with presenilin generate an active &#x3b3;-secretase complex. Neuron 38: 9-12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Elluru RG, Bloom GS, Brady ST (1995) Fast axonal transport of kinesin in the rat visual system: functionality of kinesin heavy chain isoforms. Mol Biol Cell 6: 21-40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275812</ArticleId><ArticleId IdType="pubmed">7538359</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by &#x3b2;-secretase cleavage within the secretory pathway. Nat Med 1: 1291-1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbich C, Monning U, Grund C, Masters CL, Beyreuther K (1993) Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11. J Biol Chem 268: 26571-26577.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Skehel P, Dotti CG (2000) Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell 11: 1213-1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14842</ArticleId><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS (2000) Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28: 449-459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001) Kinesin-mediated axonal transport of a membrane compartment containing &#x3b2;-secretase and presenilin-1 requires APP. Nature 414: 643-648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y, Okada Y, Tanaka Y, Harada A, Terada S, Hirokawa N (2000) KIF5C, a novel neuronal kinesin enriched in motor neurons. J Neurosci 20: 6374-6384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772948</ArticleId><ArticleId IdType="pubmed">10964943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesavapany S, Banner SJ, Lau KF, Shaw CE, Miller CC, Cooper JD, McLoughlin DM (2002) Expression of the Fe65 adapter protein in adult and developing mouse brain. Neuroscience 115: 951-960.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Lah JJ, Thinakaran G, Levey A, Sisodia SS (2000) Subcellular localization of presenilins: association with a unique membrane pool in cultured cells. Neurobiol Dis 7: 99-117.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Leem JY, Lah JJ, Slunt HH, Levey AI, Thinakaran G, Sisodia SS (2001) Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein. J Biol Chem 276: 43343-43350.</Citation><ArticleIdList><ArticleId IdType="pubmed">11564743</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 87: 1561-1565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53515</ArticleId><ArticleId IdType="pubmed">1689489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Bardel KA, Kulnane LS, Anderson JJ, Holtz G, Wagner SL, Sisodia SS, Hoeger EJ (1999) Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci 2: 695-697.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released &#x3b2;-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22: 9785-9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski JQ, Lee VM (2005) BACE overexpression alters the subcellular processing of APP and inhibits A&#x3b2; deposition in vivo. J Cell Biol 168: 291-302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS (1997) Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med 3: 756-760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Leopold PL, McDowall AW, Pfister KK, Bloom GS, Brady ST (1992) Association of kinesin with characterized membrane-bounded organelles. Cell Motil Cytoskeleton 23: 19-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">1382871</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Pfister KK, Brady S, Dahlstrom A (1999) Axonal transport and distribution of immunologically distinct kinesin heavy chains in rat neurons. J Neurosci Res 58: 226-241.</Citation><ArticleIdList><ArticleId IdType="pubmed">10502279</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcinkiewicz M, Seidah NG (2000) Coordinated expression of &#x3b2;-amyloid precursor protein and the putative &#x3b2;-secretase BACE and &#x3b1;-secretase ADAM10 in mouse and human brain. J Neurochem 75: 2133-2143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032903</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Yasukawa T, Homma Y, Ito Y, Niikura T, Hiraki T, Hirai S, Ohno S, Kita Y, Kawasumi M, Kouyama K, Yamamoto T, Kyriakis JM, Nishimoto I (2001) c-Jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1 scaffolds Alzheimer's amyloid precursor protein with JNK. J Neurosci 21: 6597-6607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763068</ArticleId><ArticleId IdType="pubmed">11517249</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Tsai MY, Szebenyi G, Brady ST (2001) Approaches to study interactions between kinesin motors and membranes. Methods Mol Biol 164: 147-162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11217604</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21: 281-293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp H, Pakaski M, Kasa P (2002) Presenilin-1 and the amyloid precursor protein are transported bidirectionally in the sciatic nerve of adult rat. Neurochem Int 41: 429-435.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213230</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister KK, Wagner MC, Stenoien DL, Brady ST, Bloom GS (1989) Monoclonal antibodies to kinesin heavy and light chains stain vesicle-like structures, but not microtubules, in cultured cells. J Cell Biol 108: 1453-1463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115510</ArticleId><ArticleId IdType="pubmed">2522455</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21: 479-505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Kamal A, Roberts EA, Goldstein LS (1999) Defective kinesin heavy chain behavior in mouse kinesin light chain mutants. J Cell Biol 146: 1277-1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156125</ArticleId><ArticleId IdType="pubmed">10491391</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE (2002) Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of A&#x3b2; amyloidosis. J Neurosci 22: 9794-9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi XP, Tugusheva K, Bruce JE, Lucka A, Wu GX, Chen-Dodson E, Price E, Li Y, Xu M, Huang Q, Sardana MK, Hazuda DJ (2003) &#x3b2;-secretase cleavage at amino acid residue 34 in the amyloid &#x3b2; peptide is dependent upon &#x3b3;-secretase activity. J Biol Chem 278: 21286-21294.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Koo EH, Hoffman PN, Perry G, Price DL (1993) Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J Neurosci 13: 3136-3142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576678</ArticleId><ArticleId IdType="pubmed">8331390</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenoien DL, Brady ST (1997) Immunochemical analysis of kinesin light chain function. Mol Biol Cell 8: 675-689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC276118</ArticleId><ArticleId IdType="pubmed">9247647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Kanai Y, Okada Y, Nonaka S, Takeda S, Harada A, Hirokawa N (1998) Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria. Cell 93: 1147-1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657148</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996) Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;&#x3b2;-secretase&#x201d; site occurs in the Golgi apparatus. J Biol Chem 271: 9390-9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, Borchelt DR, Sisodia SS (1997) Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem 272: 28415-28422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MY, Morfini G, Szebenyi G, Brady ST (2000) Release of kinesin from vesicles by hsc70 and regulation of fast axonal transport. Mol Biol Cell 11: 2161-2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14910</ArticleId><ArticleId IdType="pubmed">10848636</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PH, Elder G, Lazzarini RA, Nelson D, Trojanowski JQ, Lee VM (1995) Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits. J Cell Biol 129: 1629-1640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291190</ArticleId><ArticleId IdType="pubmed">7790359</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhey KJ, Meyer D, Deehan R, Blenis J, Schnapp BJ, Rapoport TA, Margolis B (2001) Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol 152: 959-970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198804</ArticleId><ArticleId IdType="pubmed">11238452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward BM, Moss B (2004) Vaccinia virus A36R membrane protein provides a direct link between intracellular enveloped virions and the microtubule motor kinesin. J Virol 78: 2486-2493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC369226</ArticleId><ArticleId IdType="pubmed">14963148</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57: 115-126.</Citation><ArticleIdList><ArticleId IdType="pubmed">2649245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski TP, Tanzi CL, Gindhart JG (2003) The Drosophila kinesin-I associated protein YETI binds both kinesin subunits. Biol Cell 95: 595-602.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisodia SS, Chen HY, Van der Ploeg LH (1995) &#x3b2;-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81: 525-531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17062754</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>103</Volume><Issue>44</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A peptide zipcode sufficient for anterograde transport within amyloid precursor protein.</ArticleTitle><Pagination><StartPage>16532</StartPage><EndPage>16537</EndPage><MedlinePgn>16532-7</MedlinePgn></Pagination><Abstract><AbstractText>Fast anterograde transport of membrane-bound organelles delivers molecules synthesized in the neuronal cell body outward to distant synapses. Identification of the molecular "zipcodes" on organelles that mediate attachment and activation of microtubule-based motors for this directed transport is a major area of inquiry. Here we identify a short peptide sequence (15 aa) from the cytoplasmic C terminus of amyloid precursor protein (APP-C) sufficient to mediate the anterograde transport of peptide-conjugated beads in the squid giant axon. APP-C beads travel at fast axonal transport rates (0.53 mum/s average velocity, 0.9 mum/s maximal velocity) whereas beads coupled to other peptides coinjected into the same axon remain stationary at the injection site. This transport appears physiologic, because it mimics behavior of endogenous squid organelles and of beads conjugated to C99, a polypeptide containing the full-length cytoplasmic domain of amyloid precursor protein (APP). Beads conjugated to APP lacking the APP-C domain are not transported. Coinjection of APP-C peptide reduces C99 bead motility by 75% and abolishes APP-C bead motility, suggesting that the soluble peptide competes with protein-conjugated beads for axoplasmic motor(s). The APP-C domain is conserved (13/15 aa) from squid to human, and peptides from either squid or human APP behave similarly. Thus, we have identified a conserved peptide zipcode sufficient to direct anterograde transport of exogenous cargo and suggest that one of APP's roles may be to recruit and activate axonal machinery for endogenous cargo transport.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satpute-Krishnan</LastName><ForeName>Prasanna</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Brown University Medical School, 70 Ship Street, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeGiorgis</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Conley</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bearer</LastName><ForeName>Elaine L</ForeName><Initials>EL</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>DQ913735</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS046810</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM 47562</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 046810</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049832" MajorTopicYN="N">Decapodiformes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17062754</ArticleId><ArticleId IdType="pmc">PMC1621108</ArticleId><ArticleId IdType="doi">10.1073/pnas.0607527103</ArticleId><ArticleId IdType="pii">0607527103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Enquist LW, Tomishima MJ, Gross S, Smith GA. Vet Microbiol. 2002;86:5&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11888685</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland DJ, Miranda-Saksena M, Boadle RA, Armati P, Cunningham AL. J Virol. 1999;73:8503&#x2013;8511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112870</ArticleId><ArticleId IdType="pubmed">10482603</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Saksena M, Armati P, Boadle RA, Holland DJ, Cunningham AL. J Virol. 2000;74:1827&#x2013;1839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111661</ArticleId><ArticleId IdType="pubmed">10644356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dohner K, Nagel CH, Sodeik B. Trends Microbiol. 2005;13:320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">15950476</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearer EL, Satpute-Krishnan P. Current Drug Targets Infect Disord. 2002;2:247&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616324</ArticleId><ArticleId IdType="pubmed">12462128</ArticleId></ArticleIdList></Reference><Reference><Citation>Satpute-Krishnan P, DeGiorgis JA, Bearer EL. Aging Cell. 2003;2:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622731</ArticleId><ArticleId IdType="pubmed">14677633</ArticleId></ArticleIdList></Reference><Reference><Citation>Roizman B, Knipe DM. In: Fields Virology. Knipe DM, Howley PM, editors. Vol. 2. Philadelphia: Lippincott Williams; 2001. pp. 2399&#x2013;2459.</Citation></Reference><Reference><Citation>Ohara PT, Chin MS, LaVail JH. J Virol. 2000;74:4776&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112000</ArticleId><ArticleId IdType="pubmed">10775616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycke E, Kristensson K, Svennerholm B, Vahlne A, Ziegler R. J Gen Virol. 1984;65:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6319574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensson K, Lycke E, Roytta M, Svennerholm B, Vahlne A. J Gen Virol. 1986;67:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pubmed">2427647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. Proc Natl Acad Sci USA. 2000;97:8146&#x2013;8150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16684</ArticleId><ArticleId IdType="pubmed">10884436</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena S, Goldstein LS. Neuron. 2001;32:389&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. Neuron. 2000;28:449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Nature. 2001;414:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. J Cell Sci. 2000;113:1857&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams RJ, Bray D. Nature. 1983;303:718&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">6190095</ArticleId></ArticleIdList></Reference><Reference><Citation>Terasaki M, Schmidek A, Galbraith JA, Gallant PE, Reese TS. Proc Natl Acad Sci USA. 1995;92:11500&#x2013;11503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40429</ArticleId><ArticleId IdType="pubmed">8524791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearer EL, Reese TS. J Neurocytol. 1999;28:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643673</ArticleId><ArticleId IdType="pubmed">10590510</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopfenstein DR, Tomishige M, Stuurman N, Vale RD. Cell. 2002;109:347&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851634</ArticleId><ArticleId IdType="pubmed">12015984</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale RD, Schnapp BJ, Reese TS, Sheetz MP. Cell. 1985;40:559&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578887</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Lasek RJ, Allen RD. Science. 1982;218:1129&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">6183745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale RD, Schnapp BJ, Reese TS, Sheetz MP. Cell. 1985;40:449&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578324</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang MY, Sheetz MP. Biophys J. 1995;68:283S&#x2013;284S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1281948</ArticleId><ArticleId IdType="pubmed">7787091</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman DS, Vale RD. Nat Cell Biol. 1999;1:293&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559942</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiler S, Kirchner J, Horn C, Kallipolitou A, Woehlke G, Schliwa M. Nat Cell Biol. 2000;2:333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854323</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST. EMBO J. 2004;23:2235&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419914</ArticleId><ArticleId IdType="pubmed">15152189</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. EMBO J. 2002;21:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, et al. J Neurosci. 2005;25:2386&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, et al. Cell. 1995;81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>Taru H, Iijima K, Hase M, Kirino Y, Yagi Y, Suzuki T. J Biol Chem. 2002;277:20070&#x2013;20078.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912189</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhey KJ, Meyer D, Deehan R, Blenis J, Schnapp BJ, Rapoport TA, Margolis B. J Cell Biol. 2001;152:959&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198804</ArticleId><ArticleId IdType="pubmed">11238452</ArticleId></ArticleIdList></Reference><Reference><Citation>Prahlad V, Helfand BT, Langford GM, Vale RD, Goldman RD. J Cell Sci. 2000;113:3939&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pubmed">11058081</ArticleId></ArticleIdList></Reference><Reference><Citation>Terada S, Hirokawa N. Curr Opin Neurobiol. 2000;10:566&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">11084318</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah JV, Cleveland DW. Curr Opin Cell Biol. 2002;14:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11792545</ArticleId></ArticleIdList></Reference><Reference><Citation>Setou M, Seog DH, Tanaka Y, Kanai Y, Takei Y, Kawagishi M, Hirokawa N. Nature. 2002;417:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986669</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoshima I, Yu H, Steuer ER, Sheetz MP. J Cell Biol. 1992;118:1121&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289597</ArticleId><ArticleId IdType="pubmed">1512292</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi D, Barkus RV, Pilling AD, Gassman A, Saxton WM. Curr Biol. 2005;15:2137&#x2013;2141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1532932</ArticleId><ArticleId IdType="pubmed">16332540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cescato R, Dumermuth E, Spiess M, Paganetti PA. J Neurochem. 2000;74:1131&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693945</ArticleId></ArticleIdList></Reference><Reference><Citation>Homayouni R, Rice DS, Sheldon M, Curran T. J Neurosci. 1999;19:7507&#x2013;7515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782519</ArticleId><ArticleId IdType="pubmed">10460257</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto M, Nakajima Y, Matsuyama T, Sugita M. Neuroscience. 2001;104:653&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440799</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Borg JP, Margolis B, Herz J. J Biol Chem. 1998;273:33556&#x2013;33560.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Boulan E, Musch A. Biochim Biophys Acta. 2005;1744:455&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">15927284</ArticleId></ArticleIdList></Reference><Reference><Citation>Inomata H, Nakamura Y, Hayakawa A, Takata H, Suzuki T, Miyazawa K, Kitamura N. J Biol Chem. 2003;278:22946&#x2013;22955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665528</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. J Cell Biol. 2005;171:615&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171566</ArticleId><ArticleId IdType="pubmed">16301330</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. J Neurosci. 2005;25:3741&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724916</ArticleId><ArticleId IdType="pubmed">15829626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearer EL, DeGiorgis JA, Bodner RA, Kao AW, Reese TS. Proc Natl Acad Sci USA. 1993;90:11252&#x2013;11256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47960</ArticleId><ArticleId IdType="pubmed">8248236</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe LA, Terasaki M. Methods Cell Biol. 2004;74:219&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1945233</ArticleId><ArticleId IdType="pubmed">15575609</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. J Cell Biol. 2002;156:1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, Tsien RY. Proc Natl Acad Sci USA. 2002;99:7877&#x2013;7882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122988</ArticleId><ArticleId IdType="pubmed">12060735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16815330</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>42</EndPage><MedlinePgn>29-42</MedlinePgn></Pagination><Abstract><AbstractText>Degeneration of basal forebrain cholinergic neurons (BFCNs) contributes to cognitive dysfunction in Alzheimer's disease (AD) and Down's syndrome (DS). We used Ts65Dn and Ts1Cje mouse models of DS to show that the increased dose of the amyloid precursor protein gene, App, acts to markedly decrease NGF retrograde transport and cause degeneration of BFCNs. NGF transport was also decreased in mice expressing wild-type human APP or a familial AD-linked mutant APP; while significant, the decreases were less marked and there was no evident degeneration of BFCNs. Because of evidence suggesting that the NGF transport defect was intra-axonal, we explored within cholinergic axons the status of early endosomes (EEs). NGF-containing EEs were enlarged in Ts65Dn mice and their App content was increased. Our study thus provides evidence for a pathogenic mechanism for DS in which increased expression of App, in the context of trisomy, causes abnormal transport of NGF and cholinergic neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salehi</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, USA. asalehi@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delcroix</LastName><ForeName>Jean-Dominique</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Belichenko</LastName><ForeName>Pavel V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Ke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chengbiao</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Valletta</LastName><ForeName>Janice S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Takimoto-Kimura</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kleschevnikov</LastName><ForeName>Alexander M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Sambamurti</LastName><ForeName>Kumar</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Weiming</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Villar</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>William A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Kulnane</LastName><ForeName>Laura Shapiro</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Stokin</LastName><ForeName>Gorazd B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Mobley</LastName><ForeName>William C</ForeName><Initials>WC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>31498</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16999</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38869</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9061-61-4</RegistryNumber><NameOfSubstance UI="D020932">Nerve Growth Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2006 Jul 6;51(1):1-3. doi: 10.1016/j.neuron.2006.06.019.</RefSource><PMID Version="1">16815323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020532" MajorTopicYN="N">Basal Nucleus of Meynert</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002799" MajorTopicYN="N">Cholinergic Fibers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020932" MajorTopicYN="N">Nerve Growth Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2006.05.022</ArticleId><ArticleId IdType="pii">S0896-6273(06)00414-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22323736</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>335</Volume><Issue>6075</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models.</ArticleTitle><Pagination><StartPage>1503</StartPage><EndPage>1506</EndPage><MedlinePgn>1503-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1217697</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is associated with impaired clearance of &#x3b2;-amyloid (A&#x3b2;) from the brain, a process normally facilitated by apolipoprotein E (apoE). ApoE expression is transcriptionally induced through the action of the nuclear receptors peroxisome proliferator-activated receptor gamma and liver X receptors in coordination with retinoid X receptors (RXRs). Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced clearance of soluble A&#x3b2; within hours in an apoE-dependent manner. A&#x3b2; plaque area was reduced more than 50% within just 72 hours. Furthermore, bexarotene stimulated the rapid reversal of cognitive, social, and olfactory deficits and improved neural circuit function. Thus, RXR activation stimulates physiological A&#x3b2; clearance mechanisms, resulting in the rapid reversal of a broad range of A&#x3b2;-induced deficits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Paige E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Wesson</LastName><ForeName>Daniel W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C Y Daniel</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Karlo</LastName><ForeName>J Colleen</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Zinn</LastName><ForeName>Adriana E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Casali</LastName><ForeName>Brad T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Restivo</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Goebel</LastName><ForeName>Whitney D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Brunden</LastName><ForeName>Kurt R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Donald A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG030482-03S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG037693</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC003906</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DC003906</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037693</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047488">Retinoid X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>A61RXM4375</RegistryNumber><NameOfSubstance UI="D000077610">Bexarotene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2012 Mar 23;335(6075):1447-8. doi: 10.1126/science.1220725.</RefSource><PMID Version="1">22442467</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2012 Mar 30;11(4):271. doi: 10.1038/nrd3706.</RefSource><PMID Version="1">22460119</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2013 May 24;340(6135):924-c. doi: 10.1126/science.1235809.</RefSource><PMID Version="1">23704552</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2013 May 24;340(6135):924-d. doi: 10.1126/science.1234089.</RefSource><PMID Version="1">23704553</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2013 May 24;340(6135):924-e. doi: 10.1126/science.1233937.</RefSource><PMID Version="1">23704554</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.</RefSource><PMID Version="1">23704555</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114.</RefSource><PMID Version="1">23704556</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077610" MajorTopicYN="N">Bexarotene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009812" MajorTopicYN="N">Odorants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009833" MajorTopicYN="N">Olfactory Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047495" MajorTopicYN="N">PPAR gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047488" MajorTopicYN="N">Retinoid X Receptors</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22323736</ArticleId><ArticleId IdType="mid">NIHMS460482</ArticleId><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="doi">10.1126/science.1217697</ArticleId><ArticleId IdType="pii">science.1217697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Querfurth HW, LaFerla FM. N Engl J Med. 2010;362:329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, et al. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Nat Neurosci. 2010;13:812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Saunders AM. Curr Opin Biotechnol. 1994;5:663.</Citation><ArticleIdList><ArticleId IdType="pubmed">7765750</ArticleId></ArticleIdList></Reference><Reference><Citation>Donkin JJ, et al. J Biol Chem. 2010;285:34144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962513</ArticleId><ArticleId IdType="pubmed">20739291</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, et al. Neuron. 2008;58:681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla A, et al. Mol Cell. 2001;7:161.</Citation><ArticleIdList><ArticleId IdType="pubmed">11172721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre P, Benomar Y, Staels B. Trends Endocrinol Metab. 2010;21:676.</Citation><ArticleIdList><ArticleId IdType="pubmed">20674387</ArticleId></ArticleIdList></Reference><Reference><Citation>Odegaard JI, Chawla A. Annu Rev Pathol. 2011;6:275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381938</ArticleId><ArticleId IdType="pubmed">21034223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar-Colucci S, Landreth GE. Expert Opin Ther Targets. 2011;15:1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156324</ArticleId><ArticleId IdType="pubmed">21718217</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. 1999  www.accessdata.fda.gov/drugsatfda_docs/nda/99/21055_Targretin.cfm.</Citation></Reference><Reference><Citation>Farol LT, Hymes KB. Expert Rev Anticancer Ther. 2004;4:180.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056048</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. J Neurosci. 2003;23:8844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. EMBO Rep. 2006;7:940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesson DW, Wilson DA. Behav Brain Res. 2011;216:408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975804</ArticleId><ArticleId IdType="pubmed">20804789</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy C. Physiol Behav. 1999;66:177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesson DW, Levy E, Nixon RA, Wilson DA. J Neurosci. 2010;30:505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826174</ArticleId><ArticleId IdType="pubmed">20071513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesson DW, et al. J Neurosci. 2011;31:15962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417321</ArticleId><ArticleId IdType="pubmed">22049439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopell N, Ermentrout GB, Whittington MA, Traub RD. Proc Natl Acad Sci USA. 2000;97:1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26528</ArticleId><ArticleId IdType="pubmed">10677548</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, et al. J Neurosci. 2010;30:11157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="pubmed">20720123</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, et al. J Neurosci. 2005;25:8898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, et al. Nat Neurosci. 2002;5:452.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones L, et al. PLoS ONE. 2010;5:e13950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981526</ArticleId><ArticleId IdType="pubmed">21085570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Nat Genet. 2011;43:429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Nat Genet. 2011;43:436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11224535</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1097-6256</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.</ArticleTitle><Pagination><StartPage>231</StartPage><EndPage>232</EndPage><MedlinePgn>231-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Amgen, One Amgen Center Drive, MS 29-2-B, Thousand Oaks, California 91320, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolon</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>B D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Babu-Khan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Denis</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kha</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Louis</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>W G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017933" MajorTopicYN="N">Peripheral Nervous System</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId><ArticleId IdType="doi">10.1038/85059</ArticleId><ArticleId IdType="pii">85059</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10531052</PMID><DateCompleted><Year>1999</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>286</Volume><Issue>5440</Issue><PubDate><Year>1999</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.</ArticleTitle><Pagination><StartPage>735</StartPage><EndPage>741</EndPage><MedlinePgn>735-41</MedlinePgn></Pagination><Abstract><AbstractText>Cerebral deposition of amyloid beta peptide (Abeta) is an early and critical feature of Alzheimer's disease. Abeta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of beta-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as beta-secretase. Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for beta-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amgen, Inc., One Amgen Center Drive, M/S 29-2-B, Thousand Oaks, CA 91320-1799, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>B D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Babu-Khan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mendiaz</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Denis</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Teplow</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Amarante</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Loeloff</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Edenson</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lile</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jarosinski</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Biere</LastName><ForeName>A L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Louis</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Treanor</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AF190725</AccessionNumber><AccessionNumber>AF190726</AccessionNumber><AccessionNumber>AF190727</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 1999 Nov 12;286(5443):1254</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 1999 Oct 22;286(5440):650-1. doi: 10.1126/science.286.5440.650.</RefSource><PMID Version="1">10577210</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015723" MajorTopicYN="N">Gene Library</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pii">7936</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20484628</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>20</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.</ArticleTitle><Pagination><StartPage>6862</StartPage><EndPage>6872</EndPage><MedlinePgn>6862-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1051-10.2010</ELocationID><Abstract><AbstractText>High-fat diet and certain dietary patterns are associated with higher incidence of sporadic Alzheimer's disease (AD) and cognitive decline. However, no specific therapy has been suggested to ameliorate the negative effects of high fat/high cholesterol levels on cognition and amyloid pathology. Here we show that in 9-month-old APP23 mice, a high-fat/high-cholesterol (HF) diet provided for 4 months exacerbates the AD phenotype evaluated by behavioral, morphological, and biochemical assays. To examine the therapeutic potential of liver X receptor (LXR) ligands, APP23 mice were fed HF diet supplemented with synthetic LXR agonist T0901317 (T0). Our results demonstrate that LXR ligand treatment causes a significant reduction of memory deficits observed during both acquisition and retention phases of the Morris water maze. Moreover, the effects of T0 on cognition correlate with AD-like morphological and biochemical parameters. We found a significant decrease in amyloid plaque load, insoluble Abeta and soluble Abeta oligomers. In vitro experiments with primary glia demonstrate that Abca1 is essential for the proper lipidation of ApoE and mediates the effects of T0 on Abeta degradation by microglia. Microdialysis experiments performed on awake freely moving mice showed that T0 decreased Abeta levels in the interstitial fluid of the hippocampus, supporting the conclusion that this treatment increases Abeta clearance. The data presented conclusively shows that LXR activation in the context of a metabolic challenge has critical effects on AD phenotype progression by attenuating Abeta deposition and facilitating its clearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fitz</LastName><ForeName>Nicholas F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cronican</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Tam</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fogg</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fauq</LastName><ForeName>Abdul H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lefterov</LastName><ForeName>Iliya</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Koldamova</LastName><ForeName>Radosveta</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG031956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG031956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577836">ABCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004041">Dietary Fats</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423915">T0901317</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004041" MajorTopicYN="N">Dietary Fats</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006845" MajorTopicYN="N">Hydrocarbons, Fluorinated</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="Y">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012153" MajorTopicYN="N">Retention, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20484628</ArticleId><ArticleId IdType="mid">NIHMS206679</ArticleId><ArticleId IdType="pmc">PMC2883862</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1051-10.2010</ArticleId><ArticleId IdType="pii">30/20/6862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronican AA, Fitz NF, Pham T, Fogg A, Kifer B, Koldamova R, Lefterov I. Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010;79:1310&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834822</ArticleId><ArticleId IdType="pubmed">20060385</ArticleId></ArticleIdList></Reference><Reference><Citation>George AJ, Holsinger RMD, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters CL, Li QX. APP intracellular domain is increased and soluble A[beta] is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 2004;16:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207269</ArticleId></ArticleIdList></Reference><Reference><Citation>Grefhorst A, Elzinga BM, Voshol PJ, Pl&#xf6;sch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002;277:34182&#x2013;34190.</Citation><ArticleIdList><ArticleId IdType="pubmed">12097330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaany NY, Mangelsdorf DJ. LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol. 2006;68:159&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, H&#xe4;nninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, H&#xe4;nninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, K&#xe5;reholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62:1556&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216938</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach. Curr Alzheimer Res. 2007;4:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430243</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005a;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005b;280:4079&#x2013;4088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A. 2001;98:507&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14617</ArticleId><ArticleId IdType="pubmed">11149950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener. 2007;2:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2214725</ArticleId><ArticleId IdType="pubmed">17953774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Fitz N, Cronican A, Lefterov PI, Staufenbiel M, Koldamova RP. Memory deficits in APP23/Abca1+/&#x2212; mice correlate with the level of Abeta oligomers. ASN Neuro. 2009;1:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695585</ArticleId><ArticleId IdType="pubmed">19570031</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrott MD, Greenwood CE. Dietary influences on cognitive function with aging: from high-fat diets to healthful eating. Ann N Y Acad Sci. 2007;1114:389&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986600</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng D, Hiipakka RA, Xie JT, Reardon CA, Getz GS, Liao S. Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice. Atherosclerosis. 2010;208:126&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813337</ArticleId><ArticleId IdType="pubmed">19632679</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993;342:697&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003;6:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12658281</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964604</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592856</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007;34:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol. 2006;63:1709&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024906</ArticleId><ArticleId IdType="pubmed">17030648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Glass CK. Regulation of macrophage function in inflammation and atherosclerosis. J Lipid Res. 2009;50(Suppl):S277&#x2013;S281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674700</ArticleId><ArticleId IdType="pubmed">18987388</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460&#x2013;6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington CL, Johnsen RD, Dhaliwal SS, Mamo JC. Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta. Br J Nutr. 2010;103:652&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">19860996</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, Bhat NR. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008;106:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897170</ArticleId><ArticleId IdType="pubmed">18410513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanotti I, Favari E, Sposito AC, Rothblat GH, Bernini F. Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun. 2004;321:670&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">15358158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A. 2007;104:10601&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23575824</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>15</Issue><PubDate><Year>2013</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric a&#x3b2;, and frank neuronal loss.</ArticleTitle><Pagination><StartPage>6245</StartPage><EndPage>6256</EndPage><MedlinePgn>6245-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3672-12.2013</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is hallmarked by amyloid plaques, neurofibrillary tangles, and widespread cortical neuronal loss (Selkoe, 2001). The "amyloid cascade hypothesis" posits that cerebral amyloid sets neurotoxic events into motion that precipitate Alzheimer dementia (Hardy and Allsop, 1991). Yet, faithful recapitulation of all AD features in widely used transgenic (Tg) mice engineered to overproduce A&#x3b2; peptides has been elusive. We have developed a Tg rat model (line TgF344-AD) expressing mutant human amyloid precursor protein (APPsw) and presenilin 1 (PS1&#x394;E9) genes, each independent causes of early-onset familial AD. TgF344-AD rats manifest age-dependent cerebral amyloidosis that precedes tauopathy, gliosis, apoptotic loss of neurons in the cerebral cortex and hippocampus, and cognitive disturbance. These results demonstrate progressive neurodegeneration of the Alzheimer type in these animals. The TgF344-AD rat fills a critical need for a next-generation animal model to enable basic and translational AD research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Neurosciences, S Mark Taper Imaging Center, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. robert.m.cohen@emory.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezai-Zadeh</LastName><ForeName>Kavon</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Weitz</LastName><ForeName>Tara M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Rentsendorj</LastName><ForeName>Altan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Spivak</LastName><ForeName>Inna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bholat</LastName><ForeName>Yasmin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Vasilevko</LastName><ForeName>Vitaly</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Breunig</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Rakic</LastName><ForeName>Pasko</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Agadjanyan</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Kepe</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Barrio</LastName><ForeName>Jorge R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Bannykh</LastName><ForeName>Serguei</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Szekely</LastName><ForeName>Christine A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Pechnick</LastName><ForeName>Robert N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Town</LastName><ForeName>Terrence</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>3R00AG029726-04S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076794</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG029726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG033394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R00AG029726-03</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21AG033394-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R00AG029726-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS014841</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS076794-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C538248">Amyloid angiopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011916" MajorTopicYN="N">Rats, Inbred F344</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055647" MajorTopicYN="N">Rats, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23575824</ArticleId><ArticleId IdType="mid">NIHMS466277</ArticleId><ArticleId IdType="pmc">PMC3720142</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3672-12.2013</ArticleId><ArticleId IdType="pii">33/15/6245</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001;21:RC189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763047</ArticleId><ArticleId IdType="pubmed">11734604</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CA. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol. 1979;93:74&#x2013;104. doi: 10.1037/h0077579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0077579</ArticleId><ArticleId IdType="pubmed">221551</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CA, Jung MW, McNaughton BL, Korol DL, Andreasson K, Worley PF. LTP saturation and spatial learning disruption: effects of task variables and saturation levels. J Neurosci. 1994;14:5793&#x2013;5806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576980</ArticleId><ArticleId IdType="pubmed">7931545</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl C. Apoptosis and Alzheimer's disease. J Neural Transm. 2000;107:1325&#x2013;1344. doi: 10.1007/s007020070021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020070021</ArticleId><ArticleId IdType="pubmed">11145007</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol. 1990;49:215&#x2013;224. doi: 10.1097/00005072-199005000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199005000-00003</ArticleId><ArticleId IdType="pubmed">1692337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J Neurol Sci. 1989;93:277&#x2013;287. doi: 10.1016/0022-510X(89)90197-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(89)90197-4</ArticleId><ArticleId IdType="pubmed">2556503</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756. doi: 10.1038/27351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/27351</ArticleId><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis. 2008;15:571&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667339</ArticleId><ArticleId IdType="pubmed">19096157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol. 1995;10:19&#x2013;45. doi: 10.1007/BF02740836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02740836</ArticleId><ArticleId IdType="pubmed">7598831</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204. doi: 10.1038/nature08890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08890</ArticleId><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 2002;59:398&#x2013;407. doi: 10.1212/WNL.59.3.398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.3.398</ArticleId><ArticleId IdType="pubmed">12177374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Wertkin A, Mattiace LA, Fier E, Kress Y, Davies P, Yen SH. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol. 1990;79:486&#x2013;493. doi: 10.1007/BF00296107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00296107</ArticleId><ArticleId IdType="pubmed">2158201</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Pereztur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713. doi: 10.1038/383710a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/383710a0</ArticleId><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology. 1996;46:1592&#x2013;1596. doi: 10.1212/WNL.46.6.1592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.46.6.1592</ArticleId><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M. First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging. 2012;33:1448&#x2013;1456.</Citation><ArticleIdList><ArticleId IdType="pubmed">21196063</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717f beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527. doi: 10.1038/373523a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/373523a0</ArticleId><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med. 2008;12:2263&#x2013;2280. doi: 10.1111/j.1582-4934.2008.00402.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00402.x</ArticleId><ArticleId IdType="pmc">PMC4514105</ArticleId><ArticleId IdType="pubmed">18624755</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A. 1990;87:5827&#x2013;5831. doi: 10.1073/pnas.87.15.5827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.15.5827</ArticleId><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M. Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. J Neurochem. 2009;108:1167&#x2013;1176. doi: 10.1111/j.1471-4159.2009.05869.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.05869.x</ArticleId><ArticleId IdType="pubmed">19141083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383&#x2013;388. doi: 10.1016/0165-6147(91)90609-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-6147(91)90609-V</ArticleId><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97&#x2013;100. doi: 10.1038/nm0198-097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0198-097</ArticleId><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931. doi: 10.1212/01.WNL.0000115115.98960.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000115115.98960.37</ArticleId><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165. doi: 10.1016/S1389-0344(01)00067-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-0344(01)00067-3</ArticleId><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol. 1989;135:309&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879919</ArticleId><ArticleId IdType="pubmed">2675616</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and a-beta(42) deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555. doi: 10.1073/pnas.94.4.1550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.4.1550</ArticleId><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006;413:326&#x2013;344. doi: 10.1016/S0076-6879(06)13017-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(06)13017-7</ArticleId><ArticleId IdType="pubmed">17046404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamy C, Duyckaerts C, Delaere P, Payan C, Fermanian J, Poulain V, Hauw JJ. Comparison of seven staining methods for senile plaques and neurofibrillary tangles in a prospective series of 15 elderly patients. Neuropathol Appl Neurobiol. 1989;15:563&#x2013;578. doi: 10.1111/j.1365-2990.1989.tb01255.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1989.tb01255.x</ArticleId><ArticleId IdType="pubmed">2482455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener. 2007;2:11. doi: 10.1186/1750-1326-2-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-2-11</ArticleId><ArticleId IdType="pmc">PMC1906777</ArticleId><ArticleId IdType="pubmed">17559680</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010;20:113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164597</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis. 2008;31:46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995509</ArticleId><ArticleId IdType="pubmed">18504134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862. doi: 10.1016/S0002-9440(10)65184-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65184-X</ArticleId><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P, Korvatska E, Poorkaj P, Evstafjeva Z, Robinson L, Greenup L, Leverenz J, Schellenberg GD, D'Souza I. Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol. 2008;511:788&#x2013;803. doi: 10.1002/cne.21867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21867</ArticleId><ArticleId IdType="pmc">PMC2845852</ArticleId><ArticleId IdType="pubmed">18925637</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of Abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry. 2007;46:8850&#x2013;8860. doi: 10.1021/bi700411k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi700411k</ArticleId><ArticleId IdType="pubmed">17595112</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan J, Levy M, Dickson DW, Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain. 2006;129:3020&#x2013;3034. doi: 10.1093/brain/awl255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl255</ArticleId><ArticleId IdType="pubmed">16987932</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic; 2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">6110810</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Hoe HS, Moussa CE. Beta-amyloid1&#x2013;42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem. 2010;285:7440&#x2013;7446. doi: 10.1074/jbc.M109.083915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.083915</ArticleId><ArticleId IdType="pmc">PMC2844192</ArticleId><ArticleId IdType="pubmed">20071340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenwald A, Reusche E, Ogomori K, Teichert HM. Comparison of silver stainings and immunohistology for the detection of neurofibrillary tangles and extracellular cerebral amyloid in paraffin sections. Acta Neuropathol. 1993;86:182&#x2013;186. doi: 10.1007/BF00334887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00334887</ArticleId><ArticleId IdType="pubmed">7692696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL. A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol. 1989;48:674&#x2013;691. doi: 10.1097/00005072-198911000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198911000-00009</ArticleId><ArticleId IdType="pubmed">2677252</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;2663. doi: 10.1056/NEJMoa054625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa054625</ArticleId><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadelmann C, Br&#xfc;ck W, Bancher C, Jellinger K, Lassmann H. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol. 1998;57:456&#x2013;464. doi: 10.1097/00005072-199805000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199805000-00009</ArticleId><ArticleId IdType="pubmed">9596416</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol. 2008;65:906&#x2013;912. doi: 10.1001/archneur.65.7.906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.7.906</ArticleId><ArticleId IdType="pmc">PMC2586606</ArticleId><ArticleId IdType="pubmed">18625856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292. doi: 10.1073/pnas.94.24.13287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.24.13287</ArticleId><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW. Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res. 2001;898:350&#x2013;357. doi: 10.1016/S0006-8993(01)02018-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(01)02018-2</ArticleId><ArticleId IdType="pubmed">11306022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 1999;286:2352&#x2013;2355. doi: 10.1126/science.286.5448.2352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5448.2352</ArticleId><ArticleId IdType="pubmed">10600748</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci. 2002;5:1288&#x2013;1293. doi: 10.1038/nn968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn968</ArticleId><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839. doi: 10.1021/bi001048s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi001048s</ArticleId><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002a;416:535&#x2013;539. doi: 10.1038/416535a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002b;30:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan H, Aggleton JP, Brown MW. Different contributions of the hippocampus and perirhinal cortex to recognition memory. J Neurosci. 1999;19:1142&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782155</ArticleId><ArticleId IdType="pubmed">9920675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci. 2008;28:1537&#x2013;1545. doi: 10.1523/JNEUROSCI.5066-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5066-07.2008</ArticleId><ArticleId IdType="pmc">PMC2621082</ArticleId><ArticleId IdType="pubmed">18272675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature. 1997;389:603&#x2013;606. doi: 10.1038/39321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/39321</ArticleId><ArticleId IdType="pubmed">9335500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612&#x2013;618. doi: 10.1038/87945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/87945</ArticleId><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Smit AF, Schwartz S, Chiaromonte F, Roskin KM, Haussler D, Miller W, Hardison RC. Patterns of insertions and their covariation with substitutions in the rat, mouse, and human genomes. Genome Res. 2004;14:517&#x2013;527. doi: 10.1101/gr.1984404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1984404</ArticleId><ArticleId IdType="pmc">PMC383295</ArticleId><ArticleId IdType="pubmed">15059992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiike Y, Minai R, Matsuo Y, Chen YR, Kimura T, Takashima A. Amyloid oligomer conformation in a group of natively folded proteins. PLoS One. 2008;3:e3235. doi: 10.1371/journal.pone.0003235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003235</ArticleId><ArticleId IdType="pmc">PMC2528939</ArticleId><ArticleId IdType="pubmed">18800165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Raina AK, Perry G, Smith MA. Apoptosis in Alzheimer disease: a mathematical improbability. Curr Alzheimer Res. 2006;3:393&#x2013;396. doi: 10.2174/156720506778249470.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720506778249470</ArticleId><ArticleId IdType="pubmed">17017869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23596063</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>20</Issue><PubDate><Year>2013</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden.</ArticleTitle><Pagination><StartPage>1888</StartPage><EndPage>1894</EndPage><MedlinePgn>1888-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318292a2f9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore whether prevalence, survival, and incidence of dementia have changed from 1987-1994 to 2001-2008 in Stockholm, Sweden.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study is based on 2 cross-sectional surveys of people aged 75 years or over conducted in central Stockholm: the Kungsholmen Project (KP) (1987-1989, n = 1,700) and the Swedish National study on Aging and Care in Kungsholmen (SNAC-K) (2001-2004, n = 1,575). In both surveys we diagnosed dementia according to DSM-III-R criteria, following the identical diagnostic procedure. Death certificates were used to determine survival status of KP participants as of December 1994 and SNAC-K participants as of June 2008. We used logistic and Cox models to compare prevalence and survival, controlling for major confounders. We inferred incidence of dementia according to its relationship with prevalence and survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, 225 subjects in KP and 298 in SNAC-K were diagnosed with dementia. The age- and sex-standardized prevalence of dementia was 17.5% (12.8% in men; 19.2% in women) in KP and 17.9% (10.8% in men; 20.5% in women) in SNAC-K. The adjusted odds ratio of dementia in SNAC-K vs KP was 1.17 (95% confidence interval 0.95-1.46). The multiadjusted hazard ratio of death in SNAC-K vs KP was 0.71 (0.57-0.88) in subjects with dementia, 0.68 (0.59-0.79) in those without dementia, and 0.66 (0.59-0.74) in all participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prevalence of dementia was stable from the late 1980s to the early 2000s in central Stockholm, Sweden, whereas survival of patients with dementia increased. These results suggest that incidence of dementia may have decreased during this period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Chengxuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet-Stockholm University, Stockholm, Sweden. chengxuan.qiu@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Strauss</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>B&#xe4;ckman</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2013 May 14;80(20):1824-5. doi: 10.1212/WNL.0b013e318292a368.</RefSource><PMID Version="1">23596078</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23596063</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318292a2f9</ArticleId><ArticleId IdType="pii">WNL.0b013e318292a2f9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3572454</PMID><DateCompleted><Year>1987</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-510X</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>1987</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>164</EndPage><MedlinePgn>151-64</MedlinePgn></Pagination><Abstract><AbstractText>A quantitative morphometric analysis was used to estimate neurone and synapse densities in cerebral cortical biopsy tissues from patients with dementia under 65 years of age and pathologically verified as suffering from Alzheimer's disease. Estimates of the numerical density of neurones and synapses were made in layers II-III and V of both frontal and temporal cortex. A greater loss of synapses than that of neurones was found in Alzheimer's disease, amounting to a minimum (uncorrected for atrophy) of 25% in layers II-III and 36% in layer V of the temporal cortex, and 27% in layer V of the frontal cortex. Values of synapse to neurone ratio also demonstrated this greater loss of synapses, there being on average 38% fewer synapses associated with each surviving neurone in layers II-III of the temporal cortex, 30% fewer in layer V, and a deficit of 14% in layer V of the frontal cortex. It is concluded that a major loss of synapses occurred in this group of patients with Alzheimer's disease, probably at an early stage of the disease, and that the loss is likely to form a fundamental part of the pathological process that underlies the cortical damage of this condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Sumpter</LastName><ForeName>P Q</ForeName><Initials>PQ</Initials></Author><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>P O</ForeName><Initials>PO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3572454</ArticleId><ArticleId IdType="doi">10.1016/0022-510x(87)90057-8</ArticleId><ArticleId IdType="pii">0022-510X(87)90057-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19542629</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>87</EndPage><MedlinePgn>79-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2009-1126</ELocationID><Abstract><AbstractText>Inflammation is suggested to be involved in the pathogenesis of Alzheimer's disease (AD). Serum interleukin-6 (IL-6) and high sensitivity serum reactive protein C (hsCRP) as markers of systemic inflammation were analyzed at two examinations of the ULSAM-study, a longitudinal, community-based study of elderly men (age 70, n = 1062 and age 77, n = 749). In addition, serum amyloid protein A (SAA) and urinary prostaglandin F2alpha (PGF2alpha) metabolite levels were analyzed at age 77 in this cohort. Two serial samples (at ages 70 and 77) were available from 704 individuals. Using Cox regression analyses, associations between serum IL-6, hsCRP, SAA and PGF2alpha metabolite levels and risk of AD, any type of dementia (all-cause dementia) and non-AD dementia were analyzed. On follow-up (median, 11.3 years) in the age 70 cohort, 81 subjects developed AD and 165 subjects developed all-cause dementia. Serum IL-6, hsCRP, SAA, or PGF2alpha levels were not associated with risk of AD. At age 70, high IL-6 levels were associated with an increased risk of non-AD dementia (Hazard ratio 2.21 for above vs. below/at median, 95%confidence interval 1.23-3.95, p-value = 0.008). A longitudinal change in CRP or IL-6 levels was not associated with AD ordementia. In conclusion, Serum IL-6, hsCRP, SAA, and PGF2alpha levels are not associated with the risk of AD. High serum IL-6 levels may be associated with increased risk of non-AD dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sundel&#xf6;f</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Faculty of Medicine, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilander</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Helmersson</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>R&#xf6;nnemaa</LastName><ForeName>Elina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Degerman-Gunnarsson</LastName><ForeName>Malin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Basun</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Samar</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Alzheimers Dis. 2010;20(2):681</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011153" MajorTopicYN="N">Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19542629</ArticleId><ArticleId IdType="doi">10.3233/JAD-2009-1126</ArticleId><ArticleId IdType="pii">R01457R273L1801N</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23622250</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>707</StartPage><EndPage>720</EndPage><MedlinePgn>707-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2013.03.030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(13)00387-5</ELocationID><Abstract><AbstractText>The genetics of complex disease produce alterations in the molecular interactions of cellular pathways whose collective effect may become clear through the organized structure of molecular networks. To characterize molecular systems associated with late-onset Alzheimer's disease (LOAD), we constructed gene-regulatory networks in 1,647 postmortem brain tissues from LOAD patients and nondemented subjects, and we demonstrate that LOAD reconfigures specific portions of the molecular interaction structure. Through an integrative network-based approach, we rank-ordered these network structures for relevance to LOAD pathology, highlighting an immune- and microglia-specific module that is dominated by genes involved in pathogen phagocytosis, contains TYROBP as a key regulator, and is upregulated in LOAD. Mouse microglia cells overexpressing intact or truncated TYROBP revealed expression changes that significantly overlapped the human brain TYROBP network. Thus the causal network structure is a useful predictor of response to gene perturbations and presents a framework to test models of disease mechanisms underlying LOAD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. bin.zhang@mssm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bodea</LastName><ForeName>Liviu-Gabriel</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>McElwee</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Podtelezhnikov</LastName><ForeName>Alexei A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chunsheng</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Linh</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dobrin</LastName><ForeName>Radu</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fluder</LastName><ForeName>Eugene</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Clurman</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Melquist</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Narayanan</LastName><ForeName>Manikandan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suver</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Hardik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mahajan</LastName><ForeName>Milind</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gillis</LastName><ForeName>Tammy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mysore</LastName><ForeName>Jayalakshmi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Marcy E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Molony</LastName><ForeName>Cliona</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Emilsson</LastName><ForeName>Valur</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE44768</AccessionNumber><AccessionNumber>GSE44770</AccessionNumber><AccessionNumber>GSE44771</AccessionNumber><AccessionNumber>GSE44772</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS032765</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG034290</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS032765</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110546">TYROBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23622250</ArticleId><ArticleId IdType="mid">NIHMS472534</ArticleId><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.03.030</ArticleId><ArticleId IdType="pii">S0092-8674(13)00387-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010;69:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826839</ArticleId><ArticleId IdType="pubmed">20084018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayes A, van de Lagemaat LN, Collins MO, Croning MD, Whittle IR, Choudhary JS, Grant SG. Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nat Neurosci. 2011;14:19&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040565</ArticleId><ArticleId IdType="pubmed">21170055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer&#x2019;s disease. Lancet Neurol. 2013;12:92&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">23237904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchin MM, Martin KC, de Souza AC, de Oliveira MA, Rieder CR. Nasu-Hakola disease and primary microglial dysfunction. Nat Rev Neurol. 2010;6:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20836191</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3:186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer&#x2019;s disease. Neurobiology of disease. 2010;37:503&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823849</ArticleId><ArticleId IdType="pubmed">19833208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer&#x2019;s disease. Expert Rev Neurother. 2008;8:743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841398</ArticleId><ArticleId IdType="pubmed">18344982</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun PE, Beal MF, Wallace DC. Alzheimer&#x2019;s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A. 2004;101:10726&#x2013;10731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490002</ArticleId><ArticleId IdType="pubmed">15247418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrin R, Zhu J, Molony C, Argman C, Parrish ML, Carlson S, Allan MF, Pomp D, Schadt EE. Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol. 2009;10:R55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718521</ArticleId><ArticleId IdType="pubmed">19463160</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel R, Hampel H, Du Y. Immunotherapy for Alzheimer&#x2019;s disease. Lancet Neurol. 2003;4:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849209</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda RO, Hart PE, Stork DG. Pattern classification. 2nd edn John Wily &amp; Sons, Inc; New York: 2000.</Citation></Reference><Reference><Citation>Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">18344981</ArticleId></ArticleIdList></Reference><Reference><Citation>Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer&#x2019;s disease: systematic review and meta-analysis of observational studies. BMJ (Clinical research ed) 2003;327:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165707</ArticleId><ArticleId IdType="pubmed">12869452</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusella JF, MacDonald ME. Huntington&#x2019;s disease: seeing the pathogenic process through a genetic lens. Trends Biochem Sci. 2006;31:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829072</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, J. S, Jonsson PV, S. B, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. 2012 LID - 10.1038/nature11283 [doi]. Nature doi: 10.1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Li GF, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, Halabisky B, Deng C, Mahley RW, Huang Y. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell. 2009;5:634&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992822</ArticleId><ArticleId IdType="pubmed">19951691</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer&#x2019;s disease: an epidemiological perspective. Eur J Pharmacol. 2008;585:119&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474785</ArticleId><ArticleId IdType="pubmed">18384771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani KM, Lefebvre C, Wang K, Lim WK, Basso K, Dalla-Favera R, Califano A. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Molecular systems biology. 2008;4:169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267731</ArticleId><ArticleId IdType="pubmed">18277385</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morawski M, Bruckner G, Jager C, Seeger G, Matthews RT, Arendt T. Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer&#x2019;s disease neuropathology. Brain Pathol. 2012;22:547&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639011</ArticleId><ArticleId IdType="pubmed">22126211</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray IV, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer&#x2019;s disease: a review. Exp Biol Med (Maywood) 2011;236:772&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">21680755</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, Konopka G, Iwamoto K, Langfelder P, Kato T, Horvath S, Geschwind DH. Functional organization of the transcriptome in human brain. Nat Neurosci. 2008;11:1271&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry V, Nicoll J, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;4:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors in Alzheimer&#x2019;s disease: epidemiological evidence toward intervention. J Alzheimers Dis. 2010;20</Citation><ArticleIdList><ArticleId IdType="pubmed">20182015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009;461:218&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">19741703</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadt EE, Friend SH, Shaywitz DA. A network view of disease and compound screening. Nat Rev Drug Discov. 2009;4:286&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19337271</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today. 2008;21-22:913&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">18954804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman SS, Graham BG, Sattely-Miller EA, Zervakis J, Welsh-Bohmer K. Taste, smell and neuropsychological performance of individuals at familial risk for Alzheimer&#x2019;s disease. Neurobiol Aging. 2002;23:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959402</ArticleId></ArticleIdList></Reference><Reference><Citation>Schleinitz N, Chiche L, Guia S, Bouvier G, Vernier J, Morice A, Houssaint E, Harle JR, Kaplanski G, Montero-Julian FA, et al. Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients. PloS one. 2009;4:e6264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707004</ArticleId><ArticleId IdType="pubmed">19606219</ArticleId></ArticleIdList></Reference><Reference><Citation>The Huntington&#x2019;s Disease Collaborative Research Group. H. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. Cell. 1993;72:971&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672628</ArticleId><ArticleId IdType="pubmed">19289445</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. Journal of leukocyte biology. 2006;79:596&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16365156</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber KM, Raina AK, Marlatt MW, Zhu X, Prat MI, Morelli L, Casadesus G, Perry G, Smith MA. The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech Ageing Dev. 2005;126:1019&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">15936057</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, et al. Genetic control of human brain transcript expression in Alzheimer disease. American journal of human genetics. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23761040</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>189</Issue><PubDate><Year>2013</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers.</ArticleTitle><Pagination><StartPage>189ra77</StartPage><MedlinePgn>189ra77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3005615</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is hypothesized to be caused by an overproduction or reduced clearance of amyloid-&#x3b2; (A&#x3b2;) peptide. Autosomal dominant AD (ADAD) caused by mutations in the presenilin (PSEN) gene have been postulated to result from increased production of A&#x3b2;42 compared to A&#x3b2;40 in the central nervous system (CNS). This has been demonstrated in rodent models of ADAD but not in human mutation carriers. We used compartmental modeling of stable isotope labeling kinetic (SILK) studies in human carriers of PSEN mutations and related noncarriers to evaluate the pathophysiological effects of PSEN1 and PSEN2 mutations on the production and turnover of A&#x3b2; isoforms. We compared these findings by mutation status and amount of fibrillar amyloid deposition as measured by positron emission tomography (PET) using the amyloid tracer Pittsburgh compound B (PIB). CNS A&#x3b2;42 to A&#x3b2;40 production rates were 24% higher in mutation carriers compared to noncarriers, and this was independent of fibrillar amyloid deposits quantified by PET PIB imaging. The fractional turnover rate of soluble A&#x3b2;42 relative to A&#x3b2;40 was 65% faster in mutation carriers and correlated with amyloid deposition, consistent with increased deposition of A&#x3b2;42 into plaques, leading to reduced recovery of A&#x3b2;42 in cerebrospinal fluid (CSF). Reversible exchange of A&#x3b2;42 peptides with preexisting unlabeled peptide was observed in the presence of plaques. These findings support the hypothesis that A&#x3b2;42 is overproduced in the CNS of humans with PSEN mutations that cause AD, and demonstrate that soluble A&#x3b2;42 turnover and exchange processes are altered in the presence of amyloid plaques, causing a reduction in A&#x3b2;42 concentrations in the CSF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Elbert</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Kasten</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Blazey</LastName><ForeName>Tyler</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chott</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P01AG026276-S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 GM136766</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P01 AG026272</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests.</b> R.J.B. and D.M.H. are co-inventors on U.S. patent 7,892,845 &#x201c;Methods for measuring the metabolism of neurally derived biomolecules in vivo.&#x201d; Washington University, with R.J.B. and D.M.H. as co-inventors, has also submitted the U.S. non-provisional patent application &#x201c;Methods for measuring the metabolism of CNS derived biomolecules in vivo,&#x201d; serial #12/267,974. R.J.B., D.L.E., and B.W.P. are co-inventors on U.S. Provisional Application 61/728,692 &#x201c;Methods of Diagnosing Amyloid Pathologies Using Analysis of Amyloid-Beta Enrichment Kinetics&#x201d;. R.J.B. has consulted for Pfizer, DZNE, Probiodrug AG, Medscape, En Vivo (SAB) and has research grants with AstraZeneca, Merck and Eli Lilly in the past year. Washington University, R.J.B. and D.M.H. have a financial interest in C2N Diagnostics, which uses the SILK methodology in human studies. B.W.P. provides turnover kinetics consultation services for C2N Diagnostics. C2N Diagnostics did not support this work. DMH has consulted for Pfizer, AstraZeneca, and Bristol-Myers Squibb in the last 12 months. His laboratory has received grants from Eli Lilly, AstraZeneca, Pfizer, and C2N Diagnostics that are not related to the content in this manuscript. TB has served on an advisory board for Eli Lilly and has received research funding from Avid Radiopharmaceuticals. These relationships are not related to the content in the manuscript. AG has received research funding during the last 12 months from Pfizer, Genentech, AstraZeneca and iPierian and has served as a consultant for Amgen. These relationships are not related to the content in the manuscript. JM serves on scientific advisory boards for Eisai, Esteve, Janssen Alzheimer Immunotherapy Program, Glaxo-Smith-Kline, Novartis, and Pfizer. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23761040</ArticleId><ArticleId IdType="mid">NIHMS525757</ArticleId><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3005615</ArticleId><ArticleId IdType="pii">5/189/189ra77</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2011:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. N Engl J Med. 2012:367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002:297.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, De Strooper B. The presenilins in Alzheimer&#x2019;s disease--proteolysis holds the key. Science. 1999:286.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Sweeney D, Gandy SE, Sisodia SS. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem. 1996:271.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943233</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer&#x2019;s disease. Arch Biochem Biophy. 1993:301.</Citation><ArticleIdList><ArticleId IdType="pubmed">8442665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP protects against Alzheimer/&#x2019;s disease and age-related cognitive decline. Nature. 2012:488.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature Genet. 2006:38.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991:349.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD. A familial Alzheimer&#x2019;s disease locus on chromosome 1. Science. 1995:269.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638621</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature Med. 1996:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer&#x2019;s Disease-Linked Presenilin 1 Variants Elevate A[beta]1-42/1-40 Ratio In Vitro and In Vivo. Neuron. 1996:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008:71.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer&#x2019;s disease presenilin 1 mutation. Ann Neurol. 2007:61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, D&#x2019;Hooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B. Neurotoxicity of Alzheimer&#x2019;s disease A[beta] peptides is induced by small changes in the A[beta]42 to A[beta]40 ratio. EMBO J. 2010:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioi J, Georgakopoulos A, Mehta P, Kouchi Z, Litterst CM, Baki L, Robakis NK. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. J Neurochem. 2007:101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254019</ArticleId></ArticleIdList></Reference><Reference><Citation>Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005:65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010:330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999:56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A beta(42) in humans. Ann Neurol. 2006:59.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikisch G, Hertel A, Kiessling B, Wagner T, Krasz D, Hofmann E, Wiedemann G. Three-year follow-up of a patient with early-onset Alzheimer&#x2019;s disease with presenilin-2 N141I mutation - case report and review of the literature. European Jjournal of Medical Research. 2008:13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19073399</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Reports. 2007:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006:67.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, Wiltfang J, Serneels L, Karran E, Gijsen H, Schymkowitz J, Rousseau F, Broersen K, De Strooper B. The mechanism of [gamma]-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Human Mutat. 2006:27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M. A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid &#x3b2;. Science Translational Medicine. 2012:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. J Neurosci. 2011:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta. Neuron. 1994;42(43):13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A. Beta amyloid in Alzheimer&#x2019;s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Nat Acad Sci USA. 1998:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science. 2003:300.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, Lee JP, Mantyh PW, Maggio JE. Alzheimer&#x2019;s disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry. 2000:39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10828941</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TPJ, Waudby CA, Devlin GL, Cohen SIA, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM. An Analytical Solution to the Kinetics of Breakable Filament Assembly. Science. 2009:326.</Citation><ArticleIdList><ArticleId IdType="pubmed">20007899</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbert DL, Patterson BW, Ercole L, Ovod V, Kasten T, Mawuenyega K, Yarasheski K, Morris JC, Benzinger T, Holtzman DM, Bateman RJ. Reply to: Fractional synthesis and clearance rates for amyloid [beta] Nature Med. 2011:17.</Citation></Reference><Reference><Citation>Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ. Effects of Age and Amyloid Deposition on A{beta} Dynamics in the Human Central Nervous System. Arch Neurol. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of beta-Amyloid in Mice with Alzheimer&#x2019;s Disease Pathology. Science Translational Medicine. 2012:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JBS, Kosik KS, Tariot PN, Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. The Lancet Neurology. 2012:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT., Jr Models of amyloid seeding in Alzheimer&#x2019;s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997:66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, St Jean P, Lawson M, Ehm MG, Mayeux R, Goate AM N-LNFS Consortium. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families. PloS one. 2012:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature Med. 2006:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeds DN, Cade WT, Patterson BW, Powderly WG, Klein S, Yarasheski KE. Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes. 2006:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764855</ArticleId><ArticleId IdType="pubmed">17003352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci. 2010:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913973</ArticleId><ArticleId IdType="pubmed">20463236</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci. 1998:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792617</ArticleId><ArticleId IdType="pubmed">9464999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24014289</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Alteration of the microRNA network during the progression of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1613</StartPage><EndPage>1634</EndPage><MedlinePgn>1613-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/emmm.201201974</ELocationID><Abstract><AbstractText>An overview of miRNAs altered in Alzheimer's disease (AD) was established by profiling the hippocampus of a cohort of 41 late-onset AD (LOAD) patients and 23 controls, showing deregulation of 35 miRNAs. Profiling of miRNAs in the prefrontal cortex of a second independent cohort of 49 patients grouped by Braak stages revealed 41 deregulated miRNAs. We focused on miR-132-3p which is strongly altered in both brain areas. Downregulation of this miRNA occurs already at Braak stages III and IV, before loss of neuron-specific miRNAs. Next-generation sequencing confirmed a strong decrease of miR-132-3p and of three family-related miRNAs encoded by the same miRNA cluster on chromosome 17. Deregulation of miR-132-3p in AD brain appears to occur mainly in neurons displaying Tau hyper-phosphorylation. We provide evidence that miR-132-3p may contribute to disease progression through aberrant regulation of mRNA targets in the Tau network. The transcription factor (TF) FOXO1a appears to be a key target of miR-132-3p in this pathway.</AbstractText><CopyrightInformation>&#xa9; 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, Leuven, Belgium; Center for Human Genetics, Leuven Institute for Neurodegenerative Disorders (LIND) University Hospitals Leuven, and University of Leuven, O&amp;N4, Herestraat, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossers</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Janky</LastName><ForeName>Rekin's</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Salta</LastName><ForeName>Evgenia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Frigerio</LastName><ForeName>Carlo Sala</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Barbash</LastName><ForeName>Shahar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rothman</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sierksma</LastName><ForeName>Annerieke S R</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Thathiah</LastName><ForeName>Amantha</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Papadopoulou</LastName><ForeName>Aikaterini S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Achsel</LastName><ForeName>Tilmann</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ayoubi</LastName><ForeName>Torik</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Soreq</LastName><ForeName>Hermona</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Verhaagen</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Swaab</LastName><ForeName>Dick F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Aerts</LastName><ForeName>Stein</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C547077">MIRN132 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">miR-132-3p</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword><Keyword MajorTopicYN="N">prefrontal cortex</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24014289</ArticleId><ArticleId IdType="pmc">PMC3799583</ArticleId><ArticleId IdType="doi">10.1002/emmm.201201974</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alkalay A, Rabinovici GD, Zimmerman G, Agarwal N, Kaufer D, Miller BL, Jagust WJ, Soreq H. Plasma acetylcholinesterase activity correlates with intracerebral beta-amyloid load. Curr Alzheimer Res. 2013;10:48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768143</ArticleId><ArticleId IdType="pubmed">23157337</ArticleId></ArticleIdList></Reference><Reference><Citation>Alon S, Mor E, Vigneault F, Church GM, Locatelli F, Galeano F, Gallo A, Shomron N, Eisenberg E. Systematic identification of edited microRNAs in the human brain. Genome Res. 2012;22:1533&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409266</ArticleId><ArticleId IdType="pubmed">22499667</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218662</ArticleId><ArticleId IdType="pubmed">20979621</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A, Barbash S, Shaltiel G, Goll Y, Hanin G, Greenberg DS, Ketzef M, Becker AJ, Friedman A, Soreq H. Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice. EMBO Mol Med. 2012;4:730&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494073</ArticleId><ArticleId IdType="pubmed">22628224</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D, Geyer BC, Ravid R, Mor TS, Nitsch RM, et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain. 2008;131:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056160</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossers K, Wirz KT, Meerhoff GF, Essing AH, van Dongen JW, Houba P, Kruse CG, Verhaagen J, Swaab DF. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain. 2010;133:3699&#x2013;3723.</Citation><ArticleIdList><ArticleId IdType="pubmed">20889584</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronner IF, Bochdanovits Z, Rizzu P, Kamphorst W, Ravid R, van Swieten JC, Heutink P. Comprehensive mRNA expression profiling distinguishes tauopathies and identifies shared molecular pathways. PLoS One. 2009;4:e6826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729393</ArticleId><ArticleId IdType="pubmed">19714246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambronne XA, Shen R, Auer PL, Goodman RH. Capturing microRNA targets using an RNA-induced silencing complex (RISC)-trap approach. Proc Natl Acad Sci USA. 2012;109:20473&#x2013;20478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528561</ArticleId><ArticleId IdType="pubmed">23184980</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci. 2012;32:11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, et al. Mammalian microRNAs: Experimental evaluation of novel and previously annotated genes. Genes Dev. 2010;24:992&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867214</ArticleId><ArticleId IdType="pubmed">20413612</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14:27&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18525125</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron. 2010;65:373&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018398</ArticleId><ArticleId IdType="pubmed">20159450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Ravetti M, Rosso OA, Berretta R, Moscato P. Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One. 2010;5:e10153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854141</ArticleId><ArticleId IdType="pubmed">20405009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A, De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA. 2008;105:6415&#x2013;66420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359789</ArticleId><ArticleId IdType="pubmed">18434550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis. 2013;35:335&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753694</ArticleId><ArticleId IdType="pubmed">23403535</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann C, Van de Sande B, Potier D, Aerts S. i-cisTarget: An integrative genomics method for the prediction of regulatory features and cis-regulatory modules. Nucleic Acids Res. 2012;40:e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3424583</ArticleId><ArticleId IdType="pubmed">22718975</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoekman MF, Jacobs FM, Smidt MP, Burbach JP. Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns. 2006;6:134&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">16326148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Cox K, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol. 1990;301:44&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">2127598</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis. 2008;29:438&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Roshan R, Moisoi N, Pradervand S, Moser R, Pillai B, Luthi-Carter R. Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. J Neurosci. 2013;33:5127&#x2013;5137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705001</ArticleId><ArticleId IdType="pubmed">23516279</ArticleId></ArticleIdList></Reference><Reference><Citation>Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, Lassmann H, Wekerle H, Hohlfeld R, Meinl E. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009;132:3342&#x2013;3352.</Citation><ArticleIdList><ArticleId IdType="pubmed">19952055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau P, de Strooper B. Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol. 2010;21:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD. Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci. 2008;28:11720&#x2013;11730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646797</ArticleId><ArticleId IdType="pubmed">18987208</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D, Han G, Feng X, Sun J, Duan Y, Lei H. Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One. 2012;7:e40498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398025</ArticleId><ArticleId IdType="pubmed">22815752</ArticleId></ArticleIdList></Reference><Reference><Citation>Luikart BW, Bensen AL, Washburn EK, Perederiy JV, Su KG, Li Y, Kernie SG, Parada LF, Westbrook GL. miR-132 mediates the integration of newborn neurons into the adult dentate gyrus. PLoS One. 2011;6:e19077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096628</ArticleId><ArticleId IdType="pubmed">21611182</ArticleId></ArticleIdList></Reference><Reference><Citation>Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci USA. 2010;107:20382&#x2013;20387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996687</ArticleId><ArticleId IdType="pubmed">21059906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellios N, Sugihara H, Castro J, Banerjee A, Le C, Kumar A, Crawford B, Strathmann J, Tropea D, Levine SS, et al. miR-132, an experience-dependent microRNA, is essential for visual cortex plasticity. Nat Neurosci. 2011;14:1240&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183341</ArticleId><ArticleId IdType="pubmed">21892155</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, Willoughby D, Kenny PJ, Elsworth JD, Lawrence MS, et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA. 2012;109:3125&#x2013;3130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286960</ArticleId><ArticleId IdType="pubmed">22315408</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS One. 2010;5:e8898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813862</ArticleId><ArticleId IdType="pubmed">20126538</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Kas A, D'Souza I, Zhou Y, Pham Q, Stone M, Olson MV, Schellenberg GD. A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm Genome. 2001;12:700&#x2013;7712.</Citation><ArticleIdList><ArticleId IdType="pubmed">11641718</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet. 2012;13:358&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517822</ArticleId><ArticleId IdType="pubmed">22510765</ArticleId></ArticleIdList></Reference><Reference><Citation>Remenyi J, Hunter CJ, Cole C, Ando H, Impey S, Monk CE, Martin KJ, Barton GJ, Hutvagner G, Arthur JS. Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins. Biochem J. 2010;428:281&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">20307261</ArticleId></ArticleIdList></Reference><Reference><Citation>Salta E, De Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol. 2012;11:189&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265214</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, Gotz J. Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One. 2010;5:e11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884018</ArticleId><ArticleId IdType="pubmed">20552018</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity. 2009;31:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">20005135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaltiel G, Hanan M, Wolf Y, Barbash S, Kovalev E, Shoham S, Soreq H. Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Struct Funct. 2013;218:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535403</ArticleId><ArticleId IdType="pubmed">22246100</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan L, Bossers K, Unmehopa U, Bao AM, Swaab DF. Alterations in the histaminergic system in Alzheimer's disease: A postmortem study. Neurobiol Aging. 2012;33:2585&#x2013;2598.</Citation><ArticleIdList><ArticleId IdType="pubmed">22284987</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PY, Delay C, Girard J, Papon MA, Planel E, Sergeant N, Buee L, Hebert SS. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet. 2011;20:4016&#x2013;4024.</Citation><ArticleIdList><ArticleId IdType="pubmed">21807765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. The Genetics of Alzheimer Disease. Cold Spring Harb Perspect Med. 2012;2:a006296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tognini P, Putignano E, Coatti A, Pizzorusso T. Experience-dependent expression of miR-132 regulates ocular dominance plasticity. Nat Neurosci. 2011;14:1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183093</ArticleId><ArticleId IdType="pubmed">21892154</ArticleId></ArticleIdList></Reference><Reference><Citation>Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA. 2005;102:16426&#x2013;16431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283476</ArticleId><ArticleId IdType="pubmed">16260724</ArticleId></ArticleIdList></Reference><Reference><Citation>Waggott D, Chu K, Yin S, Wouters BG, Liu FF, Boutros PC. NanoStringNorm: An extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012;28:1546&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356845</ArticleId><ArticleId IdType="pubmed">22513995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanet A, Tacheny A, Arnould T, Renard P. miR-212/132 expression and functions: Within and beyond the neuronal compartment. Nucleic Acids Res. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367188</ArticleId><ArticleId IdType="pubmed">22362752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: White matter versus gray matter. Acta Neuropathol. 2011;121:193&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073518</ArticleId><ArticleId IdType="pubmed">20936480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28:1213&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837363</ArticleId><ArticleId IdType="pubmed">18234899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L, Qin C. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull. 2009;80:268&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">19683563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Veremeyko T, Patel N, Lemere CA, Walsh DM, Esau C, Vanderburg C, Krichevsky AM. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease. Hum Mol Genet. 2013;22:3077&#x2013;3092.</Citation><ArticleIdList><ArticleId IdType="pubmed">23585551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyman SK, Knouf EC, Parkin RK, Fritz BR, Lin DW, Dennis LM, Krouse MA, Webster PJ, Tewari M. Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res. 2011;21:1450&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166830</ArticleId><ArticleId IdType="pubmed">21813625</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>